

COVID-19 Immunogenicity Analysis Report
mock Study

USG COVID-19 Response Biostatistics Team

April 28, 2021

Contents

1	Tabular Description of Immunogenicity Data	15
2	Graphical Description of Immunogenicity Data	411
2.1	Pairs plots of antibody markers for overall per-protocol cohort	411
2.2	RCDF plots of antibody markers for overall per-protocol cohort	431
2.3	Scatter plots of antibody markers versus age for overall per-protocol cohort	458
2.4	Box plots of antibody markers for overall per-protocol cohort	463
2.5	Spaghetti plots of antibody markers over time for the overall per-protocol cohort	480
2.6	RCDF plots of antibody markers by demographics for per-protocol cohort	483
2.7	Boxplots of antibody markers by demographics for per-protocol cohort	556

List of Tables

1.1	Table 1. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Negative Per-Protocol Cohort	15
1.2	Table 2. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Positive Per-Protocol Cohort	17
1.3	Table 3a. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by All participants	18
1.4	Table 3b. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Age	20
1.5	Table 3c. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Risk for Severe Covid-19	24
1.6	Table 3d. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Age, Risk for Severe Covid-19	28
1.7	Table 3e. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Sex	37
1.8	Table 3f. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Age, sex	41
1.9	Table 3g. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Hispanic or Latino ethnicity	49
1.10	Table 3h. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Race	56
1.11	Table 3i. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Underrepresented minority status	74
1.12	Table 3j. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Age, Underrepresented minority status	79
1.13	Table 4a. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by All participants	90
1.14	Table 4b. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age	91
1.15	Table 4c. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Risk for Severe Covid-19	93
1.16	Table 4d. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Risk for Severe Covid-19	95

1.17 Table 4e. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Sex	98
1.18 Table 4f. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, sex	100
1.19 Table 4g. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Hispanic or Latino ethnicity	103
1.20 Table 4h. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Race	106
1.21 Table 4i. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Underrepresented minority status	112
1.22 Table 4j. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Underrepresented minority status	114
1.23 Table 5a. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by All participants	118
1.24 Table 5b. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age	122
1.25 Table 5c. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Risk for Severe Covid-19	130
1.26 Table 5d. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Risk for Severe Covid-19	138
1.27 Table 5e. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Sex	154
1.28 Table 5f. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, sex	162
1.29 Table 5g. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Hispanic or Latino ethnicity	178
1.30 Table 5h. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Race	190
1.31 Table 5i. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Underrepresented minority status	222
1.32 Table 5j. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Underrepresented minority status	230
1.33 Table 6a. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by All participants	246
1.34 Table 6b. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age	249
1.35 Table 6c. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Risk for Severe Covid-19	255
1.36 Table 6d. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Risk for Severe Covid-19	261
1.37 Table 6e. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Sex	272
1.38 Table 6f. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, sex	278

1.39 Table 6g. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Hispanic or Latino ethnicity	289
1.40 Table 6h. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Race	298
1.41 Table 6i. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Underrepresented minority status . .	322
1.42 Table 6j. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Underrepresented minority status	328
1.43 Table 7a. The ratios of GMTs/GMCs between groups by Age	342
1.44 Table 7b. The ratios of GMTs/GMCs between groups by Risk for Severe Covid-19	346
1.45 Table 7c. The ratios of GMTs/GMCs between groups by Age < 65, Risk for Severe Covid-19	350
1.46 Table 7d. The ratios of GMTs/GMCs between groups by Age >= 65, Risk for Severe Covid-19	356
1.47 Table 7e. The ratios of GMTs/GMCs between groups by Sex	362
1.48 Table 7f. The ratios of GMTs/GMCs between groups by Hispanic or Latino ethnicity	366
1.49 Table 7g. The ratios of GMTs/GMCs between groups by Underrepresented minority status .	372
1.50 Table 8a. Differences in the responder rates, 2FRs, 4FRs between the groups by Arm	378
1.51 Table 8b. Differences in the responder rates, 2FRs, 4FRs between the groups by Baseline SARS-CoV-2	380
1.52 Table 8c. Differences in the responder rates, 2FRs, 4FRs between the groups by Age	382
1.53 Table 8d. Differences in the responder rates, 2FRs, 4FRs between the groups by Risk for Severe Covid-19	385
1.54 Table 8e. Differences in the responder rates, 2FRs, 4FRs between the groups by Age < 65, Risk for Severe Covid-19	388
1.55 Table 8f. Differences in the responder rates, 2FRs, 4FRs between the groups by Age >= 65, Risk for Severe Covid-19	392
1.56 Table 8g. Differences in the responder rates, 2FRs, 4FRs between the groups by Sex	396
1.57 Table 8h. Differences in the responder rates, 2FRs, 4FRs between the groups by Hispanic or Latino ethnicity	399
1.58 Table 8i. Differences in the responder rates, 2FRs, 4FRs between the groups by Underrepresented minority status	403
1.59 Table 9. Antibody levels in the baseline SARS-CoV-2 negative per-protocol cohort (vaccine vs. placebo)	407
1.60 Table 10. Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (vaccine vs. placebo)	408
1.61 Table 11. Antibody levels in the per-protocol cohort (vaccine recipients)	409
1.62 Table 12. Antibody levels in the per-protocol cohort (placebo recipients)	410

List of Figures

2.1	Pair plots of D29 Ab markers: baseline negative vaccine arm	412
2.2	Pair plots of D57 Ab markers: baseline negative vaccine arm	413
2.3	Pair plots of D29 fold-rise over D1 Ab markers: baseline negative vaccine arm	414
2.4	Pair plots of D57 fold-rise over D1 Ab markers: baseline negative vaccine arm	415
2.5	Pair plots of D1, D29 and D57 Binding Antibody to N: baseline negative vaccine arm	416
2.6	Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline negative vaccine arm	417
2.7	Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline negative vaccine arm	418
2.8	Pair plots of D1, D29 and D57 nAb Neutralization 50% Titer: baseline negative vaccine arm	419
2.9	Pair plots of D1, D29 and D57 nAb Neutralization 80% Titer: Baseline negative vaccine arm	420
2.10	Pair plots of D29 Ab markers: baseline positive vaccine arm	421
2.11	Pair plots of D57 Ab markers: baseline positive vaccine arm	422
2.12	Pair plots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm	423
2.13	Pair plots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm	424
2.14	Pair plots of D1, D29 and D57 Binding Antibody to N: baseline positive vaccine arm	425
2.15	Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline positive vaccine arm	426
2.16	Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline positive vaccine arm	427
2.17	Pair plots of D1, D29 and D57 nAb Neutralization 50% Titer: baseline positive vaccine arm	428
2.18	Pair plots of D1, D29 and D57 nAb Neutralization 80% Titer: Baseline positive vaccine arm	429
2.19	RCDF plots for D29 Ab markers: by baseline status x randomization arm	431
2.20	RCDF plots for D57 Ab markers: by baseline status x randomization arm	432
2.21	RCDF plots for D29 fold-rise over D1 Ab markers: by baseline status x randomization arm	433
2.22	RCDF plots for D57 fold-rise over D1 Ab markers: by baseline status x randomization arm	434
2.23	RCDF plots for D29 bAb markers: by baseline status for the vaccine arm	435
2.24	RCDF plots for D29 nAb markers: by baseline status for the vaccine arm	435
2.25	RCDF plots for D57 bAb markers: by baseline status for the vaccine arm	436
2.26	RCDF plots for D57 nAb markers: by baseline status for the vaccine arm	437
2.27	RCDF plots for D29 over D1 fold-rise bAb markers: by baseline status for the vaccine arm	438
2.28	RCDF plots for D29 over D1 fold-rise nAb markers: by baseline status for the vaccine arm	439

2.29 RCDF plots for D57 fold-rise over D1 bAb markers: by baseline status for the vaccine arm	440
2.30 RCDF plots for D57 fold-rise over D1 nAb markers: by baseline status for the vaccine arm	441
2.31 RCDF plots for D29 bAb markers: baseline negative vaccine arm	442
2.32 RCDF plots for D29 nAb markers: baseline negative vaccine arm	443
2.33 RCDF plots for D57 bAb markers: baseline negative vaccine arm	444
2.34 RCDF plots for D57 nonbAb markers: baseline negative vaccine arm	445
2.35 RCDF plots for D29 fold-rise over D1 bAb markers: baseline negative vaccine arm	446
2.36 RCDF plots for D29 fold-rise over D1 nAb markers: baseline negative vaccine arm	447
2.37 RCDF plots for D57 fold-rise over D1 bAb markers: baseline negative vaccine arm	448
2.38 RCDF plots for D57 fold-rise over D1 nAb markers: baseline negative vaccine arm	449
2.39 RCDF plots for D29 bAb markers: baseline positive vaccine arm	450
2.40 RCDF plots for D29 nAb markers: baseline positive vaccine arm	451
2.41 RCDF plots for D57 bAb markers: baseline positive vaccine arm	452
2.42 RCDF plots for D57 nonbAb markers: baseline positive vaccine arm	453
2.43 RCDF plots for D29 fold-rise over D1 bAb markers: baseline positive vaccine arm	454
2.44 RCDF plots for D29 fold-rise over D1 nAb markers: baseline positive vaccine arm	455
2.45 RCDF plots for D57 fold-rise over D1 bAb markers: baseline positive vaccine arm	456
2.46 RCDF plots for D57 fold-rise over D1 nAb markers: baseline positive vaccine arm	457
2.47 Scatter plots for D29 Ab markers vs. age: baseline negative vaccine arm	459
2.48 Scatter plots for D57 Ab markers vs. age: baseline negative vaccine arm	460
2.49 Scatter plots for D29 Ab markers vs. age: baseline positive vaccine arm	461
2.50 Scatter plots for D57 Ab markers vs. age: baseline positive vaccine arm	462
2.51 Boxplots of D29 Ab markers: baseline negative vaccine + placebo arms	464
2.52 Boxplots of D57 Ab markers: baseline negative vaccine + placebo arms	465
2.53 Boxplots of D29 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms	466
2.54 Boxplots of D57 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms	467
2.55 Boxplots of D29 Ab markers: baseline positive vaccine + placebo arms	468
2.56 Boxplots of D57 Ab markers: baseline positive vaccine + placebo arms	469
2.57 Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms	470
2.58 Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms	471
2.59 Boxplots of D29 Ab markers: baseline positive + negative vaccine arm	472
2.60 Boxplots of D57 Ab markers: baseline positive + negative vaccine arm	473
2.61 Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm	474
2.62 Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm	475
2.63 Boxplots of D29 Ab markers: baseline positive + negative placebo arm	476
2.64 Boxplots of D57 Ab markers: baseline positive + negative placebo arm	477

2.65 Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative placebo arm	478
2.66 Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative placebo arm	479
2.67 Spaghetti plots of Ab markers over time: baseline negative vaccine + placebo arm	481
2.68 Spaghetti plots of Ab markers over time: baseline positive vaccine + placebo arm	482
2.69 RCDF plots for D29 Ab markers: baseline negative vaccine arm by age groups.	484
2.70 RCDF plots for D57 Ab markers: baseline negative vaccine arm by age groups.	485
2.71 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups.	486
2.72 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups.	487
2.73 RCDF plots for D29 Ab markers: baseline negative vaccine arm by high-risk condition.	488
2.74 RCDF plots for D57 Ab markers: baseline negative vaccine arm by high-risk condition.	489
2.75 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition.	490
2.76 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition.	491
2.77 RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and high-risk condition.	492
2.78 RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and high-risk condition.	493
2.79 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition.	494
2.80 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition.	495
2.81 RCDF plots for D29 Ab markers: baseline negative vaccine arm by sex assigned at birth.	496
2.82 RCDF plots for D57 Ab markers: baseline negative vaccine arm by sex assigned at birth.	497
2.83 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth.	498
2.84 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth.	499
2.85 RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.	500
2.86 RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.	501
2.87 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.	502
2.88 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex at birth.	503
2.89 RCDF plots for D29 Ab markers: baseline negative vaccine arm by ethnicity.	504
2.90 RCDF plots for D57 Ab markers: baseline negative vaccine arm by ethnicity.	505
2.91 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity.	506
2.92 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity.	507
2.93 RCDF plots for D29 Ab markers: baseline negative vaccine arm by race.	508
2.94 RCDF plots for D57 Ab markers: baseline negative vaccine arm by race.	509

2.95 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by race.	510
2.96 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by race.	511
2.97 RCDF plots for D29 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.	512
2.98 RCDF plots for D57 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.	513
2.99 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.	514
2.100RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.	515
2.101RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.	516
2.102RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.	517
2.103RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.	518
2.104RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.	519
2.105RCDF plots for D29 Ab markers: baseline positive vaccine arm by age groups.	520
2.106RCDF plots for D57 Ab markers: baseline positive vaccine arm by age groups.	521
2.107RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups.	522
2.108RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups.	523
2.109RCDF plots for D29 Ab markers: baseline positive vaccine arm by high-risk condition.	524
2.110RCDF plots for D57 Ab markers: baseline positive vaccine arm by high-risk condition.	525
2.111RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.	526
2.112RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.	527
2.113RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and high-risk condition.	528
2.114RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and high-risk condition.	529
2.115RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.	530
2.116RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.	531
2.117RCDF plots for D29 Ab markers: baseline positive vaccine arm by sex assigned at birth.	532
2.118RCDF plots for D57 Ab markers: baseline positive vaccine arm by sex assigned at birth.	533
2.119RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.	534
2.120RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.	535
2.121RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.	536

2.122RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.	537
2.123RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.	538
2.124RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.	539
2.125RCDF plots for D29 Ab markers: baseline positive vaccine arm by ethnicity.	540
2.126RCDF plots for D57 Ab markers: baseline positive vaccine arm by ethnicity.	541
2.127RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity. .	542
2.128RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity. .	543
2.129RCDF plots for D29 Ab markers: baseline positive vaccine arm by race.	544
2.130RCDF plots for D57 Ab markers: baseline positive vaccine arm by race.	545
2.131RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race. .	546
2.132RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race. .	547
2.133RCDF plots for D29 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.	548
2.134RCDF plots for D57 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.	549
2.135RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.	550
2.136RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.	551
2.137RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.	552
2.138RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.	553
2.139RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.	554
2.140RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.	555
2.141Boxplots of D29 Ab markers: Baseline negative vaccine arm by age group.	557
2.142Boxplots of D57 Ab markers: Baseline negative vaccine arm by age group.	558
2.143Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth.	559
2.144Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth.	560
2.145Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity. .	561
2.146Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity. .	562
2.147Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race.	563
2.148Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race.	564

2.149Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group.	565
2.150Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group.	566
2.151Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.	567
2.152Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.	568
2.153Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group. . .	570
2.154Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group. . .	571
2.155Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.	572
2.156Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.	573
2.157Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.	574
2.158Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.	575
2.159Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.	576
2.160Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.	577
2.161Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.	578
2.162Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.	579
2.163Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity. . .	580
2.164Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity. . .	581
2.165Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.	582
2.166Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.	583
2.167Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.	584
2.168Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.	585
2.169Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.	586
2.170Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.	587

Chapter 1

Tabular Description of Immunogenicity Data

Table 1. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Negative Per-Protocol Cohort

Characteristics	Vaccine (N = 915)	Placebo (N = 155)	Total (N = 1070)
Age			
Age < 65	439 (48.0%)	77 (49.7%)	516 (48.2%)
Age ≥ 65	476 (52.0%)	78 (50.3%)	554 (51.8%)
Mean (Range)	58.7 (18.0, 85.0)	59.0 (18.0, 85.0)	58.7 (18.0, 85.0)
BMI			
Mean ± SD	29.6 ± 7.1	30.0 ± 7.6	29.6 ± 7.2
Risk for Severe Covid-19			
At-risk	470 (51.4%)	80 (51.6%)	550 (51.4%)
Not at-risk	445 (48.6%)	75 (48.4%)	520 (48.6%)
Age, Risk for Severe Covid-19			
Age < 65 At-risk	220 (24.0%)	39 (25.2%)	259 (24.2%)
Age < 65 Not at-risk	219 (23.9%)	38 (24.5%)	257 (24.0%)
Age ≥ 65	476 (52.0%)	78 (50.3%)	554 (51.8%)
Sex			
Female	524 (57.3%)	95 (61.3%)	619 (57.9%)
Male	391 (42.7%)	60 (38.7%)	451 (42.1%)
Hispanic or Latino ethnicity			
Hispanic or Latino	130 (14.2%)	22 (14.2%)	152 (14.2%)
Not Hispanic or Latino	690 (75.4%)	118 (76.1%)	808 (75.5%)
Not reported and unknown	95 (10.4%)	15 (9.7%)	110 (10.3%)
Race			
White Non-Hispanic	359 (39.2%)	62 (40.0%)	421 (39.3%)
Black or African American	202 (22.1%)	23 (14.8%)	225 (21.0%)
Asian	58 (6.3%)	13 (8.4%)	71 (6.6%)
American Indian or Alaska Native	22 (2.4%)	4 (2.6%)	26 (2.4%)
Native Hawaiian or Other Pacific Islander	11 (1.2%)	5 (3.2%)	16 (1.5%)
Multiracial	60 (6.6%)	10 (6.5%)	70 (6.5%)
Other	21 (2.3%)	4 (2.6%)	25 (2.3%)

(continued)

Characteristics	Vaccine (N = 915)	Placebo (N = 155)	Total (N = 1070)
Not reported and unknown	86 (9.4%)	19 (12.3%)	105 (9.8%)
Communities of Color	420 (45.9%)	66 (42.6%)	486 (45.4%)

This table summarizes the random subcohort, which was randomly sampled from the per-protocol cohort, and excludes individuals with a COVID failure event < 7 days post Day 57. The sampling was stratified by 24 strata defined by enrollment characteristics: Assigned treatment arm × Baseline SARS-CoV-2 naïve vs. non-naïve status (defined by serostatus and NAAT testing) × Randomization strata (Age < 65 and at-risk, Age < 65 and not at-risk, Age \geq 65) × Communities of color (Yes/No) defined by White Non-Hispanic vs. all others (following the primary COVE trial paper).

MOCH

Table 2. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Positive Per-Protocol Cohort

Characteristics	Vaccine (N = 269)	Placebo (N = 276)	Total (N = 545)
Age			
Age < 65	146 (54.3%)	148 (53.6%)	294 (53.9%)
Age ≥ 65	123 (45.7%)	128 (46.4%)	251 (46.1%)
Mean (Range)	55.2 (18.0, 85.0)	56.0 (18.0, 85.0)	55.6 (18.0, 85.0)
BMI			
Mean ± SD	30.1 ± 7.0	29.9 ± 6.9	30.0 ± 6.9
Risk for Severe Covid-19			
At-risk	120 (44.6%)	130 (47.1%)	250 (45.9%)
Not at-risk	149 (55.4%)	146 (52.9%)	295 (54.1%)
Age, Risk for Severe Covid-19			
Age < 65 At-risk	70 (26.0%)	75 (27.2%)	145 (26.6%)
Age < 65 Not at-risk	76 (28.3%)	73 (26.4%)	149 (27.3%)
Age ≥ 65	123 (45.7%)	128 (46.4%)	251 (46.1%)
Sex			
Female	156 (58.0%)	154 (55.8%)	310 (56.9%)
Male	113 (42.0%)	122 (44.2%)	235 (43.1%)
Hispanic or Latino ethnicity			
Hispanic or Latino	34 (12.6%)	25 (9.1%)	59 (10.8%)
Not Hispanic or Latino	197 (73.2%)	222 (80.4%)	419 (76.9%)
Not reported and unknown	38 (14.1%)	29 (10.5%)	67 (12.3%)
Race			
White Non-Hispanic	107 (39.8%)	127 (46.0%)	234 (42.9%)
Black or African American	50 (18.6%)	58 (21.0%)	108 (19.8%)
Asian	19 (7.1%)	18 (6.5%)	37 (6.8%)
American Indian or Alaska Native	7 (2.6%)	4 (1.4%)	11 (2.0%)
Native Hawaiian or Other Pacific Islander	6 (2.2%)	4 (1.4%)	10 (1.8%)
Multiracial	11 (4.1%)	14 (5.1%)	25 (4.6%)
Other	8 (3.0%)	7 (2.5%)	15 (2.8%)
Not reported and unknown	25 (9.3%)	24 (8.7%)	49 (9.0%)
Communities of Color	110 (40.9%)	112 (40.6%)	222 (40.7%)

This table summarizes the random subcohort, which was randomly sampled from the per-protocol cohort, and excludes individuals with a COVID failure event < 7 days post Day 57. The sampling was stratified by 24 strata defined by enrollment characteristics: Assigned treatment arm × Baseline SARS-CoV-2 naïve vs. non-naïve status (defined by serostatus and NAAT testing) × Randomization strata (Age < 65 and at-risk, Age < 65 and not at-risk, Age ≥ 65) × Communities of color (Yes/No) defined by White Non-Hispanic vs. all others (following the primary COVE trial paper).

Table 3a. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by All participants

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
All participants								
	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	915	13297/13297 = 100.0% (100.0%, 100.0%)	13297/13297 = 100.0% (100.0%, 100.0%)	13250.2/13297 = 99.6% (97.5%, 100.0%)
	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	915	13297/13297 = 100.0% (100.0%, 100.0%)	13297/13297 = 100.0% (100.0%, 100.0%)	13297/13297 = 100.0% (100.0%, 100.0%)
	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	915	13297/13297 = 100.0% (100.0%, 100.0%)	13297/13297 = 100.0% (100.0%, 100.0%)	13297/13297 = 100.0% (100.0%, 100.0%)
	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	269	1399/1399 = 100.0% (100.0%, 100.0%)	1399/1399 = 100.0% (100.0%, 100.0%)	1399/1399 = 100.0% (100.0%, 100.0%)
	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	269	1399/1399 = 100.0% (100.0%, 100.0%)	1399/1399 = 100.0% (100.0%, 100.0%)	1399/1399 = 100.0% (100.0%, 100.0%)
	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	269	1399/1399 = 100.0% (100.0%, 100.0%)	1399/1399 = 100.0% (100.0%, 100.0%)	1399/1399 = 100.0% (100.0%, 100.0%)
	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	155	0/13381 = 0.0% (0.0%, 0.0%)	0/13381 = 0.0% (0.0%, 0.0%)	0/13381 = 0.0% (0.0%, 0.0%)
	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	155	0/13381 = 0.0% (0.0%, 0.0%)	0/13381 = 0.0% (0.0%, 0.0%)	0/13381 = 0.0% (0.0%, 0.0%)
	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	155	0/13381 = 0.0% (0.0%, 0.0%)	0/13381 = 0.0% (0.0%, 0.0%)	0/13381 = 0.0% (0.0%, 0.0%)
	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	276	1276/1276 = 100.0% (100.0%, 100.0%)	1276/1276 = 100.0% (100.0%, 100.0%)	1276/1276 = 100.0% (100.0%, 100.0%)
	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	276	1276/1276 = 100.0% (100.0%, 100.0%)	1276/1276 = 100.0% (100.0%, 100.0%)	1276/1276 = 100.0% (100.0%, 100.0%)
	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	276	1276/1276 = 100.0% (100.0%, 100.0%)	1276/1276 = 100.0% (100.0%, 100.0%)	1276/1276 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	915	13297/13297 = 100.0% (100.0%, 100.0%)	13297/13297 = 100.0% (100.0%, 100.0%)	13297/13297 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	915	13297/13297 = 100.0% (100.0%, 100.0%)	13297/13297 = 100.0% (100.0%, 100.0%)	13297/13297 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	915	13297/13297 = 100.0% (100.0%, 100.0%)	13297/13297 = 100.0% (100.0%, 100.0%)	13297/13297 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	269	1399/1399 = 100.0% (100.0%, 100.0%)	1399/1399 = 100.0% (100.0%, 100.0%)	1399/1399 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	269	1399/1399 = 100.0% (100.0%, 100.0%)	1399/1399 = 100.0% (100.0%, 100.0%)	1399/1399 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	269	1399/1399 = 100.0% (100.0%, 100.0%)	1399/1399 = 100.0% (100.0%, 100.0%)	1399/1399 = 100.0% (100.0%, 100.0%)
	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	155	0/13381 = 0.0% (0.0%, 0.0%)	0/13381 = 0.0% (0.0%, 0.0%)	0/13381 = 0.0% (0.0%, 0.0%)
	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	155	0/13381 = 0.0% (0.0%, 0.0%)	0/13381 = 0.0% (0.0%, 0.0%)	0/13381 = 0.0% (0.0%, 0.0%)
	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	155	0/13381 = 0.0% (0.0%, 0.0%)	0/13381 = 0.0% (0.0%, 0.0%)	0/13381 = 0.0% (0.0%, 0.0%)
	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	276	1276/1276 = 100.0% (100.0%, 100.0%)	1276/1276 = 100.0% (100.0%, 100.0%)	1276/1276 = 100.0% (100.0%, 100.0%)
	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	276	1276/1276 = 100.0% (100.0%, 100.0%)	1276/1276 = 100.0% (100.0%, 100.0%)	1276/1276 = 100.0% (100.0%, 100.0%)
	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	276	1276/1276 = 100.0% (100.0%, 100.0%)	1276/1276 = 100.0% (100.0%, 100.0%)	1276/1276 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.
Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3b. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Age

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Age								
Age < 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	439	10464/10464 = 100.0% (100.0%, 100.0%)	10464/10464 = 100.0% (100.0%, 100.0%)	10417.2/10464 = 99.6% (96.9%, 99.9%)
Age < 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	439	10464/10464 = 100.0% (100.0%, 100.0%)	10464/10464 = 100.0% (100.0%, 100.0%)	10464/10464 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	439	10464/10464 = 100.0% (100.0%, 100.0%)	10464/10464 = 100.0% (100.0%, 100.0%)	10464/10464 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	146	1130/1130 = 100.0% (100.0%, 100.0%)	1130/1130 = 100.0% (100.0%, 100.0%)	1130/1130 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	146	1130/1130 = 100.0% (100.0%, 100.0%)	1130/1130 = 100.0% (100.0%, 100.0%)	1130/1130 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	146	1130/1130 = 100.0% (100.0%, 100.0%)	1130/1130 = 100.0% (100.0%, 100.0%)	1130/1130 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	77	0/10233 = 0.0% (0.0%, 0.0%)	0/10233 = 0.0% (0.0%, 0.0%)	0/10233 = 0.0% (0.0%, 0.0%)
Age < 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	77	0/10233 = 0.0% (0.0%, 0.0%)	0/10233 = 0.0% (0.0%, 0.0%)	0/10233 = 0.0% (0.0%, 0.0%)
Age < 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	77	0/10233 = 0.0% (0.0%, 0.0%)	0/10233 = 0.0% (0.0%, 0.0%)	0/10233 = 0.0% (0.0%, 0.0%)
Age < 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	148	1027/1027 = 100.0% (100.0%, 100.0%)	1027/1027 = 100.0% (100.0%, 100.0%)	1027/1027 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	148	1027/1027 = 100.0% (100.0%, 100.0%)	1027/1027 = 100.0% (100.0%, 100.0%)	1027/1027 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	148	1027/1027 = 100.0% (100.0%, 100.0%)	1027/1027 = 100.0% (100.0%, 100.0%)	1027/1027 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	439	10464/10464 = 100.0% (100.0%, 100.0%)	10464/10464 = 100.0% (100.0%, 100.0%)	10464/10464 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	439	10464/10464 = 100.0% (100.0%, 100.0%)	10464/10464 = 100.0% (100.0%, 100.0%)	10464/10464 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	439	10464/10464 = 100.0% (100.0%, 100.0%)	10464/10464 = 100.0% (100.0%, 100.0%)	10464/10464 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	146	1130/1130 = 100.0% (100.0%, 100.0%)	1130/1130 = 100.0% (100.0%, 100.0%)	1130/1130 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	146	1130/1130 = 100.0% (100.0%, 100.0%)	1130/1130 = 100.0% (100.0%, 100.0%)	1130/1130 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	146	1130/1130 = 100.0% (100.0%, 100.0%)	1130/1130 = 100.0% (100.0%, 100.0%)	1130/1130 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	77	0/10233 = 0.0% (0.0%, 0.0%)	0/10233 = 0.0% (0.0%, 0.0%)	0/10233 = 0.0% (0.0%, 0.0%)
Age < 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	77	0/10233 = 0.0% (0.0%, 0.0%)	0/10233 = 0.0% (0.0%, 0.0%)	0/10233 = 0.0% (0.0%, 0.0%)
Age < 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	77	0/10233 = 0.0% (0.0%, 0.0%)	0/10233 = 0.0% (0.0%, 0.0%)	0/10233 = 0.0% (0.0%, 0.0%)
Age < 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	148	1027/1027 = 100.0% (100.0%, 100.0%)	1027/1027 = 100.0% (100.0%, 100.0%)	1027/1027 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	148	1027/1027 = 100.0% (100.0%, 100.0%)	1027/1027 = 100.0% (100.0%, 100.0%)	1027/1027 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	148	1027/1027 = 100.0% (100.0%, 100.0%)	1027/1027 = 100.0% (100.0%, 100.0%)	1027/1027 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	476	2833/2833 = 100.0% (100.0%, 100.0%)	2833/2833 = 100.0% (100.0%, 100.0%)	2833/2833 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	476	2833/2833 = 100.0% (100.0%, 100.0%)	2833/2833 = 100.0% (100.0%, 100.0%)	2833/2833 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	476	2833/2833 = 100.0% (100.0%, 100.0%)	2833/2833 = 100.0% (100.0%, 100.0%)	2833/2833 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	123	269/269 = 100.0% (100.0%, 100.0%)	269/269 = 100.0% (100.0%, 100.0%)	269/269 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	123	269/269 = 100.0% (100.0%, 100.0%)	269/269 = 100.0% (100.0%, 100.0%)	269/269 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	123	269/269 = 100.0% (100.0%, 100.0%)	269/269 = 100.0% (100.0%, 100.0%)	269/269 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	78	0/3148 = 0.0% (0.0%, 0.0%)	0/3148 = 0.0% (0.0%, 0.0%)	0/3148 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	78	0/3148 = 0.0% (0.0%, 0.0%)	0/3148 = 0.0% (0.0%, 0.0%)	0/3148 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	78	0/3148 = 0.0% (0.0%, 0.0%)	0/3148 = 0.0% (0.0%, 0.0%)	0/3148 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	128	249/249 = 100.0% (100.0%, 100.0%)	249/249 = 100.0% (100.0%, 100.0%)	249/249 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	128	249/249 = 100.0% (100.0%, 100.0%)	249/249 = 100.0% (100.0%, 100.0%)	249/249 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	128	249/249 = 100.0% (100.0%, 100.0%)	249/249 = 100.0% (100.0%, 100.0%)	249/249 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	476	2833/2833 = 100.0% (100.0%, 100.0%)	2833/2833 = 100.0% (100.0%, 100.0%)	2833/2833 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	476	2833/2833 = 100.0% (100.0%, 100.0%)	2833/2833 = 100.0% (100.0%, 100.0%)	2833/2833 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	476	2833/2833 = 100.0% (100.0%, 100.0%)	2833/2833 = 100.0% (100.0%, 100.0%)	2833/2833 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	123	269/269 = 100.0% (100.0%, 100.0%)	269/269 = 100.0% (100.0%, 100.0%)	269/269 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	123	269/269 = 100.0% (100.0%, 100.0%)	269/269 = 100.0% (100.0%, 100.0%)	269/269 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	123	269/269 = 100.0% (100.0%, 100.0%)	269/269 = 100.0% (100.0%, 100.0%)	269/269 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	78	0/3148 = 0.0% (0.0%, 0.0%)	0/3148 = 0.0% (0.0%, 0.0%)	0/3148 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	78	0/3148 = 0.0% (0.0%, 0.0%)	0/3148 = 0.0% (0.0%, 0.0%)	0/3148 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	78	0/3148 = 0.0% (0.0%, 0.0%)	0/3148 = 0.0% (0.0%, 0.0%)	0/3148 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	128	249/249 = 100.0% (100.0%, 100.0%)	249/249 = 100.0% (100.0%, 100.0%)	249/249 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	128	249/249 = 100.0% (100.0%, 100.0%)	249/249 = 100.0% (100.0%, 100.0%)	249/249 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	128	249/249 = 100.0% (100.0%, 100.0%)	249/249 = 100.0% (100.0%, 100.0%)	249/249 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3c. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Risk for Severe Covid-19								
At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	470	3637.9/3637.9 = 100.0% (100.0%, 100.0%)	3637.9/3637.9 = 100.0% (100.0%, 100.0%)	3637.9/3637.9 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	470	3637.9/3637.9 = 100.0% (100.0%, 100.0%)	3637.9/3637.9 = 100.0% (100.0%, 100.0%)	3637.9/3637.9 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	470	3637.9/3637.9 = 100.0% (100.0%, 100.0%)	3637.9/3637.9 = 100.0% (100.0%, 100.0%)	3637.9/3637.9 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	120	357.6/357.6 = 100.0% (100.0%, 100.0%)	357.6/357.6 = 100.0% (100.0%, 100.0%)	357.6/357.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	357.6/357.6 = 100.0% (100.0%, 100.0%)	357.6/357.6 = 100.0% (100.0%, 100.0%)	357.6/357.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	357.6/357.6 = 100.0% (100.0%, 100.0%)	357.6/357.6 = 100.0% (100.0%, 100.0%)	357.6/357.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	80	0/4055.1 = 0.0% (0.0%, 0.0%)	0/4055.1 = 0.0% (0.0%, 0.0%)	0/4055.1 = 0.0% (0.0%, 0.0%)
At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	80	0/4055.1 = 0.0% (0.0%, 0.0%)	0/4055.1 = 0.0% (0.0%, 0.0%)	0/4055.1 = 0.0% (0.0%, 0.0%)
At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	80	0/4055.1 = 0.0% (0.0%, 0.0%)	0/4055.1 = 0.0% (0.0%, 0.0%)	0/4055.1 = 0.0% (0.0%, 0.0%)
At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	130	322/322 = 100.0% (100.0%, 100.0%)	322/322 = 100.0% (100.0%, 100.0%)	322/322 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	130	322/322 = 100.0% (100.0%, 100.0%)	322/322 = 100.0% (100.0%, 100.0%)	322/322 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	130	322/322 = 100.0% (100.0%, 100.0%)	322/322 = 100.0% (100.0%, 100.0%)	322/322 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	470	3637.9/3637.9 = 100.0% (100.0%, 100.0%)	3637.9/3637.9 = 100.0% (100.0%, 100.0%)	3637.9/3637.9 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	470	3637.9/3637.9 = 100.0% (100.0%, 100.0%)	3637.9/3637.9 = 100.0% (100.0%, 100.0%)	3637.9/3637.9 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	470	3637.9/3637.9 = 100.0% (100.0%, 100.0%)	3637.9/3637.9 = 100.0% (100.0%, 100.0%)	3637.9/3637.9 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	120	357.6/357.6 = 100.0% (100.0%, 100.0%)	357.6/357.6 = 100.0% (100.0%, 100.0%)	357.6/357.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	357.6/357.6 = 100.0% (100.0%, 100.0%)	357.6/357.6 = 100.0% (100.0%, 100.0%)	357.6/357.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	357.6/357.6 = 100.0% (100.0%, 100.0%)	357.6/357.6 = 100.0% (100.0%, 100.0%)	357.6/357.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	80	0/4055.1 = 0.0% (0.0%, 0.0%)	0/4055.1 = 0.0% (0.0%, 0.0%)	0/4055.1 = 0.0% (0.0%, 0.0%)
At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	80	0/4055.1 = 0.0% (0.0%, 0.0%)	0/4055.1 = 0.0% (0.0%, 0.0%)	0/4055.1 = 0.0% (0.0%, 0.0%)
At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	80	0/4055.1 = 0.0% (0.0%, 0.0%)	0/4055.1 = 0.0% (0.0%, 0.0%)	0/4055.1 = 0.0% (0.0%, 0.0%)
At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	130	322/322 = 100.0% (100.0%, 100.0%)	322/322 = 100.0% (100.0%, 100.0%)	322/322 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	130	322/322 = 100.0% (100.0%, 100.0%)	322/322 = 100.0% (100.0%, 100.0%)	322/322 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	130	322/322 = 100.0% (100.0%, 100.0%)	322/322 = 100.0% (100.0%, 100.0%)	322/322 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	445	9659.1/9659.1 = 100.0% (100.0%, 100.0%)	9659.1/9659.1 = 100.0% (100.0%, 100.0%)	9612.2/9659.1 = 99.5% (96.6%, 99.9%)
Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	445	9659.1/9659.1 = 100.0% (100.0%, 100.0%)	9659.1/9659.1 = 100.0% (100.0%, 100.0%)	9659.1/9659.1 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	445	9659.1/9659.1 = 100.0% (100.0%, 100.0%)	9659.1/9659.1 = 100.0% (100.0%, 100.0%)	9659.1/9659.1 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	149	1041.4/1041.4 = 100.0% (100.0%, 100.0%)	1041.4/1041.4 = 100.0% (100.0%, 100.0%)	1041.4/1041.4 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	149	1041.4/1041.4 = 100.0% (100.0%, 100.0%)	1041.4/1041.4 = 100.0% (100.0%, 100.0%)	1041.4/1041.4 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	149	1041.4/1041.4 = 100.0% (100.0%, 100.0%)	1041.4/1041.4 = 100.0% (100.0%, 100.0%)	1041.4/1041.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	75	0/9325.9 = 0.0% (0.0%, 0.0%)	0/9325.9 = 0.0% (0.0%, 0.0%)	0/9325.9 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	75	0/9325.9 = 0.0% (0.0%, 0.0%)	0/9325.9 = 0.0% (0.0%, 0.0%)	0/9325.9 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	75	0/9325.9 = 0.0% (0.0%, 0.0%)	0/9325.9 = 0.0% (0.0%, 0.0%)	0/9325.9 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	146	954/954 = 100.0% (100.0%, 100.0%)	954/954 = 100.0% (100.0%, 100.0%)	954/954 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	146	954/954 = 100.0% (100.0%, 100.0%)	954/954 = 100.0% (100.0%, 100.0%)	954/954 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	146	954/954 = 100.0% (100.0%, 100.0%)	954/954 = 100.0% (100.0%, 100.0%)	954/954 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	445	9659.1/9659.1 = 100.0% (100.0%, 100.0%)	9659.1/9659.1 = 100.0% (100.0%, 100.0%)	9659.1/9659.1 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	445	9659.1/9659.1 = 100.0% (100.0%, 100.0%)	9659.1/9659.1 = 100.0% (100.0%, 100.0%)	9659.1/9659.1 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	445	9659.1/9659.1 = 100.0% (100.0%, 100.0%)	9659.1/9659.1 = 100.0% (100.0%, 100.0%)	9659.1/9659.1 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	149	1041.4/1041.4 = 100.0% (100.0%, 100.0%)	1041.4/1041.4 = 100.0% (100.0%, 100.0%)	1041.4/1041.4 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	149	1041.4/1041.4 = 100.0% (100.0%, 100.0%)	1041.4/1041.4 = 100.0% (100.0%, 100.0%)	1041.4/1041.4 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	149	1041.4/1041.4 = 100.0% (100.0%, 100.0%)	1041.4/1041.4 = 100.0% (100.0%, 100.0%)	1041.4/1041.4 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	75	0/9325.9 = 0.0% (0.0%, 0.0%)	0/9325.9 = 0.0% (0.0%, 0.0%)	0/9325.9 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	75	0/9325.9 = 0.0% (0.0%, 0.0%)	0/9325.9 = 0.0% (0.0%, 0.0%)	0/9325.9 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	75	0/9325.9 = 0.0% (0.0%, 0.0%)	0/9325.9 = 0.0% (0.0%, 0.0%)	0/9325.9 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	146	954/954 = 100.0% (100.0%, 100.0%)	954/954 = 100.0% (100.0%, 100.0%)	954/954 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	146	954/954 = 100.0% (100.0%, 100.0%)	954/954 = 100.0% (100.0%, 100.0%)	954/954 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	146	954/954 = 100.0% (100.0%, 100.0%)	954/954 = 100.0% (100.0%, 100.0%)	954/954 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3d. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Age, Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Age, Risk for Severe Covid-19								
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	220	2180/2180 = 100.0% (100.0%, 100.0%)	2180/2180 = 100.0% (100.0%, 100.0%)	2180/2180 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	220	2180/2180 = 100.0% (100.0%, 100.0%)	2180/2180 = 100.0% (100.0%, 100.0%)	2180/2180 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	220	2180/2180 = 100.0% (100.0%, 100.0%)	2180/2180 = 100.0% (100.0%, 100.0%)	2180/2180 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	70	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	70	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	70	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	39	0/2402 = 0.0% (0.0%, 0.0%)	0/2402 = 0.0% (0.0%, 0.0%)	0/2402 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0/2402 = 0.0% (0.0%, 0.0%)	0/2402 = 0.0% (0.0%, 0.0%)	0/2402 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	39	0/2402 = 0.0% (0.0%, 0.0%)	0/2402 = 0.0% (0.0%, 0.0%)	0/2402 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	75	214/214 = 100.0% (100.0%, 100.0%)	214/214 = 100.0% (100.0%, 100.0%)	214/214 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	75	214/214 = 100.0% (100.0%, 100.0%)	214/214 = 100.0% (100.0%, 100.0%)	214/214 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	75	214/214 = 100.0% (100.0%, 100.0%)	214/214 = 100.0% (100.0%, 100.0%)	214/214 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	220	2180/2180 = 100.0% (100.0%, 100.0%)	2180/2180 = 100.0% (100.0%, 100.0%)	2180/2180 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	220	2180/2180 = 100.0% (100.0%, 100.0%)	2180/2180 = 100.0% (100.0%, 100.0%)	2180/2180 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	220	2180/2180 = 100.0% (100.0%, 100.0%)	2180/2180 = 100.0% (100.0%, 100.0%)	2180/2180 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	70	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	70	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	70	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	39	0/2402 = 0.0% (0.0%, 0.0%)	0/2402 = 0.0% (0.0%, 0.0%)	0/2402 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0/2402 = 0.0% (0.0%, 0.0%)	0/2402 = 0.0% (0.0%, 0.0%)	0/2402 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	39	0/2402 = 0.0% (0.0%, 0.0%)	0/2402 = 0.0% (0.0%, 0.0%)	0/2402 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	75	214/214 = 100.0% (100.0%, 100.0%)	214/214 = 100.0% (100.0%, 100.0%)	214/214 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	75	214/214 = 100.0% (100.0%, 100.0%)	214/214 = 100.0% (100.0%, 100.0%)	214/214 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	75	214/214 = 100.0% (100.0%, 100.0%)	214/214 = 100.0% (100.0%, 100.0%)	214/214 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	219	8284/8284 = 100.0% (100.0%, 100.0%)	8284/8284 = 100.0% (100.0%, 100.0%)	8237.2/8284 = 99.4% (96.0%, 99.9%)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	219	8284/8284 = 100.0% (100.0%, 100.0%)	8284/8284 = 100.0% (100.0%, 100.0%)	8284/8284 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	219	8284/8284 = 100.0% (100.0%, 100.0%)	8284/8284 = 100.0% (100.0%, 100.0%)	8284/8284 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	76	882/882 = 100.0% (100.0%, 100.0%)	882/882 = 100.0% (100.0%, 100.0%)	882/882 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	882/882 = 100.0% (100.0%, 100.0%)	882/882 = 100.0% (100.0%, 100.0%)	882/882 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	882/882 = 100.0% (100.0%, 100.0%)	882/882 = 100.0% (100.0%, 100.0%)	882/882 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	38	0/7831 = 0.0% (0.0%, 0.0%)	0/7831 = 0.0% (0.0%, 0.0%)	0/7831 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	38	0/7831 = 0.0% (0.0%, 0.0%)	0/7831 = 0.0% (0.0%, 0.0%)	0/7831 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	38	0/7831 = 0.0% (0.0%, 0.0%)	0/7831 = 0.0% (0.0%, 0.0%)	0/7831 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	73	813/813 = 100.0% (100.0%, 100.0%)	813/813 = 100.0% (100.0%, 100.0%)	813/813 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	73	813/813 = 100.0% (100.0%, 100.0%)	813/813 = 100.0% (100.0%, 100.0%)	813/813 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	73	813/813 = 100.0% (100.0%, 100.0%)	813/813 = 100.0% (100.0%, 100.0%)	813/813 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	219	8284/8284 = 100.0% (100.0%, 100.0%)	8284/8284 = 100.0% (100.0%, 100.0%)	8284/8284 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	219	8284/8284 = 100.0% (100.0%, 100.0%)	8284/8284 = 100.0% (100.0%, 100.0%)	8284/8284 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	219	8284/8284 = 100.0% (100.0%, 100.0%)	8284/8284 = 100.0% (100.0%, 100.0%)	8284/8284 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	76	882/882 = 100.0% (100.0%, 100.0%)	882/882 = 100.0% (100.0%, 100.0%)	882/882 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	882/882 = 100.0% (100.0%, 100.0%)	882/882 = 100.0% (100.0%, 100.0%)	882/882 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	882/882 = 100.0% (100.0%, 100.0%)	882/882 = 100.0% (100.0%, 100.0%)	882/882 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	38	0/7831 = 0.0% (0.0%, 0.0%)	0/7831 = 0.0% (0.0%, 0.0%)	0/7831 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	38	0/7831 = 0.0% (0.0%, 0.0%)	0/7831 = 0.0% (0.0%, 0.0%)	0/7831 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	38	0/7831 = 0.0% (0.0%, 0.0%)	0/7831 = 0.0% (0.0%, 0.0%)	0/7831 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	73	813/813 = 100.0% (100.0%, 100.0%)	813/813 = 100.0% (100.0%, 100.0%)	813/813 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	73	813/813 = 100.0% (100.0%, 100.0%)	813/813 = 100.0% (100.0%, 100.0%)	813/813 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	73	813/813 = 100.0% (100.0%, 100.0%)	813/813 = 100.0% (100.0%, 100.0%)	813/813 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	250	1457.9/1457.9 = 100.0% (100.0%, 100.0%)	1457.9/1457.9 = 100.0% (100.0%, 100.0%)	1457.9/1457.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	250	1457.9/1457.9 = 100.0% (100.0%, 100.0%)	1457.9/1457.9 = 100.0% (100.0%, 100.0%)	1457.9/1457.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	250	1457.9/1457.9 = 100.0% (100.0%, 100.0%)	1457.9/1457.9 = 100.0% (100.0%, 100.0%)	1457.9/1457.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	50	109.6/109.6 = 100.0% (100.0%, 100.0%)	109.6/109.6 = 100.0% (100.0%, 100.0%)	109.6/109.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	109.6/109.6 = 100.0% (100.0%, 100.0%)	109.6/109.6 = 100.0% (100.0%, 100.0%)	109.6/109.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	109.6/109.6 = 100.0% (100.0%, 100.0%)	109.6/109.6 = 100.0% (100.0%, 100.0%)	109.6/109.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	41	0/1653.1 = 0.0% (0.0%, 0.0%)	0/1653.1 = 0.0% (0.0%, 0.0%)	0/1653.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	41	0/1653.1 = 0.0% (0.0%, 0.0%)	0/1653.1 = 0.0% (0.0%, 0.0%)	0/1653.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	41	0/1653.1 = 0.0% (0.0%, 0.0%)	0/1653.1 = 0.0% (0.0%, 0.0%)	0/1653.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	55	108/108 = 100.0% (100.0%, 100.0%)	108/108 = 100.0% (100.0%, 100.0%)	108/108 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	55	108/108 = 100.0% (100.0%, 100.0%)	108/108 = 100.0% (100.0%, 100.0%)	108/108 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	55	108/108 = 100.0% (100.0%, 100.0%)	108/108 = 100.0% (100.0%, 100.0%)	108/108 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	250	1457.9/1457.9 = 100.0% (100.0%, 100.0%)	1457.9/1457.9 = 100.0% (100.0%, 100.0%)	1457.9/1457.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	250	1457.9/1457.9 = 100.0% (100.0%, 100.0%)	1457.9/1457.9 = 100.0% (100.0%, 100.0%)	1457.9/1457.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	250	1457.9/1457.9 = 100.0% (100.0%, 100.0%)	1457.9/1457.9 = 100.0% (100.0%, 100.0%)	1457.9/1457.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	50	109.6/109.6 = 100.0% (100.0%, 100.0%)	109.6/109.6 = 100.0% (100.0%, 100.0%)	109.6/109.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	109.6/109.6 = 100.0% (100.0%, 100.0%)	109.6/109.6 = 100.0% (100.0%, 100.0%)	109.6/109.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	109.6/109.6 = 100.0% (100.0%, 100.0%)	109.6/109.6 = 100.0% (100.0%, 100.0%)	109.6/109.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	41	0/1653.1 = 0.0% (0.0%, 0.0%)	0/1653.1 = 0.0% (0.0%, 0.0%)	0/1653.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	41	0/1653.1 = 0.0% (0.0%, 0.0%)	0/1653.1 = 0.0% (0.0%, 0.0%)	0/1653.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	41	0/1653.1 = 0.0% (0.0%, 0.0%)	0/1653.1 = 0.0% (0.0%, 0.0%)	0/1653.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	55	108/108 = 100.0% (100.0%, 100.0%)	108/108 = 100.0% (100.0%, 100.0%)	108/108 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	55	108/108 = 100.0% (100.0%, 100.0%)	108/108 = 100.0% (100.0%, 100.0%)	108/108 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	55	108/108 = 100.0% (100.0%, 100.0%)	108/108 = 100.0% (100.0%, 100.0%)	108/108 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	226	1375.1/1375.1 = 100.0% (100.0%, 100.0%)	1375.1/1375.1 = 100.0% (100.0%, 100.0%)	1375.1/1375.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	226	1375.1/1375.1 = 100.0% (100.0%, 100.0%)	1375.1/1375.1 = 100.0% (100.0%, 100.0%)	1375.1/1375.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	226	1375.1/1375.1 = 100.0% (100.0%, 100.0%)	1375.1/1375.1 = 100.0% (100.0%, 100.0%)	1375.1/1375.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	73	159.4/159.4 = 100.0% (100.0%, 100.0%)	159.4/159.4 = 100.0% (100.0%, 100.0%)	159.4/159.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	159.4/159.4 = 100.0% (100.0%, 100.0%)	159.4/159.4 = 100.0% (100.0%, 100.0%)	159.4/159.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	159.4/159.4 = 100.0% (100.0%, 100.0%)	159.4/159.4 = 100.0% (100.0%, 100.0%)	159.4/159.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	37	0/1494.9 = 0.0% (0.0%, 0.0%)	0/1494.9 = 0.0% (0.0%, 0.0%)	0/1494.9 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0/1494.9 = 0.0% (0.0%, 0.0%)	0/1494.9 = 0.0% (0.0%, 0.0%)	0/1494.9 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0/1494.9 = 0.0% (0.0%, 0.0%)	0/1494.9 = 0.0% (0.0%, 0.0%)	0/1494.9 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	73	141/141 = 100.0% (100.0%, 100.0%)	141/141 = 100.0% (100.0%, 100.0%)	141/141 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	73	141/141 = 100.0% (100.0%, 100.0%)	141/141 = 100.0% (100.0%, 100.0%)	141/141 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	73	141/141 = 100.0% (100.0%, 100.0%)	141/141 = 100.0% (100.0%, 100.0%)	141/141 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	226	1375.1/1375.1 = 100.0% (100.0%, 100.0%)	1375.1/1375.1 = 100.0% (100.0%, 100.0%)	1375.1/1375.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	226	1375.1/1375.1 = 100.0% (100.0%, 100.0%)	1375.1/1375.1 = 100.0% (100.0%, 100.0%)	1375.1/1375.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	226	1375.1/1375.1 = 100.0% (100.0%, 100.0%)	1375.1/1375.1 = 100.0% (100.0%, 100.0%)	1375.1/1375.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	73	159.4/159.4 = 100.0% (100.0%, 100.0%)	159.4/159.4 = 100.0% (100.0%, 100.0%)	159.4/159.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	159.4/159.4 = 100.0% (100.0%, 100.0%)	159.4/159.4 = 100.0% (100.0%, 100.0%)	159.4/159.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	159.4/159.4 = 100.0% (100.0%, 100.0%)	159.4/159.4 = 100.0% (100.0%, 100.0%)	159.4/159.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	37	0/1494.9 = 0.0% (0.0%, 0.0%)	0/1494.9 = 0.0% (0.0%, 0.0%)	0/1494.9 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0/1494.9 = 0.0% (0.0%, 0.0%)	0/1494.9 = 0.0% (0.0%, 0.0%)	0/1494.9 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0/1494.9 = 0.0% (0.0%, 0.0%)	0/1494.9 = 0.0% (0.0%, 0.0%)	0/1494.9 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	73	141/141 = 100.0% (100.0%, 100.0%)	141/141 = 100.0% (100.0%, 100.0%)	141/141 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	73	141/141 = 100.0% (100.0%, 100.0%)	141/141 = 100.0% (100.0%, 100.0%)	141/141 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	73	141/141 = 100.0% (100.0%, 100.0%)	141/141 = 100.0% (100.0%, 100.0%)	141/141 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3e. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Sex								
Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	391	5205.7/5205.7 = 100.0% (100.0%, 100.0%)	5205.7/5205.7 = 100.0% (100.0%, 100.0%)	5158.8/5205.7 = 99.1% (93.9%, 99.9%)
Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	391	5205.7/5205.7 = 100.0% (100.0%, 100.0%)	5205.7/5205.7 = 100.0% (100.0%, 100.0%)	5205.7/5205.7 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	391	5205.7/5205.7 = 100.0% (100.0%, 100.0%)	5205.7/5205.7 = 100.0% (100.0%, 100.0%)	5205.7/5205.7 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	113	549/549 = 100.0% (100.0%, 100.0%)	549/549 = 100.0% (100.0%, 100.0%)	549/549 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	113	549/549 = 100.0% (100.0%, 100.0%)	549/549 = 100.0% (100.0%, 100.0%)	549/549 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	113	549/549 = 100.0% (100.0%, 100.0%)	549/549 = 100.0% (100.0%, 100.0%)	549/549 = 100.0% (100.0%, 100.0%)
Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	60	0/4873.5 = 0.0% (0.0%, 0.0%)	0/4873.5 = 0.0% (0.0%, 0.0%)	0/4873.5 = 0.0% (0.0%, 0.0%)
Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	60	0/4873.5 = 0.0% (0.0%, 0.0%)	0/4873.5 = 0.0% (0.0%, 0.0%)	0/4873.5 = 0.0% (0.0%, 0.0%)
Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	60	0/4873.5 = 0.0% (0.0%, 0.0%)	0/4873.5 = 0.0% (0.0%, 0.0%)	0/4873.5 = 0.0% (0.0%, 0.0%)
Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	122	527.7/527.7 = 100.0% (100.0%, 100.0%)	527.7/527.7 = 100.0% (100.0%, 100.0%)	527.7/527.7 = 100.0% (100.0%, 100.0%)
Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	122	527.7/527.7 = 100.0% (100.0%, 100.0%)	527.7/527.7 = 100.0% (100.0%, 100.0%)	527.7/527.7 = 100.0% (100.0%, 100.0%)
Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	122	527.7/527.7 = 100.0% (100.0%, 100.0%)	527.7/527.7 = 100.0% (100.0%, 100.0%)	527.7/527.7 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	391	5205.7/5205.7 = 100.0% (100.0%, 100.0%)	5205.7/5205.7 = 100.0% (100.0%, 100.0%)	5205.7/5205.7 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	391	5205.7/5205.7 = 100.0% (100.0%, 100.0%)	5205.7/5205.7 = 100.0% (100.0%, 100.0%)	5205.7/5205.7 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	391	5205.7/5205.7 = 100.0% (100.0%, 100.0%)	5205.7/5205.7 = 100.0% (100.0%, 100.0%)	5205.7/5205.7 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	113	549/549 = 100.0% (100.0%, 100.0%)	549/549 = 100.0% (100.0%, 100.0%)	549/549 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	113	549/549 = 100.0% (100.0%, 100.0%)	549/549 = 100.0% (100.0%, 100.0%)	549/549 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	113	549/549 = 100.0% (100.0%, 100.0%)	549/549 = 100.0% (100.0%, 100.0%)	549/549 = 100.0% (100.0%, 100.0%)
Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	60	0/4873.5 = 0.0% (0.0%, 0.0%)	0/4873.5 = 0.0% (0.0%, 0.0%)	0/4873.5 = 0.0% (0.0%, 0.0%)
Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	60	0/4873.5 = 0.0% (0.0%, 0.0%)	0/4873.5 = 0.0% (0.0%, 0.0%)	0/4873.5 = 0.0% (0.0%, 0.0%)
Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	60	0/4873.5 = 0.0% (0.0%, 0.0%)	0/4873.5 = 0.0% (0.0%, 0.0%)	0/4873.5 = 0.0% (0.0%, 0.0%)
Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	122	527.7/527.7 = 100.0% (100.0%, 100.0%)	527.7/527.7 = 100.0% (100.0%, 100.0%)	527.7/527.7 = 100.0% (100.0%, 100.0%)
Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	122	527.7/527.7 = 100.0% (100.0%, 100.0%)	527.7/527.7 = 100.0% (100.0%, 100.0%)	527.7/527.7 = 100.0% (100.0%, 100.0%)
Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	122	527.7/527.7 = 100.0% (100.0%, 100.0%)	527.7/527.7 = 100.0% (100.0%, 100.0%)	527.7/527.7 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	524	8091.3/8091.3 = 100.0% (100.0%, 100.0%)	8091.3/8091.3 = 100.0% (100.0%, 100.0%)	8091.3/8091.3 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	524	8091.3/8091.3 = 100.0% (100.0%, 100.0%)	8091.3/8091.3 = 100.0% (100.0%, 100.0%)	8091.3/8091.3 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	524	8091.3/8091.3 = 100.0% (100.0%, 100.0%)	8091.3/8091.3 = 100.0% (100.0%, 100.0%)	8091.3/8091.3 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	156	850/850 = 100.0% (100.0%, 100.0%)	850/850 = 100.0% (100.0%, 100.0%)	850/850 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	156	850/850 = 100.0% (100.0%, 100.0%)	850/850 = 100.0% (100.0%, 100.0%)	850/850 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	156	850/850 = 100.0% (100.0%, 100.0%)	850/850 = 100.0% (100.0%, 100.0%)	850/850 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	95	0/8507.5 = 0.0% (0.0%, 0.0%)	0/8507.5 = 0.0% (0.0%, 0.0%)	0/8507.5 = 0.0% (0.0%, 0.0%)
Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	95	0/8507.5 = 0.0% (0.0%, 0.0%)	0/8507.5 = 0.0% (0.0%, 0.0%)	0/8507.5 = 0.0% (0.0%, 0.0%)
Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	95	0/8507.5 = 0.0% (0.0%, 0.0%)	0/8507.5 = 0.0% (0.0%, 0.0%)	0/8507.5 = 0.0% (0.0%, 0.0%)
Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	154	748.3/748.3 = 100.0% (100.0%, 100.0%)	748.3/748.3 = 100.0% (100.0%, 100.0%)	748.3/748.3 = 100.0% (100.0%, 100.0%)
Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	154	748.3/748.3 = 100.0% (100.0%, 100.0%)	748.3/748.3 = 100.0% (100.0%, 100.0%)	748.3/748.3 = 100.0% (100.0%, 100.0%)
Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	154	748.3/748.3 = 100.0% (100.0%, 100.0%)	748.3/748.3 = 100.0% (100.0%, 100.0%)	748.3/748.3 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	524	8091.3/8091.3 = 100.0% (100.0%, 100.0%)	8091.3/8091.3 = 100.0% (100.0%, 100.0%)	8091.3/8091.3 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	524	8091.3/8091.3 = 100.0% (100.0%, 100.0%)	8091.3/8091.3 = 100.0% (100.0%, 100.0%)	8091.3/8091.3 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	524	8091.3/8091.3 = 100.0% (100.0%, 100.0%)	8091.3/8091.3 = 100.0% (100.0%, 100.0%)	8091.3/8091.3 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	156	850/850 = 100.0% (100.0%, 100.0%)	850/850 = 100.0% (100.0%, 100.0%)	850/850 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	156	850/850 = 100.0% (100.0%, 100.0%)	850/850 = 100.0% (100.0%, 100.0%)	850/850 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	156	850/850 = 100.0% (100.0%, 100.0%)	850/850 = 100.0% (100.0%, 100.0%)	850/850 = 100.0% (100.0%, 100.0%)
Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	95	0/8507.5 = 0.0% (0.0%, 0.0%)	0/8507.5 = 0.0% (0.0%, 0.0%)	0/8507.5 = 0.0% (0.0%, 0.0%)
Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	95	0/8507.5 = 0.0% (0.0%, 0.0%)	0/8507.5 = 0.0% (0.0%, 0.0%)	0/8507.5 = 0.0% (0.0%, 0.0%)
Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	95	0/8507.5 = 0.0% (0.0%, 0.0%)	0/8507.5 = 0.0% (0.0%, 0.0%)	0/8507.5 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	154	748.3/748.3 = 100.0% (100.0%, 100.0%)	748.3/748.3 = 100.0% (100.0%, 100.0%)	748.3/748.3 = 100.0% (100.0%, 100.0%)
Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	154	748.3/748.3 = 100.0% (100.0%, 100.0%)	748.3/748.3 = 100.0% (100.0%, 100.0%)	748.3/748.3 = 100.0% (100.0%, 100.0%)
Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	154	748.3/748.3 = 100.0% (100.0%, 100.0%)	748.3/748.3 = 100.0% (100.0%, 100.0%)	748.3/748.3 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3f. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Age, sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Age, sex								
Age < 65 Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	266	6555.3/6555.3 = 100.0% (100.0%, 100.0%)	6555.3/6555.3 = 100.0% (100.0%, 100.0%)	6555.3/6555.3 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	266	6555.3/6555.3 = 100.0% (100.0%, 100.0%)	6555.3/6555.3 = 100.0% (100.0%, 100.0%)	6555.3/6555.3 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	266	6555.3/6555.3 = 100.0% (100.0%, 100.0%)	6555.3/6555.3 = 100.0% (100.0%, 100.0%)	6555.3/6555.3 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	90	709.9/709.9 = 100.0% (100.0%, 100.0%)	709.9/709.9 = 100.0% (100.0%, 100.0%)	709.9/709.9 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	90	709.9/709.9 = 100.0% (100.0%, 100.0%)	709.9/709.9 = 100.0% (100.0%, 100.0%)	709.9/709.9 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	90	709.9/709.9 = 100.0% (100.0%, 100.0%)	709.9/709.9 = 100.0% (100.0%, 100.0%)	709.9/709.9 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	50	0/6717.4 = 0.0% (0.0%, 0.0%)	0/6717.4 = 0.0% (0.0%, 0.0%)	0/6717.4 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	50	0/6717.4 = 0.0% (0.0%, 0.0%)	0/6717.4 = 0.0% (0.0%, 0.0%)	0/6717.4 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	50	0/6717.4 = 0.0% (0.0%, 0.0%)	0/6717.4 = 0.0% (0.0%, 0.0%)	0/6717.4 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	85	613.4/613.4 = 100.0% (100.0%, 100.0%)	613.4/613.4 = 100.0% (100.0%, 100.0%)	613.4/613.4 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	85	613.4/613.4 = 100.0% (100.0%, 100.0%)	613.4/613.4 = 100.0% (100.0%, 100.0%)	613.4/613.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	85	613.4/613.4 = 100.0% (100.0%, 100.0%)	613.4/613.4 = 100.0% (100.0%, 100.0%)	613.4/613.4 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	266	6555.3/6555.3 = 100.0% (100.0%, 100.0%)	6555.3/6555.3 = 100.0% (100.0%, 100.0%)	6555.3/6555.3 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	266	6555.3/6555.3 = 100.0% (100.0%, 100.0%)	6555.3/6555.3 = 100.0% (100.0%, 100.0%)	6555.3/6555.3 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	266	6555.3/6555.3 = 100.0% (100.0%, 100.0%)	6555.3/6555.3 = 100.0% (100.0%, 100.0%)	6555.3/6555.3 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	90	709.9/709.9 = 100.0% (100.0%, 100.0%)	709.9/709.9 = 100.0% (100.0%, 100.0%)	709.9/709.9 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	90	709.9/709.9 = 100.0% (100.0%, 100.0%)	709.9/709.9 = 100.0% (100.0%, 100.0%)	709.9/709.9 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	90	709.9/709.9 = 100.0% (100.0%, 100.0%)	709.9/709.9 = 100.0% (100.0%, 100.0%)	709.9/709.9 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	50	0/6717.4 = 0.0% (0.0%, 0.0%)	0/6717.4 = 0.0% (0.0%, 0.0%)	0/6717.4 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	50	0/6717.4 = 0.0% (0.0%, 0.0%)	0/6717.4 = 0.0% (0.0%, 0.0%)	0/6717.4 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	50	0/6717.4 = 0.0% (0.0%, 0.0%)	0/6717.4 = 0.0% (0.0%, 0.0%)	0/6717.4 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	85	613.4/613.4 = 100.0% (100.0%, 100.0%)	613.4/613.4 = 100.0% (100.0%, 100.0%)	613.4/613.4 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	85	613.4/613.4 = 100.0% (100.0%, 100.0%)	613.4/613.4 = 100.0% (100.0%, 100.0%)	613.4/613.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	85	613.4/613.4 = 100.0% (100.0%, 100.0%)	613.4/613.4 = 100.0% (100.0%, 100.0%)	613.4/613.4 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	173	3908.7/3908.7 = 100.0% (100.0%, 100.0%)	3908.7/3908.7 = 100.0% (100.0%, 100.0%)	3861.8/3908.7 = 98.8% (91.9%, 99.8%)
Age < 65 Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	173	3908.7/3908.7 = 100.0% (100.0%, 100.0%)	3908.7/3908.7 = 100.0% (100.0%, 100.0%)	3908.7/3908.7 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	173	3908.7/3908.7 = 100.0% (100.0%, 100.0%)	3908.7/3908.7 = 100.0% (100.0%, 100.0%)	3908.7/3908.7 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	56	420.1/420.1 = 100.0% (100.0%, 100.0%)	420.1/420.1 = 100.0% (100.0%, 100.0%)	420.1/420.1 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	56	420.1/420.1 = 100.0% (100.0%, 100.0%)	420.1/420.1 = 100.0% (100.0%, 100.0%)	420.1/420.1 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	56	420.1/420.1 = 100.0% (100.0%, 100.0%)	420.1/420.1 = 100.0% (100.0%, 100.0%)	420.1/420.1 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	27	0/3515.6 = 0.0% (0.0%, 0.0%)	0/3515.6 = 0.0% (0.0%, 0.0%)	0/3515.6 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	27	0/3515.6 = 0.0% (0.0%, 0.0%)	0/3515.6 = 0.0% (0.0%, 0.0%)	0/3515.6 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	27	0/3515.6 = 0.0% (0.0%, 0.0%)	0/3515.6 = 0.0% (0.0%, 0.0%)	0/3515.6 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	63	413.6/413.6 = 100.0% (100.0%, 100.0%)	413.6/413.6 = 100.0% (100.0%, 100.0%)	413.6/413.6 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	63	413.6/413.6 = 100.0% (100.0%, 100.0%)	413.6/413.6 = 100.0% (100.0%, 100.0%)	413.6/413.6 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	63	413.6/413.6 = 100.0% (100.0%, 100.0%)	413.6/413.6 = 100.0% (100.0%, 100.0%)	413.6/413.6 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	173	3908.7/3908.7 = 100.0% (100.0%, 100.0%)	3908.7/3908.7 = 100.0% (100.0%, 100.0%)	3908.7/3908.7 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	173	3908.7/3908.7 = 100.0% (100.0%, 100.0%)	3908.7/3908.7 = 100.0% (100.0%, 100.0%)	3908.7/3908.7 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	173	3908.7/3908.7 = 100.0% (100.0%, 100.0%)	3908.7/3908.7 = 100.0% (100.0%, 100.0%)	3908.7/3908.7 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	56	420.1/420.1 = 100.0% (100.0%, 100.0%)	420.1/420.1 = 100.0% (100.0%, 100.0%)	420.1/420.1 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	56	420.1/420.1 = 100.0% (100.0%, 100.0%)	420.1/420.1 = 100.0% (100.0%, 100.0%)	420.1/420.1 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	56	420.1/420.1 = 100.0% (100.0%, 100.0%)	420.1/420.1 = 100.0% (100.0%, 100.0%)	420.1/420.1 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	27	0/3515.6 = 0.0% (0.0%, 0.0%)	0/3515.6 = 0.0% (0.0%, 0.0%)	0/3515.6 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	27	0/3515.6 = 0.0% (0.0%, 0.0%)	0/3515.6 = 0.0% (0.0%, 0.0%)	0/3515.6 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	27	0/3515.6 = 0.0% (0.0%, 0.0%)	0/3515.6 = 0.0% (0.0%, 0.0%)	0/3515.6 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	63	413.6/413.6 = 100.0% (100.0%, 100.0%)	413.6/413.6 = 100.0% (100.0%, 100.0%)	413.6/413.6 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	63	413.6/413.6 = 100.0% (100.0%, 100.0%)	413.6/413.6 = 100.0% (100.0%, 100.0%)	413.6/413.6 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	63	413.6/413.6 = 100.0% (100.0%, 100.0%)	413.6/413.6 = 100.0% (100.0%, 100.0%)	413.6/413.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	218	1297/1297 = 100.0% (100.0%, 100.0%)	1297/1297 = 100.0% (100.0%, 100.0%)	1297/1297 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	1297/1297 = 100.0% (100.0%, 100.0%)	1297/1297 = 100.0% (100.0%, 100.0%)	1297/1297 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	1297/1297 = 100.0% (100.0%, 100.0%)	1297/1297 = 100.0% (100.0%, 100.0%)	1297/1297 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	57	128.9/128.9 = 100.0% (100.0%, 100.0%)	128.9/128.9 = 100.0% (100.0%, 100.0%)	128.9/128.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	57	128.9/128.9 = 100.0% (100.0%, 100.0%)	128.9/128.9 = 100.0% (100.0%, 100.0%)	128.9/128.9 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	57	128.9/128.9 = 100.0% (100.0%, 100.0%)	128.9/128.9 = 100.0% (100.0%, 100.0%)	128.9/128.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	33	0/1357.9 = 0.0% (0.0%, 0.0%)	0/1357.9 = 0.0% (0.0%, 0.0%)	0/1357.9 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0/1357.9 = 0.0% (0.0%, 0.0%)	0/1357.9 = 0.0% (0.0%, 0.0%)	0/1357.9 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0/1357.9 = 0.0% (0.0%, 0.0%)	0/1357.9 = 0.0% (0.0%, 0.0%)	0/1357.9 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	59	114.2/114.2 = 100.0% (100.0%, 100.0%)	114.2/114.2 = 100.0% (100.0%, 100.0%)	114.2/114.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	59	114.2/114.2 = 100.0% (100.0%, 100.0%)	114.2/114.2 = 100.0% (100.0%, 100.0%)	114.2/114.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	59	114.2/114.2 = 100.0% (100.0%, 100.0%)	114.2/114.2 = 100.0% (100.0%, 100.0%)	114.2/114.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	218	1297/1297 = 100.0% (100.0%, 100.0%)	1297/1297 = 100.0% (100.0%, 100.0%)	1297/1297 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	1297/1297 = 100.0% (100.0%, 100.0%)	1297/1297 = 100.0% (100.0%, 100.0%)	1297/1297 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	1297/1297 = 100.0% (100.0%, 100.0%)	1297/1297 = 100.0% (100.0%, 100.0%)	1297/1297 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	57	128.9/128.9 = 100.0% (100.0%, 100.0%)	128.9/128.9 = 100.0% (100.0%, 100.0%)	128.9/128.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	57	128.9/128.9 = 100.0% (100.0%, 100.0%)	128.9/128.9 = 100.0% (100.0%, 100.0%)	128.9/128.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	57	128.9/128.9 = 100.0% (100.0%, 100.0%)	128.9/128.9 = 100.0% (100.0%, 100.0%)	128.9/128.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	33	0/1357.9 = 0.0% (0.0%, 0.0%)	0/1357.9 = 0.0% (0.0%, 0.0%)	0/1357.9 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0/1357.9 = 0.0% (0.0%, 0.0%)	0/1357.9 = 0.0% (0.0%, 0.0%)	0/1357.9 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0/1357.9 = 0.0% (0.0%, 0.0%)	0/1357.9 = 0.0% (0.0%, 0.0%)	0/1357.9 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	59	114.2/114.2 = 100.0% (100.0%, 100.0%)	114.2/114.2 = 100.0% (100.0%, 100.0%)	114.2/114.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	59	114.2/114.2 = 100.0% (100.0%, 100.0%)	114.2/114.2 = 100.0% (100.0%, 100.0%)	114.2/114.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	59	114.2/114.2 = 100.0% (100.0%, 100.0%)	114.2/114.2 = 100.0% (100.0%, 100.0%)	114.2/114.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	258	1536/1536 = 100.0% (100.0%, 100.0%)	1536/1536 = 100.0% (100.0%, 100.0%)	1536/1536 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	258	1536/1536 = 100.0% (100.0%, 100.0%)	1536/1536 = 100.0% (100.0%, 100.0%)	1536/1536 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	258	1536/1536 = 100.0% (100.0%, 100.0%)	1536/1536 = 100.0% (100.0%, 100.0%)	1536/1536 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	66	140.1/140.1 = 100.0% (100.0%, 100.0%)	140.1/140.1 = 100.0% (100.0%, 100.0%)	140.1/140.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	66	140.1/140.1 = 100.0% (100.0%, 100.0%)	140.1/140.1 = 100.0% (100.0%, 100.0%)	140.1/140.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	66	140.1/140.1 = 100.0% (100.0%, 100.0%)	140.1/140.1 = 100.0% (100.0%, 100.0%)	140.1/140.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	45	0/1790.1 = 0.0% (0.0%, 0.0%)	0/1790.1 = 0.0% (0.0%, 0.0%)	0/1790.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	45	0/1790.1 = 0.0% (0.0%, 0.0%)	0/1790.1 = 0.0% (0.0%, 0.0%)	0/1790.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	45	0/1790.1 = 0.0% (0.0%, 0.0%)	0/1790.1 = 0.0% (0.0%, 0.0%)	0/1790.1 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	69	134.8/134.8 = 100.0% (100.0%, 100.0%)	134.8/134.8 = 100.0% (100.0%, 100.0%)	134.8/134.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	69	134.8/134.8 = 100.0% (100.0%, 100.0%)	134.8/134.8 = 100.0% (100.0%, 100.0%)	134.8/134.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	69	134.8/134.8 = 100.0% (100.0%, 100.0%)	134.8/134.8 = 100.0% (100.0%, 100.0%)	134.8/134.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	258	1536/1536 = 100.0% (100.0%, 100.0%)	1536/1536 = 100.0% (100.0%, 100.0%)	1536/1536 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	258	1536/1536 = 100.0% (100.0%, 100.0%)	1536/1536 = 100.0% (100.0%, 100.0%)	1536/1536 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	258	1536/1536 = 100.0% (100.0%, 100.0%)	1536/1536 = 100.0% (100.0%, 100.0%)	1536/1536 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	66	140.1/140.1 = 100.0% (100.0%, 100.0%)	140.1/140.1 = 100.0% (100.0%, 100.0%)	140.1/140.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	66	140.1/140.1 = 100.0% (100.0%, 100.0%)	140.1/140.1 = 100.0% (100.0%, 100.0%)	140.1/140.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	66	140.1/140.1 = 100.0% (100.0%, 100.0%)	140.1/140.1 = 100.0% (100.0%, 100.0%)	140.1/140.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	45	0/1790.1 = 0.0% (0.0%, 0.0%)	0/1790.1 = 0.0% (0.0%, 0.0%)	0/1790.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	45	0/1790.1 = 0.0% (0.0%, 0.0%)	0/1790.1 = 0.0% (0.0%, 0.0%)	0/1790.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	45	0/1790.1 = 0.0% (0.0%, 0.0%)	0/1790.1 = 0.0% (0.0%, 0.0%)	0/1790.1 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	69	134.8/134.8 = 100.0% (100.0%, 100.0%)	134.8/134.8 = 100.0% (100.0%, 100.0%)	134.8/134.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	69	134.8/134.8 = 100.0% (100.0%, 100.0%)	134.8/134.8 = 100.0% (100.0%, 100.0%)	134.8/134.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	69	134.8/134.8 = 100.0% (100.0%, 100.0%)	134.8/134.8 = 100.0% (100.0%, 100.0%)	134.8/134.8 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3g. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Hispanic or Latino ethnicity

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Hispanic or Latino ethnicity								
Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	130	1388.1/1388.1 = 100.0% (100.0%, 100.0%)	1388.1/1388.1 = 100.0% (100.0%, 100.0%)	1388.1/1388.1 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	130	1388.1/1388.1 = 100.0% (100.0%, 100.0%)	1388.1/1388.1 = 100.0% (100.0%, 100.0%)	1388.1/1388.1 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	130	1388.1/1388.1 = 100.0% (100.0%, 100.0%)	1388.1/1388.1 = 100.0% (100.0%, 100.0%)	1388.1/1388.1 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	34	129.4/129.4 = 100.0% (100.0%, 100.0%)	129.4/129.4 = 100.0% (100.0%, 100.0%)	129.4/129.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	34	129.4/129.4 = 100.0% (100.0%, 100.0%)	129.4/129.4 = 100.0% (100.0%, 100.0%)	129.4/129.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	34	129.4/129.4 = 100.0% (100.0%, 100.0%)	129.4/129.4 = 100.0% (100.0%, 100.0%)	129.4/129.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	22	0/1015.8 = 0.0% (0.0%, 0.0%)	0/1015.8 = 0.0% (0.0%, 0.0%)	0/1015.8 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	22	0/1015.8 = 0.0% (0.0%, 0.0%)	0/1015.8 = 0.0% (0.0%, 0.0%)	0/1015.8 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	22	0/1015.8 = 0.0% (0.0%, 0.0%)	0/1015.8 = 0.0% (0.0%, 0.0%)	0/1015.8 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	25	90.1/90.1 = 100.0% (100.0%, 100.0%)	90.1/90.1 = 100.0% (100.0%, 100.0%)	90.1/90.1 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	25	90.1/90.1 = 100.0% (100.0%, 100.0%)	90.1/90.1 = 100.0% (100.0%, 100.0%)	90.1/90.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	25	90.1/90.1 = 100.0% (100.0%, 100.0%)	90.1/90.1 = 100.0% (100.0%, 100.0%)	90.1/90.1 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	130	1388.1/1388.1 = 100.0% (100.0%, 100.0%)	1388.1/1388.1 = 100.0% (100.0%, 100.0%)	1388.1/1388.1 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	130	1388.1/1388.1 = 100.0% (100.0%, 100.0%)	1388.1/1388.1 = 100.0% (100.0%, 100.0%)	1388.1/1388.1 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	130	1388.1/1388.1 = 100.0% (100.0%, 100.0%)	1388.1/1388.1 = 100.0% (100.0%, 100.0%)	1388.1/1388.1 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	34	129.4/129.4 = 100.0% (100.0%, 100.0%)	129.4/129.4 = 100.0% (100.0%, 100.0%)	129.4/129.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	34	129.4/129.4 = 100.0% (100.0%, 100.0%)	129.4/129.4 = 100.0% (100.0%, 100.0%)	129.4/129.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	34	129.4/129.4 = 100.0% (100.0%, 100.0%)	129.4/129.4 = 100.0% (100.0%, 100.0%)	129.4/129.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	22	0/1015.8 = 0.0% (0.0%, 0.0%)	0/1015.8 = 0.0% (0.0%, 0.0%)	0/1015.8 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	22	0/1015.8 = 0.0% (0.0%, 0.0%)	0/1015.8 = 0.0% (0.0%, 0.0%)	0/1015.8 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	22	0/1015.8 = 0.0% (0.0%, 0.0%)	0/1015.8 = 0.0% (0.0%, 0.0%)	0/1015.8 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	25	90.1/90.1 = 100.0% (100.0%, 100.0%)	90.1/90.1 = 100.0% (100.0%, 100.0%)	90.1/90.1 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	25	90.1/90.1 = 100.0% (100.0%, 100.0%)	90.1/90.1 = 100.0% (100.0%, 100.0%)	90.1/90.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	25	90.1/90.1 = 100.0% (100.0%, 100.0%)	90.1/90.1 = 100.0% (100.0%, 100.0%)	90.1/90.1 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	690	10338.6/10338.6 = 100.0% (100.0%, 100.0%)	10338.6/10338.6 = 100.0% (100.0%, 100.0%)	10291.7/10338.6 = 99.5% (96.8%, 99.9%)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	690	10338.6/10338.6 = 100.0% (100.0%, 100.0%)	10338.6/10338.6 = 100.0% (100.0%, 100.0%)	10338.6/10338.6 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	690	10338.6/10338.6 = 100.0% (100.0%, 100.0%)	10338.6/10338.6 = 100.0% (100.0%, 100.0%)	10338.6/10338.6 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	197	1055.1/1055.1 = 100.0% (100.0%, 100.0%)	1055.1/1055.1 = 100.0% (100.0%, 100.0%)	1055.1/1055.1 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	197	1055.1/1055.1 = 100.0% (100.0%, 100.0%)	1055.1/1055.1 = 100.0% (100.0%, 100.0%)	1055.1/1055.1 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	197	1055.1/1055.1 = 100.0% (100.0%, 100.0%)	1055.1/1055.1 = 100.0% (100.0%, 100.0%)	1055.1/1055.1 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	118	0/10825.9 = 0.0% (0.0%, 0.0%)	0/10825.9 = 0.0% (0.0%, 0.0%)	0/10825.9 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	118	0/10825.9 = 0.0% (0.0%, 0.0%)	0/10825.9 = 0.0% (0.0%, 0.0%)	0/10825.9 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	118	0/10825.9 = 0.0% (0.0%, 0.0%)	0/10825.9 = 0.0% (0.0%, 0.0%)	0/10825.9 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	222	1063.5/1063.5 = 100.0% (100.0%, 100.0%)	1063.5/1063.5 = 100.0% (100.0%, 100.0%)	1063.5/1063.5 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	222	1063.5/1063.5 = 100.0% (100.0%, 100.0%)	1063.5/1063.5 = 100.0% (100.0%, 100.0%)	1063.5/1063.5 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	222	1063.5/1063.5 = 100.0% (100.0%, 100.0%)	1063.5/1063.5 = 100.0% (100.0%, 100.0%)	1063.5/1063.5 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	690	10338.6/10338.6 = 100.0% (100.0%, 100.0%)	10338.6/10338.6 = 100.0% (100.0%, 100.0%)	10338.6/10338.6 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	690	10338.6/10338.6 = 100.0% (100.0%, 100.0%)	10338.6/10338.6 = 100.0% (100.0%, 100.0%)	10338.6/10338.6 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	690	10338.6/10338.6 = 100.0% (100.0%, 100.0%)	10338.6/10338.6 = 100.0% (100.0%, 100.0%)	10338.6/10338.6 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	197	1055.1/1055.1 = 100.0% (100.0%, 100.0%)	1055.1/1055.1 = 100.0% (100.0%, 100.0%)	1055.1/1055.1 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	197	1055.1/1055.1 = 100.0% (100.0%, 100.0%)	1055.1/1055.1 = 100.0% (100.0%, 100.0%)	1055.1/1055.1 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	197	1055.1/1055.1 = 100.0% (100.0%, 100.0%)	1055.1/1055.1 = 100.0% (100.0%, 100.0%)	1055.1/1055.1 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	118	0/10825.9 = 0.0% (0.0%, 0.0%)	0/10825.9 = 0.0% (0.0%, 0.0%)	0/10825.9 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	118	0/10825.9 = 0.0% (0.0%, 0.0%)	0/10825.9 = 0.0% (0.0%, 0.0%)	0/10825.9 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	118	0/10825.9 = 0.0% (0.0%, 0.0%)	0/10825.9 = 0.0% (0.0%, 0.0%)	0/10825.9 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	222	1063.5/1063.5 = 100.0% (100.0%, 100.0%)	1063.5/1063.5 = 100.0% (100.0%, 100.0%)	1063.5/1063.5 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	222	1063.5/1063.5 = 100.0% (100.0%, 100.0%)	1063.5/1063.5 = 100.0% (100.0%, 100.0%)	1063.5/1063.5 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	222	1063.5/1063.5 = 100.0% (100.0%, 100.0%)	1063.5/1063.5 = 100.0% (100.0%, 100.0%)	1063.5/1063.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	95	1570.4/1570.4 = 100.0% (100.0%, 100.0%)	1570.4/1570.4 = 100.0% (100.0%, 100.0%)	1570.4/1570.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	95	1570.4/1570.4 = 100.0% (100.0%, 100.0%)	1570.4/1570.4 = 100.0% (100.0%, 100.0%)	1570.4/1570.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	95	1570.4/1570.4 = 100.0% (100.0%, 100.0%)	1570.4/1570.4 = 100.0% (100.0%, 100.0%)	1570.4/1570.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	38	214.4/214.4 = 100.0% (100.0%, 100.0%)	214.4/214.4 = 100.0% (100.0%, 100.0%)	214.4/214.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	38	214.4/214.4 = 100.0% (100.0%, 100.0%)	214.4/214.4 = 100.0% (100.0%, 100.0%)	214.4/214.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	38	214.4/214.4 = 100.0% (100.0%, 100.0%)	214.4/214.4 = 100.0% (100.0%, 100.0%)	214.4/214.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	15	0/1539.4 = 0.0% (0.0%, 0.0%)	0/1539.4 = 0.0% (0.0%, 0.0%)	0/1539.4 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	15	0/1539.4 = 0.0% (0.0%, 0.0%)	0/1539.4 = 0.0% (0.0%, 0.0%)	0/1539.4 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	15	0/1539.4 = 0.0% (0.0%, 0.0%)	0/1539.4 = 0.0% (0.0%, 0.0%)	0/1539.4 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	29	122.4/122.4 = 100.0% (100.0%, 100.0%)	122.4/122.4 = 100.0% (100.0%, 100.0%)	122.4/122.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	29	122.4/122.4 = 100.0% (100.0%, 100.0%)	122.4/122.4 = 100.0% (100.0%, 100.0%)	122.4/122.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not reported and unknown	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	29	122.4/122.4 = 100.0% (100.0%, 100.0%)	122.4/122.4 = 100.0% (100.0%, 100.0%)	122.4/122.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	95	1570.4/1570.4 = 100.0% (100.0%, 100.0%)	1570.4/1570.4 = 100.0% (100.0%, 100.0%)	1570.4/1570.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	95	1570.4/1570.4 = 100.0% (100.0%, 100.0%)	1570.4/1570.4 = 100.0% (100.0%, 100.0%)	1570.4/1570.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	95	1570.4/1570.4 = 100.0% (100.0%, 100.0%)	1570.4/1570.4 = 100.0% (100.0%, 100.0%)	1570.4/1570.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	38	214.4/214.4 = 100.0% (100.0%, 100.0%)	214.4/214.4 = 100.0% (100.0%, 100.0%)	214.4/214.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	38	214.4/214.4 = 100.0% (100.0%, 100.0%)	214.4/214.4 = 100.0% (100.0%, 100.0%)	214.4/214.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	38	214.4/214.4 = 100.0% (100.0%, 100.0%)	214.4/214.4 = 100.0% (100.0%, 100.0%)	214.4/214.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	15	0/1539.4 = 0.0% (0.0%, 0.0%)	0/1539.4 = 0.0% (0.0%, 0.0%)	0/1539.4 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	15	0/1539.4 = 0.0% (0.0%, 0.0%)	0/1539.4 = 0.0% (0.0%, 0.0%)	0/1539.4 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	15	0/1539.4 = 0.0% (0.0%, 0.0%)	0/1539.4 = 0.0% (0.0%, 0.0%)	0/1539.4 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	29	122.4/122.4 = 100.0% (100.0%, 100.0%)	122.4/122.4 = 100.0% (100.0%, 100.0%)	122.4/122.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	29	122.4/122.4 = 100.0% (100.0%, 100.0%)	122.4/122.4 = 100.0% (100.0%, 100.0%)	122.4/122.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not reported and unknown	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	29	122.4/122.4 = 100.0% (100.0%, 100.0%)	122.4/122.4 = 100.0% (100.0%, 100.0%)	122.4/122.4 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.



Table 3h. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Race

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Race								
White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	359	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	107	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	107	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	107	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	62	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	62	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	62	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	127	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	127	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	127	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	359	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	107	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	107	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	107	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	62	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	62	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	62	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	127	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	127	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	127	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	202	1936.1/1936.1 = 100.0% (100.0%, 100.0%)	1936.1/1936.1 = 100.0% (100.0%, 100.0%)	1936.1/1936.1 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	202	1936.1/1936.1 = 100.0% (100.0%, 100.0%)	1936.1/1936.1 = 100.0% (100.0%, 100.0%)	1936.1/1936.1 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	202	1936.1/1936.1 = 100.0% (100.0%, 100.0%)	1936.1/1936.1 = 100.0% (100.0%, 100.0%)	1936.1/1936.1 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	50	177.9/177.9 = 100.0% (100.0%, 100.0%)	177.9/177.9 = 100.0% (100.0%, 100.0%)	177.9/177.9 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	177.9/177.9 = 100.0% (100.0%, 100.0%)	177.9/177.9 = 100.0% (100.0%, 100.0%)	177.9/177.9 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	177.9/177.9 = 100.0% (100.0%, 100.0%)	177.9/177.9 = 100.0% (100.0%, 100.0%)	177.9/177.9 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	23	0/1559.4 = 0.0% (0.0%, 0.0%)	0/1559.4 = 0.0% (0.0%, 0.0%)	0/1559.4 = 0.0% (0.0%, 0.0%)
Black or African American	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	23	0/1559.4 = 0.0% (0.0%, 0.0%)	0/1559.4 = 0.0% (0.0%, 0.0%)	0/1559.4 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Black or African American	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	23	0/1559.4 = 0.0% (0.0%, 0.0%)	0/1559.4 = 0.0% (0.0%, 0.0%)	0/1559.4 = 0.0% (0.0%, 0.0%)
Black or African American	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	58	231.3/231.3 = 100.0% (100.0%, 100.0%)	231.3/231.3 = 100.0% (100.0%, 100.0%)	231.3/231.3 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	58	231.3/231.3 = 100.0% (100.0%, 100.0%)	231.3/231.3 = 100.0% (100.0%, 100.0%)	231.3/231.3 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	58	231.3/231.3 = 100.0% (100.0%, 100.0%)	231.3/231.3 = 100.0% (100.0%, 100.0%)	231.3/231.3 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	202	1936.1/1936.1 = 100.0% (100.0%, 100.0%)	1936.1/1936.1 = 100.0% (100.0%, 100.0%)	1936.1/1936.1 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	202	1936.1/1936.1 = 100.0% (100.0%, 100.0%)	1936.1/1936.1 = 100.0% (100.0%, 100.0%)	1936.1/1936.1 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	202	1936.1/1936.1 = 100.0% (100.0%, 100.0%)	1936.1/1936.1 = 100.0% (100.0%, 100.0%)	1936.1/1936.1 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	50	177.9/177.9 = 100.0% (100.0%, 100.0%)	177.9/177.9 = 100.0% (100.0%, 100.0%)	177.9/177.9 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	177.9/177.9 = 100.0% (100.0%, 100.0%)	177.9/177.9 = 100.0% (100.0%, 100.0%)	177.9/177.9 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Black or African American	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	177.9/177.9 = 100.0% (100.0%, 100.0%)	177.9/177.9 = 100.0% (100.0%, 100.0%)	177.9/177.9 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	23	0/1559.4 = 0.0% (0.0%, 0.0%)	0/1559.4 = 0.0% (0.0%, 0.0%)	0/1559.4 = 0.0% (0.0%, 0.0%)
Black or African American	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	23	0/1559.4 = 0.0% (0.0%, 0.0%)	0/1559.4 = 0.0% (0.0%, 0.0%)	0/1559.4 = 0.0% (0.0%, 0.0%)
Black or African American	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	23	0/1559.4 = 0.0% (0.0%, 0.0%)	0/1559.4 = 0.0% (0.0%, 0.0%)	0/1559.4 = 0.0% (0.0%, 0.0%)
Black or African American	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	58	231.3/231.3 = 100.0% (100.0%, 100.0%)	231.3/231.3 = 100.0% (100.0%, 100.0%)	231.3/231.3 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	58	231.3/231.3 = 100.0% (100.0%, 100.0%)	231.3/231.3 = 100.0% (100.0%, 100.0%)	231.3/231.3 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	58	231.3/231.3 = 100.0% (100.0%, 100.0%)	231.3/231.3 = 100.0% (100.0%, 100.0%)	231.3/231.3 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	58	689.4/689.4 = 100.0% (100.0%, 100.0%)	689.4/689.4 = 100.0% (100.0%, 100.0%)	689.4/689.4 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	58	689.4/689.4 = 100.0% (100.0%, 100.0%)	689.4/689.4 = 100.0% (100.0%, 100.0%)	689.4/689.4 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	58	689.4/689.4 = 100.0% (100.0%, 100.0%)	689.4/689.4 = 100.0% (100.0%, 100.0%)	689.4/689.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Asian	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	19	58.3/58.3 = 100.0% (100.0%, 100.0%)	58.3/58.3 = 100.0% (100.0%, 100.0%)	58.3/58.3 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	19	58.3/58.3 = 100.0% (100.0%, 100.0%)	58.3/58.3 = 100.0% (100.0%, 100.0%)	58.3/58.3 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	19	58.3/58.3 = 100.0% (100.0%, 100.0%)	58.3/58.3 = 100.0% (100.0%, 100.0%)	58.3/58.3 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	13	0/1335.3 = 0.0% (0.0%, 0.0%)	0/1335.3 = 0.0% (0.0%, 0.0%)	0/1335.3 = 0.0% (0.0%, 0.0%)
Asian	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	13	0/1335.3 = 0.0% (0.0%, 0.0%)	0/1335.3 = 0.0% (0.0%, 0.0%)	0/1335.3 = 0.0% (0.0%, 0.0%)
Asian	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	13	0/1335.3 = 0.0% (0.0%, 0.0%)	0/1335.3 = 0.0% (0.0%, 0.0%)	0/1335.3 = 0.0% (0.0%, 0.0%)
Asian	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	18	57.4/57.4 = 100.0% (100.0%, 100.0%)	57.4/57.4 = 100.0% (100.0%, 100.0%)	57.4/57.4 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	18	57.4/57.4 = 100.0% (100.0%, 100.0%)	57.4/57.4 = 100.0% (100.0%, 100.0%)	57.4/57.4 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	18	57.4/57.4 = 100.0% (100.0%, 100.0%)	57.4/57.4 = 100.0% (100.0%, 100.0%)	57.4/57.4 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	58	689.4/689.4 = 100.0% (100.0%, 100.0%)	689.4/689.4 = 100.0% (100.0%, 100.0%)	689.4/689.4 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	58	689.4/689.4 = 100.0% (100.0%, 100.0%)	689.4/689.4 = 100.0% (100.0%, 100.0%)	689.4/689.4 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	58	689.4/689.4 = 100.0% (100.0%, 100.0%)	689.4/689.4 = 100.0% (100.0%, 100.0%)	689.4/689.4 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	19	58.3/58.3 = 100.0% (100.0%, 100.0%)	58.3/58.3 = 100.0% (100.0%, 100.0%)	58.3/58.3 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	19	58.3/58.3 = 100.0% (100.0%, 100.0%)	58.3/58.3 = 100.0% (100.0%, 100.0%)	58.3/58.3 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	19	58.3/58.3 = 100.0% (100.0%, 100.0%)	58.3/58.3 = 100.0% (100.0%, 100.0%)	58.3/58.3 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Asian	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	13	0/1335.3 = 0.0% (0.0%, 0.0%)	0/1335.3 = 0.0% (0.0%, 0.0%)	0/1335.3 = 0.0% (0.0%, 0.0%)
Asian	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	13	0/1335.3 = 0.0% (0.0%, 0.0%)	0/1335.3 = 0.0% (0.0%, 0.0%)	0/1335.3 = 0.0% (0.0%, 0.0%)
Asian	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	13	0/1335.3 = 0.0% (0.0%, 0.0%)	0/1335.3 = 0.0% (0.0%, 0.0%)	0/1335.3 = 0.0% (0.0%, 0.0%)
Asian	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	18	57.4/57.4 = 100.0% (100.0%, 100.0%)	57.4/57.4 = 100.0% (100.0%, 100.0%)	57.4/57.4 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	18	57.4/57.4 = 100.0% (100.0%, 100.0%)	57.4/57.4 = 100.0% (100.0%, 100.0%)	57.4/57.4 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	18	57.4/57.4 = 100.0% (100.0%, 100.0%)	57.4/57.4 = 100.0% (100.0%, 100.0%)	57.4/57.4 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	22	226.5/226.5 = 100.0% (100.0%, 100.0%)	226.5/226.5 = 100.0% (100.0%, 100.0%)	226.5/226.5 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	22	226.5/226.5 = 100.0% (100.0%, 100.0%)	226.5/226.5 = 100.0% (100.0%, 100.0%)	226.5/226.5 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	22	226.5/226.5 = 100.0% (100.0%, 100.0%)	226.5/226.5 = 100.0% (100.0%, 100.0%)	226.5/226.5 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	7	39.4/39.4 = 100.0% (100.0%, 100.0%)	39.4/39.4 = 100.0% (100.0%, 100.0%)	39.4/39.4 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	7	39.4/39.4 = 100.0% (100.0%, 100.0%)	39.4/39.4 = 100.0% (100.0%, 100.0%)	39.4/39.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	7	39.4/39.4 = 100.0% (100.0%, 100.0%)	39.4/39.4 = 100.0% (100.0%, 100.0%)	39.4/39.4 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	4	0/287.4 = 0.0%	0/287.4 = 0.0%	0/287.4 = 0.0%
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0/287.4 = 0.0%	0/287.4 = 0.0%	0/287.4 = 0.0%
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0/287.4 = 0.0%	0/287.4 = 0.0%	0/287.4 = 0.0%
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	4	30.4/30.4 = 100.0% (100.0%, 100.0%)	30.4/30.4 = 100.0% (100.0%, 100.0%)	30.4/30.4 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	4	30.4/30.4 = 100.0% (100.0%, 100.0%)	30.4/30.4 = 100.0% (100.0%, 100.0%)	30.4/30.4 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	4	30.4/30.4 = 100.0% (100.0%, 100.0%)	30.4/30.4 = 100.0% (100.0%, 100.0%)	30.4/30.4 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	22	226.5/226.5 = 100.0% (100.0%, 100.0%)	226.5/226.5 = 100.0% (100.0%, 100.0%)	226.5/226.5 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	22	226.5/226.5 = 100.0% (100.0%, 100.0%)	226.5/226.5 = 100.0% (100.0%, 100.0%)	226.5/226.5 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	22	226.5/226.5 = 100.0% (100.0%, 100.0%)	226.5/226.5 = 100.0% (100.0%, 100.0%)	226.5/226.5 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	7	39.4/39.4 = 100.0% (100.0%, 100.0%)	39.4/39.4 = 100.0% (100.0%, 100.0%)	39.4/39.4 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	7	39.4/39.4 = 100.0% (100.0%, 100.0%)	39.4/39.4 = 100.0% (100.0%, 100.0%)	39.4/39.4 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	7	39.4/39.4 = 100.0% (100.0%, 100.0%)	39.4/39.4 = 100.0% (100.0%, 100.0%)	39.4/39.4 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	4	0/287.4 = 0.0%	0/287.4 = 0.0%	0/287.4 = 0.0%
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0/287.4 = 0.0%	0/287.4 = 0.0%	0/287.4 = 0.0%
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0/287.4 = 0.0%	0/287.4 = 0.0%	0/287.4 = 0.0%
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	4	30.4/30.4 = 100.0% (100.0%, 100.0%)	30.4/30.4 = 100.0% (100.0%, 100.0%)	30.4/30.4 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	4	30.4/30.4 = 100.0% (100.0%, 100.0%)	30.4/30.4 = 100.0% (100.0%, 100.0%)	30.4/30.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	4	30.4/30.4 = 100.0% (100.0%, 100.0%)	30.4/30.4 = 100.0% (100.0%, 100.0%)	30.4/30.4 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	11	125.8/125.8 = 100.0% (100.0%, 100.0%)	125.8/125.8 = 100.0% (100.0%, 100.0%)	125.8/125.8 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	11	125.8/125.8 = 100.0% (100.0%, 100.0%)	125.8/125.8 = 100.0% (100.0%, 100.0%)	125.8/125.8 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	11	125.8/125.8 = 100.0% (100.0%, 100.0%)	125.8/125.8 = 100.0% (100.0%, 100.0%)	125.8/125.8 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	6	26.1/26.1 = 100.0% (100.0%, 100.0%)	26.1/26.1 = 100.0% (100.0%, 100.0%)	26.1/26.1 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	26.1/26.1 = 100.0% (100.0%, 100.0%)	26.1/26.1 = 100.0% (100.0%, 100.0%)	26.1/26.1 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	26.1/26.1 = 100.0% (100.0%, 100.0%)	26.1/26.1 = 100.0% (100.0%, 100.0%)	26.1/26.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	5	0/316.4 = 0.0% (0.0%, 0.0%)	0/316.4 = 0.0% (0.0%, 0.0%)	0/316.4 = 0.0% (0.0%, 0.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	5	0/316.4 = 0.0% (0.0%, 0.0%)	0/316.4 = 0.0% (0.0%, 0.0%)	0/316.4 = 0.0% (0.0%, 0.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	5	0/316.4 = 0.0% (0.0%, 0.0%)	0/316.4 = 0.0% (0.0%, 0.0%)	0/316.4 = 0.0% (0.0%, 0.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	4	13/13 = 100.0% (100.0%, 100.0%)	13/13 = 100.0% (100.0%, 100.0%)	13/13 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	4	13/13 = 100.0% (100.0%, 100.0%)	13/13 = 100.0% (100.0%, 100.0%)	13/13 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	4	13/13 = 100.0% (100.0%, 100.0%)	13/13 = 100.0% (100.0%, 100.0%)	13/13 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	11	125.8/125.8 = 100.0% (100.0%, 100.0%)	125.8/125.8 = 100.0% (100.0%, 100.0%)	125.8/125.8 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	11	125.8/125.8 = 100.0% (100.0%, 100.0%)	125.8/125.8 = 100.0% (100.0%, 100.0%)	125.8/125.8 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	11	125.8/125.8 = 100.0% (100.0%, 100.0%)	125.8/125.8 = 100.0% (100.0%, 100.0%)	125.8/125.8 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	6	26.1/26.1 = 100.0% (100.0%, 100.0%)	26.1/26.1 = 100.0% (100.0%, 100.0%)	26.1/26.1 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	26.1/26.1 = 100.0% (100.0%, 100.0%)	26.1/26.1 = 100.0% (100.0%, 100.0%)	26.1/26.1 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	26.1/26.1 = 100.0% (100.0%, 100.0%)	26.1/26.1 = 100.0% (100.0%, 100.0%)	26.1/26.1 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	5	0/316.4 = 0.0% (0.0%, 0.0%)	0/316.4 = 0.0% (0.0%, 0.0%)	0/316.4 = 0.0% (0.0%, 0.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	5	0/316.4 = 0.0% (0.0%, 0.0%)	0/316.4 = 0.0% (0.0%, 0.0%)	0/316.4 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	5	0/316.4 = 0.0% (0.0%, 0.0%)	0/316.4 = 0.0% (0.0%, 0.0%)	0/316.4 = 0.0% (0.0%, 0.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	4	13/13 = 100.0% (100.0%, 100.0%)	13/13 = 100.0% (100.0%, 100.0%)	13/13 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	4	13/13 = 100.0% (100.0%, 100.0%)	13/13 = 100.0% (100.0%, 100.0%)	13/13 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	4	13/13 = 100.0% (100.0%, 100.0%)	13/13 = 100.0% (100.0%, 100.0%)	13/13 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	60	641.2/641.2 = 100.0% (100.0%, 100.0%)	641.2/641.2 = 100.0% (100.0%, 100.0%)	641.2/641.2 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	60	641.2/641.2 = 100.0% (100.0%, 100.0%)	641.2/641.2 = 100.0% (100.0%, 100.0%)	641.2/641.2 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	60	641.2/641.2 = 100.0% (100.0%, 100.0%)	641.2/641.2 = 100.0% (100.0%, 100.0%)	641.2/641.2 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	11	45.8/45.8 = 100.0% (100.0%, 100.0%)	45.8/45.8 = 100.0% (100.0%, 100.0%)	45.8/45.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	11	45.8/45.8 = 100.0% (100.0%, 100.0%)	45.8/45.8 = 100.0% (100.0%, 100.0%)	45.8/45.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	11	45.8/45.8 = 100.0% (100.0%, 100.0%)	45.8/45.8 = 100.0% (100.0%, 100.0%)	45.8/45.8 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Multiracial	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	10	0/496.6 = 0.0% (0.0%, 0.0%)	0/496.6 = 0.0% (0.0%, 0.0%)	0/496.6 = 0.0% (0.0%, 0.0%)
Multiracial	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	10	0/496.6 = 0.0% (0.0%, 0.0%)	0/496.6 = 0.0% (0.0%, 0.0%)	0/496.6 = 0.0% (0.0%, 0.0%)
Multiracial	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	10	0/496.6 = 0.0% (0.0%, 0.0%)	0/496.6 = 0.0% (0.0%, 0.0%)	0/496.6 = 0.0% (0.0%, 0.0%)
Multiracial	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	14	56.8/56.8 = 100.0% (100.0%, 100.0%)	56.8/56.8 = 100.0% (100.0%, 100.0%)	56.8/56.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	14	56.8/56.8 = 100.0% (100.0%, 100.0%)	56.8/56.8 = 100.0% (100.0%, 100.0%)	56.8/56.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	14	56.8/56.8 = 100.0% (100.0%, 100.0%)	56.8/56.8 = 100.0% (100.0%, 100.0%)	56.8/56.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	60	641.2/641.2 = 100.0% (100.0%, 100.0%)	641.2/641.2 = 100.0% (100.0%, 100.0%)	641.2/641.2 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	60	641.2/641.2 = 100.0% (100.0%, 100.0%)	641.2/641.2 = 100.0% (100.0%, 100.0%)	641.2/641.2 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	60	641.2/641.2 = 100.0% (100.0%, 100.0%)	641.2/641.2 = 100.0% (100.0%, 100.0%)	641.2/641.2 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	11	45.8/45.8 = 100.0% (100.0%, 100.0%)	45.8/45.8 = 100.0% (100.0%, 100.0%)	45.8/45.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	11	45.8/45.8 = 100.0% (100.0%, 100.0%)	45.8/45.8 = 100.0% (100.0%, 100.0%)	45.8/45.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	11	45.8/45.8 = 100.0% (100.0%, 100.0%)	45.8/45.8 = 100.0% (100.0%, 100.0%)	45.8/45.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	10	0/496.6 = 0.0% (0.0%, 0.0%)	0/496.6 = 0.0% (0.0%, 0.0%)	0/496.6 = 0.0% (0.0%, 0.0%)
Multiracial	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	10	0/496.6 = 0.0% (0.0%, 0.0%)	0/496.6 = 0.0% (0.0%, 0.0%)	0/496.6 = 0.0% (0.0%, 0.0%)
Multiracial	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	10	0/496.6 = 0.0% (0.0%, 0.0%)	0/496.6 = 0.0% (0.0%, 0.0%)	0/496.6 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Multiracial	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	14	56.8/56.8 = 100.0% (100.0%, 100.0%)	56.8/56.8 = 100.0% (100.0%, 100.0%)	56.8/56.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	14	56.8/56.8 = 100.0% (100.0%, 100.0%)	56.8/56.8 = 100.0% (100.0%, 100.0%)	56.8/56.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	14	56.8/56.8 = 100.0% (100.0%, 100.0%)	56.8/56.8 = 100.0% (100.0%, 100.0%)	56.8/56.8 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	21	192.5/192.5 = 100.0% (100.0%, 100.0%)	192.5/192.5 = 100.0% (100.0%, 100.0%)	192.5/192.5 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	21	192.5/192.5 = 100.0% (100.0%, 100.0%)	192.5/192.5 = 100.0% (100.0%, 100.0%)	192.5/192.5 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	21	192.5/192.5 = 100.0% (100.0%, 100.0%)	192.5/192.5 = 100.0% (100.0%, 100.0%)	192.5/192.5 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	8	43.3/43.3 = 100.0% (100.0%, 100.0%)	43.3/43.3 = 100.0% (100.0%, 100.0%)	43.3/43.3 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	8	43.3/43.3 = 100.0% (100.0%, 100.0%)	43.3/43.3 = 100.0% (100.0%, 100.0%)	43.3/43.3 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	8	43.3/43.3 = 100.0% (100.0%, 100.0%)	43.3/43.3 = 100.0% (100.0%, 100.0%)	43.3/43.3 = 100.0% (100.0%, 100.0%)
Other	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	4	0/151.2 = 0.0% (0.0%, 0.0%)	0/151.2 = 0.0% (0.0%, 0.0%)	0/151.2 = 0.0% (0.0%, 0.0%)
Other	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0/151.2 = 0.0% (0.0%, 0.0%)	0/151.2 = 0.0% (0.0%, 0.0%)	0/151.2 = 0.0% (0.0%, 0.0%)
Other	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0/151.2 = 0.0% (0.0%, 0.0%)	0/151.2 = 0.0% (0.0%, 0.0%)	0/151.2 = 0.0% (0.0%, 0.0%)
Other	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	7	14.5/14.5 = 100.0% (100.0%, 100.0%)	14.5/14.5 = 100.0% (100.0%, 100.0%)	14.5/14.5 = 100.0% (100.0%, 100.0%)
Other	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	7	14.5/14.5 = 100.0% (100.0%, 100.0%)	14.5/14.5 = 100.0% (100.0%, 100.0%)	14.5/14.5 = 100.0% (100.0%, 100.0%)
Other	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	7	14.5/14.5 = 100.0% (100.0%, 100.0%)	14.5/14.5 = 100.0% (100.0%, 100.0%)	14.5/14.5 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Other	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	21	192.5/192.5 = 100.0% (100.0%, 100.0%)	192.5/192.5 = 100.0% (100.0%, 100.0%)	192.5/192.5 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	21	192.5/192.5 = 100.0% (100.0%, 100.0%)	192.5/192.5 = 100.0% (100.0%, 100.0%)	192.5/192.5 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	21	192.5/192.5 = 100.0% (100.0%, 100.0%)	192.5/192.5 = 100.0% (100.0%, 100.0%)	192.5/192.5 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	8	43.3/43.3 = 100.0% (100.0%, 100.0%)	43.3/43.3 = 100.0% (100.0%, 100.0%)	43.3/43.3 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	8	43.3/43.3 = 100.0% (100.0%, 100.0%)	43.3/43.3 = 100.0% (100.0%, 100.0%)	43.3/43.3 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	8	43.3/43.3 = 100.0% (100.0%, 100.0%)	43.3/43.3 = 100.0% (100.0%, 100.0%)	43.3/43.3 = 100.0% (100.0%, 100.0%)
Other	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	4	0/151.2 = 0.0% (0.0%, 0.0%)	0/151.2 = 0.0% (0.0%, 0.0%)	0/151.2 = 0.0% (0.0%, 0.0%)
Other	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0/151.2 = 0.0% (0.0%, 0.0%)	0/151.2 = 0.0% (0.0%, 0.0%)	0/151.2 = 0.0% (0.0%, 0.0%)
Other	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0/151.2 = 0.0% (0.0%, 0.0%)	0/151.2 = 0.0% (0.0%, 0.0%)	0/151.2 = 0.0% (0.0%, 0.0%)
Other	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	7	14.5/14.5 = 100.0% (100.0%, 100.0%)	14.5/14.5 = 100.0% (100.0%, 100.0%)	14.5/14.5 = 100.0% (100.0%, 100.0%)
Other	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	7	14.5/14.5 = 100.0% (100.0%, 100.0%)	14.5/14.5 = 100.0% (100.0%, 100.0%)	14.5/14.5 = 100.0% (100.0%, 100.0%)
Other	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	7	14.5/14.5 = 100.0% (100.0%, 100.0%)	14.5/14.5 = 100.0% (100.0%, 100.0%)	14.5/14.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	86	1654.7/1654.7 = 100.0% (100.0%, 100.0%)	1654.7/1654.7 = 100.0% (100.0%, 100.0%)	1607.8/1654.7 = 97.2% (82.0%, 99.6%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	86	1654.7/1654.7 = 100.0% (100.0%, 100.0%)	1654.7/1654.7 = 100.0% (100.0%, 100.0%)	1654.7/1654.7 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	86	1654.7/1654.7 = 100.0% (100.0%, 100.0%)	1654.7/1654.7 = 100.0% (100.0%, 100.0%)	1654.7/1654.7 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not reported and unknown	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	25	186.7/186.7 = 100.0% (100.0%, 100.0%)	186.7/186.7 = 100.0% (100.0%, 100.0%)	186.7/186.7 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	25	186.7/186.7 = 100.0% (100.0%, 100.0%)	186.7/186.7 = 100.0% (100.0%, 100.0%)	186.7/186.7 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	25	186.7/186.7 = 100.0% (100.0%, 100.0%)	186.7/186.7 = 100.0% (100.0%, 100.0%)	186.7/186.7 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	19	0/1887.3 = 0.0% (0.0%, 0.0%)	0/1887.3 = 0.0% (0.0%, 0.0%)	0/1887.3 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	19	0/1887.3 = 0.0% (0.0%, 0.0%)	0/1887.3 = 0.0% (0.0%, 0.0%)	0/1887.3 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	19	0/1887.3 = 0.0% (0.0%, 0.0%)	0/1887.3 = 0.0% (0.0%, 0.0%)	0/1887.3 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	24	90.4/90.4 = 100.0% (100.0%, 100.0%)	90.4/90.4 = 100.0% (100.0%, 100.0%)	90.4/90.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	24	90.4/90.4 = 100.0% (100.0%, 100.0%)	90.4/90.4 = 100.0% (100.0%, 100.0%)	90.4/90.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	24	90.4/90.4 = 100.0% (100.0%, 100.0%)	90.4/90.4 = 100.0% (100.0%, 100.0%)	90.4/90.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	86	1654.7/1654.7 = 100.0% (100.0%, 100.0%)	1654.7/1654.7 = 100.0% (100.0%, 100.0%)	1654.7/1654.7 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	86	1654.7/1654.7 = 100.0% (100.0%, 100.0%)	1654.7/1654.7 = 100.0% (100.0%, 100.0%)	1654.7/1654.7 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	86	1654.7/1654.7 = 100.0% (100.0%, 100.0%)	1654.7/1654.7 = 100.0% (100.0%, 100.0%)	1654.7/1654.7 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not reported and unknown	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	25	186.7/186.7 = 100.0% (100.0%, 100.0%)	186.7/186.7 = 100.0% (100.0%, 100.0%)	186.7/186.7 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	25	186.7/186.7 = 100.0% (100.0%, 100.0%)	186.7/186.7 = 100.0% (100.0%, 100.0%)	186.7/186.7 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	25	186.7/186.7 = 100.0% (100.0%, 100.0%)	186.7/186.7 = 100.0% (100.0%, 100.0%)	186.7/186.7 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	19	0/1887.3 = 0.0% (0.0%, 0.0%)	0/1887.3 = 0.0% (0.0%, 0.0%)	0/1887.3 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	19	0/1887.3 = 0.0% (0.0%, 0.0%)	0/1887.3 = 0.0% (0.0%, 0.0%)	0/1887.3 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	19	0/1887.3 = 0.0% (0.0%, 0.0%)	0/1887.3 = 0.0% (0.0%, 0.0%)	0/1887.3 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	24	90.4/90.4 = 100.0% (100.0%, 100.0%)	90.4/90.4 = 100.0% (100.0%, 100.0%)	90.4/90.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	24	90.4/90.4 = 100.0% (100.0%, 100.0%)	90.4/90.4 = 100.0% (100.0%, 100.0%)	90.4/90.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	24	90.4/90.4 = 100.0% (100.0%, 100.0%)	90.4/90.4 = 100.0% (100.0%, 100.0%)	90.4/90.4 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3i. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Underrepresented minority status								
Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	420	4355/4355 = 100.0% (100.0%, 100.0%)	4355/4355 = 100.0% (100.0%, 100.0%)	4355/4355 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	420	4355/4355 = 100.0% (100.0%, 100.0%)	4355/4355 = 100.0% (100.0%, 100.0%)	4355/4355 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	420	4355/4355 = 100.0% (100.0%, 100.0%)	4355/4355 = 100.0% (100.0%, 100.0%)	4355/4355 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	110	420/420 = 100.0% (100.0%, 100.0%)	420/420 = 100.0% (100.0%, 100.0%)	420/420 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	110	420/420 = 100.0% (100.0%, 100.0%)	420/420 = 100.0% (100.0%, 100.0%)	420/420 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	110	420/420 = 100.0% (100.0%, 100.0%)	420/420 = 100.0% (100.0%, 100.0%)	420/420 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	66	0/4349 = 0.0% (0.0%, 0.0%)	0/4349 = 0.0% (0.0%, 0.0%)	0/4349 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0/4349 = 0.0% (0.0%, 0.0%)	0/4349 = 0.0% (0.0%, 0.0%)	0/4349 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0/4349 = 0.0% (0.0%, 0.0%)	0/4349 = 0.0% (0.0%, 0.0%)	0/4349 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	112	434/434 = 100.0% (100.0%, 100.0%)	434/434 = 100.0% (100.0%, 100.0%)	434/434 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	112	434/434 = 100.0% (100.0%, 100.0%)	434/434 = 100.0% (100.0%, 100.0%)	434/434 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	112	434/434 = 100.0% (100.0%, 100.0%)	434/434 = 100.0% (100.0%, 100.0%)	434/434 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	420	4355/4355 = 100.0% (100.0%, 100.0%)	4355/4355 = 100.0% (100.0%, 100.0%)	4355/4355 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	420	4355/4355 = 100.0% (100.0%, 100.0%)	4355/4355 = 100.0% (100.0%, 100.0%)	4355/4355 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	420	4355/4355 = 100.0% (100.0%, 100.0%)	4355/4355 = 100.0% (100.0%, 100.0%)	4355/4355 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	110	420/420 = 100.0% (100.0%, 100.0%)	420/420 = 100.0% (100.0%, 100.0%)	420/420 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	110	420/420 = 100.0% (100.0%, 100.0%)	420/420 = 100.0% (100.0%, 100.0%)	420/420 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	110	420/420 = 100.0% (100.0%, 100.0%)	420/420 = 100.0% (100.0%, 100.0%)	420/420 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	66	0/4349 = 0.0% (0.0%, 0.0%)	0/4349 = 0.0% (0.0%, 0.0%)	0/4349 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0/4349 = 0.0% (0.0%, 0.0%)	0/4349 = 0.0% (0.0%, 0.0%)	0/4349 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0/4349 = 0.0% (0.0%, 0.0%)	0/4349 = 0.0% (0.0%, 0.0%)	0/4349 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	112	434/434 = 100.0% (100.0%, 100.0%)	434/434 = 100.0% (100.0%, 100.0%)	434/434 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	112	434/434 = 100.0% (100.0%, 100.0%)	434/434 = 100.0% (100.0%, 100.0%)	434/434 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	112	434/434 = 100.0% (100.0%, 100.0%)	434/434 = 100.0% (100.0%, 100.0%)	434/434 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	359	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	107	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	107	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	107	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	62	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	62	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	62	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	127	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	127	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	127	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	359	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	107	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	107	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	107	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	62	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	62	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	62	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	127	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	127	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	127	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3j. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Age, Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Age, Underrepresented minority status								
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	202	3395/3395 = 100.0% (100.0%, 100.0%)	3395/3395 = 100.0% (100.0%, 100.0%)	3395/3395 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	202	3395/3395 = 100.0% (100.0%, 100.0%)	3395/3395 = 100.0% (100.0%, 100.0%)	3395/3395 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	202	3395/3395 = 100.0% (100.0%, 100.0%)	3395/3395 = 100.0% (100.0%, 100.0%)	3395/3395 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	60	335/335 = 100.0% (100.0%, 100.0%)	335/335 = 100.0% (100.0%, 100.0%)	335/335 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	60	335/335 = 100.0% (100.0%, 100.0%)	335/335 = 100.0% (100.0%, 100.0%)	335/335 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	60	335/335 = 100.0% (100.0%, 100.0%)	335/335 = 100.0% (100.0%, 100.0%)	335/335 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	30	0/3306 = 0.0% (0.0%, 0.0%)	0/3306 = 0.0% (0.0%, 0.0%)	0/3306 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	30	0/3306 = 0.0% (0.0%, 0.0%)	0/3306 = 0.0% (0.0%, 0.0%)	0/3306 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	30	0/3306 = 0.0% (0.0%, 0.0%)	0/3306 = 0.0% (0.0%, 0.0%)	0/3306 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	65	350/350 = 100.0% (100.0%, 100.0%)	350/350 = 100.0% (100.0%, 100.0%)	350/350 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	65	350/350 = 100.0% (100.0%, 100.0%)	350/350 = 100.0% (100.0%, 100.0%)	350/350 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	65	350/350 = 100.0% (100.0%, 100.0%)	350/350 = 100.0% (100.0%, 100.0%)	350/350 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	202	3395/3395 = 100.0% (100.0%, 100.0%)	3395/3395 = 100.0% (100.0%, 100.0%)	3395/3395 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	202	3395/3395 = 100.0% (100.0%, 100.0%)	3395/3395 = 100.0% (100.0%, 100.0%)	3395/3395 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	202	3395/3395 = 100.0% (100.0%, 100.0%)	3395/3395 = 100.0% (100.0%, 100.0%)	3395/3395 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	60	335/335 = 100.0% (100.0%, 100.0%)	335/335 = 100.0% (100.0%, 100.0%)	335/335 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	60	335/335 = 100.0% (100.0%, 100.0%)	335/335 = 100.0% (100.0%, 100.0%)	335/335 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	60	335/335 = 100.0% (100.0%, 100.0%)	335/335 = 100.0% (100.0%, 100.0%)	335/335 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	30	0/3306 = 0.0% (0.0%, 0.0%)	0/3306 = 0.0% (0.0%, 0.0%)	0/3306 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	30	0/3306 = 0.0% (0.0%, 0.0%)	0/3306 = 0.0% (0.0%, 0.0%)	0/3306 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	30	0/3306 = 0.0% (0.0%, 0.0%)	0/3306 = 0.0% (0.0%, 0.0%)	0/3306 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	65	350/350 = 100.0% (100.0%, 100.0%)	350/350 = 100.0% (100.0%, 100.0%)	350/350 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	65	350/350 = 100.0% (100.0%, 100.0%)	350/350 = 100.0% (100.0%, 100.0%)	350/350 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	65	350/350 = 100.0% (100.0%, 100.0%)	350/350 = 100.0% (100.0%, 100.0%)	350/350 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	171	5105.2/5105.2 = 100.0% (100.0%, 100.0%)	5105.2/5105.2 = 100.0% (100.0%, 100.0%)	5105.2/5105.2 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	171	5105.2/5105.2 = 100.0% (100.0%, 100.0%)	5105.2/5105.2 = 100.0% (100.0%, 100.0%)	5105.2/5105.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	171	5105.2/5105.2 = 100.0% (100.0%, 100.0%)	5105.2/5105.2 = 100.0% (100.0%, 100.0%)	5105.2/5105.2 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	56	493.4/493.4 = 100.0% (100.0%, 100.0%)	493.4/493.4 = 100.0% (100.0%, 100.0%)	493.4/493.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	56	493.4/493.4 = 100.0% (100.0%, 100.0%)	493.4/493.4 = 100.0% (100.0%, 100.0%)	493.4/493.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	56	493.4/493.4 = 100.0% (100.0%, 100.0%)	493.4/493.4 = 100.0% (100.0%, 100.0%)	493.4/493.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	32	0/4518.4 = 0.0% (0.0%, 0.0%)	0/4518.4 = 0.0% (0.0%, 0.0%)	0/4518.4 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0/4518.4 = 0.0% (0.0%, 0.0%)	0/4518.4 = 0.0% (0.0%, 0.0%)	0/4518.4 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0/4518.4 = 0.0% (0.0%, 0.0%)	0/4518.4 = 0.0% (0.0%, 0.0%)	0/4518.4 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	64	571.6/571.6 = 100.0% (100.0%, 100.0%)	571.6/571.6 = 100.0% (100.0%, 100.0%)	571.6/571.6 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	64	571.6/571.6 = 100.0% (100.0%, 100.0%)	571.6/571.6 = 100.0% (100.0%, 100.0%)	571.6/571.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	64	571.6/571.6 = 100.0% (100.0%, 100.0%)	571.6/571.6 = 100.0% (100.0%, 100.0%)	571.6/571.6 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	171	5105.2/5105.2 = 100.0% (100.0%, 100.0%)	5105.2/5105.2 = 100.0% (100.0%, 100.0%)	5105.2/5105.2 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	171	5105.2/5105.2 = 100.0% (100.0%, 100.0%)	5105.2/5105.2 = 100.0% (100.0%, 100.0%)	5105.2/5105.2 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	171	5105.2/5105.2 = 100.0% (100.0%, 100.0%)	5105.2/5105.2 = 100.0% (100.0%, 100.0%)	5105.2/5105.2 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	56	493.4/493.4 = 100.0% (100.0%, 100.0%)	493.4/493.4 = 100.0% (100.0%, 100.0%)	493.4/493.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	56	493.4/493.4 = 100.0% (100.0%, 100.0%)	493.4/493.4 = 100.0% (100.0%, 100.0%)	493.4/493.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	56	493.4/493.4 = 100.0% (100.0%, 100.0%)	493.4/493.4 = 100.0% (100.0%, 100.0%)	493.4/493.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	32	0/4518.4 = 0.0% (0.0%, 0.0%)	0/4518.4 = 0.0% (0.0%, 0.0%)	0/4518.4 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0/4518.4 = 0.0% (0.0%, 0.0%)	0/4518.4 = 0.0% (0.0%, 0.0%)	0/4518.4 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0/4518.4 = 0.0% (0.0%, 0.0%)	0/4518.4 = 0.0% (0.0%, 0.0%)	0/4518.4 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	64	571.6/571.6 = 100.0% (100.0%, 100.0%)	571.6/571.6 = 100.0% (100.0%, 100.0%)	571.6/571.6 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	64	571.6/571.6 = 100.0% (100.0%, 100.0%)	571.6/571.6 = 100.0% (100.0%, 100.0%)	571.6/571.6 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	64	571.6/571.6 = 100.0% (100.0%, 100.0%)	571.6/571.6 = 100.0% (100.0%, 100.0%)	571.6/571.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	218	960/960 = 100.0% (100.0%, 100.0%)	960/960 = 100.0% (100.0%, 100.0%)	960/960 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	960/960 = 100.0% (100.0%, 100.0%)	960/960 = 100.0% (100.0%, 100.0%)	960/960 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	960/960 = 100.0% (100.0%, 100.0%)	960/960 = 100.0% (100.0%, 100.0%)	960/960 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	50	85/85 = 100.0% (100.0%, 100.0%)	85/85 = 100.0% (100.0%, 100.0%)	85/85 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	85/85 = 100.0% (100.0%, 100.0%)	85/85 = 100.0% (100.0%, 100.0%)	85/85 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	85/85 = 100.0% (100.0%, 100.0%)	85/85 = 100.0% (100.0%, 100.0%)	85/85 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	36	0/1043 = 0.0% (0.0%, 0.0%)	0/1043 = 0.0% (0.0%, 0.0%)	0/1043 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0/1043 = 0.0% (0.0%, 0.0%)	0/1043 = 0.0% (0.0%, 0.0%)	0/1043 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0/1043 = 0.0% (0.0%, 0.0%)	0/1043 = 0.0% (0.0%, 0.0%)	0/1043 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	47	84/84 = 100.0% (100.0%, 100.0%)	84/84 = 100.0% (100.0%, 100.0%)	84/84 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	47	84/84 = 100.0% (100.0%, 100.0%)	84/84 = 100.0% (100.0%, 100.0%)	84/84 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	47	84/84 = 100.0% (100.0%, 100.0%)	84/84 = 100.0% (100.0%, 100.0%)	84/84 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	218	960/960 = 100.0% (100.0%, 100.0%)	960/960 = 100.0% (100.0%, 100.0%)	960/960 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	960/960 = 100.0% (100.0%, 100.0%)	960/960 = 100.0% (100.0%, 100.0%)	960/960 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	960/960 = 100.0% (100.0%, 100.0%)	960/960 = 100.0% (100.0%, 100.0%)	960/960 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	50	85/85 = 100.0% (100.0%, 100.0%)	85/85 = 100.0% (100.0%, 100.0%)	85/85 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	85/85 = 100.0% (100.0%, 100.0%)	85/85 = 100.0% (100.0%, 100.0%)	85/85 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	85/85 = 100.0% (100.0%, 100.0%)	85/85 = 100.0% (100.0%, 100.0%)	85/85 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	36	0/1043 = 0.0% (0.0%, 0.0%)	0/1043 = 0.0% (0.0%, 0.0%)	0/1043 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0/1043 = 0.0% (0.0%, 0.0%)	0/1043 = 0.0% (0.0%, 0.0%)	0/1043 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0/1043 = 0.0% (0.0%, 0.0%)	0/1043 = 0.0% (0.0%, 0.0%)	0/1043 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	47	84/84 = 100.0% (100.0%, 100.0%)	84/84 = 100.0% (100.0%, 100.0%)	84/84 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	47	84/84 = 100.0% (100.0%, 100.0%)	84/84 = 100.0% (100.0%, 100.0%)	84/84 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	47	84/84 = 100.0% (100.0%, 100.0%)	84/84 = 100.0% (100.0%, 100.0%)	84/84 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	188	1364.8/1364.8 = 100.0% (100.0%, 100.0%)	1364.8/1364.8 = 100.0% (100.0%, 100.0%)	1364.8/1364.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	188	1364.8/1364.8 = 100.0% (100.0%, 100.0%)	1364.8/1364.8 = 100.0% (100.0%, 100.0%)	1364.8/1364.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	188	1364.8/1364.8 = 100.0% (100.0%, 100.0%)	1364.8/1364.8 = 100.0% (100.0%, 100.0%)	1364.8/1364.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	51	128.5/128.5 = 100.0% (100.0%, 100.0%)	128.5/128.5 = 100.0% (100.0%, 100.0%)	128.5/128.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	51	128.5/128.5 = 100.0% (100.0%, 100.0%)	128.5/128.5 = 100.0% (100.0%, 100.0%)	128.5/128.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	51	128.5/128.5 = 100.0% (100.0%, 100.0%)	128.5/128.5 = 100.0% (100.0%, 100.0%)	128.5/128.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	30	0/1503.6 = 0.0% (0.0%, 0.0%)	0/1503.6 = 0.0% (0.0%, 0.0%)	0/1503.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	30	0/1503.6 = 0.0% (0.0%, 0.0%)	0/1503.6 = 0.0% (0.0%, 0.0%)	0/1503.6 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	30	0/1503.6 = 0.0% (0.0%, 0.0%)	0/1503.6 = 0.0% (0.0%, 0.0%)	0/1503.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	63	128.3/128.3 = 100.0% (100.0%, 100.0%)	128.3/128.3 = 100.0% (100.0%, 100.0%)	128.3/128.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	63	128.3/128.3 = 100.0% (100.0%, 100.0%)	128.3/128.3 = 100.0% (100.0%, 100.0%)	128.3/128.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	63	128.3/128.3 = 100.0% (100.0%, 100.0%)	128.3/128.3 = 100.0% (100.0%, 100.0%)	128.3/128.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	188	1364.8/1364.8 = 100.0% (100.0%, 100.0%)	1364.8/1364.8 = 100.0% (100.0%, 100.0%)	1364.8/1364.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	188	1364.8/1364.8 = 100.0% (100.0%, 100.0%)	1364.8/1364.8 = 100.0% (100.0%, 100.0%)	1364.8/1364.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	188	1364.8/1364.8 = 100.0% (100.0%, 100.0%)	1364.8/1364.8 = 100.0% (100.0%, 100.0%)	1364.8/1364.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	51	128.5/128.5 = 100.0% (100.0%, 100.0%)	128.5/128.5 = 100.0% (100.0%, 100.0%)	128.5/128.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	51	128.5/128.5 = 100.0% (100.0%, 100.0%)	128.5/128.5 = 100.0% (100.0%, 100.0%)	128.5/128.5 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	51	128.5/128.5 = 100.0% (100.0%, 100.0%)	128.5/128.5 = 100.0% (100.0%, 100.0%)	128.5/128.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	30	0/1503.6 = 0.0% (0.0%, 0.0%)	0/1503.6 = 0.0% (0.0%, 0.0%)	0/1503.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	30	0/1503.6 = 0.0% (0.0%, 0.0%)	0/1503.6 = 0.0% (0.0%, 0.0%)	0/1503.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	30	0/1503.6 = 0.0% (0.0%, 0.0%)	0/1503.6 = 0.0% (0.0%, 0.0%)	0/1503.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	63	128.3/128.3 = 100.0% (100.0%, 100.0%)	128.3/128.3 = 100.0% (100.0%, 100.0%)	128.3/128.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	63	128.3/128.3 = 100.0% (100.0%, 100.0%)	128.3/128.3 = 100.0% (100.0%, 100.0%)	128.3/128.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	63	128.3/128.3 = 100.0% (100.0%, 100.0%)	128.3/128.3 = 100.0% (100.0%, 100.0%)	128.3/128.3 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4a. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by All participants

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
All participants								
	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	915	13297/13297 = 100.0% (100.0%, 100.0%)	13297/13297 = 100.0% (100.0%, 100.0%)	13251.7/13297 = 99.7% (99.1%, 99.9%)
	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	269	1399/1399 = 100.0% (100.0%, 100.0%)	1399/1399 = 100.0% (100.0%, 100.0%)	1399/1399 = 100.0% (100.0%, 100.0%)
	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	155	0/13381 = 0.0% (0.0%, 0.0%)	0/13381 = 0.0% (0.0%, 0.0%)	0/13381 = 0.0% (0.0%, 0.0%)
	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	276	1272.9/1276 = 99.8% (98.3%, 100.0%)	1272.9/1276 = 99.8% (98.3%, 100.0%)	1258.1/1276 = 98.6% (92.9%, 99.7%)
	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	915	13297/13297 = 100.0% (100.0%, 100.0%)	13297/13297 = 100.0% (100.0%, 100.0%)	13297/13297 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	269	1399/1399 = 100.0% (100.0%, 100.0%)	1399/1399 = 100.0% (100.0%, 100.0%)	1399/1399 = 100.0% (100.0%, 100.0%)
	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	155	0/13381 = 0.0% (0.0%, 0.0%)	0/13381 = 0.0% (0.0%, 0.0%)	0/13381 = 0.0% (0.0%, 0.0%)
	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	276	1276/1276 = 100.0% (100.0%, 100.0%)	1276/1276 = 100.0% (100.0%, 100.0%)	1276/1276 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4b. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age								
Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	439	10464/10464 = 100.0% (100.0%, 100.0%)	10464/10464 = 100.0% (100.0%, 100.0%)	10426/10464 = 99.6% (98.9%, 99.9%)
Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	146	1130/1130 = 100.0% (100.0%, 100.0%)	1130/1130 = 100.0% (100.0%, 100.0%)	1130/1130 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	77	0/10233 = 0.0% (0.0%, 0.0%)	0/10233 = 0.0% (0.0%, 0.0%)	0/10233 = 0.0% (0.0%, 0.0%)
Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	148	1023.9/1027 = 99.7% (97.9%, 100.0%)	1023.9/1027 = 99.7% (97.9%, 100.0%)	1009.1/1027 = 98.3% (91.2%, 99.7%)
Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	439	10464/10464 = 100.0% (100.0%, 100.0%)	10464/10464 = 100.0% (100.0%, 100.0%)	10464/10464 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	146	1130/1130 = 100.0% (100.0%, 100.0%)	1130/1130 = 100.0% (100.0%, 100.0%)	1130/1130 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	77	0/10233 = 0.0% (0.0%, 0.0%)	0/10233 = 0.0% (0.0%, 0.0%)	0/10233 = 0.0% (0.0%, 0.0%)
Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	148	1027/1027 = 100.0% (100.0%, 100.0%)	1027/1027 = 100.0% (100.0%, 100.0%)	1027/1027 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	476	2833/2833 = 100.0% (100.0%, 100.0%)	2833/2833 = 100.0% (100.0%, 100.0%)	2825.7/2833 = 99.7% (98.2%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	123	269/269 = 100.0% (100.0%, 100.0%)	269/269 = 100.0% (100.0%, 100.0%)	269/269 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	78	0/3148 = 0.0% (0.0%, 0.0%)	0/3148 = 0.0% (0.0%, 0.0%)	0/3148 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	128	249/249 = 100.0% (100.0%, 100.0%)	249/249 = 100.0% (100.0%, 100.0%)	249/249 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	476	2833/2833 = 100.0% (100.0%, 100.0%)	2833/2833 = 100.0% (100.0%, 100.0%)	2833/2833 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	123	269/269 = 100.0% (100.0%, 100.0%)	269/269 = 100.0% (100.0%, 100.0%)	269/269 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	78	0/3148 = 0.0% (0.0%, 0.0%)	0/3148 = 0.0% (0.0%, 0.0%)	0/3148 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age ≥ 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	128	249/249 = 100.0% (100.0%, 100.0%)	249/249 = 100.0% (100.0%, 100.0%)	249/249 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4c. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Risk for Severe Covid-19								
At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	470	3637.9/3637.9 = 100.0% (100.0%, 100.0%)	3637.9/3637.9 = 100.0% (100.0%, 100.0%)	3592.7/3637.9 = 98.8% (96.7%, 99.5%)
At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	120	357.6/357.6 = 100.0% (100.0%, 100.0%)	357.6/357.6 = 100.0% (100.0%, 100.0%)	357.6/357.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	80	0/4055.1 = 0.0% (0.0%, 0.0%)	0/4055.1 = 0.0% (0.0%, 0.0%)	0/4055.1 = 0.0% (0.0%, 0.0%)
At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	130	319/322 = 99.0% (93.4%, 99.9%)	319/322 = 99.0% (93.4%, 99.9%)	319/322 = 99.0% (93.4%, 99.9%)
At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	470	3637.9/3637.9 = 100.0% (100.0%, 100.0%)	3637.9/3637.9 = 100.0% (100.0%, 100.0%)	3637.9/3637.9 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	120	357.6/357.6 = 100.0% (100.0%, 100.0%)	357.6/357.6 = 100.0% (100.0%, 100.0%)	357.6/357.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	80	0/4055.1 = 0.0% (0.0%, 0.0%)	0/4055.1 = 0.0% (0.0%, 0.0%)	0/4055.1 = 0.0% (0.0%, 0.0%)
At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	130	322/322 = 100.0% (100.0%, 100.0%)	322/322 = 100.0% (100.0%, 100.0%)	322/322 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	445	9659.1/9659.1 = 100.0% (100.0%, 100.0%)	9659.1/9659.1 = 100.0% (100.0%, 100.0%)	9659.1/9659.1 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	149	1041.4/1041.4 = 100.0% (100.0%, 100.0%)	1041.4/1041.4 = 100.0% (100.0%, 100.0%)	1041.4/1041.4 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	75	0/9325.9 = 0.0% (0.0%, 0.0%)	0/9325.9 = 0.0% (0.0%, 0.0%)	0/9325.9 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	146	954/954 = 100.0% (100.0%, 100.0%)	954/954 = 100.0% (100.0%, 100.0%)	939.2/954 = 98.5% (89.5%, 99.8%)
Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	445	9659.1/9659.1 = 100.0% (100.0%, 100.0%)	9659.1/9659.1 = 100.0% (100.0%, 100.0%)	9659.1/9659.1 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	149	1041.4/1041.4 = 100.0% (100.0%, 100.0%)	1041.4/1041.4 = 100.0% (100.0%, 100.0%)	1041.4/1041.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	75	0/9325.9 = 0.0% (0.0%, 0.0%)	0/9325.9 = 0.0% (0.0%, 0.0%)	0/9325.9 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	146	954/954 = 100.0% (100.0%, 100.0%)	954/954 = 100.0% (100.0%, 100.0%)	954/954 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4d. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age, Risk for Severe Covid-19								
Age < 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	220	2180/2180 = 100.0% (100.0%, 100.0%)	2180/2180 = 100.0% (100.0%, 100.0%)	2142/2180 = 98.3% (94.7%, 99.4%)
Age < 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	70	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	39	0/2402 = 0.0% (0.0%, 0.0%)	0/2402 = 0.0% (0.0%, 0.0%)	0/2402 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	75	210.9/214 = 98.6% (90.1%, 99.8%)	210.9/214 = 98.6% (90.1%, 99.8%)	210.9/214 = 98.6% (90.1%, 99.8%)
Age < 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	220	2180/2180 = 100.0% (100.0%, 100.0%)	2180/2180 = 100.0% (100.0%, 100.0%)	2180/2180 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	70	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)	248/248 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	39	0/2402 = 0.0% (0.0%, 0.0%)	0/2402 = 0.0% (0.0%, 0.0%)	0/2402 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	75	214/214 = 100.0% (100.0%, 100.0%)	214/214 = 100.0% (100.0%, 100.0%)	214/214 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	219	8284/8284 = 100.0% (100.0%, 100.0%)	8284/8284 = 100.0% (100.0%, 100.0%)	8284/8284 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	76	882/882 = 100.0% (100.0%, 100.0%)	882/882 = 100.0% (100.0%, 100.0%)	882/882 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	38	0/7831 = 0.0% (0.0%, 0.0%)	0/7831 = 0.0% (0.0%, 0.0%)	0/7831 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	73	813/813 = 100.0% (100.0%, 100.0%)	813/813 = 100.0% (100.0%, 100.0%)	798.2/813 = 98.2% (87.6%, 99.8%)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	219	8284/8284 = 100.0% (100.0%, 100.0%)	8284/8284 = 100.0% (100.0%, 100.0%)	8284/8284 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	76	882/882 = 100.0% (100.0%, 100.0%)	882/882 = 100.0% (100.0%, 100.0%)	882/882 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	38	0/7831 = 0.0% (0.0%, 0.0%)	0/7831 = 0.0% (0.0%, 0.0%)	0/7831 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	73	813/813 = 100.0% (100.0%, 100.0%)	813/813 = 100.0% (100.0%, 100.0%)	813/813 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	250	1457.9/1457.9 = 100.0% (100.0%, 100.0%)	1457.9/1457.9 = 100.0% (100.0%, 100.0%)	1450.7/1457.9 = 99.5% (96.5%, 99.9%)
Age ≥ 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	50	109.6/109.6 = 100.0% (100.0%, 100.0%)	109.6/109.6 = 100.0% (100.0%, 100.0%)	109.6/109.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	41	0/1653.1 = 0.0% (0.0%, 0.0%)	0/1653.1 = 0.0% (0.0%, 0.0%)	0/1653.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	55	108/108 = 100.0% (100.0%, 100.0%)	108/108 = 100.0% (100.0%, 100.0%)	108/108 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	250	1457.9/1457.9 = 100.0% (100.0%, 100.0%)	1457.9/1457.9 = 100.0% (100.0%, 100.0%)	1457.9/1457.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	50	109.6/109.6 = 100.0% (100.0%, 100.0%)	109.6/109.6 = 100.0% (100.0%, 100.0%)	109.6/109.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	41	0/1653.1 = 0.0% (0.0%, 0.0%)	0/1653.1 = 0.0% (0.0%, 0.0%)	0/1653.1 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age ≥ 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	55	108/108 = 100.0% (100.0%, 100.0%)	108/108 = 100.0% (100.0%, 100.0%)	108/108 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	226	1375.1/1375.1 = 100.0% (100.0%, 100.0%)	1375.1/1375.1 = 100.0% (100.0%, 100.0%)	1375.1/1375.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	73	159.4/159.4 = 100.0% (100.0%, 100.0%)	159.4/159.4 = 100.0% (100.0%, 100.0%)	159.4/159.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	37	0/1494.9 = 0.0% (0.0%, 0.0%)	0/1494.9 = 0.0% (0.0%, 0.0%)	0/1494.9 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	73	141/141 = 100.0% (100.0%, 100.0%)	141/141 = 100.0% (100.0%, 100.0%)	141/141 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	226	1375.1/1375.1 = 100.0% (100.0%, 100.0%)	1375.1/1375.1 = 100.0% (100.0%, 100.0%)	1375.1/1375.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	73	159.4/159.4 = 100.0% (100.0%, 100.0%)	159.4/159.4 = 100.0% (100.0%, 100.0%)	159.4/159.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	37	0/1494.9 = 0.0% (0.0%, 0.0%)	0/1494.9 = 0.0% (0.0%, 0.0%)	0/1494.9 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	73	141/141 = 100.0% (100.0%, 100.0%)	141/141 = 100.0% (100.0%, 100.0%)	141/141 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4e. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Sex								
Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	391	5205.7/5205.7 = 100.0% (100.0%, 100.0%)	5205.7/5205.7 = 100.0% (100.0%, 100.0%)	5173.1/5205.7 = 99.4% (98.0%, 99.8%)
Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	113	549/549 = 100.0% (100.0%, 100.0%)	549/549 = 100.0% (100.0%, 100.0%)	549/549 = 100.0% (100.0%, 100.0%)
Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	60	0/4873.5 = 0.0% (0.0%, 0.0%)	0/4873.5 = 0.0% (0.0%, 0.0%)	0/4873.5 = 0.0% (0.0%, 0.0%)
Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	122	527.7/527.7 = 100.0% (100.0%, 100.0%)	527.7/527.7 = 100.0% (100.0%, 100.0%)	513/527.7 = 97.2% (82.3%, 99.6%)
Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	391	5205.7/5205.7 = 100.0% (100.0%, 100.0%)	5205.7/5205.7 = 100.0% (100.0%, 100.0%)	5205.7/5205.7 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	113	549/549 = 100.0% (100.0%, 100.0%)	549/549 = 100.0% (100.0%, 100.0%)	549/549 = 100.0% (100.0%, 100.0%)
Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	60	0/4873.5 = 0.0% (0.0%, 0.0%)	0/4873.5 = 0.0% (0.0%, 0.0%)	0/4873.5 = 0.0% (0.0%, 0.0%)
Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	122	527.7/527.7 = 100.0% (100.0%, 100.0%)	527.7/527.7 = 100.0% (100.0%, 100.0%)	527.7/527.7 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	524	8091.3/8091.3 = 100.0% (100.0%, 100.0%)	8091.3/8091.3 = 100.0% (100.0%, 100.0%)	8078.6/8091.3 = 99.8% (98.9%, 100.0%)
Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	156	850/850 = 100.0% (100.0%, 100.0%)	850/850 = 100.0% (100.0%, 100.0%)	850/850 = 100.0% (100.0%, 100.0%)
Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	95	0/8507.5 = 0.0% (0.0%, 0.0%)	0/8507.5 = 0.0% (0.0%, 0.0%)	0/8507.5 = 0.0% (0.0%, 0.0%)
Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	154	745.2/748.3 = 99.6% (97.1%, 99.9%)	745.2/748.3 = 99.6% (97.1%, 99.9%)	745.2/748.3 = 99.6% (97.1%, 99.9%)
Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	524	8091.3/8091.3 = 100.0% (100.0%, 100.0%)	8091.3/8091.3 = 100.0% (100.0%, 100.0%)	8091.3/8091.3 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	156	850/850 = 100.0% (100.0%, 100.0%)	850/850 = 100.0% (100.0%, 100.0%)	850/850 = 100.0% (100.0%, 100.0%)
Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	95	0/8507.5 = 0.0% (0.0%, 0.0%)	0/8507.5 = 0.0% (0.0%, 0.0%)	0/8507.5 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	154	748.3/748.3 = 100.0% (100.0%, 100.0%)	748.3/748.3 = 100.0% (100.0%, 100.0%)	748.3/748.3 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4f. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age, sex								
Age < 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	266	6555.3/6555.3 = 100.0% (100.0%, 100.0%)	6555.3/6555.3 = 100.0% (100.0%, 100.0%)	6542.7/6555.3 = 99.8% (98.6%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	90	709.9/709.9 = 100.0% (100.0%, 100.0%)	709.9/709.9 = 100.0% (100.0%, 100.0%)	709.9/709.9 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	50	0/6717.4 = 0.0% (0.0%, 0.0%)	0/6717.4 = 0.0% (0.0%, 0.0%)	0/6717.4 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	85	610.4/613.4 = 99.5% (96.4%, 99.9%)	610.4/613.4 = 99.5% (96.4%, 99.9%)	610.4/613.4 = 99.5% (96.4%, 99.9%)
Age < 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	266	6555.3/6555.3 = 100.0% (100.0%, 100.0%)	6555.3/6555.3 = 100.0% (100.0%, 100.0%)	6555.3/6555.3 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	90	709.9/709.9 = 100.0% (100.0%, 100.0%)	709.9/709.9 = 100.0% (100.0%, 100.0%)	709.9/709.9 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	50	0/6717.4 = 0.0% (0.0%, 0.0%)	0/6717.4 = 0.0% (0.0%, 0.0%)	0/6717.4 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	85	613.4/613.4 = 100.0% (100.0%, 100.0%)	613.4/613.4 = 100.0% (100.0%, 100.0%)	613.4/613.4 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	173	3908.7/3908.7 = 100.0% (100.0%, 100.0%)	3908.7/3908.7 = 100.0% (100.0%, 100.0%)	3883.3/3908.7 = 99.4% (97.4%, 99.8%)
Age < 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	56	420.1/420.1 = 100.0% (100.0%, 100.0%)	420.1/420.1 = 100.0% (100.0%, 100.0%)	420.1/420.1 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	27	0/3515.6 = 0.0% (0.0%, 0.0%)	0/3515.6 = 0.0% (0.0%, 0.0%)	0/3515.6 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	63	413.6/413.6 = 100.0% (100.0%, 100.0%)	413.6/413.6 = 100.0% (100.0%, 100.0%)	398.8/413.6 = 96.4% (77.8%, 99.5%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age < 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	173	3908.7/3908.7 = 100.0% (100.0%, 100.0%)	3908.7/3908.7 = 100.0% (100.0%, 100.0%)	3908.7/3908.7 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	56	420.1/420.1 = 100.0% (100.0%, 100.0%)	420.1/420.1 = 100.0% (100.0%, 100.0%)	420.1/420.1 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	27	0/3515.6 = 0.0% (0.0%, 0.0%)	0/3515.6 = 0.0% (0.0%, 0.0%)	0/3515.6 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	63	413.6/413.6 = 100.0% (100.0%, 100.0%)	413.6/413.6 = 100.0% (100.0%, 100.0%)	413.6/413.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	218	1297/1297 = 100.0% (100.0%, 100.0%)	1297/1297 = 100.0% (100.0%, 100.0%)	1289.8/1297 = 99.4% (96.1%, 99.9%)
Age ≥ 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	57	128.9/128.9 = 100.0% (100.0%, 100.0%)	128.9/128.9 = 100.0% (100.0%, 100.0%)	128.9/128.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	33	0/1357.9 = 0.0% (0.0%, 0.0%)	0/1357.9 = 0.0% (0.0%, 0.0%)	0/1357.9 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	59	114.2/114.2 = 100.0% (100.0%, 100.0%)	114.2/114.2 = 100.0% (100.0%, 100.0%)	114.2/114.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	218	1297/1297 = 100.0% (100.0%, 100.0%)	1297/1297 = 100.0% (100.0%, 100.0%)	1297/1297 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	57	128.9/128.9 = 100.0% (100.0%, 100.0%)	128.9/128.9 = 100.0% (100.0%, 100.0%)	128.9/128.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	33	0/1357.9 = 0.0% (0.0%, 0.0%)	0/1357.9 = 0.0% (0.0%, 0.0%)	0/1357.9 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	59	114.2/114.2 = 100.0% (100.0%, 100.0%)	114.2/114.2 = 100.0% (100.0%, 100.0%)	114.2/114.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	258	1536/1536 = 100.0% (100.0%, 100.0%)	1536/1536 = 100.0% (100.0%, 100.0%)	1536/1536 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	66	140.1/140.1 = 100.0% (100.0%, 100.0%)	140.1/140.1 = 100.0% (100.0%, 100.0%)	140.1/140.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	45	0/1790.1 = 0.0% (0.0%, 0.0%)	0/1790.1 = 0.0% (0.0%, 0.0%)	0/1790.1 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age ≥ 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	69	134.8/134.8 = 100.0% (100.0%, 100.0%)	134.8/134.8 = 100.0% (100.0%, 100.0%)	134.8/134.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	258	1536/1536 = 100.0% (100.0%, 100.0%)	1536/1536 = 100.0% (100.0%, 100.0%)	1536/1536 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	66	140.1/140.1 = 100.0% (100.0%, 100.0%)	140.1/140.1 = 100.0% (100.0%, 100.0%)	140.1/140.1 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	45	0/1790.1 = 0.0% (0.0%, 0.0%)	0/1790.1 = 0.0% (0.0%, 0.0%)	0/1790.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	69	134.8/134.8 = 100.0% (100.0%, 100.0%)	134.8/134.8 = 100.0% (100.0%, 100.0%)	134.8/134.8 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4g. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Hispanic or Latino ethnicity

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Hispanic or Latino ethnicity								
Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	130	1388.1/1388.1 = 100.0% (100.0%, 100.0%)	1388.1/1388.1 = 100.0% (100.0%, 100.0%)	1388.1/1388.1 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	34	129.4/129.4 = 100.0% (100.0%, 100.0%)	129.4/129.4 = 100.0% (100.0%, 100.0%)	129.4/129.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	22	0/1015.8 = 0.0% (0.0%, 0.0%)	0/1015.8 = 0.0% (0.0%, 0.0%)	0/1015.8 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	25	90.1/90.1 = 100.0% (100.0%, 100.0%)	90.1/90.1 = 100.0% (100.0%, 100.0%)	90.1/90.1 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	130	1388.1/1388.1 = 100.0% (100.0%, 100.0%)	1388.1/1388.1 = 100.0% (100.0%, 100.0%)	1388.1/1388.1 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	34	129.4/129.4 = 100.0% (100.0%, 100.0%)	129.4/129.4 = 100.0% (100.0%, 100.0%)	129.4/129.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	22	0/1015.8 = 0.0% (0.0%, 0.0%)	0/1015.8 = 0.0% (0.0%, 0.0%)	0/1015.8 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	25	90.1/90.1 = 100.0% (100.0%, 100.0%)	90.1/90.1 = 100.0% (100.0%, 100.0%)	90.1/90.1 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	690	10338.6/10338.6 = 100.0% (100.0%, 100.0%)	10338.6/10338.6 = 100.0% (100.0%, 100.0%)	10318.6/10338.6 = 99.8% (99.2%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	197	1055.1/1055.1 = 100.0% (100.0%, 100.0%)	1055.1/1055.1 = 100.0% (100.0%, 100.0%)	1055.1/1055.1 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	118	0/10825.9 = 0.0% (0.0%, 0.0%)	0/10825.9 = 0.0% (0.0%, 0.0%)	0/10825.9 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	222	1060.5/1063.5 = 99.7% (97.9%, 100.0%)	1060.5/1063.5 = 99.7% (97.9%, 100.0%)	1045.7/1063.5 = 98.3% (91.5%, 99.7%)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	690	10338.6/10338.6 = 100.0% (100.0%, 100.0%)	10338.6/10338.6 = 100.0% (100.0%, 100.0%)	10338.6/10338.6 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	197	1055.1/1055.1 = 100.0% (100.0%, 100.0%)	1055.1/1055.1 = 100.0% (100.0%, 100.0%)	1055.1/1055.1 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	118	0/10825.9 = 0.0% (0.0%, 0.0%)	0/10825.9 = 0.0% (0.0%, 0.0%)	0/10825.9 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	222	1063.5/1063.5 = 100.0% (100.0%, 100.0%)	1063.5/1063.5 = 100.0% (100.0%, 100.0%)	1063.5/1063.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	95	1570.4/1570.4 = 100.0% (100.0%, 100.0%)	1570.4/1570.4 = 100.0% (100.0%, 100.0%)	1545/1570.4 = 98.4% (93.6%, 99.6%)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	38	214.4/214.4 = 100.0% (100.0%, 100.0%)	214.4/214.4 = 100.0% (100.0%, 100.0%)	214.4/214.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	15	0/1539.4 = 0.0% (0.0%, 0.0%)	0/1539.4 = 0.0% (0.0%, 0.0%)	0/1539.4 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	29	122.4/122.4 = 100.0% (100.0%, 100.0%)	122.4/122.4 = 100.0% (100.0%, 100.0%)	122.4/122.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	95	1570.4/1570.4 = 100.0% (100.0%, 100.0%)	1570.4/1570.4 = 100.0% (100.0%, 100.0%)	1570.4/1570.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	38	214.4/214.4 = 100.0% (100.0%, 100.0%)	214.4/214.4 = 100.0% (100.0%, 100.0%)	214.4/214.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	15	0/1539.4 = 0.0% (0.0%, 0.0%)	0/1539.4 = 0.0% (0.0%, 0.0%)	0/1539.4 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	29	122.4/122.4 = 100.0% (100.0%, 100.0%)	122.4/122.4 = 100.0% (100.0%, 100.0%)	122.4/122.4 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4h. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Race

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Race								
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	359	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)	6457.3/6470 = 99.8% (98.6%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	107	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	62	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	127	696.9/699.9 = 99.6% (96.9%, 99.9%)	696.9/699.9 = 99.6% (96.9%, 99.9%)	682.1/699.9 = 97.4% (87.3%, 99.5%)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	359	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	107	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	62	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	127	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	202	1936.1/1936.1 = 100.0% (100.0%, 100.0%)	1936.1/1936.1 = 100.0% (100.0%, 100.0%)	1936.1/1936.1 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	50	177.9/177.9 = 100.0% (100.0%, 100.0%)	177.9/177.9 = 100.0% (100.0%, 100.0%)	177.9/177.9 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Black or African American	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	23	0/1559.4 = 0.0% (0.0%, 0.0%)	0/1559.4 = 0.0% (0.0%, 0.0%)	0/1559.4 = 0.0% (0.0%, 0.0%)
Black or African American	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	58	231.3/231.3 = 100.0% (100.0%, 100.0%)	231.3/231.3 = 100.0% (100.0%, 100.0%)	231.3/231.3 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	202	1936.1/1936.1 = 100.0% (100.0%, 100.0%)	1936.1/1936.1 = 100.0% (100.0%, 100.0%)	1936.1/1936.1 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	50	177.9/177.9 = 100.0% (100.0%, 100.0%)	177.9/177.9 = 100.0% (100.0%, 100.0%)	177.9/177.9 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	23	0/1559.4 = 0.0% (0.0%, 0.0%)	0/1559.4 = 0.0% (0.0%, 0.0%)	0/1559.4 = 0.0% (0.0%, 0.0%)
Black or African American	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	58	231.3/231.3 = 100.0% (100.0%, 100.0%)	231.3/231.3 = 100.0% (100.0%, 100.0%)	231.3/231.3 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	58	689.4/689.4 = 100.0% (100.0%, 100.0%)	689.4/689.4 = 100.0% (100.0%, 100.0%)	689.4/689.4 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	19	58.3/58.3 = 100.0% (100.0%, 100.0%)	58.3/58.3 = 100.0% (100.0%, 100.0%)	58.3/58.3 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	13	0/1335.3 = 0.0% (0.0%, 0.0%)	0/1335.3 = 0.0% (0.0%, 0.0%)	0/1335.3 = 0.0% (0.0%, 0.0%)
Asian	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	18	57.4/57.4 = 100.0% (100.0%, 100.0%)	57.4/57.4 = 100.0% (100.0%, 100.0%)	57.4/57.4 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	58	689.4/689.4 = 100.0% (100.0%, 100.0%)	689.4/689.4 = 100.0% (100.0%, 100.0%)	689.4/689.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Asian	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	19	58.3/58.3 = 100.0% (100.0%, 100.0%)	58.3/58.3 = 100.0% (100.0%, 100.0%)	58.3/58.3 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	13	0/1335.3 = 0.0% (0.0%, 0.0%)	0/1335.3 = 0.0% (0.0%, 0.0%)	0/1335.3 = 0.0% (0.0%, 0.0%)
Asian	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	18	57.4/57.4 = 100.0% (100.0%, 100.0%)	57.4/57.4 = 100.0% (100.0%, 100.0%)	57.4/57.4 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	22	226.5/226.5 = 100.0% (100.0%, 100.0%)	226.5/226.5 = 100.0% (100.0%, 100.0%)	226.5/226.5 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	7	39.4/39.4 = 100.0% (100.0%, 100.0%)	39.4/39.4 = 100.0% (100.0%, 100.0%)	39.4/39.4 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	4	0/287.4 = 0.0%	0/287.4 = 0.0%	0/287.4 = 0.0%
American Indian or Alaska Native	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	4	30.4/30.4 = 100.0% (100.0%, 100.0%)	30.4/30.4 = 100.0% (100.0%, 100.0%)	30.4/30.4 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	22	226.5/226.5 = 100.0% (100.0%, 100.0%)	226.5/226.5 = 100.0% (100.0%, 100.0%)	226.5/226.5 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	7	39.4/39.4 = 100.0% (100.0%, 100.0%)	39.4/39.4 = 100.0% (100.0%, 100.0%)	39.4/39.4 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	4	0/287.4 = 0.0%	0/287.4 = 0.0%	0/287.4 = 0.0%

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
American Indian or Alaska Native	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	4	30.4/30.4 = 100.0% (100.0%, 100.0%)	30.4/30.4 = 100.0% (100.0%, 100.0%)	30.4/30.4 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	11	125.8/125.8 = 100.0% (100.0%, 100.0%)	125.8/125.8 = 100.0% (100.0%, 100.0%)	125.8/125.8 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	6	26.1/26.1 = 100.0% (100.0%, 100.0%)	26.1/26.1 = 100.0% (100.0%, 100.0%)	26.1/26.1 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5	0/316.4 = 0.0% (0.0%, 0.0%)	0/316.4 = 0.0% (0.0%, 0.0%)	0/316.4 = 0.0% (0.0%, 0.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	4	13/13 = 100.0% (100.0%, 100.0%)	13/13 = 100.0% (100.0%, 100.0%)	13/13 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	11	125.8/125.8 = 100.0% (100.0%, 100.0%)	125.8/125.8 = 100.0% (100.0%, 100.0%)	125.8/125.8 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	6	26.1/26.1 = 100.0% (100.0%, 100.0%)	26.1/26.1 = 100.0% (100.0%, 100.0%)	26.1/26.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5	0/316.4 = 0.0% (0.0%, 0.0%)	0/316.4 = 0.0% (0.0%, 0.0%)	0/316.4 = 0.0% (0.0%, 0.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	4	13/13 = 100.0% (100.0%, 100.0%)	13/13 = 100.0% (100.0%, 100.0%)	13/13 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	60	641.2/641.2 = 100.0% (100.0%, 100.0%)	641.2/641.2 = 100.0% (100.0%, 100.0%)	641.2/641.2 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	11	45.8/45.8 = 100.0% (100.0%, 100.0%)	45.8/45.8 = 100.0% (100.0%, 100.0%)	45.8/45.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	10	0/496.6 = 0.0% (0.0%, 0.0%)	0/496.6 = 0.0% (0.0%, 0.0%)	0/496.6 = 0.0% (0.0%, 0.0%)
Multiracial	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	14	56.8/56.8 = 100.0% (100.0%, 100.0%)	56.8/56.8 = 100.0% (100.0%, 100.0%)	56.8/56.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	60	641.2/641.2 = 100.0% (100.0%, 100.0%)	641.2/641.2 = 100.0% (100.0%, 100.0%)	641.2/641.2 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	11	45.8/45.8 = 100.0% (100.0%, 100.0%)	45.8/45.8 = 100.0% (100.0%, 100.0%)	45.8/45.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	10	0/496.6 = 0.0% (0.0%, 0.0%)	0/496.6 = 0.0% (0.0%, 0.0%)	0/496.6 = 0.0% (0.0%, 0.0%)
Multiracial	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	14	56.8/56.8 = 100.0% (100.0%, 100.0%)	56.8/56.8 = 100.0% (100.0%, 100.0%)	56.8/56.8 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	21	192.5/192.5 = 100.0% (100.0%, 100.0%)	192.5/192.5 = 100.0% (100.0%, 100.0%)	192.5/192.5 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	8	43.3/43.3 = 100.0% (100.0%, 100.0%)	43.3/43.3 = 100.0% (100.0%, 100.0%)	43.3/43.3 = 100.0% (100.0%, 100.0%)
Other	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	4	0/151.2 = 0.0% (0.0%, 0.0%)	0/151.2 = 0.0% (0.0%, 0.0%)	0/151.2 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Other	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	7	14.5/14.5 = 100.0% (100.0%, 100.0%)	14.5/14.5 = 100.0% (100.0%, 100.0%)	14.5/14.5 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	21	192.5/192.5 = 100.0% (100.0%, 100.0%)	192.5/192.5 = 100.0% (100.0%, 100.0%)	192.5/192.5 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	8	43.3/43.3 = 100.0% (100.0%, 100.0%)	43.3/43.3 = 100.0% (100.0%, 100.0%)	43.3/43.3 = 100.0% (100.0%, 100.0%)
Other	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	4	0/151.2 = 0.0% (0.0%, 0.0%)	0/151.2 = 0.0% (0.0%, 0.0%)	0/151.2 = 0.0% (0.0%, 0.0%)
Other	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	7	14.5/14.5 = 100.0% (100.0%, 100.0%)	14.5/14.5 = 100.0% (100.0%, 100.0%)	14.5/14.5 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	86	1654.7/1654.7 = 100.0% (100.0%, 100.0%)	1654.7/1654.7 = 100.0% (100.0%, 100.0%)	1647.4/1654.7 = 99.6% (96.8%, 99.9%)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	25	186.7/186.7 = 100.0% (100.0%, 100.0%)	186.7/186.7 = 100.0% (100.0%, 100.0%)	186.7/186.7 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	19	0/1887.3 = 0.0% (0.0%, 0.0%)	0/1887.3 = 0.0% (0.0%, 0.0%)	0/1887.3 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	24	90.4/90.4 = 100.0% (100.0%, 100.0%)	90.4/90.4 = 100.0% (100.0%, 100.0%)	90.4/90.4 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	86	1654.7/1654.7 = 100.0% (100.0%, 100.0%)	1654.7/1654.7 = 100.0% (100.0%, 100.0%)	1654.7/1654.7 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	25	186.7/186.7 = 100.0% (100.0%, 100.0%)	186.7/186.7 = 100.0% (100.0%, 100.0%)	186.7/186.7 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	19	0/1887.3 = 0.0% (0.0%, 0.0%)	0/1887.3 = 0.0% (0.0%, 0.0%)	0/1887.3 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	24	90.4/90.4 = 100.0% (100.0%, 100.0%)	90.4/90.4 = 100.0% (100.0%, 100.0%)	90.4/90.4 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4i. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Underrepresented minority status								
Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	420	4355/4355 = 100.0% (100.0%, 100.0%)	4355/4355 = 100.0% (100.0%, 100.0%)	4355/4355 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	110	420/420 = 100.0% (100.0%, 100.0%)	420/420 = 100.0% (100.0%, 100.0%)	420/420 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	66	0/4349 = 0.0% (0.0%, 0.0%)	0/4349 = 0.0% (0.0%, 0.0%)	0/4349 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	112	434/434 = 100.0% (100.0%, 100.0%)	434/434 = 100.0% (100.0%, 100.0%)	434/434 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	420	4355/4355 = 100.0% (100.0%, 100.0%)	4355/4355 = 100.0% (100.0%, 100.0%)	4355/4355 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	110	420/420 = 100.0% (100.0%, 100.0%)	420/420 = 100.0% (100.0%, 100.0%)	420/420 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	66	0/4349 = 0.0% (0.0%, 0.0%)	0/4349 = 0.0% (0.0%, 0.0%)	0/4349 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	112	434/434 = 100.0% (100.0%, 100.0%)	434/434 = 100.0% (100.0%, 100.0%)	434/434 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	359	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)	6457.3/6470 = 99.8% (98.6%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	107	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	62	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	127	696.9/699.9 = 99.6% (96.9%, 99.9%)	696.9/699.9 = 99.6% (96.9%, 99.9%)	682.1/699.9 = 97.4% (87.3%, 99.5%)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	359	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)	6470/6470 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	107	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)	622/622 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	62	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)	0/6021.9 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	127	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)	699.9/699.9 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4j. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age, Underrepresented minority status								
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	202	3395/3395 = 100.0% (100.0%, 100.0%)	3395/3395 = 100.0% (100.0%, 100.0%)	3395/3395 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	60	335/335 = 100.0% (100.0%, 100.0%)	335/335 = 100.0% (100.0%, 100.0%)	335/335 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	30	0/3306 = 0.0% (0.0%, 0.0%)	0/3306 = 0.0% (0.0%, 0.0%)	0/3306 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	65	350/350 = 100.0% (100.0%, 100.0%)	350/350 = 100.0% (100.0%, 100.0%)	350/350 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	202	3395/3395 = 100.0% (100.0%, 100.0%)	3395/3395 = 100.0% (100.0%, 100.0%)	3395/3395 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	60	335/335 = 100.0% (100.0%, 100.0%)	335/335 = 100.0% (100.0%, 100.0%)	335/335 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	30	0/3306 = 0.0% (0.0%, 0.0%)	0/3306 = 0.0% (0.0%, 0.0%)	0/3306 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	65	350/350 = 100.0% (100.0%, 100.0%)	350/350 = 100.0% (100.0%, 100.0%)	350/350 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	171	5105.2/5105.2 = 100.0% (100.0%, 100.0%)	5105.2/5105.2 = 100.0% (100.0%, 100.0%)	5092.5/5105.2 = 99.8% (98.2%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	56	493.4/493.4 = 100.0% (100.0%, 100.0%)	493.4/493.4 = 100.0% (100.0%, 100.0%)	493.4/493.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	32	0/4518.4 = 0.0% (0.0%, 0.0%)	0/4518.4 = 0.0% (0.0%, 0.0%)	0/4518.4 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	64	568.5/571.6 = 99.5% (96.1%, 99.9%)	568.5/571.6 = 99.5% (96.1%, 99.9%)	553.7/571.6 = 96.9% (84.5%, 99.4%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	171	5105.2/5105.2 = 100.0% (100.0%, 100.0%)	5105.2/5105.2 = 100.0% (100.0%, 100.0%)	5105.2/5105.2 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	56	493.4/493.4 = 100.0% (100.0%, 100.0%)	493.4/493.4 = 100.0% (100.0%, 100.0%)	493.4/493.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	32	0/4518.4 = 0.0% (0.0%, 0.0%)	0/4518.4 = 0.0% (0.0%, 0.0%)	0/4518.4 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	64	571.6/571.6 = 100.0% (100.0%, 100.0%)	571.6/571.6 = 100.0% (100.0%, 100.0%)	571.6/571.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	218	960/960 = 100.0% (100.0%, 100.0%)	960/960 = 100.0% (100.0%, 100.0%)	960/960 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age ≥ 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	50	85/85 = 100.0% (100.0%, 100.0%)	85/85 = 100.0% (100.0%, 100.0%)	85/85 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	36	0/1043 = 0.0% (0.0%, 0.0%)	0/1043 = 0.0% (0.0%, 0.0%)	0/1043 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	47	84/84 = 100.0% (100.0%, 100.0%)	84/84 = 100.0% (100.0%, 100.0%)	84/84 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	218	960/960 = 100.0% (100.0%, 100.0%)	960/960 = 100.0% (100.0%, 100.0%)	960/960 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	50	85/85 = 100.0% (100.0%, 100.0%)	85/85 = 100.0% (100.0%, 100.0%)	85/85 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	36	0/1043 = 0.0% (0.0%, 0.0%)	0/1043 = 0.0% (0.0%, 0.0%)	0/1043 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	47	84/84 = 100.0% (100.0%, 100.0%)	84/84 = 100.0% (100.0%, 100.0%)	84/84 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	188	1364.8/1364.8 = 100.0% (100.0%, 100.0%)	1364.8/1364.8 = 100.0% (100.0%, 100.0%)	1364.8/1364.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	51	128.5/128.5 = 100.0% (100.0%, 100.0%)	128.5/128.5 = 100.0% (100.0%, 100.0%)	128.5/128.5 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	30	0/1503.6 = 0.0% (0.0%, 0.0%)	0/1503.6 = 0.0% (0.0%, 0.0%)	0/1503.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	63	128.3/128.3 = 100.0% (100.0%, 100.0%)	128.3/128.3 = 100.0% (100.0%, 100.0%)	128.3/128.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	188	1364.8/1364.8 = 100.0% (100.0%, 100.0%)	1364.8/1364.8 = 100.0% (100.0%, 100.0%)	1364.8/1364.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	51	128.5/128.5 = 100.0% (100.0%, 100.0%)	128.5/128.5 = 100.0% (100.0%, 100.0%)	128.5/128.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	30	0/1503.6 = 0.0% (0.0%, 0.0%)	0/1503.6 = 0.0% (0.0%, 0.0%)	0/1503.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	63	128.3/128.3 = 100.0% (100.0%, 100.0%)	128.3/128.3 = 100.0% (100.0%, 100.0%)	128.3/128.3 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 5a. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by All participants

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
All participants						
	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	915	0.02 (0.02, 0.02)
	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	915	0.27 (0.27, 0.27)
	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	915	0.09 (0.09, 0.09)
	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	915	5.00 (5.00, 5.00)
	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	915	5.00 (5.00, 5.00)
	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	269	0.02 (0.02, 0.02)
	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	269	0.27 (0.27, 0.28)
	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	269	0.09 (0.09, 0.09)
	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	269	5.00 (5.00, 5.00)
	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	269	5.00 (5.00, 5.00)
	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	155	0.02 (0.02, 0.02)
	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	155	0.27 (0.27, 0.27)
	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	155	0.09 (0.09, 0.09)
	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	155	5.06 (4.97, 5.14)
	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	155	5.10 (4.95, 5.26)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	276	0.02 (0.02, 0.02)
	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	276	0.27 (0.27, 0.27)
	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	276	0.09 (0.09, 0.09)
	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	276	5.00 (5.00, 5.00)
	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	276	5.00 (5.00, 5.00)
	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	915	62.87 (53.77, 73.52)
	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	915	700.18 (608.59, 805.55)
	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	915	412.01 (364.96, 465.13)
	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	915	225.10 (209.62, 241.74)
	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	915	46.79 (43.69, 50.12)
	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	269	103.45 (79.96, 133.83)
	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	269	1269.77 (1009.63, 1596.93)
	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	269	766.27 (626.05, 937.90)
	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	269	354.90 (317.58, 396.60)
	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	269	76.03 (68.29, 84.64)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	155	0.02 (0.02, 0.02)
	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	155	0.27 (0.27, 0.27)
	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	155	0.09 (0.09, 0.09)
	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	155	5.01 (4.99, 5.04)
	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	155	5.04 (4.99, 5.09)
	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	276	29.12 (22.05, 38.45)
	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	276	369.13 (289.11, 471.31)
	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	276	186.46 (150.24, 231.43)
	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	276	109.67 (96.21, 125.02)
	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	276	25.20 (22.40, 28.34)
	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	915	858.71 (706.57, 1043.61)
	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	915	31262.39 (26797.12, 36471.73)
	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	915	21267.84 (18637.15, 24269.85)
	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	915	10118.66 (9384.97, 10909.71)
	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	915	1464.36 (1363.33, 1572.87)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	269	2216.51 (1602.80, 3065.20)
	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	269	73550.05 (58195.76, 92955.40)
	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	269	51328.47 (41972.47, 62770.00)
	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	269	27542.73 (24378.19, 31118.07)
	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	269	4408.72 (3893.97, 4991.51)
	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	155	0.02 (0.02, 0.02)
	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	155	0.27 (0.27, 0.27)
	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	155	0.09 (0.09, 0.09)
	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	155	5.00 (5.00, 5.00)
	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	155	5.02 (4.98, 5.06)
	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	276	373.57 (268.20, 520.32)
	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	276	13174.89 (10267.01, 16906.37)
	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	276	7011.64 (5627.97, 8735.50)
	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	276	3530.63 (3123.48, 3990.86)
	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	276	767.20 (679.53, 866.17)

Table 5b. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age						
Age < 65	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	439	0.02 (0.02, 0.02)
Age < 65	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	439	0.27 (0.27, 0.27)
Age < 65	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	439	0.09 (0.09, 0.09)
Age < 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	439	5.00 (5.00, 5.00)
Age < 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	439	5.00 (5.00, 5.00)
Age < 65	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	146	0.02 (0.02, 0.02)
Age < 65	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	146	0.28 (0.27, 0.28)
Age < 65	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	146	0.09 (0.09, 0.09)
Age < 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	146	5.00 (5.00, 5.00)
Age < 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	146	5.00 (5.00, 5.00)
Age < 65	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	77	0.02 (0.02, 0.02)
Age < 65	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	77	0.27 (0.27, 0.27)
Age < 65	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	77	0.09 (0.09, 0.09)
Age < 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	77	5.06 (4.95, 5.17)
Age < 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	77	5.13 (4.93, 5.34)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	148	0.02 (0.02, 0.02)
Age < 65	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	148	0.27 (0.27, 0.27)
Age < 65	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	148	0.09 (0.09, 0.09)
Age < 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	148	5.00 (5.00, 5.00)
Age < 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	148	5.00 (5.00, 5.00)
Age < 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	439	50.34 (41.46, 61.11)
Age < 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	439	550.94 (463.04, 655.53)
Age < 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	439	321.20 (276.30, 373.39)
Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	439	207.85 (190.33, 226.99)
Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	439	44.22 (40.61, 48.14)
Age < 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	146	79.94 (58.66, 108.95)
Age < 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	146	999.08 (758.84, 1315.39)
Age < 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	146	610.04 (478.76, 777.31)
Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	146	309.64 (271.19, 353.54)
Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	146	71.33 (62.71, 81.14)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	77	0.02 (0.02, 0.02)
Age < 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	77	0.27 (0.27, 0.27)
Age < 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	77	0.09 (0.09, 0.09)
Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	77	5.02 (4.98, 5.05)
Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	77	5.00 (5.00, 5.00)
Age < 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	148	21.99 (15.74, 30.72)
Age < 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	148	287.32 (213.80, 386.13)
Age < 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	148	139.33 (107.34, 180.85)
Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	148	99.72 (85.10, 116.85)
Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	148	23.32 (20.23, 26.87)
Age < 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	439	670.07 (526.00, 853.60)
Age < 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	439	24070.27 (19874.19, 29152.28)
Age < 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	439	16814.24 (14267.46, 19815.61)
Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	439	9490.17 (8656.06, 10404.66)
Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	439	1397.30 (1279.13, 1526.39)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	146	1663.57 (1123.53, 2463.21)
Age < 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	146	57082.50 (42972.14, 75826.14)
Age < 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	146	42890.13 (33529.63, 54863.81)
Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	146	24881.39 (21477.94, 28824.16)
Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	146	4228.18 (3638.81, 4913.01)
Age < 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	77	0.02 (0.02, 0.02)
Age < 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	77	0.27 (0.27, 0.27)
Age < 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	77	0.09 (0.09, 0.09)
Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	77	5.00 (5.00, 5.00)
Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	77	5.00 (5.00, 5.00)
Age < 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	148	289.22 (193.94, 431.30)
Age < 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	148	9706.29 (7200.73, 13083.69)
Age < 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	148	5041.42 (3870.53, 6566.51)
Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	148	3221.65 (2778.88, 3734.97)
Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	148	728.07 (628.05, 844.02)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	476	0.02 (0.02, 0.02)
Age \geq 65	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	476	0.27 (0.27, 0.27)
Age \geq 65	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	476	0.09 (0.09, 0.09)
Age \geq 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	476	5.00 (5.00, 5.00)
Age \geq 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	476	5.00 (5.00, 5.00)
Age \geq 65	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	123	0.02 (0.02, 0.02)
Age \geq 65	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	123	0.27 (0.27, 0.27)
Age \geq 65	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	123	0.09 (0.09, 0.09)
Age \geq 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	123	5.00 (5.00, 5.00)
Age \geq 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	123	5.00 (5.00, 5.00)
Age \geq 65	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	78	0.02 (0.02, 0.02)
Age \geq 65	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	78	0.27 (0.27, 0.27)
Age \geq 65	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	78	0.09 (0.09, 0.09)
Age \geq 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	78	5.06 (4.95, 5.17)
Age \geq 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	78	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	128	0.02 (0.02, 0.02)
Age \geq 65	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	128	0.27 (0.27, 0.27)
Age \geq 65	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	128	0.09 (0.09, 0.09)
Age \geq 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	128	5.00 (5.00, 5.00)
Age \geq 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	128	5.00 (5.00, 5.00)
Age \geq 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	476	142.97 (122.29, 167.15)
Age \geq 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	476	1697.17 (1476.47, 1950.87)
Age \geq 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	476	1033.49 (921.14, 1159.53)
Age \geq 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	476	302.19 (279.71, 326.47)
Age \geq 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	476	57.69 (53.68, 61.99)
Age \geq 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	123	305.43 (229.49, 406.50)
Age \geq 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	123	3476.30 (2675.49, 4516.80)
Age \geq 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	123	1996.92 (1588.01, 2511.12)
Age \geq 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	123	629.50 (550.72, 719.56)
Age \geq 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	123	99.38 (87.21, 113.25)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	78	0.02 (0.02, 0.02)
Age ≥ 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	78	0.27 (0.27, 0.27)
Age ≥ 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	78	0.09 (0.09, 0.09)
Age ≥ 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	78	5.00 (5.00, 5.00)
Age ≥ 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	78	5.16 (4.94, 5.38)
Age ≥ 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	128	92.71 (67.40, 127.53)
Age ≥ 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	128	1037.48 (810.01, 1328.81)
Age ≥ 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	128	620.20 (506.97, 758.71)
Age ≥ 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	128	162.38 (141.07, 186.91)
Age ≥ 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	128	34.70 (30.29, 39.75)
Age ≥ 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	476	2146.59 (1771.78, 2600.69)
Age ≥ 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	476	82110.63 (71014.15, 94941.01)
Age ≥ 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	476	50657.32 (44864.13, 57198.57)
Age ≥ 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	476	12822.88 (11646.56, 14118.02)
Age ≥ 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	476	1741.16 (1611.24, 1881.54)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	123	7399.38 (5407.50, 10124.98)
Age \geq 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	123	213304.93 (174553.45, 260659.38)
Age \geq 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	123	109149.12 (96376.34, 123614.67)
Age \geq 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	123	42208.09 (36925.09, 48246.95)
Age \geq 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	123	5255.28 (4583.13, 6026.00)
Age \geq 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	78	0.02 (0.02, 0.02)
Age \geq 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	78	0.27 (0.27, 0.27)
Age \geq 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	78	0.09 (0.09, 0.09)
Age \geq 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	78	5.00 (5.00, 5.00)
Age \geq 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	78	5.09 (4.92, 5.26)
Age \geq 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	128	1073.37 (733.41, 1570.91)
Age \geq 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	128	46456.10 (34649.89, 62285.03)
Age \geq 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	128	27335.34 (22100.74, 33809.76)
Age \geq 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	128	5151.11 (4476.77, 5927.03)
Age \geq 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	128	952.05 (844.89, 1072.80)

Table 5c. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Risk for Severe Covid-19						
At-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	470	0.02 (0.02, 0.02)
At-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	470	0.27 (0.27, 0.27)
At-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	470	0.09 (0.09, 0.09)
At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	470	5.00 (5.00, 5.00)
At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	470	5.00 (5.00, 5.00)
At-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	120	0.02 (0.02, 0.02)
At-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	0.27 (0.27, 0.27)
At-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	0.09 (0.09, 0.09)
At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	120	5.00 (5.00, 5.00)
At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	120	5.00 (5.00, 5.00)
At-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	80	0.02 (0.02, 0.02)
At-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	80	0.27 (0.27, 0.27)
At-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	80	0.09 (0.09, 0.09)
At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	80	5.18 (4.90, 5.49)
At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	80	5.08 (4.92, 5.25)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
At-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	130	0.02 (0.02, 0.02)
At-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	130	0.27 (0.27, 0.27)
At-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	130	0.09 (0.09, 0.09)
At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	130	5.00 (5.00, 5.00)
At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	130	5.00 (5.00, 5.00)
At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	470	77.19 (63.87, 93.30)
At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	470	789.30 (668.92, 931.35)
At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	470	491.89 (424.55, 569.92)
At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	470	235.72 (214.95, 258.50)
At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	470	45.83 (42.33, 49.62)
At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	120	102.78 (69.98, 150.97)
At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	1259.80 (895.65, 1771.99)
At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	765.93 (596.13, 984.11)
At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	120	361.93 (307.30, 426.28)
At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	120	73.56 (62.44, 86.67)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	80	0.02 (0.02, 0.02)
At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	80	0.27 (0.27, 0.27)
At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	80	0.09 (0.09, 0.09)
At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	80	5.04 (4.96, 5.12)
At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	80	5.12 (4.96, 5.29)
At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	130	37.13 (27.28, 50.54)
At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	130	424.65 (331.07, 544.67)
At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	130	244.01 (195.94, 303.87)
At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	130	111.25 (96.73, 127.96)
At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	130	27.62 (24.40, 31.27)
At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	470	945.85 (763.79, 1171.29)
At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	470	34720.06 (28933.29, 41664.21)
At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	470	21888.00 (18578.88, 25786.52)
At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	470	9196.69 (8308.44, 10179.89)
At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	470	1390.11 (1276.66, 1513.64)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	120	2297.78 (1510.26, 3495.95)
At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	85028.77 (62305.26, 116039.82)
At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	40668.98 (31140.77, 53112.55)
At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	120	28755.58 (24251.77, 34095.79)
At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	120	4090.48 (3547.49, 4716.60)
At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	80	0.02 (0.02, 0.02)
At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	80	0.27 (0.27, 0.27)
At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	80	0.09 (0.09, 0.09)
At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	80	5.00 (5.00, 5.00)
At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	80	5.00 (5.00, 5.00)
At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	130	486.41 (324.43, 729.28)
At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	130	19654.96 (14854.37, 26007.01)
At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	130	8847.05 (6916.88, 11315.83)
At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	130	4062.41 (3499.24, 4716.23)
At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	130	820.34 (722.23, 931.77)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	445	0.02 (0.02, 0.02)
Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	445	0.27 (0.27, 0.27)
Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	445	0.09 (0.09, 0.09)
Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	445	5.00 (5.00, 5.00)
Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	445	5.00 (5.00, 5.00)
Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	149	0.02 (0.02, 0.02)
Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	149	0.28 (0.27, 0.28)
Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	149	0.09 (0.09, 0.09)
Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	149	5.00 (5.00, 5.00)
Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	149	5.00 (5.00, 5.00)
Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	75	0.02 (0.02, 0.02)
Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	75	0.27 (0.27, 0.27)
Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	75	0.09 (0.09, 0.09)
Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	75	5.00 (5.00, 5.00)
Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	75	5.11 (4.90, 5.33)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	146	0.02 (0.02, 0.02)
Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	146	0.27 (0.27, 0.27)
Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	146	0.09 (0.09, 0.09)
Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	146	5.00 (5.00, 5.00)
Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	146	5.00 (5.00, 5.00)
Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	445	58.20 (47.48, 71.34)
Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	445	669.28 (557.20, 803.92)
Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	445	385.41 (329.00, 451.48)
Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	445	221.23 (201.80, 242.53)
Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	445	47.16 (43.11, 51.59)
Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	149	103.67 (75.22, 142.90)
Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	149	1273.21 (956.64, 1694.55)
Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	149	766.38 (591.79, 992.49)
Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	149	352.51 (306.78, 405.06)
Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	149	76.90 (67.33, 87.82)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	75	0.02 (0.02, 0.02)
Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	75	0.27 (0.27, 0.27)
Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	75	0.09 (0.09, 0.09)
Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	75	5.00 (5.00, 5.00)
Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	75	5.00 (5.00, 5.00)
Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	146	26.82 (18.76, 38.36)
Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	146	352.08 (256.56, 483.16)
Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	146	170.28 (128.67, 225.34)
Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	146	109.14 (92.18, 129.23)
Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	146	24.43 (20.99, 28.43)
Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	445	828.01 (640.59, 1070.26)
Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	445	30051.32 (24568.10, 36758.30)
Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	445	21038.85 (17721.65, 24976.97)
Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	445	10489.39 (9525.84, 11550.39)
Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	445	1493.34 (1360.60, 1639.02)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	149	2189.27 (1449.90, 3305.67)
Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	149	69976.84 (52002.56, 94163.80)
Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	149	55600.01 (43091.39, 71739.64)
Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	149	27138.15 (23277.88, 31638.58)
Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	149	4523.62 (3856.72, 5305.85)
Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	75	0.02 (0.02, 0.02)
Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	75	0.27 (0.27, 0.27)
Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	75	0.09 (0.09, 0.09)
Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	75	5.00 (5.00, 5.00)
Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	75	5.03 (4.97, 5.09)
Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	146	341.72 (224.08, 521.11)
Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	146	11510.67 (8354.80, 15858.60)
Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	146	6482.33 (4883.38, 8604.81)
Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	146	3367.31 (2880.87, 3935.88)
Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	146	750.04 (641.36, 877.15)

Table 5d. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age, Risk for Severe Covid-19						
Age < 65 At-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	220	0.02 (0.02, 0.02)
Age < 65 At-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	220	0.27 (0.27, 0.27)
Age < 65 At-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	220	0.09 (0.09, 0.09)
Age < 65 At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	220	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	220	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	70	0.02 (0.02, 0.02)
Age < 65 At-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	70	0.27 (0.27, 0.27)
Age < 65 At-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	70	0.09 (0.09, 0.09)
Age < 65 At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	70	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	70	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	39	0.02 (0.02, 0.03)
Age < 65 At-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0.27 (0.27, 0.27)
Age < 65 At-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	39	0.09 (0.09, 0.09)
Age < 65 At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	39	5.24 (4.78, 5.74)
Age < 65 At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	39	5.14 (4.87, 5.42)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 At-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	75	0.02 (0.02, 0.02)
Age < 65 At-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	75	0.27 (0.27, 0.27)
Age < 65 At-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	75	0.09 (0.09, 0.09)
Age < 65 At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	75	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	75	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	220	54.07 (40.95, 71.40)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	220	503.60 (397.09, 638.67)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	220	332.00 (268.07, 411.17)
Age < 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	220	212.49 (186.23, 242.45)
Age < 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	220	41.10 (36.64, 46.11)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	70	67.42 (40.49, 112.26)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	70	817.14 (525.77, 1269.97)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	70	535.85 (390.80, 734.74)
Age < 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	70	287.26 (233.02, 354.12)
Age < 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	70	65.43 (52.75, 81.15)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	39	0.02 (0.02, 0.02)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0.27 (0.27, 0.27)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	39	0.09 (0.09, 0.09)
Age < 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	39	5.07 (4.93, 5.21)
Age < 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	39	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	75	26.22 (17.94, 38.32)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	75	315.62 (233.23, 427.13)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	75	159.73 (122.51, 208.25)
Age < 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	75	96.69 (80.78, 115.72)
Age < 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	75	25.25 (21.55, 29.59)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	220	628.93 (463.68, 853.08)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	220	22762.87 (17544.34, 29533.64)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	220	15450.04 (12172.41, 19610.21)
Age < 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	220	8428.13 (7385.70, 9617.68)
Age < 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	220	1285.60 (1142.45, 1446.69)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	70	1486.58 (855.25, 2583.97)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	70	56974.72 (37716.89, 86065.40)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	70	27693.95 (19363.41, 39608.45)
Age < 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	70	25397.99 (20296.59, 31781.59)
Age < 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	70	3733.57 (3118.28, 4470.27)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	39	0.02 (0.02, 0.02)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0.27 (0.27, 0.27)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	39	0.09 (0.09, 0.09)
Age < 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	39	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	39	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	75	338.79 (197.52, 581.09)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	75	12141.73 (8663.79, 17015.83)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	75	5816.74 (4249.24, 7962.47)
Age < 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	75	3737.70 (3080.39, 4535.26)
Age < 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	75	759.28 (641.98, 898.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	219	0.02 (0.02, 0.02)
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	219	0.27 (0.27, 0.27)
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	219	0.09 (0.09, 0.09)
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	219	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	219	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	76	0.02 (0.02, 0.02)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	0.28 (0.27, 0.28)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	0.09 (0.09, 0.09)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	76	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	76	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	38	0.02 (0.02, 0.02)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	38	0.27 (0.27, 0.27)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	38	0.09 (0.09, 0.09)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	38	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	38	5.13 (4.88, 5.39)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	73	0.02 (0.02, 0.02)
Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	73	0.27 (0.27, 0.27)
Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	73	0.09 (0.09, 0.09)
Age < 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	73	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	73	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	219	49.40 (39.10, 62.40)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	219	564.12 (457.06, 696.27)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	219	318.42 (265.52, 381.85)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	219	206.65 (185.92, 229.69)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	219	45.07 (40.66, 49.97)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	76	83.86 (57.94, 121.39)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	1057.18 (760.21, 1470.16)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	632.69 (469.91, 851.86)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	76	316.24 (269.66, 370.86)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	76	73.09 (62.68, 85.22)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	38	0.02 (0.02, 0.02)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	38	0.27 (0.27, 0.27)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	38	0.09 (0.09, 0.09)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	38	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	38	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	73	20.99 (13.93, 31.65)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	73	280.30 (194.63, 403.69)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	73	134.41 (97.41, 185.46)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	73	100.53 (82.75, 122.13)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	73	22.83 (19.18, 27.18)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	219	681.33 (507.23, 915.18)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	219	24426.63 (19367.89, 30806.69)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	219	17192.84 (14108.05, 20952.13)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	219	9791.25 (8763.61, 10939.39)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	219	1428.27 (1283.08, 1589.89)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	76	1717.03 (1064.38, 2769.88)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	57112.84 (40456.58, 80626.59)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	48503.57 (35987.59, 65372.42)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	76	24738.04 (20712.74, 29545.62)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	76	4378.70 (3637.43, 5271.02)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	38	0.02 (0.02, 0.02)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	38	0.27 (0.27, 0.27)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	38	0.09 (0.09, 0.09)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	38	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	38	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	73	277.43 (170.92, 450.31)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	73	9150.84 (6343.15, 13201.30)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	73	4855.12 (3513.49, 6709.03)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	73	3098.09 (2588.80, 3707.57)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	73	720.07 (600.63, 863.27)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 At-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	250	0.02 (0.02, 0.02)
Age \geq 65 At-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	250	0.27 (0.27, 0.28)
Age \geq 65 At-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	250	0.09 (0.09, 0.09)
Age \geq 65 At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	250	5.00 (5.00, 5.00)
Age \geq 65 At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	250	5.00 (5.00, 5.00)
Age \geq 65 At-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	50	0.02 (0.02, 0.02)
Age \geq 65 At-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	0.27 (0.27, 0.27)
Age \geq 65 At-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	0.09 (0.09, 0.09)
Age \geq 65 At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	50	5.00 (5.00, 5.00)
Age \geq 65 At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	50	5.00 (5.00, 5.00)
Age \geq 65 At-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	41	0.02 (0.02, 0.02)
Age \geq 65 At-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	41	0.27 (0.27, 0.27)
Age \geq 65 At-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	41	0.09 (0.09, 0.09)
Age \geq 65 At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	41	5.11 (4.90, 5.32)
Age \geq 65 At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	41	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 At-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	55	0.02 (0.02, 0.02)
Age \geq 65 At-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	55	0.27 (0.27, 0.27)
Age \geq 65 At-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	55	0.09 (0.09, 0.09)
Age \geq 65 At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	55	5.00 (5.00, 5.00)
Age \geq 65 At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	55	5.00 (5.00, 5.00)
Age \geq 65 At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	250	131.44 (105.77, 163.33)
Age \geq 65 At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	250	1545.48 (1268.71, 1882.61)
Age \geq 65 At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	250	885.47 (747.60, 1048.77)
Age \geq 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	250	275.29 (244.82, 309.56)
Age \geq 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	250	53.93 (48.92, 59.45)
Age \geq 65 At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	50	266.81 (177.47, 401.13)
Age \geq 65 At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	3354.69 (2235.79, 5033.53)
Age \geq 65 At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	1718.71 (1241.63, 2379.11)
Age \geq 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	50	610.47 (501.61, 742.97)
Age \geq 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	50	95.89 (77.90, 118.03)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	41	0.02 (0.02, 0.02)
Age \geq 65 At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	41	0.27 (0.27, 0.27)
Age \geq 65 At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	41	0.09 (0.09, 0.09)
Age \geq 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	41	5.00 (5.00, 5.00)
Age \geq 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	41	5.30 (4.90, 5.74)
Age \geq 65 At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	55	73.96 (45.08, 121.37)
Age \geq 65 At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	55	764.29 (508.32, 1149.16)
Age \geq 65 At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	55	564.82 (411.46, 775.35)
Age \geq 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	55	146.90 (119.82, 180.10)
Age \geq 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	55	33.00 (27.31, 39.89)
Age \geq 65 At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	250	1741.05 (1331.24, 2277.00)
Age \geq 65 At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	250	65274.79 (52121.10, 81748.04)
Age \geq 65 At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	250	36847.42 (30394.53, 44670.29)
Age \geq 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	250	10478.59 (8946.35, 12273.26)
Age \geq 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	250	1562.43 (1389.38, 1757.04)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	50	6154.26 (3806.20, 9950.87)
Age \geq 65 At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	210361.50 (154533.61, 286358.15)
Age \geq 65 At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	97009.56 (78402.66, 120032.33)
Age \geq 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	50	38081.92 (30737.43, 47181.34)
Age \geq 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	50	5028.99 (4054.58, 6237.58)
Age \geq 65 At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	41	0.02 (0.02, 0.02)
Age \geq 65 At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	41	0.27 (0.27, 0.27)
Age \geq 65 At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	41	0.09 (0.09, 0.09)
Age \geq 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	41	5.00 (5.00, 5.00)
Age \geq 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	41	5.00 (5.00, 5.00)
Age \geq 65 At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	55	995.72 (587.77, 1686.79)
Age \geq 65 At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	55	51030.23 (33245.99, 78327.78)
Age \geq 65 At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	55	20301.57 (14770.16, 27904.48)
Age \geq 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	55	4791.24 (3838.80, 5979.99)
Age \geq 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	55	956.14 (799.60, 1143.33)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	226	0.02 (0.02, 0.02)
Age \geq 65 Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	226	0.27 (0.27, 0.27)
Age \geq 65 Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	226	0.09 (0.09, 0.09)
Age \geq 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	226	5.00 (5.00, 5.00)
Age \geq 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	226	5.00 (5.00, 5.00)
Age \geq 65 Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	73	0.02 (0.02, 0.02)
Age \geq 65 Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	0.27 (0.27, 0.27)
Age \geq 65 Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	0.09 (0.09, 0.10)
Age \geq 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	73	5.00 (5.00, 5.00)
Age \geq 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	73	5.00 (5.00, 5.00)
Age \geq 65 Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	37	0.02 (0.02, 0.02)
Age \geq 65 Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0.27 (0.27, 0.27)
Age \geq 65 Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0.09 (0.09, 0.09)
Age \geq 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	37	5.00 (5.00, 5.00)
Age \geq 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	37	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	73	0.02 (0.02, 0.02)
Age \geq 65 Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	73	0.27 (0.27, 0.27)
Age \geq 65 Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	73	0.09 (0.09, 0.09)
Age \geq 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	73	5.00 (5.00, 5.00)
Age \geq 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	73	5.00 (5.00, 5.00)
Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	226	156.30 (124.69, 195.94)
Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	226	1874.30 (1540.73, 2280.09)
Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	226	1217.52 (1045.45, 1417.92)
Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	226	333.58 (302.43, 367.93)
Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	226	61.96 (55.76, 68.86)
Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	73	335.19 (226.79, 495.41)
Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	3562.49 (2532.00, 5012.37)
Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	2213.98 (1618.00, 3029.47)
Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	73	642.93 (536.91, 769.89)
Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	73	101.86 (86.13, 120.46)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	37	0.02 (0.02, 0.02)
Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0.27 (0.27, 0.27)
Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0.09 (0.09, 0.09)
Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	37	5.00 (5.00, 5.00)
Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	37	5.00 (5.00, 5.00)
Age \geq 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	73	110.24 (72.93, 166.64)
Age \geq 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	73	1311.30 (975.26, 1763.13)
Age \geq 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	73	666.29 (514.14, 863.47)
Age \geq 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	73	175.33 (144.79, 212.33)
Age \geq 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	73	36.06 (29.78, 43.67)
Age \geq 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	226	2680.19 (2040.81, 3519.89)
Age \geq 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	226	104726.56 (87880.85, 124801.38)
Age \geq 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	226	70991.30 (62313.78, 80877.21)
Age \geq 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	226	15883.67 (14375.29, 17550.33)
Age \geq 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	226	1953.02 (1770.10, 2154.84)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	73	8399.02 (5561.59, 12684.06)
Age \geq 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	215353.16 (165458.59, 280293.59)
Age \geq 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	118368.75 (102113.55, 137211.58)
Age \geq 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	73	45302.51 (38314.50, 53565.04)
Age \geq 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	73	5416.78 (4538.51, 6465.02)
Age \geq 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	37	0.02 (0.02, 0.02)
Age \geq 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0.27 (0.27, 0.27)
Age \geq 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0.09 (0.09, 0.09)
Age \geq 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	37	5.00 (5.00, 5.00)
Age \geq 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	37	5.18 (4.83, 5.56)
Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	73	1136.96 (664.28, 1945.99)
Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	73	43229.76 (28989.15, 64465.93)
Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	73	34335.80 (26089.81, 45188.05)
Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	73	5445.13 (4550.33, 6515.89)
Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	73	948.92 (808.13, 1114.24)

Table 5e. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Sex						
Male	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	391	0.02 (0.02, 0.02)
Male	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	391	0.27 (0.27, 0.28)
Male	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	391	0.09 (0.09, 0.09)
Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	391	5.00 (5.00, 5.00)
Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	391	5.00 (5.00, 5.00)
Male	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	113	0.02 (0.02, 0.03)
Male	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	113	0.27 (0.27, 0.27)
Male	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	113	0.09 (0.09, 0.09)
Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	113	5.00 (5.00, 5.00)
Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	113	5.00 (5.00, 5.00)
Male	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	60	0.02 (0.02, 0.02)
Male	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	60	0.27 (0.27, 0.27)
Male	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	60	0.09 (0.09, 0.09)
Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	60	5.00 (5.00, 5.00)
Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	60	5.21 (4.81, 5.64)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Male	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	122	0.02 (0.02, 0.02)
Male	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	122	0.27 (0.27, 0.27)
Male	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	122	0.09 (0.09, 0.09)
Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	122	5.00 (5.00, 5.00)
Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	122	5.00 (5.00, 5.00)
Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	391	63.73 (48.94, 83.00)
Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	391	686.74 (538.39, 875.98)
Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	391	424.11 (345.09, 521.23)
Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	391	232.36 (207.20, 260.57)
Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	391	46.32 (41.50, 51.70)
Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	113	128.96 (81.98, 202.86)
Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	113	1679.06 (1146.41, 2459.20)
Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	113	890.79 (627.61, 1264.34)
Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	113	392.07 (325.19, 472.71)
Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	113	73.92 (63.98, 85.41)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	60	0.02 (0.02, 0.02)
Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	60	0.27 (0.27, 0.27)
Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	60	0.09 (0.09, 0.09)
Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	60	5.00 (5.00, 5.00)
Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	60	5.00 (5.00, 5.00)
Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	122	29.73 (18.99, 46.54)
Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	122	375.73 (244.88, 576.49)
Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	122	186.79 (132.30, 263.73)
Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	122	108.95 (87.10, 136.29)
Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	122	24.29 (20.06, 29.42)
Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	391	860.98 (647.12, 1145.53)
Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	391	32724.44 (25648.10, 41753.15)
Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	391	22736.75 (18515.45, 27920.45)
Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	391	10067.09 (8894.08, 11394.80)
Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	391	1448.63 (1278.89, 1640.90)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	113	2852.89 (1608.45, 5060.14)
Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	113	79526.50 (57294.11, 110385.94)
Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	113	51096.13 (36091.24, 72339.28)
Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	113	29355.83 (24695.73, 34895.28)
Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	113	4573.39 (3833.83, 5455.62)
Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	60	0.02 (0.02, 0.02)
Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	60	0.27 (0.27, 0.27)
Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	60	0.09 (0.09, 0.09)
Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	60	5.00 (5.00, 5.00)
Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	60	5.06 (4.95, 5.17)
Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	122	486.99 (283.09, 837.75)
Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	122	12582.62 (8551.77, 18513.39)
Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	122	7272.61 (5061.17, 10450.32)
Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	122	3292.67 (2674.97, 4053.01)
Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	122	778.67 (645.62, 939.14)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Female	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	524	0.02 (0.02, 0.02)
Female	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	524	0.27 (0.27, 0.27)
Female	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	524	0.09 (0.09, 0.09)
Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	524	5.00 (5.00, 5.00)
Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	524	5.00 (5.00, 5.00)
Female	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	156	0.02 (0.02, 0.02)
Female	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	156	0.28 (0.27, 0.29)
Female	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	156	0.09 (0.09, 0.09)
Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	156	5.00 (5.00, 5.00)
Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	156	5.00 (5.00, 5.00)
Female	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	95	0.02 (0.02, 0.02)
Female	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	95	0.27 (0.27, 0.27)
Female	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	95	0.09 (0.09, 0.09)
Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	95	5.09 (4.95, 5.23)
Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	95	5.04 (4.96, 5.12)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Female	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	154	0.02 (0.02, 0.02)
Female	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	154	0.27 (0.27, 0.27)
Female	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	154	0.09 (0.09, 0.09)
Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	154	5.00 (5.00, 5.00)
Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	154	5.00 (5.00, 5.00)
Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	524	62.33 (51.30, 75.73)
Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	524	708.96 (597.35, 841.42)
Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	524	404.40 (347.20, 471.03)
Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	524	220.56 (201.24, 241.73)
Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	524	47.10 (43.13, 51.43)
Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	156	89.72 (65.17, 123.51)
Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	156	1060.09 (795.02, 1413.53)
Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	156	695.25 (542.26, 891.39)
Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	156	332.78 (288.74, 383.54)
Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	156	77.42 (66.65, 89.93)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	95	0.02 (0.02, 0.02)
Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	95	0.27 (0.27, 0.27)
Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	95	0.09 (0.09, 0.09)
Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	95	5.02 (4.98, 5.06)
Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	95	5.06 (4.98, 5.14)
Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	154	28.69 (20.03, 41.10)
Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	154	364.55 (272.15, 488.32)
Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	154	186.23 (140.19, 247.39)
Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	154	110.18 (94.06, 129.07)
Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	154	25.86 (22.29, 30.00)
Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	524	857.25 (658.34, 1116.26)
Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	524	30356.48 (24829.23, 37114.15)
Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	524	20373.35 (17108.20, 24261.67)
Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	524	10151.98 (9238.25, 11156.09)
Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	524	1474.56 (1353.14, 1606.88)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	156	1883.05 (1269.61, 2792.88)
Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	156	69930.48 (50459.38, 96915.01)
Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	156	51479.11 (40279.83, 65792.22)
Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	156	26431.53 (22340.26, 31272.05)
Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	156	4305.52 (3631.22, 5105.02)
Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	95	0.02 (0.02, 0.02)
Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	95	0.27 (0.27, 0.27)
Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	95	0.09 (0.09, 0.09)
Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	95	5.00 (5.00, 5.00)
Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	95	5.00 (5.00, 5.00)
Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	154	309.85 (204.43, 469.64)
Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	154	13609.31 (9748.76, 18998.66)
Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	154	6833.23 (5149.68, 9067.18)
Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	154	3708.74 (3194.21, 4306.14)
Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	154	759.20 (647.30, 890.45)

Table 5f. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age, sex						
Age < 65 Female	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	266	0.02 (0.02, 0.02)
Age < 65 Female	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	266	0.27 (0.27, 0.27)
Age < 65 Female	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	266	0.09 (0.09, 0.09)
Age < 65 Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	266	5.00 (5.00, 5.00)
Age < 65 Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	266	5.00 (5.00, 5.00)
Age < 65 Female	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	90	0.02 (0.02, 0.02)
Age < 65 Female	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	90	0.28 (0.27, 0.29)
Age < 65 Female	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	90	0.09 (0.09, 0.09)
Age < 65 Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	90	5.00 (5.00, 5.00)
Age < 65 Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	90	5.00 (5.00, 5.00)
Age < 65 Female	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	50	0.02 (0.02, 0.02)
Age < 65 Female	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	50	0.27 (0.27, 0.27)
Age < 65 Female	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	50	0.09 (0.09, 0.09)
Age < 65 Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	50	5.08 (4.92, 5.25)
Age < 65 Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	50	5.05 (4.95, 5.15)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Female	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	85	0.02 (0.02, 0.02)
Age < 65 Female	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	85	0.27 (0.27, 0.27)
Age < 65 Female	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	85	0.09 (0.09, 0.09)
Age < 65 Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	85	5.00 (5.00, 5.00)
Age < 65 Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	85	5.00 (5.00, 5.00)
Age < 65 Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	266	52.32 (41.41, 66.10)
Age < 65 Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	266	586.22 (477.60, 719.53)
Age < 65 Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	266	332.67 (277.17, 399.28)
Age < 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	266	208.25 (186.54, 232.50)
Age < 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	266	45.18 (40.63, 50.25)
Age < 65 Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	90	71.96 (49.60, 104.40)
Age < 65 Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	90	865.76 (620.13, 1208.68)
Age < 65 Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	90	589.41 (441.63, 786.64)
Age < 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	90	295.10 (250.45, 347.71)
Age < 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	90	72.72 (61.02, 86.67)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	50	0.02 (0.02, 0.02)
Age < 65 Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	50	0.27 (0.27, 0.27)
Age < 65 Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	50	0.09 (0.09, 0.09)
Age < 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	50	5.02 (4.98, 5.07)
Age < 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	50	5.00 (5.00, 5.00)
Age < 65 Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	85	21.95 (14.41, 33.42)
Age < 65 Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	85	291.67 (206.65, 411.68)
Age < 65 Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	85	142.39 (102.03, 198.73)
Age < 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	85	100.42 (83.32, 121.02)
Age < 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	85	24.03 (20.17, 28.62)
Age < 65 Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	266	700.73 (509.35, 964.01)
Age < 65 Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	266	24346.16 (19116.30, 31006.82)
Age < 65 Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	266	16770.41 (13590.72, 20694.03)
Age < 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	266	9837.17 (8794.76, 11003.14)
Age < 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	266	1440.80 (1299.69, 1597.23)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	90	1432.97 (904.78, 2269.49)
Age < 65 Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	90	57041.36 (38864.72, 83719.01)
Age < 65 Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	90	43840.57 (32785.50, 58623.35)
Age < 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	90	23628.65 (19415.79, 28755.60)
Age < 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	90	4108.12 (3361.98, 5019.85)
Age < 65 Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	50	0.02 (0.02, 0.02)
Age < 65 Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	50	0.27 (0.27, 0.27)
Age < 65 Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	50	0.09 (0.09, 0.09)
Age < 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	50	5.00 (5.00, 5.00)
Age < 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	50	5.00 (5.00, 5.00)
Age < 65 Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	85	239.00 (146.75, 389.25)
Age < 65 Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	85	10551.82 (7136.45, 15601.72)
Age < 65 Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	85	4982.39 (3591.66, 6911.63)
Age < 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	85	3439.26 (2884.31, 4100.97)
Age < 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	85	734.98 (606.97, 889.99)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Male	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	173	0.02 (0.02, 0.02)
Age < 65 Male	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	173	0.27 (0.27, 0.28)
Age < 65 Male	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	173	0.09 (0.09, 0.09)
Age < 65 Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	173	5.00 (5.00, 5.00)
Age < 65 Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	173	5.00 (5.00, 5.00)
Age < 65 Male	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	56	0.02 (0.02, 0.03)
Age < 65 Male	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	56	0.27 (0.27, 0.27)
Age < 65 Male	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	56	0.09 (0.09, 0.09)
Age < 65 Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	56	5.00 (5.00, 5.00)
Age < 65 Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	56	5.00 (5.00, 5.00)
Age < 65 Male	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	27	0.02 (0.02, 0.02)
Age < 65 Male	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	27	0.27 (0.27, 0.27)
Age < 65 Male	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	27	0.09 (0.09, 0.09)
Age < 65 Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	27	5.00 (5.00, 5.00)
Age < 65 Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	27	5.29 (4.74, 5.91)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Male	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	63	0.02 (0.02, 0.02)
Age < 65 Male	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	63	0.27 (0.27, 0.27)
Age < 65 Male	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	63	0.09 (0.09, 0.09)
Age < 65 Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	63	5.00 (5.00, 5.00)
Age < 65 Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	63	5.00 (5.00, 5.00)
Age < 65 Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	173	47.18 (33.63, 66.19)
Age < 65 Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	173	496.48 (363.24, 678.59)
Age < 65 Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	173	302.84 (233.08, 393.48)
Age < 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	173	207.18 (178.99, 239.82)
Age < 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	173	42.64 (37.03, 49.09)
Age < 65 Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	56	95.50 (54.57, 167.13)
Age < 65 Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	56	1272.62 (793.15, 2041.95)
Age < 65 Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	56	646.54 (420.84, 993.29)
Age < 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	56	335.85 (267.77, 421.23)
Age < 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	56	69.04 (57.83, 82.42)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	27	0.02 (0.02, 0.02)
Age < 65 Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	27	0.27 (0.27, 0.27)
Age < 65 Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	27	0.09 (0.09, 0.09)
Age < 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	27	5.00 (5.00, 5.00)
Age < 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	27	5.00 (5.00, 5.00)
Age < 65 Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	63	22.05 (12.74, 38.17)
Age < 65 Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	63	280.99 (166.00, 475.62)
Age < 65 Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	63	134.91 (88.77, 205.03)
Age < 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	63	98.69 (74.76, 130.28)
Age < 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	63	22.30 (17.59, 28.26)
Age < 65 Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	173	621.62 (432.26, 893.94)
Age < 65 Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	173	23614.57 (17287.13, 32257.97)
Age < 65 Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	173	16888.00 (12988.38, 21958.42)
Age < 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	173	8935.47 (7635.96, 10456.14)
Age < 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	173	1327.27 (1130.08, 1558.87)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	56	2140.61 (1037.06, 4418.46)
Age < 65 Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	56	57152.08 (38247.10, 85401.53)
Age < 65 Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	56	41330.85 (26530.18, 64388.51)
Age < 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	56	27150.79 (21897.54, 33664.30)
Age < 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	56	4439.05 (3557.09, 5539.70)
Age < 65 Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	27	0.02 (0.02, 0.02)
Age < 65 Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	27	0.27 (0.27, 0.27)
Age < 65 Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	27	0.09 (0.09, 0.09)
Age < 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	27	5.00 (5.00, 5.00)
Age < 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	27	5.00 (5.00, 5.00)
Age < 65 Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	63	383.79 (196.58, 749.28)
Age < 65 Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	63	8575.22 (5437.68, 13523.13)
Age < 65 Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	63	5130.27 (3306.26, 7960.57)
Age < 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	63	2923.96 (2269.14, 3767.74)
Age < 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	63	717.95 (569.55, 905.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Male	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	218	0.02 (0.02, 0.02)
Age \geq 65 Male	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	0.27 (0.27, 0.28)
Age \geq 65 Male	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	0.09 (0.09, 0.09)
Age \geq 65 Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	218	5.00 (5.00, 5.00)
Age \geq 65 Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	218	5.00 (5.00, 5.00)
Age \geq 65 Male	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	57	0.02 (0.02, 0.02)
Age \geq 65 Male	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	57	0.27 (0.27, 0.27)
Age \geq 65 Male	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	57	0.09 (0.09, 0.10)
Age \geq 65 Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	57	5.00 (5.00, 5.00)
Age \geq 65 Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	57	5.00 (5.00, 5.00)
Age \geq 65 Male	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	33	0.02 (0.02, 0.02)
Age \geq 65 Male	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0.27 (0.27, 0.27)
Age \geq 65 Male	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0.09 (0.09, 0.09)
Age \geq 65 Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	33	5.00 (5.00, 5.00)
Age \geq 65 Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	33	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Male	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	59	0.02 (0.02, 0.02)
Age \geq 65 Male	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	59	0.27 (0.27, 0.27)
Age \geq 65 Male	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	59	0.09 (0.09, 0.09)
Age \geq 65 Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	59	5.00 (5.00, 5.00)
Age \geq 65 Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	59	5.00 (5.00, 5.00)
Age \geq 65 Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	218	157.72 (125.55, 198.14)
Age \geq 65 Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	1825.52 (1508.02, 2209.86)
Age \geq 65 Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	1170.24 (995.80, 1375.24)
Age \geq 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	218	328.29 (293.31, 367.45)
Age \geq 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	218	59.47 (53.35, 66.30)
Age \geq 65 Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	57	343.21 (220.13, 535.10)
Age \geq 65 Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	57	4143.69 (2844.30, 6036.70)
Age \geq 65 Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	57	2531.76 (1814.49, 3532.55)
Age \geq 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	57	649.36 (527.11, 799.97)
Age \geq 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	57	92.36 (76.33, 111.76)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	33	0.02 (0.02, 0.02)
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0.27 (0.27, 0.27)
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0.09 (0.09, 0.09)
Age ≥ 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	33	5.00 (5.00, 5.00)
Age ≥ 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	33	5.00 (5.00, 5.00)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	59	87.68 (56.86, 135.21)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	59	1076.11 (749.69, 1544.66)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	59	606.91 (457.49, 805.13)
Age ≥ 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	59	155.88 (129.03, 188.33)
Age ≥ 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	59	33.11 (27.56, 39.77)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	218	2297.83 (1738.54, 3037.05)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	87473.39 (71286.39, 107335.96)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	55710.29 (47159.64, 65811.28)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	218	14420.06 (12597.51, 16506.29)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	218	1885.68 (1685.17, 2110.03)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	57	7275.85 (4530.79, 11684.05)
Age \geq 65 Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	57	233434.03 (173634.71, 313828.06)
Age \geq 65 Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	57	102004.55 (83418.77, 124731.25)
Age \geq 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	57	37863.91 (30980.10, 46277.32)
Age \geq 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	57	5040.13 (4110.77, 6179.59)
Age \geq 65 Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	33	0.02 (0.02, 0.02)
Age \geq 65 Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0.27 (0.27, 0.27)
Age \geq 65 Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0.09 (0.09, 0.09)
Age \geq 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	33	5.00 (5.00, 5.00)
Age \geq 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	33	5.20 (4.82, 5.62)
Age \geq 65 Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	59	1153.70 (652.07, 2041.21)
Age \geq 65 Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	59	50450.18 (33144.60, 76791.42)
Age \geq 65 Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	59	25736.28 (19104.18, 34670.75)
Age \geq 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	59	5062.20 (4098.06, 6253.16)
Age \geq 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	59	1044.85 (868.63, 1256.81)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65 Female	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	258	0.02 (0.02, 0.02)
Age ≥ 65 Female	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	258	0.27 (0.27, 0.27)
Age ≥ 65 Female	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	258	0.09 (0.09, 0.09)
Age ≥ 65 Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	258	5.00 (5.00, 5.00)
Age ≥ 65 Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	258	5.00 (5.00, 5.00)
Age ≥ 65 Female	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	66	0.02 (0.02, 0.02)
Age ≥ 65 Female	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	66	0.27 (0.27, 0.27)
Age ≥ 65 Female	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	66	0.09 (0.09, 0.09)
Age ≥ 65 Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	66	5.00 (5.00, 5.00)
Age ≥ 65 Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	66	5.00 (5.00, 5.00)
Age ≥ 65 Female	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	45	0.02 (0.02, 0.02)
Age ≥ 65 Female	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	45	0.27 (0.27, 0.27)
Age ≥ 65 Female	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	45	0.09 (0.09, 0.09)
Age ≥ 65 Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	45	5.10 (4.91, 5.29)
Age ≥ 65 Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	45	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Female	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	69	0.02 (0.02, 0.02)
Age \geq 65 Female	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	69	0.27 (0.27, 0.27)
Age \geq 65 Female	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	69	0.09 (0.09, 0.09)
Age \geq 65 Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	69	5.00 (5.00, 5.00)
Age \geq 65 Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	69	5.00 (5.00, 5.00)
Age \geq 65 Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	258	131.59 (106.10, 163.20)
Age \geq 65 Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	258	1595.85 (1306.73, 1948.93)
Age \geq 65 Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	258	930.53 (791.39, 1094.14)
Age \geq 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	258	281.77 (253.52, 313.16)
Age \geq 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	258	56.23 (51.08, 61.89)
Age \geq 65 Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	66	274.36 (190.49, 395.16)
Age \geq 65 Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	66	2957.62 (2062.39, 4241.44)
Age \geq 65 Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	66	1605.23 (1182.33, 2179.40)
Age \geq 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	66	611.76 (516.06, 725.22)
Age \geq 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	66	106.31 (89.02, 126.96)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	45	0.02 (0.02, 0.02)
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	45	0.27 (0.27, 0.27)
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	45	0.09 (0.09, 0.09)
Age ≥ 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	45	5.00 (5.00, 5.00)
Age ≥ 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	45	5.28 (4.91, 5.68)
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	69	97.21 (61.27, 154.22)
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	69	1005.84 (715.64, 1413.71)
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	69	631.68 (475.18, 839.73)
Age ≥ 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	69	168.09 (137.04, 206.18)
Age ≥ 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	69	36.11 (29.64, 44.00)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	258	2026.66 (1555.75, 2640.11)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	258	77839.10 (63430.65, 95520.46)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	258	46749.14 (39284.12, 55632.72)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	258	11612.78 (10143.10, 13295.41)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	258	1627.78 (1463.40, 1810.62)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	66	7514.89 (4955.01, 11397.28)
Age \geq 65 Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	66	196321.44 (149772.65, 257337.41)
Age \geq 65 Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	66	116163.88 (100005.55, 134932.97)
Age \geq 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	66	46644.01 (39166.26, 55549.44)
Age \geq 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	66	5461.33 (4548.48, 6557.38)
Age \geq 65 Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	45	0.02 (0.02, 0.02)
Age \geq 65 Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	45	0.27 (0.27, 0.27)
Age \geq 65 Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	45	0.09 (0.09, 0.09)
Age \geq 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	45	5.00 (5.00, 5.00)
Age \geq 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	45	5.00 (5.00, 5.00)
Age \geq 65 Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	69	1009.72 (606.19, 1681.86)
Age \geq 65 Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	69	43321.33 (28822.13, 65114.47)
Age \geq 65 Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	69	28767.28 (21312.22, 38830.14)
Age \geq 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	69	5227.64 (4334.16, 6305.30)
Age \geq 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	69	879.92 (755.03, 1025.47)

Table 5g. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Hispanic or Latino ethnicity

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Hispanic or Latino ethnicity						
Hispanic or Latino	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	130	0.02 (0.02, 0.02)
Hispanic or Latino	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	130	0.28 (0.27, 0.28)
Hispanic or Latino	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	130	0.09 (0.09, 0.09)
Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	130	5.00 (5.00, 5.00)
Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	130	5.00 (5.00, 5.00)
Hispanic or Latino	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	34	0.02 (0.02, 0.02)
Hispanic or Latino	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	34	0.27 (0.27, 0.27)
Hispanic or Latino	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	34	0.09 (0.09, 0.09)
Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	34	5.00 (5.00, 5.00)
Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	34	5.00 (5.00, 5.00)
Hispanic or Latino	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	22	0.02 (0.02, 0.02)
Hispanic or Latino	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	22	0.27 (0.27, 0.27)
Hispanic or Latino	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	22	0.09 (0.09, 0.09)
Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	22	5.00 (5.00, 5.00)
Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	22	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Hispanic or Latino	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	25	0.02 (0.02, 0.02)
Hispanic or Latino	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	25	0.27 (0.27, 0.27)
Hispanic or Latino	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	25	0.09 (0.09, 0.09)
Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	25	5.00 (5.00, 5.00)
Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	25	5.00 (5.00, 5.00)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	130	60.33 (36.37, 100.10)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	130	649.64 (426.15, 990.35)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	130	429.89 (300.02, 615.99)
Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	130	218.54 (178.87, 267.01)
Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	130	47.19 (40.03, 55.63)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	34	156.84 (97.66, 251.86)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	34	1802.92 (997.30, 3259.31)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	34	860.11 (483.13, 1531.23)
Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	34	422.79 (343.71, 520.07)
Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	34	99.26 (72.44, 136.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	22	0.02 (0.02, 0.02)
Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	22	0.27 (0.27, 0.27)
Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	22	0.09 (0.09, 0.09)
Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	22	5.00 (5.00, 5.00)
Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	22	5.00 (5.00, 5.00)
Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	25	27.27 (11.85, 62.73)
Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	25	287.56 (144.28, 573.16)
Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	25	153.40 (83.92, 280.40)
Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	25	95.90 (70.22, 130.96)
Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	25	19.66 (12.45, 31.04)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	130	879.44 (524.28, 1475.18)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	130	33410.70 (21948.17, 50859.60)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	130	22661.15 (16064.43, 31966.75)
Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	130	9829.86 (8024.03, 12042.10)
Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	130	1555.12 (1293.23, 1870.04)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	34	4237.38 (2216.18, 8101.97)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	34	74710.38 (43552.70, 128158.30)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	34	63564.70 (40153.56, 100625.47)
Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	34	31045.07 (22915.33, 42059.02)
Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	34	5552.76 (4103.33, 7514.16)
Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	22	0.02 (0.02, 0.02)
Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	22	0.27 (0.27, 0.27)
Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	22	0.09 (0.09, 0.09)
Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	22	5.00 (5.00, 5.00)
Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	22	5.00 (5.00, 5.00)
Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	25	385.13 (160.23, 925.71)
Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	25	9826.60 (4321.51, 22344.55)
Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	25	5657.91 (2980.05, 10742.12)
Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	25	4437.92 (2841.54, 6931.14)
Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	25	679.28 (482.63, 956.05)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	690	0.02 (0.02, 0.02)
Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	690	0.27 (0.27, 0.27)
Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	690	0.09 (0.09, 0.09)
Not Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	690	5.00 (5.00, 5.00)
Not Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	690	5.00 (5.00, 5.00)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	197	0.02 (0.02, 0.02)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	197	0.28 (0.27, 0.28)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	197	0.09 (0.09, 0.09)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	197	5.00 (5.00, 5.00)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	197	5.00 (5.00, 5.00)
Not Hispanic or Latino	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	118	0.02 (0.02, 0.02)
Not Hispanic or Latino	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	118	0.27 (0.27, 0.27)
Not Hispanic or Latino	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	118	0.09 (0.09, 0.09)
Not Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	118	5.02 (4.98, 5.05)
Not Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	118	5.12 (4.93, 5.32)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not Hispanic or Latino	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	222	0.02 (0.02, 0.02)
Not Hispanic or Latino	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	222	0.27 (0.27, 0.27)
Not Hispanic or Latino	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	222	0.09 (0.09, 0.09)
Not Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	222	5.00 (5.00, 5.00)
Not Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	222	5.00 (5.00, 5.00)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	690	65.21 (54.65, 77.82)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	690	718.94 (613.76, 842.15)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	690	406.18 (355.64, 463.90)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	690	226.42 (208.69, 245.65)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	690	46.77 (43.20, 50.64)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	197	100.08 (73.54, 136.20)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	197	1196.84 (936.10, 1530.21)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	197	734.74 (583.20, 925.66)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	197	351.93 (308.42, 401.59)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	197	73.00 (64.52, 82.59)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	118	0.02 (0.02, 0.02)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	118	0.27 (0.27, 0.27)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	118	0.09 (0.09, 0.09)
Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	118	5.00 (5.00, 5.00)
Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	118	5.02 (4.98, 5.07)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	222	26.83 (19.52, 36.90)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	222	347.35 (264.93, 455.41)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	222	180.77 (141.23, 231.39)
Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	222	107.35 (92.28, 124.88)
Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	222	25.54 (22.37, 29.16)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	690	848.00 (678.26, 1060.22)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	690	30702.10 (25812.13, 36518.45)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	690	21967.61 (18906.24, 25524.68)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	690	10230.06 (9395.39, 11138.88)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	690	1434.87 (1323.77, 1555.30)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	197	2136.00 (1467.76, 3108.47)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	197	71208.98 (53904.99, 94067.70)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	197	49850.34 (39401.72, 63069.74)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	197	26571.74 (22955.30, 30757.94)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	197	4334.34 (3733.53, 5031.84)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	118	0.02 (0.02, 0.02)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	118	0.27 (0.27, 0.27)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	118	0.09 (0.09, 0.09)
Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	118	5.00 (5.00, 5.00)
Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	118	5.03 (4.98, 5.07)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	222	351.33 (239.85, 514.62)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	222	13001.44 (9786.27, 17272.92)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	222	6907.85 (5381.50, 8867.11)
Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	222	3445.73 (3009.83, 3944.76)
Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	222	765.56 (665.91, 880.11)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	95	0.02 (0.02, 0.02)
Not reported and unknown	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	95	0.27 (0.27, 0.27)
Not reported and unknown	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	95	0.09 (0.09, 0.09)
Not reported and unknown	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	95	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	95	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	38	0.03 (0.02, 0.03)
Not reported and unknown	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	38	0.27 (0.27, 0.27)
Not reported and unknown	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	38	0.09 (0.09, 0.09)
Not reported and unknown	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	38	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	38	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	15	0.02 (0.02, 0.03)
Not reported and unknown	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	15	0.27 (0.27, 0.27)
Not reported and unknown	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	15	0.09 (0.09, 0.09)
Not reported and unknown	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	15	5.38 (4.65, 6.22)
Not reported and unknown	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	15	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	29	0.02 (0.02, 0.02)
Not reported and unknown	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	29	0.27 (0.27, 0.27)
Not reported and unknown	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	29	0.09 (0.09, 0.09)
Not reported and unknown	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	29	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	29	5.00 (5.00, 5.00)
Not reported and unknown	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	95	51.26 (32.44, 81.01)
Not reported and unknown	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	95	628.56 (402.57, 981.43)
Not reported and unknown	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	95	435.85 (279.03, 680.78)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	95	222.39 (179.35, 275.75)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	95	46.61 (37.76, 57.53)
Not reported and unknown	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	38	94.68 (46.77, 191.66)
Not reported and unknown	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	38	1374.69 (613.01, 3082.77)
Not reported and unknown	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	38	878.75 (493.89, 1563.51)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	38	332.76 (243.29, 455.12)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	38	79.08 (60.14, 103.98)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	15	0.02 (0.02, 0.02)
Not reported and unknown	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	15	0.27 (0.27, 0.27)
Not reported and unknown	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	15	0.09 (0.09, 0.09)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	15	5.11 (4.89, 5.34)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	15	5.15 (4.85, 5.47)
Not reported and unknown	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	29	62.14 (37.66, 102.51)
Not reported and unknown	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	29	752.52 (384.29, 1473.56)
Not reported and unknown	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	29	281.80 (166.29, 477.54)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	29	145.79 (114.57, 185.52)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	29	26.92 (21.26, 34.10)
Not reported and unknown	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	95	913.21 (498.21, 1673.91)
Not reported and unknown	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	95	33206.04 (19716.89, 55923.67)
Not reported and unknown	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	95	16248.13 (10509.97, 25119.17)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	95	9659.01 (7544.15, 12366.74)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	95	1587.54 (1255.01, 2008.17)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	38	1798.25 (673.61, 4800.54)
Not reported and unknown	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	38	85427.72 (47001.77, 155268.53)
Not reported and unknown	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	38	52088.94 (29682.61, 91409.01)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	38	30571.57 (22852.32, 40898.28)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	38	4170.50 (3140.86, 5537.69)
Not reported and unknown	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	15	0.02 (0.02, 0.02)
Not reported and unknown	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	15	0.27 (0.27, 0.27)
Not reported and unknown	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	15	0.09 (0.09, 0.09)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	15	5.00 (5.00, 5.00)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	15	5.00 (5.00, 5.00)
Not reported and unknown	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	29	622.61 (294.33, 1317.02)
Not reported and unknown	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	29	18343.57 (9662.64, 34823.47)
Not reported and unknown	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	29	9346.96 (4825.37, 18105.49)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	29	3686.49 (2496.63, 5443.43)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	29	854.83 (659.14, 1108.61)

Table 5h. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Race

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Race						
White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	359	0.02 (0.02, 0.02)
White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	0.27 (0.27, 0.27)
White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	0.09 (0.09, 0.09)
White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	359	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	359	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	107	0.02 (0.02, 0.02)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	107	0.28 (0.27, 0.29)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	107	0.09 (0.09, 0.10)
White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	107	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	107	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	62	0.02 (0.02, 0.02)
White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	62	0.27 (0.27, 0.27)
White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	62	0.09 (0.09, 0.09)
White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	62	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	62	5.05 (4.95, 5.16)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	127	0.02 (0.02, 0.02)
White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	127	0.27 (0.27, 0.27)
White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	127	0.09 (0.09, 0.09)
White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	127	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	127	5.00 (5.00, 5.00)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	359	70.77 (56.05, 89.37)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	773.49 (621.49, 962.67)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	422.61 (352.48, 506.70)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	359	235.11 (211.32, 261.58)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	359	50.07 (45.40, 55.23)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	107	85.84 (58.74, 125.44)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	107	1255.38 (899.56, 1751.96)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	107	832.71 (610.95, 1134.96)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	107	348.92 (294.71, 413.10)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	107	75.10 (62.84, 89.77)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	62	0.02 (0.02, 0.02)
White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	62	0.27 (0.27, 0.27)
White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	62	0.09 (0.09, 0.09)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	62	5.00 (5.00, 5.00)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	62	5.04 (4.96, 5.13)
White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	127	23.47 (15.78, 34.91)
White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	127	316.63 (227.60, 440.49)
White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	127	171.59 (123.82, 237.80)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	127	101.14 (83.06, 123.15)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	127	24.15 (20.58, 28.34)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	359	925.49 (690.41, 1240.61)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	34327.41 (27434.02, 42952.92)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	23871.82 (19501.19, 29222.00)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	359	10804.86 (9666.02, 12077.88)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	359	1468.18 (1326.37, 1625.16)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	107	2249.02 (1326.44, 3813.30)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	107	72774.32 (48721.26, 108702.06)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	107	44161.88 (31425.62, 62059.94)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	107	27316.51 (23011.03, 32427.56)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	107	4354.20 (3537.98, 5358.73)
White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	62	0.02 (0.02, 0.02)
White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	62	0.27 (0.27, 0.27)
White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	62	0.09 (0.09, 0.09)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	62	5.00 (5.00, 5.00)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	62	5.05 (4.96, 5.14)
White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	127	250.49 (157.30, 398.86)
White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	127	11525.87 (8138.57, 16322.99)
White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	127	6096.79 (4463.25, 8328.19)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	127	3155.01 (2644.10, 3764.64)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	127	732.01 (614.16, 872.46)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Black or African American	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	202	0.02 (0.02, 0.02)
Black or African American	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	202	0.27 (0.27, 0.27)
Black or African American	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	202	0.09 (0.09, 0.09)
Black or African American	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	202	5.00 (5.00, 5.00)
Black or African American	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	202	5.00 (5.00, 5.00)
Black or African American	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	50	0.03 (0.02, 0.03)
Black or African American	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	0.27 (0.27, 0.27)
Black or African American	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	0.09 (0.09, 0.09)
Black or African American	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	50	5.00 (5.00, 5.00)
Black or African American	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	50	5.00 (5.00, 5.00)
Black or African American	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	23	0.02 (0.02, 0.02)
Black or African American	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	23	0.27 (0.27, 0.27)
Black or African American	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	23	0.09 (0.09, 0.09)
Black or African American	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	23	5.00 (5.00, 5.00)
Black or African American	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	23	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Black or African American	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	58	0.02 (0.02, 0.02)
Black or African American	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	58	0.27 (0.27, 0.27)
Black or African American	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	58	0.09 (0.09, 0.09)
Black or African American	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	58	5.00 (5.00, 5.00)
Black or African American	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	58	5.00 (5.00, 5.00)
Black or African American	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	202	52.42 (39.17, 70.17)
Black or African American	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	202	620.22 (474.43, 810.80)
Black or African American	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	202	387.21 (305.84, 490.23)
Black or African American	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	202	212.14 (186.86, 240.85)
Black or African American	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	202	41.78 (36.97, 47.21)
Black or African American	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	50	196.59 (104.35, 370.40)
Black or African American	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	1479.60 (829.63, 2638.80)
Black or African American	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	818.12 (557.51, 1200.57)
Black or African American	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	50	435.79 (335.60, 565.89)
Black or African American	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	50	78.24 (63.94, 95.74)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Black or African American	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	23	0.02 (0.02, 0.02)
Black or African American	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	23	0.27 (0.27, 0.27)
Black or African American	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	23	0.09 (0.09, 0.09)
Black or African American	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	23	5.00 (5.00, 5.00)
Black or African American	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	23	5.00 (5.00, 5.00)
Black or African American	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	58	28.70 (17.47, 47.16)
Black or African American	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	58	338.23 (204.94, 558.22)
Black or African American	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	58	179.69 (125.87, 256.51)
Black or African American	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	58	113.50 (91.67, 140.53)
Black or African American	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	58	27.30 (21.59, 34.52)
Black or African American	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	202	738.67 (516.16, 1057.10)
Black or African American	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	202	27279.78 (19431.21, 38298.52)
Black or African American	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	202	20087.93 (15736.42, 25642.75)
Black or African American	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	202	10042.98 (8775.43, 11493.62)
Black or African American	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	202	1420.41 (1260.42, 1600.72)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Black or African American	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	50	4111.66 (2413.36, 7005.07)
Black or African American	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	84576.93 (48644.19, 147052.68)
Black or African American	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	64957.80 (45985.03, 91758.46)
Black or African American	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	50	27598.17 (21558.09, 35330.55)
Black or African American	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	50	4845.70 (4021.54, 5838.75)
Black or African American	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	23	0.02 (0.02, 0.02)
Black or African American	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	23	0.27 (0.27, 0.27)
Black or African American	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	23	0.09 (0.09, 0.09)
Black or African American	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	23	5.00 (5.00, 5.00)
Black or African American	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	23	5.00 (5.00, 5.00)
Black or African American	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	58	623.51 (345.55, 1125.06)
Black or African American	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	58	14588.83 (9060.46, 23490.40)
Black or African American	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	58	6206.43 (4239.35, 9086.23)
Black or African American	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	58	3855.38 (3059.99, 4857.51)
Black or African American	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	58	879.96 (673.10, 1150.39)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Asian	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	58	0.02 (0.02, 0.02)
Asian	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	58	0.27 (0.27, 0.27)
Asian	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	58	0.09 (0.09, 0.09)
Asian	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	58	5.00 (5.00, 5.00)
Asian	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	58	5.00 (5.00, 5.00)
Asian	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	19	0.02 (0.02, 0.02)
Asian	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	19	0.27 (0.27, 0.27)
Asian	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	19	0.09 (0.09, 0.09)
Asian	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	19	5.00 (5.00, 5.00)
Asian	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	19	5.00 (5.00, 5.00)
Asian	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	13	0.02 (0.02, 0.02)
Asian	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	13	0.27 (0.27, 0.27)
Asian	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	13	0.09 (0.09, 0.09)
Asian	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	13	5.13 (4.87, 5.40)
Asian	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	13	5.81 (4.39, 7.67)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Asian	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	18	0.02 (0.02, 0.02)
Asian	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	18	0.27 (0.27, 0.27)
Asian	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	18	0.09 (0.09, 0.09)
Asian	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	18	5.00 (5.00, 5.00)
Asian	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	18	5.00 (5.00, 5.00)
Asian	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	58	69.59 (41.46, 116.83)
Asian	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	58	764.80 (467.68, 1250.68)
Asian	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	58	442.90 (321.43, 610.28)
Asian	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	58	219.76 (175.38, 275.39)
Asian	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	58	50.55 (40.41, 63.22)
Asian	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	19	133.55 (66.57, 267.93)
Asian	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	19	1081.45 (380.81, 3071.21)
Asian	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	19	685.37 (350.63, 1339.68)
Asian	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	19	424.25 (310.80, 579.12)
Asian	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	19	58.38 (48.10, 70.84)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Asian	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	13	0.02 (0.02, 0.02)
Asian	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	13	0.27 (0.27, 0.27)
Asian	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	13	0.09 (0.09, 0.09)
Asian	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	13	5.00 (5.00, 5.00)
Asian	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	13	5.00 (5.00, 5.00)
Asian	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	18	41.69 (14.44, 120.37)
Asian	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	18	626.25 (273.15, 1435.79)
Asian	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	18	287.83 (112.62, 735.63)
Asian	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	18	116.33 (67.78, 199.64)
Asian	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	18	29.61 (14.92, 58.74)
Asian	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	58	822.44 (370.89, 1823.72)
Asian	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	58	25888.47 (15267.00, 43899.45)
Asian	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	58	23238.49 (15781.39, 34219.25)
Asian	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	58	9016.02 (7117.66, 11420.70)
Asian	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	58	1458.82 (1150.77, 1849.34)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Asian	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	19	2895.47 (1440.80, 5818.80)
Asian	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	19	60327.08 (28464.78, 127854.76)
Asian	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	19	31276.83 (16469.52, 59396.98)
Asian	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	19	32100.41 (23835.64, 43230.91)
Asian	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	19	3203.90 (1752.84, 5856.21)
Asian	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	13	0.02 (0.02, 0.02)
Asian	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	13	0.27 (0.27, 0.27)
Asian	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	13	0.09 (0.09, 0.09)
Asian	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	13	5.00 (5.00, 5.00)
Asian	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	13	5.00 (5.00, 5.00)
Asian	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	18	1689.81 (521.28, 5477.86)
Asian	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	18	21925.41 (8565.77, 56121.45)
Asian	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	18	15372.32 (5814.76, 40639.33)
Asian	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	18	5168.98 (3146.00, 8492.79)
Asian	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	18	836.93 (474.22, 1477.08)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
American Indian or Alaska Native	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	22	0.02 (0.02, 0.02)
American Indian or Alaska Native	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	22	0.27 (0.27, 0.27)
American Indian or Alaska Native	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	22	0.09 (0.09, 0.09)
American Indian or Alaska Native	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	22	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	22	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	7	0.02 (0.02, 0.02)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	7	0.27 (0.27, 0.27)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	7	0.09 (0.09, 0.09)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	7	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	7	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	4	0.03 (0.02, 0.04)
American Indian or Alaska Native	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0.27 (0.27, 0.27)
American Indian or Alaska Native	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0.09 (0.09, 0.09)
American Indian or Alaska Native	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	4	7.39 (3.28, 16.69)
American Indian or Alaska Native	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
American Indian or Alaska Native	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	4	0.02 (0.02, 0.02)
American Indian or Alaska Native	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	4	0.27 (0.27, 0.27)
American Indian or Alaska Native	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	4	0.09 (0.09, 0.09)
American Indian or Alaska Native	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	22	41.62 (11.12, 155.70)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	22	426.30 (143.40, 1267.31)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	22	309.74 (144.02, 666.14)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	22	193.23 (102.70, 363.58)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	22	38.71 (26.82, 55.86)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	7	299.44 (235.70, 380.42)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	7	1006.23 (553.15, 1830.42)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	7	546.85 (199.35, 1500.08)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	7	470.94 (411.86, 538.48)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	7	95.50 (57.44, 158.76)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	4	0.02 (0.02, 0.02)
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0.27 (0.27, 0.27)
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0.09 (0.09, 0.09)
American Indian or Alaska Native	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	4	5.62 (4.41, 7.16)
American Indian or Alaska Native	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	4	7.28 (5.54, 9.56)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	4	82.52 (34.36, 198.19)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	4	39.39 (17.54, 88.47)
American Indian or Alaska Native	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	4	70.42 (57.81, 85.79)
American Indian or Alaska Native	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	4	12.16 (6.86, 21.57)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	22	623.84 (153.56, 2534.29)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	22	18798.13 (7373.08, 47926.98)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	22	10898.97 (4756.30, 24974.76)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	22	7991.67 (6041.09, 10572.07)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	22	1394.65 (810.96, 2398.47)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	7	2449.33 (344.90, 17393.92)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	7	111270.11 (31885.09, 388301.85)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	7	93808.44 (46821.32, 187949.08)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	7	46209.69 (25394.88, 84085.28)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	7	7891.42 (6621.02, 9405.57)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	4	0.02 (0.02, 0.02)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0.27 (0.27, 0.27)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0.09 (0.09, 0.09)
American Indian or Alaska Native	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	4	30.79 (1.14, 830.37)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	4	1689.25 (684.84, 4166.79)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	4	3036.98 (1287.44, 7164.04)
American Indian or Alaska Native	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	4	1815.62 (967.91, 3405.75)
American Indian or Alaska Native	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	4	383.53 (327.73, 448.83)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	11	0.02 (0.02, 0.02)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	11	0.27 (0.27, 0.27)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	11	0.09 (0.09, 0.09)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	11	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	11	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	6	0.02 (0.02, 0.02)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	0.27 (0.27, 0.27)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	0.09 (0.09, 0.09)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	6	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	6	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	5	0.02 (0.02, 0.02)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	5	0.27 (0.27, 0.27)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	5	0.09 (0.09, 0.09)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	4	0.02 (0.02, 0.02)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	4	0.27 (0.27, 0.27)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	4	0.09 (0.09, 0.09)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	11	51.33 (14.95, 176.18)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	11	1035.86 (188.21, 5701.08)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	11	308.62 (75.49, 1261.75)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	11	183.85 (103.40, 326.89)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	11	46.76 (24.37, 89.71)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	6	58.71 (9.44, 365.30)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	898.14 (139.86, 5767.71)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	598.08 (134.42, 2661.10)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	6	224.65 (101.43, 497.57)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	6	62.52 (30.81, 126.85)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	5	0.02 (0.02, 0.02)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	5	0.27 (0.27, 0.27)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	5	0.09 (0.09, 0.09)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	4	51.71 (16.43, 162.76)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	4	855.53 (326.10, 2244.47)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	4	297.09 (102.82, 858.42)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	4	130.33 (72.06, 235.72)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	4	41.50 (30.63, 56.21)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	11	1583.05 (143.29, 17489.39)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	11	22166.22 (4016.60, 122327.82)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	11	21332.32 (5492.11, 82858.49)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	11	13135.28 (7969.15, 21650.41)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	11	1911.89 (1127.47, 3242.05)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	6	1699.48 (289.41, 9979.75)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	73472.20 (13302.98, 405786.15)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	35073.79 (8119.82, 151502.23)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	6	34285.62 (10528.62, 111648.42)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	6	3522.47 (1406.94, 8818.97)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	5	0.02 (0.02, 0.02)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	5	0.27 (0.27, 0.27)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	5	0.09 (0.09, 0.09)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	4	840.40 (258.53, 2731.86)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	4	38923.51 (28410.91, 53325.98)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	4	27169.76 (15245.45, 48420.73)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	4	2408.35 (1380.09, 4202.74)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	4	1338.63 (850.69, 2106.44)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Multiracial	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	60	0.02 (0.02, 0.02)
Multiracial	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	60	0.27 (0.27, 0.27)
Multiracial	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	60	0.09 (0.09, 0.09)
Multiracial	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	60	5.00 (5.00, 5.00)
Multiracial	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	60	5.00 (5.00, 5.00)
Multiracial	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	11	0.02 (0.02, 0.02)
Multiracial	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	11	0.27 (0.27, 0.27)
Multiracial	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	11	0.09 (0.09, 0.09)
Multiracial	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	11	5.00 (5.00, 5.00)
Multiracial	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	11	5.00 (5.00, 5.00)
Multiracial	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	10	0.02 (0.02, 0.02)
Multiracial	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	10	0.27 (0.27, 0.27)
Multiracial	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	10	0.09 (0.09, 0.09)
Multiracial	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	10	5.00 (5.00, 5.00)
Multiracial	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	10	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Multiracial	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	14	0.02 (0.02, 0.02)
Multiracial	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	14	0.27 (0.27, 0.27)
Multiracial	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	14	0.09 (0.09, 0.09)
Multiracial	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	14	5.00 (5.00, 5.00)
Multiracial	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	14	5.00 (5.00, 5.00)
Multiracial	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	60	55.11 (27.73, 109.50)
Multiracial	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	60	575.00 (339.93, 972.61)
Multiracial	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	60	357.72 (246.30, 519.55)
Multiracial	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	60	226.10 (174.72, 292.59)
Multiracial	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	60	53.45 (41.88, 68.20)
Multiracial	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	11	110.28 (33.79, 359.87)
Multiracial	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	11	842.92 (269.03, 2641.00)
Multiracial	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	11	657.77 (146.44, 2954.53)
Multiracial	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	11	338.14 (192.74, 593.24)
Multiracial	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	11	99.51 (52.04, 190.28)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Multiracial	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	10	0.02 (0.02, 0.02)
Multiracial	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	10	0.27 (0.27, 0.27)
Multiracial	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	10	0.09 (0.09, 0.09)
Multiracial	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	10	5.00 (5.00, 5.00)
Multiracial	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	10	5.00 (5.00, 5.00)
Multiracial	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	14	28.40 (12.34, 65.36)
Multiracial	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	14	207.00 (99.98, 428.59)
Multiracial	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	14	102.78 (58.21, 181.49)
Multiracial	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	14	92.32 (65.91, 129.32)
Multiracial	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	14	16.00 (9.25, 27.69)
Multiracial	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	60	1056.78 (465.41, 2399.56)
Multiracial	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	60	30098.69 (18275.30, 49571.36)
Multiracial	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	60	23197.01 (15392.49, 34958.69)
Multiracial	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	60	9070.94 (6824.45, 12056.94)
Multiracial	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	60	1351.04 (1109.85, 1644.63)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Multiracial	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	11	1970.31 (483.58, 8027.89)
Multiracial	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	11	32820.90 (8779.20, 122700.48)
Multiracial	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	11	43616.02 (15105.29, 125939.78)
Multiracial	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	11	23660.37 (12308.57, 45481.58)
Multiracial	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	11	4331.41 (2462.23, 7619.54)
Multiracial	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	10	0.02 (0.02, 0.02)
Multiracial	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	10	0.27 (0.27, 0.27)
Multiracial	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	10	0.09 (0.09, 0.09)
Multiracial	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	10	5.00 (5.00, 5.00)
Multiracial	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	10	5.00 (5.00, 5.00)
Multiracial	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	14	410.91 (155.76, 1084.06)
Multiracial	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	14	7705.74 (3441.63, 17253.01)
Multiracial	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	14	3367.56 (1816.17, 6244.14)
Multiracial	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	14	3188.11 (2095.39, 4850.68)
Multiracial	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	14	594.43 (437.77, 807.14)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Other	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	21	0.02 (0.02, 0.02)
Other	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	21	0.27 (0.27, 0.27)
Other	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	21	0.09 (0.09, 0.09)
Other	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	21	5.00 (5.00, 5.00)
Other	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	21	5.00 (5.00, 5.00)
Other	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	8	0.02 (0.02, 0.02)
Other	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	8	0.27 (0.27, 0.27)
Other	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	8	0.09 (0.09, 0.09)
Other	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	8	5.00 (5.00, 5.00)
Other	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	8	5.00 (5.00, 5.00)
Other	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	4	0.02 (0.02, 0.02)
Other	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0.27 (0.27, 0.27)
Other	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0.09 (0.09, 0.09)
Other	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)
Other	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Other	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	7	0.02 (0.02, 0.02)
Other	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	7	0.27 (0.27, 0.27)
Other	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	7	0.09 (0.09, 0.09)
Other	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	7	5.00 (5.00, 5.00)
Other	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	7	5.00 (5.00, 5.00)
Other	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	21	27.23 (13.78, 53.82)
Other	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	21	418.49 (221.82, 789.53)
Other	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	21	234.97 (115.77, 476.92)
Other	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	21	163.35 (128.16, 208.20)
Other	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	21	35.94 (20.73, 62.31)
Other	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	8	192.12 (77.42, 476.73)
Other	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	8	2930.46 (1290.00, 6657.09)
Other	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	8	845.09 (362.50, 1970.15)
Other	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	8	437.76 (290.31, 660.11)
Other	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	8	77.88 (50.06, 121.14)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Other	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	4	0.02 (0.02, 0.02)
Other	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0.27 (0.27, 0.27)
Other	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0.09 (0.09, 0.09)
Other	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)
Other	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)
Other	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	7	19.07 (4.60, 79.10)
Other	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	7	390.93 (123.89, 1233.60)
Other	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	7	201.95 (66.38, 614.36)
Other	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	7	101.94 (54.01, 192.42)
Other	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	7	22.80 (11.37, 45.72)
Other	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	21	895.74 (160.73, 4991.76)
Other	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	21	18055.97 (4458.23, 73127.28)
Other	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	21	15473.74 (7185.26, 33323.31)
Other	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	21	5915.17 (3335.14, 10491.08)
Other	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	21	1374.55 (847.70, 2228.84)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Other	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	8	5603.16 (2097.03, 14971.36)
Other	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	8	60786.89 (33758.87, 109454.06)
Other	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	8	63547.88 (25199.21, 160256.37)
Other	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	8	28339.45 (18536.74, 43326.09)
Other	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	8	5463.27 (2666.19, 11194.77)
Other	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	4	0.02 (0.02, 0.02)
Other	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0.27 (0.27, 0.27)
Other	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0.09 (0.09, 0.09)
Other	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)
Other	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)
Other	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	7	373.78 (63.76, 2191.26)
Other	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	7	9100.48 (2896.08, 28596.84)
Other	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	7	8645.11 (2704.19, 27637.86)
Other	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	7	3363.07 (2119.12, 5337.24)
Other	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	7	552.38 (332.19, 918.54)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	86	0.02 (0.02, 0.02)
Not reported and unknown	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	86	0.28 (0.27, 0.28)
Not reported and unknown	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	86	0.09 (0.09, 0.09)
Not reported and unknown	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	86	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	86	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	25	0.02 (0.02, 0.02)
Not reported and unknown	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	25	0.27 (0.27, 0.27)
Not reported and unknown	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	25	0.09 (0.09, 0.09)
Not reported and unknown	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	25	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	25	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	19	0.02 (0.02, 0.02)
Not reported and unknown	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	19	0.27 (0.27, 0.27)
Not reported and unknown	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	19	0.09 (0.09, 0.09)
Not reported and unknown	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	19	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	19	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	24	0.02 (0.02, 0.02)
Not reported and unknown	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	24	0.27 (0.27, 0.27)
Not reported and unknown	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	24	0.09 (0.09, 0.09)
Not reported and unknown	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	24	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	24	5.00 (5.00, 5.00)
Not reported and unknown	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	86	55.01 (33.04, 91.59)
Not reported and unknown	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	86	595.75 (406.96, 872.13)
Not reported and unknown	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	86	362.48 (255.95, 513.35)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	86	210.20 (165.11, 267.60)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	86	36.20 (28.27, 46.35)
Not reported and unknown	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	25	75.01 (28.93, 194.46)
Not reported and unknown	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	25	1072.44 (640.30, 1796.24)
Not reported and unknown	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	25	609.57 (316.48, 1174.10)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	25	304.00 (205.97, 448.70)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	25	72.96 (53.68, 99.18)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	19	0.02 (0.02, 0.02)
Not reported and unknown	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	19	0.27 (0.27, 0.27)
Not reported and unknown	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	19	0.09 (0.09, 0.09)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	19	5.00 (5.00, 5.00)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	19	5.12 (4.88, 5.38)
Not reported and unknown	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	24	111.72 (36.48, 342.08)
Not reported and unknown	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	24	918.16 (340.70, 2474.41)
Not reported and unknown	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	24	361.93 (163.87, 799.38)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	24	191.84 (121.39, 303.15)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	24	36.92 (23.53, 57.94)
Not reported and unknown	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	86	662.31 (365.26, 1200.94)
Not reported and unknown	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	86	24290.22 (14883.34, 39642.62)
Not reported and unknown	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	86	16435.89 (10879.55, 24829.93)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	86	9186.30 (7186.05, 11743.33)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	86	1301.38 (1005.32, 1684.62)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	25	1029.28 (418.57, 2531.03)
Not reported and unknown	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	25	72598.19 (43488.88, 121191.84)
Not reported and unknown	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	25	65369.01 (42302.55, 101012.97)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	25	21255.49 (13116.68, 34444.39)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	25	4235.58 (2991.27, 5997.50)
Not reported and unknown	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	19	0.02 (0.02, 0.02)
Not reported and unknown	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	19	0.27 (0.27, 0.27)
Not reported and unknown	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	19	0.09 (0.09, 0.09)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	19	5.00 (5.00, 5.00)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	19	5.00 (5.00, 5.00)
Not reported and unknown	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	24	944.69 (294.27, 3032.73)
Not reported and unknown	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	24	34049.21 (9185.79, 126211.18)
Not reported and unknown	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	24	15466.09 (4535.90, 52734.84)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	24	4758.56 (2708.14, 8361.41)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	24	1102.39 (759.70, 1599.66)

Table 5i. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Underrepresented minority status						
Communities of Color	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	420	0.02 (0.02, 0.02)
Communities of Color	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	420	0.27 (0.27, 0.28)
Communities of Color	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	420	0.09 (0.09, 0.09)
Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	420	5.00 (5.00, 5.00)
Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	420	5.00 (5.00, 5.00)
Communities of Color	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	110	0.02 (0.02, 0.03)
Communities of Color	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	110	0.27 (0.27, 0.27)
Communities of Color	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	110	0.09 (0.09, 0.09)
Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	110	5.00 (5.00, 5.00)
Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	110	5.00 (5.00, 5.00)
Communities of Color	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	66	0.02 (0.02, 0.02)
Communities of Color	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.27 (0.27, 0.27)
Communities of Color	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.09 (0.09, 0.09)
Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	66	5.17 (4.90, 5.45)
Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	66	5.24 (4.78, 5.73)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Communities of Color	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	112	0.02 (0.02, 0.02)
Communities of Color	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	112	0.27 (0.27, 0.27)
Communities of Color	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	112	0.09 (0.09, 0.09)
Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	112	5.00 (5.00, 5.00)
Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	112	5.00 (5.00, 5.00)
Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	420	57.98 (45.97, 73.14)
Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	420	664.37 (542.05, 814.30)
Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	420	405.04 (342.49, 479.00)
Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	420	218.67 (198.49, 240.90)
Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	420	46.34 (42.33, 50.73)
Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	110	168.27 (116.47, 243.10)
Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	110	1358.84 (945.07, 1953.77)
Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	110	765.48 (567.32, 1032.87)
Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	110	408.66 (349.47, 477.89)
Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	110	80.17 (68.61, 93.68)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	66	0.02 (0.02, 0.02)
Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.27 (0.27, 0.27)
Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.09 (0.09, 0.09)
Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	66	5.04 (4.96, 5.12)
Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	66	5.00 (5.00, 5.00)
Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	112	28.33 (19.89, 40.35)
Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	112	326.35 (231.97, 459.13)
Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	112	167.58 (126.64, 221.76)
Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	112	107.63 (92.18, 125.68)
Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	112	24.98 (20.54, 30.39)
Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	420	853.62 (637.81, 1142.44)
Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	420	28930.91 (22912.52, 36530.15)
Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	420	21293.85 (17960.45, 25245.92)
Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	420	9791.89 (8862.62, 10818.59)
Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	420	1481.62 (1347.39, 1629.23)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	110	3358.53 (2264.87, 4980.30)
Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	110	73040.18 (51647.13, 103294.58)
Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	110	57796.58 (43867.82, 76147.94)
Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	110	30116.79 (25155.99, 36055.86)
Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	110	4843.03 (4028.40, 5822.39)
Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	66	0.02 (0.02, 0.02)
Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.27 (0.27, 0.27)
Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.09 (0.09, 0.09)
Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	66	5.00 (5.00, 5.00)
Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	66	5.00 (5.00, 5.00)
Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	112	547.77 (327.05, 917.44)
Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	112	12723.66 (8864.28, 18263.34)
Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	112	6914.16 (5158.96, 9266.54)
Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	112	3911.62 (3256.22, 4698.94)
Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	112	783.30 (648.80, 945.68)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	359	0.02 (0.02, 0.02)
White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	0.27 (0.27, 0.27)
White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	0.09 (0.09, 0.09)
White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	359	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	359	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	107	0.02 (0.02, 0.02)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	107	0.28 (0.27, 0.29)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	107	0.09 (0.09, 0.10)
White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	107	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	107	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	62	0.02 (0.02, 0.02)
White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	62	0.27 (0.27, 0.27)
White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	62	0.09 (0.09, 0.09)
White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	62	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	62	5.05 (4.95, 5.16)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	127	0.02 (0.02, 0.02)
White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	127	0.27 (0.27, 0.27)
White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	127	0.09 (0.09, 0.09)
White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	127	5.00 (5.00, 5.00)
White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	127	5.00 (5.00, 5.00)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	359	70.77 (56.05, 89.37)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	773.49 (621.49, 962.67)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	422.61 (352.48, 506.70)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	359	235.11 (211.32, 261.58)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	359	50.07 (45.40, 55.23)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	107	85.84 (58.74, 125.44)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	107	1255.38 (899.56, 1751.96)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	107	832.71 (610.95, 1134.96)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	107	348.92 (294.71, 413.10)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	107	75.10 (62.84, 89.77)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	62	0.02 (0.02, 0.02)
White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	62	0.27 (0.27, 0.27)
White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	62	0.09 (0.09, 0.09)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	62	5.00 (5.00, 5.00)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	62	5.04 (4.96, 5.13)
White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	127	23.47 (15.78, 34.91)
White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	127	316.63 (227.60, 440.49)
White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	127	171.59 (123.82, 237.80)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	127	101.14 (83.06, 123.15)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	127	24.15 (20.58, 28.34)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	359	925.49 (690.41, 1240.61)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	34327.41 (27434.02, 42952.92)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	23871.82 (19501.19, 29222.00)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	359	10804.86 (9666.02, 12077.88)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	359	1468.18 (1326.37, 1625.16)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	107	2249.02 (1326.44, 3813.30)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	107	72774.32 (48721.26, 108702.06)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	107	44161.88 (31425.62, 62059.94)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	107	27316.51 (23011.03, 32427.56)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	107	4354.20 (3537.98, 5358.73)
White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	62	0.02 (0.02, 0.02)
White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	62	0.27 (0.27, 0.27)
White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	62	0.09 (0.09, 0.09)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	62	5.00 (5.00, 5.00)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	62	5.05 (4.96, 5.14)
White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	127	250.49 (157.30, 398.86)
White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	127	11525.87 (8138.57, 16322.99)
White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	127	6096.79 (4463.25, 8328.19)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	127	3155.01 (2644.10, 3764.64)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	127	732.01 (614.16, 872.46)

Table 5j. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age, Underrepresented minority status						
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	202	0.02 (0.02, 0.02)
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	202	0.27 (0.27, 0.28)
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	202	0.09 (0.09, 0.09)
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	202	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	202	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	60	0.02 (0.02, 0.03)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	60	0.27 (0.27, 0.27)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	60	0.09 (0.09, 0.09)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	60	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	60	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	30	0.02 (0.02, 0.02)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	30	0.27 (0.27, 0.27)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	30	0.09 (0.09, 0.09)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	30	5.17 (4.84, 5.53)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	30	5.31 (4.72, 5.98)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Communities of Color	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	65	0.02 (0.02, 0.02)
Age < 65 Communities of Color	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	65	0.27 (0.27, 0.27)
Age < 65 Communities of Color	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	65	0.09 (0.09, 0.09)
Age < 65 Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	65	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	65	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	202	49.67 (37.19, 66.33)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	202	527.70 (409.41, 680.17)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	202	323.55 (262.58, 398.67)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	202	205.17 (182.08, 231.19)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	202	44.63 (39.89, 49.93)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	60	148.07 (95.13, 230.48)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	60	1085.62 (699.91, 1683.89)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	60	608.97 (424.50, 873.59)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	60	367.95 (305.38, 443.34)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	60	76.60 (63.42, 92.51)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	30	0.02 (0.02, 0.02)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	30	0.27 (0.27, 0.27)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	30	0.09 (0.09, 0.09)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	30	5.05 (4.95, 5.15)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	30	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	65	19.80 (13.13, 29.87)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	65	231.94 (154.95, 347.18)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	65	122.42 (88.21, 169.90)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	65	97.27 (81.18, 116.56)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	65	22.27 (17.59, 28.20)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	202	703.91 (488.76, 1013.76)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	202	22699.33 (16955.83, 30388.35)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	202	17344.59 (14041.15, 21425.23)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	202	9504.36 (8419.55, 10728.95)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	202	1445.62 (1285.26, 1625.99)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	60	2983.13 (1857.90, 4789.86)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	60	56076.90 (36777.54, 85503.79)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	60	48389.96 (34492.47, 67886.94)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	60	27755.32 (22312.67, 34525.58)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	60	4756.11 (3797.88, 5956.12)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	30	0.02 (0.02, 0.02)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	30	0.27 (0.27, 0.27)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	30	0.09 (0.09, 0.09)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	30	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	30	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	65	462.53 (248.62, 860.48)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	65	9500.81 (6175.91, 14615.71)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	65	4840.29 (3438.86, 6812.85)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	65	3601.45 (2895.47, 4479.57)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	65	731.08 (582.87, 916.97)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	171	0.02 (0.02, 0.02)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	171	0.27 (0.27, 0.27)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	171	0.09 (0.09, 0.09)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	171	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	171	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	56	0.02 (0.02, 0.02)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	56	0.28 (0.27, 0.29)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	56	0.09 (0.09, 0.10)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	56	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	56	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	32	0.02 (0.02, 0.02)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0.27 (0.27, 0.27)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0.09 (0.09, 0.09)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	32	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	32	5.07 (4.93, 5.22)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.02)
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	64	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	64	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	171	55.95 (41.96, 74.61)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	171	612.78 (467.83, 802.62)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	171	332.43 (266.04, 415.38)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	171	217.19 (190.45, 247.69)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	171	48.05 (42.59, 54.21)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	56	60.13 (38.16, 94.77)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	56	984.16 (658.56, 1470.74)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	56	663.42 (456.28, 964.61)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	56	296.17 (242.20, 362.17)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	56	68.60 (55.21, 85.24)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	32	0.02 (0.02, 0.02)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0.27 (0.27, 0.27)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0.09 (0.09, 0.09)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	32	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	32	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	64	18.41 (11.49, 29.49)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	64	258.27 (174.34, 382.62)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	64	133.01 (89.97, 196.63)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	64	91.90 (72.58, 116.37)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	64	22.78 (18.83, 27.54)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	171	717.12 (499.17, 1030.25)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	171	26979.94 (20466.97, 35565.46)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	171	19303.30 (15027.58, 24795.56)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	171	10081.72 (8805.33, 11543.13)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	171	1390.12 (1227.25, 1574.61)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	56	1640.17 (857.37, 3137.69)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	56	53872.53 (32928.51, 88137.91)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	56	35348.28 (23164.17, 53941.10)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	56	24417.31 (19839.35, 30051.64)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	56	4132.14 (3200.69, 5334.67)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	32	0.02 (0.02, 0.02)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0.27 (0.27, 0.27)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0.09 (0.09, 0.09)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	32	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	32	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	64	188.68 (108.49, 328.13)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	64	8590.33 (5712.34, 12918.32)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	64	4474.39 (3095.25, 6468.02)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	64	2904.62 (2352.77, 3585.92)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	64	699.22 (565.84, 864.05)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Communities of Color	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	218	0.02 (0.02, 0.02)
Age \geq 65 Communities of Color	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	0.27 (0.27, 0.27)
Age \geq 65 Communities of Color	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	0.09 (0.09, 0.09)
Age \geq 65 Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	218	5.00 (5.00, 5.00)
Age \geq 65 Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	218	5.00 (5.00, 5.00)
Age \geq 65 Communities of Color	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	50	0.02 (0.02, 0.03)
Age \geq 65 Communities of Color	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	0.27 (0.27, 0.27)
Age \geq 65 Communities of Color	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	0.09 (0.09, 0.09)
Age \geq 65 Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	50	5.00 (5.00, 5.00)
Age \geq 65 Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	50	5.00 (5.00, 5.00)
Age \geq 65 Communities of Color	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	36	0.02 (0.02, 0.02)
Age \geq 65 Communities of Color	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0.27 (0.27, 0.27)
Age \geq 65 Communities of Color	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0.09 (0.09, 0.09)
Age \geq 65 Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	36	5.17 (4.84, 5.52)
Age \geq 65 Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	36	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Communities of Color	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	47	0.02 (0.02, 0.02)
Age \geq 65 Communities of Color	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	47	0.27 (0.27, 0.27)
Age \geq 65 Communities of Color	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	47	0.09 (0.09, 0.09)
Age \geq 65 Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	47	5.00 (5.00, 5.00)
Age \geq 65 Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	47	5.00 (5.00, 5.00)
Age \geq 65 Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	218	100.21 (78.15, 128.49)
Age \geq 65 Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	1500.16 (1219.10, 1846.03)
Age \geq 65 Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	896.38 (752.55, 1067.69)
Age \geq 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	218	273.96 (243.07, 308.77)
Age \geq 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	218	52.92 (47.74, 58.66)
Age \geq 65 Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	50	278.52 (169.10, 458.75)
Age \geq 65 Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	3291.51 (2147.99, 5043.80)
Age \geq 65 Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	1885.63 (1328.32, 2676.76)
Age \geq 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	50	618.00 (495.72, 770.44)
Age \geq 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	50	95.96 (79.19, 116.28)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	36	0.02 (0.02, 0.02)
Age \geq 65 Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0.27 (0.27, 0.27)
Age \geq 65 Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0.09 (0.09, 0.09)
Age \geq 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	36	5.00 (5.00, 5.00)
Age \geq 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	36	5.00 (5.00, 5.00)
Age \geq 65 Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	47	125.96 (74.24, 213.72)
Age \geq 65 Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	47	1353.98 (895.38, 2047.47)
Age \geq 65 Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	47	620.10 (430.84, 892.50)
Age \geq 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	47	164.09 (127.59, 211.03)
Age \geq 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	47	40.29 (32.64, 49.73)
Age \geq 65 Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	218	1688.22 (1269.07, 2245.80)
Age \geq 65 Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	68222.07 (54395.34, 85563.41)
Age \geq 65 Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	43986.32 (36438.31, 53097.87)
Age \geq 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	218	10880.29 (9417.18, 12570.71)
Age \geq 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	218	1616.29 (1444.18, 1808.92)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	50	5358.34 (3114.03, 9220.17)
Age \geq 65 Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	206976.79 (149201.94, 287123.54)
Age \geq 65 Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	116399.58 (93420.70, 145030.61)
Age \geq 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	50	41550.09 (33605.32, 51373.13)
Age \geq 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	50	5201.33 (4241.88, 6377.77)
Age \geq 65 Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	36	0.02 (0.02, 0.02)
Age \geq 65 Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0.27 (0.27, 0.27)
Age \geq 65 Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0.09 (0.09, 0.09)
Age \geq 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	36	5.00 (5.00, 5.00)
Age \geq 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	36	5.00 (5.00, 5.00)
Age \geq 65 Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	47	1108.29 (597.42, 2056.02)
Age \geq 65 Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	47	42969.45 (28034.74, 65860.20)
Age \geq 65 Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	47	30550.91 (21148.88, 44132.75)
Age \geq 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	47	5518.88 (4280.94, 7114.80)
Age \geq 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	47	1044.20 (831.98, 1310.54)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	188	0.02 (0.02, 0.02)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	188	0.27 (0.27, 0.28)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	188	0.09 (0.09, 0.09)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	188	5.00 (5.00, 5.00)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	188	5.00 (5.00, 5.00)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	51	0.02 (0.02, 0.02)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	51	0.27 (0.27, 0.27)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	51	0.09 (0.09, 0.09)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	51	5.00 (5.00, 5.00)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	51	5.00 (5.00, 5.00)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	30	0.02 (0.02, 0.02)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	30	0.27 (0.27, 0.27)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	30	0.09 (0.09, 0.09)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	30	5.00 (5.00, 5.00)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	30	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	63	0.02 (0.02, 0.02)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	63	0.27 (0.27, 0.27)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	63	0.09 (0.09, 0.09)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	63	5.00 (5.00, 5.00)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	63	5.00 (5.00, 5.00)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	188	170.43 (135.85, 213.81)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	188	1848.52 (1494.71, 2286.07)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	188	1037.28 (871.16, 1235.07)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	188	316.28 (282.70, 353.84)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	188	58.43 (52.42, 65.12)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	51	336.52 (222.95, 507.95)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	51	3195.40 (2152.61, 4743.36)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	51	1992.25 (1397.99, 2839.13)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	51	654.56 (534.20, 802.05)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	51	106.35 (87.08, 129.88)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	30	0.02 (0.02, 0.02)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	30	0.27 (0.27, 0.27)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	30	0.09 (0.09, 0.09)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	30	5.00 (5.00, 5.00)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	30	5.18 (4.84, 5.53)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	63	69.22 (43.28, 110.72)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	63	784.51 (544.71, 1129.89)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	63	533.61 (412.78, 689.81)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	63	154.97 (127.43, 188.47)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	63	31.37 (25.59, 38.45)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	188	2402.91 (1815.63, 3180.15)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	188	84508.84 (67880.09, 105211.17)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	188	52840.35 (44230.13, 63126.71)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	188	14000.79 (12068.14, 16242.96)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	188	1801.06 (1600.12, 2027.24)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	51	7555.31 (4785.85, 11927.38)
Age \geq 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	51	230839.41 (173912.58, 306400.11)
Age \geq 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	51	103785.84 (86236.46, 124906.57)
Age \geq 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	51	42020.27 (34485.98, 51200.60)
Age \geq 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	51	5323.15 (4305.26, 6581.69)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	30	0.02 (0.02, 0.02)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	30	0.27 (0.27, 0.27)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	30	0.09 (0.09, 0.09)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	30	5.00 (5.00, 5.00)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	30	5.18 (4.83, 5.56)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	63	884.92 (523.48, 1495.94)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	63	42687.87 (27119.91, 67192.49)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	63	24187.43 (17726.62, 33003.01)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	63	4559.82 (3733.36, 5569.23)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	63	897.72 (765.46, 1052.85)

Table 6a. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by All participants

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
All participants								
	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	915	0.02 (0.02, 0.02)	62.87 (53.77, 73.52)	2608.65 (2230.81, 3050.48)
	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	915	0.27 (0.27, 0.27)	700.18 (608.59, 805.55)	2569.01 (2233.55, 2954.86)
	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	915	0.09 (0.09, 0.09)	412.01 (364.96, 465.13)	4577.87 (4055.08, 5168.07)
	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	915	5.00 (5.00, 5.00)	225.10 (209.62, 241.74)	45.02 (41.92, 48.35)
	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	915	5.00 (5.00, 5.00)	46.79 (43.69, 50.12)	9.36 (8.74, 10.02)
	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	269	0.02 (0.02, 0.02)	103.45 (79.96, 133.83)	4276.50 (3308.33, 5528.02)
	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	269	0.27 (0.27, 0.28)	1269.77 (1009.63, 1596.93)	4623.24 (3692.83, 5788.07)
	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	269	0.09 (0.09, 0.09)	766.27 (626.05, 937.90)	8418.53 (6892.42, 10282.54)
	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	269	5.00 (5.00, 5.00)	354.90 (317.58, 396.60)	70.98 (63.52, 79.32)
	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	269	5.00 (5.00, 5.00)	76.03 (68.29, 84.64)	15.21 (13.66, 16.93)
	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	155	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (0.99, 1.00)
	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	155	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	155	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	155	5.06 (4.97, 5.14)	5.01 (4.99, 5.04)	0.99 (0.98, 1.00)
	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	155	5.10 (4.95, 5.26)	5.04 (4.99, 5.09)	0.99 (0.96, 1.02)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	276	0.02 (0.02, 0.02)	29.12 (22.05, 38.45)	1213.25 (918.71, 1602.22)
	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	276	0.27 (0.27, 0.27)	369.13 (289.11, 471.31)	1357.10 (1062.90, 1732.74)
	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	276	0.09 (0.09, 0.09)	186.46 (150.24, 231.43)	2069.38 (1667.49, 2568.14)
	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	276	5.00 (5.00, 5.00)	109.67 (96.21, 125.02)	21.93 (19.24, 25.00)
	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	276	5.00 (5.00, 5.00)	25.20 (22.40, 28.34)	5.04 (4.48, 5.67)
	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	915	0.02 (0.02, 0.02)	858.71 (706.57, 1043.61)	35627.60 (29305.04, 43314.25)
	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	915	0.27 (0.27, 0.27)	31262.39 (26797.12, 36471.73)	114704.34 (98342.34, 133788.61)
	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	915	0.09 (0.09, 0.09)	21267.84 (18637.15, 24269.85)	236309.31 (207079.50, 269664.99)
	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	915	5.00 (5.00, 5.00)	10118.66 (9384.97, 10909.71)	2023.73 (1876.99, 2181.94)
	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	915	5.00 (5.00, 5.00)	1464.36 (1363.33, 1572.87)	292.87 (272.67, 314.57)
	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	269	0.02 (0.02, 0.02)	2216.51 (1602.80, 3065.20)	91631.72 (66280.94, 126678.52)
	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	269	0.27 (0.27, 0.28)	73550.05 (58195.76, 92955.40)	267796.68 (212456.64, 337551.53)
	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	269	0.09 (0.09, 0.09)	51328.47 (41972.47, 62770.00)	563914.23 (461750.60, 688681.86)
	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	269	5.00 (5.00, 5.00)	27542.73 (24378.19, 31118.07)	5508.55 (4875.64, 6223.61)
	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	269	5.00 (5.00, 5.00)	4408.72 (3893.97, 4991.51)	881.74 (778.79, 998.30)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	155	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (0.99, 1.00)
	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	155	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	155	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	155	5.06 (4.97, 5.14)	5.00 (5.00, 5.00)	0.99 (0.97, 1.01)
	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	155	5.10 (4.95, 5.26)	5.02 (4.98, 5.06)	0.98 (0.95, 1.02)
	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	276	0.02 (0.02, 0.02)	373.57 (268.20, 520.32)	15565.21 (11175.19, 21679.81)
	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	276	0.27 (0.27, 0.27)	13174.89 (10267.01, 16906.37)	48437.11 (37746.36, 62155.76)
	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	276	0.09 (0.09, 0.09)	7011.64 (5627.97, 8735.50)	77815.69 (62463.48, 96941.15)
	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	276	5.00 (5.00, 5.00)	3530.63 (3123.48, 3990.86)	706.13 (624.70, 798.17)
	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	276	5.00 (5.00, 5.00)	767.20 (679.53, 866.17)	153.44 (135.91, 173.23)

Table 6b. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age								
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	439	0.02 (0.02, 0.02)	50.34 (41.46, 61.11)	2086.05 (1718.10, 2532.81)
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	439	0.27 (0.27, 0.27)	550.94 (463.04, 655.53)	2021.52 (1699.54, 2404.49)
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	439	0.09 (0.09, 0.09)	321.20 (276.30, 373.39)	3568.87 (3070.04, 4148.76)
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	439	5.00 (5.00, 5.00)	207.85 (190.33, 226.99)	41.57 (38.07, 45.40)
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	439	5.00 (5.00, 5.00)	44.22 (40.61, 48.14)	8.84 (8.12, 9.63)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	146	0.02 (0.02, 0.02)	79.94 (58.66, 108.95)	3302.15 (2425.55, 4495.56)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	146	0.28 (0.27, 0.28)	999.08 (758.84, 1315.39)	3629.29 (2772.73, 4750.46)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	146	0.09 (0.09, 0.09)	610.04 (478.76, 777.31)	6706.34 (5275.88, 8524.65)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	146	5.00 (5.00, 5.00)	309.64 (271.19, 353.54)	61.93 (54.24, 70.71)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	146	5.00 (5.00, 5.00)	71.33 (62.71, 81.14)	14.27 (12.54, 16.23)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	77	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (0.99, 1.00)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	77	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	77	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	77	5.06 (4.95, 5.17)	5.02 (4.98, 5.05)	0.99 (0.98, 1.01)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	77	5.13 (4.93, 5.34)	5.00 (5.00, 5.00)	0.97 (0.94, 1.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	148	0.02 (0.02, 0.02)	21.99 (15.74, 30.72)	916.22 (655.73, 1280.18)
Age < 65	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	148	0.27 (0.27, 0.27)	287.32 (213.80, 386.13)	1056.33 (786.02, 1419.61)
Age < 65	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	148	0.09 (0.09, 0.09)	139.33 (107.34, 180.85)	1548.12 (1192.71, 2009.45)
Age < 65	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	148	5.00 (5.00, 5.00)	99.72 (85.10, 116.85)	19.94 (17.02, 23.37)
Age < 65	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	148	5.00 (5.00, 5.00)	23.32 (20.23, 26.87)	4.66 (4.05, 5.37)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	439	0.02 (0.02, 0.02)	670.07 (526.00, 853.60)	27768.90 (21788.49, 35390.80)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	439	0.27 (0.27, 0.27)	24070.27 (19874.19, 29152.28)	88318.88 (72942.98, 106935.93)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	439	0.09 (0.09, 0.09)	16814.24 (14267.46, 19815.61)	186824.86 (158527.39, 220173.48)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	439	5.00 (5.00, 5.00)	9490.17 (8656.06, 10404.66)	1898.03 (1731.21, 2080.93)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	439	5.00 (5.00, 5.00)	1397.30 (1279.13, 1526.39)	279.46 (255.83, 305.28)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	146	0.02 (0.02, 0.02)	1663.57 (1123.53, 2463.21)	68716.45 (46426.16, 101708.84)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	146	0.28 (0.27, 0.28)	57082.50 (42972.14, 75826.14)	207359.16 (156633.92, 274511.57)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	146	0.09 (0.09, 0.09)	42890.13 (33529.63, 54863.81)	471505.60 (369224.66, 602119.93)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	146	5.00 (5.00, 5.00)	24881.39 (21477.94, 28824.16)	4976.28 (4295.59, 5764.83)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	146	5.00 (5.00, 5.00)	4228.18 (3638.81, 4913.01)	845.64 (727.76, 982.60)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	77	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (0.99, 1.00)
Age < 65	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	77	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	77	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	77	5.06 (4.95, 5.17)	5.00 (5.00, 5.00)	0.99 (0.97, 1.01)
Age < 65	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	77	5.13 (4.93, 5.34)	5.00 (5.00, 5.00)	0.97 (0.94, 1.01)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	148	0.02 (0.02, 0.02)	289.22 (193.94, 431.30)	12050.88 (8081.00, 17970.99)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	148	0.27 (0.27, 0.27)	9706.29 (7200.73, 13083.69)	35684.89 (26473.26, 48101.79)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	148	0.09 (0.09, 0.09)	5041.42 (3870.53, 6566.51)	56015.76 (43005.91, 72961.27)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	148	5.00 (5.00, 5.00)	3221.65 (2778.88, 3734.97)	644.33 (555.78, 746.99)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	148	5.00 (5.00, 5.00)	728.07 (628.05, 844.02)	145.61 (125.61, 168.80)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	476	0.02 (0.02, 0.02)	142.97 (122.29, 167.15)	5957.03 (5095.33, 6964.46)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	476	0.27 (0.27, 0.27)	1697.17 (1476.47, 1950.87)	6226.27 (5417.46, 7155.84)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	476	0.09 (0.09, 0.09)	1033.49 (921.14, 1159.53)	11483.18 (10234.93, 12883.67)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	476	5.00 (5.00, 5.00)	302.19 (279.71, 326.47)	60.44 (55.94, 65.29)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	476	5.00 (5.00, 5.00)	57.69 (53.68, 61.99)	11.54 (10.74, 12.40)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	123	0.02 (0.02, 0.02)	305.43 (229.49, 406.50)	12670.61 (9519.61, 16864.59)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	123	0.27 (0.27, 0.27)	3476.30 (2675.49, 4516.80)	12780.51 (9836.36, 16605.89)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	123	0.09 (0.09, 0.09)	1996.92 (1588.01, 2511.12)	21880.72 (17486.05, 27379.89)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	123	5.00 (5.00, 5.00)	629.50 (550.72, 719.56)	125.90 (110.14, 143.91)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	123	5.00 (5.00, 5.00)	99.38 (87.21, 113.25)	19.88 (17.44, 22.65)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	78	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	78	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	78	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	78	5.06 (4.95, 5.17)	5.00 (5.00, 5.00)	0.99 (0.97, 1.01)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	78	5.00 (5.00, 5.00)	5.16 (4.94, 5.38)	1.03 (0.99, 1.08)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	128	0.02 (0.02, 0.02)	92.71 (67.40, 127.53)	3863.10 (2808.37, 5313.93)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	128	0.27 (0.27, 0.27)	1037.48 (810.01, 1328.81)	3814.25 (2977.99, 4885.34)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	128	0.09 (0.09, 0.09)	620.20 (506.97, 758.71)	6849.75 (5611.65, 8361.02)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	128	5.00 (5.00, 5.00)	162.38 (141.07, 186.91)	32.48 (28.21, 37.38)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	128	5.00 (5.00, 5.00)	34.70 (30.29, 39.75)	6.94 (6.06, 7.95)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	476	0.02 (0.02, 0.02)	2146.59 (1771.78, 2600.69)	89441.27 (73824.21, 108362.02)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	476	0.27 (0.27, 0.27)	82110.63 (71014.15, 94941.01)	301232.49 (260542.00, 348277.86)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	476	0.09 (0.09, 0.09)	50657.32 (44864.13, 57198.57)	562859.13 (498490.33, 635539.70)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	476	5.00 (5.00, 5.00)	12822.88 (11646.56, 14118.02)	2564.58 (2329.31, 2823.60)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	476	5.00 (5.00, 5.00)	1741.16 (1611.24, 1881.54)	348.23 (322.25, 376.31)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	123	0.02 (0.02, 0.02)	7399.38 (5407.50, 10124.98)	306956.06 (224449.41, 419791.81)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	123	0.27 (0.27, 0.27)	213304.93 (174553.45, 260659.38)	784209.31 (641740.63, 958306.54)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	123	0.09 (0.09, 0.09)	109149.12 (96376.34, 123614.67)	1195971.69 (1056099.00, 1354369.51)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	123	5.00 (5.00, 5.00)	42208.09 (36925.09, 48246.95)	8441.62 (7385.02, 9649.39)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	123	5.00 (5.00, 5.00)	5255.28 (4583.13, 6026.00)	1051.06 (916.63, 1205.20)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	78	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	78	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	78	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	78	5.06 (4.95, 5.17)	5.00 (5.00, 5.00)	0.99 (0.97, 1.01)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	78	5.00 (5.00, 5.00)	5.09 (4.92, 5.26)	1.02 (0.98, 1.05)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	128	0.02 (0.02, 0.02)	1073.37 (733.41, 1570.91)	44723.66 (30558.77, 65454.39)
Age ≥ 65	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	128	0.27 (0.27, 0.27)	46456.10 (34649.89, 62285.03)	170794.50 (127389.32, 228989.08)
Age ≥ 65	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	128	0.09 (0.09, 0.09)	27335.34 (22100.74, 33809.76)	301903.27 (244355.96, 373003.32)
Age ≥ 65	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	128	5.00 (5.00, 5.00)	5151.11 (4476.77, 5927.03)	1030.22 (895.35, 1185.41)
Age ≥ 65	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	128	5.00 (5.00, 5.00)	952.05 (844.89, 1072.80)	190.41 (168.98, 214.56)

Table 6c. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Risk for Severe Covid-19								
At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	470	0.02 (0.02, 0.02)	77.19 (63.87, 93.30)	3216.35 (2661.20, 3887.32)
At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	470	0.27 (0.27, 0.27)	789.30 (668.92, 931.35)	2897.02 (2455.45, 3418.00)
At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	470	0.09 (0.09, 0.09)	491.89 (424.55, 569.92)	5465.50 (4717.20, 6332.50)
At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	470	5.00 (5.00, 5.00)	235.72 (214.95, 258.50)	47.14 (42.99, 51.70)
At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	470	5.00 (5.00, 5.00)	45.83 (42.33, 49.62)	9.17 (8.47, 9.92)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	120	0.02 (0.02, 0.02)	102.78 (69.98, 150.97)	4282.57 (2915.69, 6290.26)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	0.27 (0.27, 0.27)	1259.80 (895.65, 1771.99)	4631.61 (3292.84, 6514.67)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	0.09 (0.09, 0.09)	765.93 (596.13, 984.11)	8510.37 (6623.65, 10934.50)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	120	5.00 (5.00, 5.00)	361.93 (307.30, 426.28)	72.39 (61.46, 85.26)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	120	5.00 (5.00, 5.00)	73.56 (62.44, 86.67)	14.71 (12.49, 17.33)
At-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	80	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.97, 1.01)
At-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	80	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
At-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	80	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	80	5.18 (4.90, 5.49)	5.04 (4.96, 5.12)	0.97 (0.93, 1.01)
At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	80	5.08 (4.92, 5.25)	5.12 (4.96, 5.29)	1.01 (0.96, 1.06)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
At-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	130	0.02 (0.02, 0.02)	37.13 (27.28, 50.54)	1547.19 (1136.75, 2105.83)
At-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	130	0.27 (0.27, 0.27)	424.65 (331.07, 544.67)	1561.20 (1217.18, 2002.45)
At-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	130	0.09 (0.09, 0.09)	244.01 (195.94, 303.87)	2698.63 (2170.38, 3355.47)
At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	130	5.00 (5.00, 5.00)	111.25 (96.73, 127.96)	22.25 (19.35, 25.59)
At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	130	5.00 (5.00, 5.00)	27.62 (24.40, 31.27)	5.52 (4.88, 6.25)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	470	0.02 (0.02, 0.02)	945.85 (763.79, 1171.29)	39410.31 (31824.75, 48803.92)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	470	0.27 (0.27, 0.27)	34720.06 (28933.29, 41664.21)	127434.91 (106203.14, 152911.26)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	470	0.09 (0.09, 0.09)	21888.00 (18578.88, 25786.52)	243200.01 (206431.95, 286516.91)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	470	5.00 (5.00, 5.00)	9196.69 (8308.44, 10179.89)	1839.34 (1661.69, 2035.98)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	470	5.00 (5.00, 5.00)	1390.11 (1276.66, 1513.64)	278.02 (255.33, 302.73)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	120	0.02 (0.02, 0.02)	2297.78 (1510.26, 3495.95)	95740.77 (62927.44, 145664.50)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	0.27 (0.27, 0.27)	85028.77 (62305.26, 116039.82)	312605.76 (229063.45, 426617.00)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	0.09 (0.09, 0.09)	40668.98 (31140.77, 53112.55)	451877.52 (346008.53, 590139.46)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	120	5.00 (5.00, 5.00)	28755.58 (24251.77, 34095.79)	5751.12 (4850.35, 6819.16)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	120	5.00 (5.00, 5.00)	4090.48 (3547.49, 4716.60)	818.10 (709.50, 943.32)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
At-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	80	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.97, 1.01)
At-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	80	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
At-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	80	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	80	5.18 (4.90, 5.49)	5.00 (5.00, 5.00)	0.96 (0.91, 1.02)
At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	80	5.08 (4.92, 5.25)	5.00 (5.00, 5.00)	0.98 (0.95, 1.02)
At-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	130	0.02 (0.02, 0.02)	486.41 (324.43, 729.28)	20267.11 (13517.71, 30386.49)
At-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	130	0.27 (0.27, 0.27)	19654.96 (14854.37, 26007.01)	72260.90 (54611.64, 95614.00)
At-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	130	0.09 (0.09, 0.09)	8847.05 (6916.88, 11315.83)	97844.10 (76570.76, 125027.72)
At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	130	5.00 (5.00, 5.00)	4062.41 (3499.24, 4716.23)	812.48 (699.85, 943.25)
At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	130	5.00 (5.00, 5.00)	820.34 (722.23, 931.77)	164.07 (144.45, 186.35)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	445	0.02 (0.02, 0.02)	58.20 (47.48, 71.34)	2410.80 (1966.33, 2955.74)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	445	0.27 (0.27, 0.27)	669.28 (557.20, 803.92)	2455.34 (2044.87, 2948.20)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	445	0.09 (0.09, 0.09)	385.41 (329.00, 451.48)	4282.29 (3655.53, 5016.50)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	445	5.00 (5.00, 5.00)	221.23 (201.80, 242.53)	44.25 (40.36, 48.51)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	445	5.00 (5.00, 5.00)	47.16 (43.11, 51.59)	9.43 (8.62, 10.32)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	149	0.02 (0.02, 0.02)	103.67 (75.22, 142.90)	4274.42 (3104.96, 5884.36)
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	149	0.28 (0.27, 0.28)	1273.21 (956.64, 1694.55)	4620.37 (3494.45, 6109.06)
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	149	0.09 (0.09, 0.09)	766.38 (591.79, 992.49)	8387.22 (6495.71, 10829.51)
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	149	5.00 (5.00, 5.00)	352.51 (306.78, 405.06)	70.50 (61.36, 81.01)
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	149	5.00 (5.00, 5.00)	76.90 (67.33, 87.82)	15.38 (13.47, 17.56)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	75	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	75	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	75	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	75	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	75	5.11 (4.90, 5.33)	5.00 (5.00, 5.00)	0.98 (0.94, 1.02)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	146	0.02 (0.02, 0.02)	26.82 (18.76, 38.36)	1117.64 (781.52, 1598.32)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	146	0.27 (0.27, 0.27)	352.08 (256.56, 483.16)	1294.41 (943.25, 1776.31)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	146	0.09 (0.09, 0.09)	170.28 (128.67, 225.34)	1891.98 (1429.65, 2503.82)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	146	5.00 (5.00, 5.00)	109.14 (92.18, 129.23)	21.83 (18.44, 25.85)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	146	5.00 (5.00, 5.00)	24.43 (20.99, 28.43)	4.89 (4.20, 5.69)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	445	0.02 (0.02, 0.02)	828.01 (640.59, 1070.26)	34298.98 (26522.13, 44356.17)
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	445	0.27 (0.27, 0.27)	30051.32 (24568.10, 36758.30)	110246.43 (90158.56, 134810.01)
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	445	0.09 (0.09, 0.09)	21038.85 (17721.65, 24976.97)	233764.97 (196907.24, 277521.84)
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	445	5.00 (5.00, 5.00)	10489.39 (9525.84, 11550.39)	2097.88 (1905.17, 2310.08)
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	445	5.00 (5.00, 5.00)	1493.34 (1360.60, 1639.02)	298.67 (272.12, 327.80)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	149	0.02 (0.02, 0.02)	2189.27 (1449.90, 3305.67)	90261.72 (59803.65, 136232.13)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	149	0.28 (0.27, 0.28)	69976.84 (52002.56, 94163.80)	253940.04 (189428.99, 340420.67)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	149	0.09 (0.09, 0.09)	55600.01 (43091.39, 71739.64)	608479.56 (472490.83, 783607.54)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	149	5.00 (5.00, 5.00)	27138.15 (23277.88, 31638.58)	5427.63 (4655.58, 6327.72)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	149	5.00 (5.00, 5.00)	4523.62 (3856.72, 5305.85)	904.72 (771.34, 1061.17)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	75	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	75	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	75	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	75	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	75	5.11 (4.90, 5.33)	5.03 (4.97, 5.09)	0.98 (0.94, 1.03)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	146	0.02 (0.02, 0.02)	341.72 (224.08, 521.11)	14238.22 (9336.70, 21712.91)
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	146	0.27 (0.27, 0.27)	11510.67 (8354.80, 15858.60)	42318.63 (30716.18, 58303.69)
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	146	0.09 (0.09, 0.09)	6482.33 (4883.38, 8604.81)	72025.90 (54259.83, 95609.04)
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	146	5.00 (5.00, 5.00)	3367.31 (2880.87, 3935.88)	673.46 (576.17, 787.18)
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	146	5.00 (5.00, 5.00)	750.04 (641.36, 877.15)	150.01 (128.27, 175.43)

Table 6d. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age, Risk for Severe Covid-19								
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	220	0.02 (0.02, 0.02)	54.07 (40.95, 71.40)	2253.12 (1706.42, 2974.96)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	220	0.27 (0.27, 0.27)	503.60 (397.09, 638.67)	1851.46 (1459.90, 2348.05)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	220	0.09 (0.09, 0.09)	332.00 (268.07, 411.17)	3688.84 (2978.52, 4568.56)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	220	5.00 (5.00, 5.00)	212.49 (186.23, 242.45)	42.50 (37.25, 48.49)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	220	5.00 (5.00, 5.00)	41.10 (36.64, 46.11)	8.22 (7.33, 9.22)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	70	0.02 (0.02, 0.02)	67.42 (40.49, 112.26)	2809.23 (1687.16, 4677.55)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	70	0.27 (0.27, 0.27)	817.14 (525.77, 1269.97)	3004.18 (1932.98, 4669.00)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	70	0.09 (0.09, 0.09)	535.85 (390.80, 734.74)	5953.88 (4342.19, 8163.78)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	70	5.00 (5.00, 5.00)	287.26 (233.02, 354.12)	57.45 (46.60, 70.82)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	70	5.00 (5.00, 5.00)	65.43 (52.75, 81.15)	13.09 (10.55, 16.23)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	39	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.98 (0.95, 1.02)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	39	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	39	5.24 (4.78, 5.74)	5.07 (4.93, 5.21)	0.97 (0.91, 1.03)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	39	5.14 (4.87, 5.42)	5.00 (5.00, 5.00)	0.97 (0.92, 1.03)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	75	0.02 (0.02, 0.02)	26.22 (17.94, 38.32)	1092.58 (747.67, 1596.62)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	75	0.27 (0.27, 0.27)	315.62 (233.23, 427.13)	1160.38 (857.45, 1570.34)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	75	0.09 (0.09, 0.09)	159.73 (122.51, 208.25)	1774.77 (1361.26, 2313.87)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	75	5.00 (5.00, 5.00)	96.69 (80.78, 115.72)	19.34 (16.16, 23.14)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	75	5.00 (5.00, 5.00)	25.25 (21.55, 29.59)	5.05 (4.31, 5.92)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	220	0.02 (0.02, 0.02)	628.93 (463.68, 853.08)	26205.50 (19320.06, 35544.82)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	220	0.27 (0.27, 0.27)	22762.87 (17544.34, 29533.64)	83687.03 (64501.26, 108579.56)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	220	0.09 (0.09, 0.09)	15450.04 (12172.41, 19610.21)	171667.07 (135249.04, 217891.25)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	220	5.00 (5.00, 5.00)	8428.13 (7385.70, 9617.68)	1685.63 (1477.14, 1923.54)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	220	5.00 (5.00, 5.00)	1285.60 (1142.45, 1446.69)	257.12 (228.49, 289.34)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	70	0.02 (0.02, 0.02)	1486.58 (855.25, 2583.97)	61941.04 (35635.28, 107665.55)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	70	0.27 (0.27, 0.27)	56974.72 (37716.89, 86065.40)	209465.90 (138665.04, 316416.90)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	70	0.09 (0.09, 0.09)	27693.95 (19363.41, 39608.45)	307710.56 (215149.04, 440093.94)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	70	5.00 (5.00, 5.00)	25397.99 (20296.59, 31781.59)	5079.60 (4059.32, 6356.32)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	70	5.00 (5.00, 5.00)	3733.57 (3118.28, 4470.27)	746.71 (623.66, 894.05)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	39	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.98 (0.95, 1.02)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	39	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	39	5.24 (4.78, 5.74)	5.00 (5.00, 5.00)	0.95 (0.87, 1.05)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	39	5.14 (4.87, 5.42)	5.00 (5.00, 5.00)	0.97 (0.92, 1.03)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	75	0.02 (0.02, 0.02)	338.79 (197.52, 581.09)	14116.05 (8229.89, 24212.12)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	75	0.27 (0.27, 0.27)	12141.73 (8663.79, 17015.83)	44638.71 (31852.17, 62558.21)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	75	0.09 (0.09, 0.09)	5816.74 (4249.24, 7962.47)	64630.40 (47213.76, 88471.84)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	75	5.00 (5.00, 5.00)	3737.70 (3080.39, 4535.26)	747.54 (616.08, 907.05)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	75	5.00 (5.00, 5.00)	759.28 (641.98, 898.01)	151.86 (128.40, 179.60)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	219	0.02 (0.02, 0.02)	49.40 (39.10, 62.40)	2044.18 (1617.76, 2583.01)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	219	0.27 (0.27, 0.27)	564.12 (457.06, 696.27)	2068.81 (1676.89, 2552.33)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	219	0.09 (0.09, 0.09)	318.42 (265.52, 381.85)	3537.96 (2950.25, 4242.74)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	219	5.00 (5.00, 5.00)	206.65 (185.92, 229.69)	41.33 (37.18, 45.94)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	219	5.00 (5.00, 5.00)	45.07 (40.66, 49.97)	9.01 (8.13, 9.99)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	76	0.02 (0.02, 0.02)	83.86 (57.94, 121.39)	3455.72 (2391.06, 4994.43)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	0.28 (0.27, 0.28)	1057.18 (760.21, 1470.16)	3827.41 (2774.40, 5280.10)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	0.09 (0.09, 0.09)	632.69 (469.91, 851.86)	6934.55 (5166.95, 9306.84)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	76	5.00 (5.00, 5.00)	316.24 (269.66, 370.86)	63.25 (53.93, 74.17)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	76	5.00 (5.00, 5.00)	73.09 (62.68, 85.22)	14.62 (12.54, 17.04)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	38	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	38	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	38	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	38	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	38	5.13 (4.88, 5.39)	5.00 (5.00, 5.00)	0.97 (0.93, 1.02)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	73	0.02 (0.02, 0.02)	20.99 (13.93, 31.65)	874.73 (580.21, 1318.74)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	73	0.27 (0.27, 0.27)	280.30 (194.63, 403.69)	1030.53 (715.56, 1484.15)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	73	0.09 (0.09, 0.09)	134.41 (97.41, 185.46)	1493.44 (1082.35, 2060.65)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	73	5.00 (5.00, 5.00)	100.53 (82.75, 122.13)	20.11 (16.55, 24.43)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	73	5.00 (5.00, 5.00)	22.83 (19.18, 27.18)	4.57 (3.84, 5.44)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	219	0.02 (0.02, 0.02)	681.33 (507.23, 915.18)	28195.60 (20978.44, 37895.67)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	219	0.27 (0.27, 0.27)	24426.63 (19367.89, 30806.69)	89579.83 (71054.06, 112935.80)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	219	0.09 (0.09, 0.09)	17192.84 (14108.05, 20952.13)	191031.55 (156756.13, 232801.44)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	219	5.00 (5.00, 5.00)	9791.25 (8763.61, 10939.39)	1958.25 (1752.72, 2187.88)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	219	5.00 (5.00, 5.00)	1428.27 (1283.08, 1589.89)	285.65 (256.62, 317.98)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	76	0.02 (0.02, 0.02)	1717.03 (1064.38, 2769.88)	70751.71 (43880.32, 114078.56)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	76	0.28 (0.27, 0.28)	57112.84 (40456.58, 80626.59)	206770.62 (147144.61, 290558.32)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	76	0.09 (0.09, 0.09)	48503.57 (35987.59, 65372.42)	531620.66 (395332.54, 714893.16)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	76	5.00 (5.00, 5.00)	24738.04 (20712.74, 29545.62)	4947.61 (4142.55, 5909.12)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	76	5.00 (5.00, 5.00)	4378.70 (3637.43, 5271.02)	875.74 (727.49, 1054.20)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	38	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	38	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	38	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	38	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	38	5.13 (4.88, 5.39)	5.00 (5.00, 5.00)	0.97 (0.93, 1.02)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	73	0.02 (0.02, 0.02)	277.43 (170.92, 450.31)	11559.44 (7121.52, 18762.93)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	73	0.27 (0.27, 0.27)	9150.84 (6343.15, 13201.30)	33642.78 (23320.40, 48534.20)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	73	0.09 (0.09, 0.09)	4855.12 (3513.49, 6709.03)	53945.73 (39038.82, 74544.83)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	73	5.00 (5.00, 5.00)	3098.09 (2588.80, 3707.57)	619.62 (517.76, 741.51)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	73	5.00 (5.00, 5.00)	720.07 (600.63, 863.27)	144.01 (120.13, 172.65)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	250	0.02 (0.02, 0.02)	131.44 (105.77, 163.33)	5476.52 (4407.11, 6805.44)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	250	0.27 (0.27, 0.28)	1545.48 (1268.71, 1882.61)	5658.34 (4647.22, 6889.46)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	250	0.09 (0.09, 0.09)	885.47 (747.60, 1048.77)	9838.61 (8306.69, 11653.04)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	250	5.00 (5.00, 5.00)	275.29 (244.82, 309.56)	55.06 (48.96, 61.91)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	250	5.00 (5.00, 5.00)	53.93 (48.92, 59.45)	10.79 (9.78, 11.89)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	50	0.02 (0.02, 0.02)	266.81 (177.47, 401.13)	11117.22 (7394.60, 16713.90)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	0.27 (0.27, 0.27)	3354.69 (2235.79, 5033.53)	12333.42 (8219.83, 18505.62)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	0.09 (0.09, 0.09)	1718.71 (1241.63, 2379.11)	19096.81 (13795.87, 26434.61)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	50	5.00 (5.00, 5.00)	610.47 (501.61, 742.97)	122.09 (100.32, 148.59)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	50	5.00 (5.00, 5.00)	95.89 (77.90, 118.03)	19.18 (15.58, 23.61)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	41	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	41	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	41	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	41	5.11 (4.90, 5.32)	5.00 (5.00, 5.00)	0.98 (0.94, 1.02)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	41	5.00 (5.00, 5.00)	5.30 (4.90, 5.74)	1.06 (0.98, 1.15)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	55	0.02 (0.02, 0.02)	73.96 (45.08, 121.37)	3081.85 (1878.17, 5056.96)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	55	0.27 (0.27, 0.27)	764.29 (508.32, 1149.16)	2809.89 (1868.82, 4224.84)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	55	0.09 (0.09, 0.09)	564.82 (411.46, 775.35)	6189.36 (4544.24, 8430.05)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	55	5.00 (5.00, 5.00)	146.90 (119.82, 180.10)	29.38 (23.96, 36.02)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	55	5.00 (5.00, 5.00)	33.00 (27.31, 39.89)	6.60 (5.46, 7.98)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	250	0.02 (0.02, 0.02)	1741.05 (1331.24, 2277.00)	72543.69 (55468.52, 94875.19)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	250	0.27 (0.27, 0.28)	65274.79 (52121.10, 81748.04)	238985.74 (190877.89, 299218.44)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	250	0.09 (0.09, 0.09)	36847.42 (30394.53, 44670.29)	409415.80 (337717.02, 496336.55)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	250	5.00 (5.00, 5.00)	10478.59 (8946.35, 12273.26)	2095.72 (1789.27, 2454.65)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	250	5.00 (5.00, 5.00)	1562.43 (1389.38, 1757.04)	312.49 (277.88, 351.41)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	50	0.02 (0.02, 0.02)	6154.26 (3806.20, 9950.87)	256427.70 (158591.54, 414619.61)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	0.27 (0.27, 0.27)	210361.50 (154533.61, 286358.15)	773387.86 (568138.27, 1052787.33)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	0.09 (0.09, 0.09)	97009.56 (78402.66, 120032.33)	1077883.96 (871140.65, 1333692.59)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	50	5.00 (5.00, 5.00)	38081.92 (30737.43, 47181.34)	7616.38 (6147.49, 9436.27)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	50	5.00 (5.00, 5.00)	5028.99 (4054.58, 6237.58)	1005.80 (810.92, 1247.52)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	41	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	41	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	41	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	41	5.11 (4.90, 5.32)	5.00 (5.00, 5.00)	0.98 (0.94, 1.02)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	41	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	55	0.02 (0.02, 0.02)	995.72 (587.77, 1686.79)	41488.15 (24490.55, 70282.89)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	55	0.27 (0.27, 0.27)	51030.23 (33245.99, 78327.78)	187611.15 (122227.92, 287969.76)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	55	0.09 (0.09, 0.09)	20301.57 (14770.16, 27904.48)	222465.35 (162645.10, 304287.26)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	55	5.00 (5.00, 5.00)	4791.24 (3838.80, 5979.99)	958.25 (767.76, 1196.00)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	55	5.00 (5.00, 5.00)	956.14 (799.60, 1143.33)	191.23 (159.92, 228.67)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	226	0.02 (0.02, 0.02)	156.30 (124.69, 195.94)	6512.61 (5195.27, 8163.99)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	226	0.27 (0.27, 0.27)	1874.30 (1540.73, 2280.09)	6890.80 (5664.44, 8382.67)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	226	0.09 (0.09, 0.09)	1217.52 (1045.45, 1417.92)	13528.04 (11616.11, 15754.66)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	226	5.00 (5.00, 5.00)	333.58 (302.43, 367.93)	66.72 (60.49, 73.59)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	226	5.00 (5.00, 5.00)	61.96 (55.76, 68.86)	12.39 (11.15, 13.77)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	73	0.02 (0.02, 0.02)	335.19 (226.79, 495.41)	13863.17 (9377.04, 20495.55)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	0.27 (0.27, 0.27)	3562.49 (2532.00, 5012.37)	13097.37 (9308.82, 18427.82)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	0.09 (0.09, 0.10)	2213.98 (1618.00, 3029.47)	24027.49 (17735.09, 32552.43)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	73	5.00 (5.00, 5.00)	642.93 (536.91, 769.89)	128.59 (107.38, 153.98)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	73	5.00 (5.00, 5.00)	101.86 (86.13, 120.46)	20.37 (17.23, 24.09)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	37	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	37	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	37	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	73	0.02 (0.02, 0.02)	110.24 (72.93, 166.64)	4593.50 (3038.85, 6943.49)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	73	0.27 (0.27, 0.27)	1311.30 (975.26, 1763.13)	4820.96 (3585.51, 6482.10)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	73	0.09 (0.09, 0.09)	666.29 (514.14, 863.47)	7403.24 (5712.63, 9594.16)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	73	5.00 (5.00, 5.00)	175.33 (144.79, 212.33)	35.07 (28.96, 42.47)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	73	5.00 (5.00, 5.00)	36.06 (29.78, 43.67)	7.21 (5.96, 8.73)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	226	0.02 (0.02, 0.02)	2680.19 (2040.81, 3519.89)	111674.68 (85033.71, 146662.25)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	226	0.27 (0.27, 0.27)	104726.56 (87880.85, 124801.38)	385024.10 (323091.37, 458828.60)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	226	0.09 (0.09, 0.09)	70991.30 (62313.78, 80877.21)	788792.22 (692375.29, 898635.72)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	226	5.00 (5.00, 5.00)	15883.67 (14375.29, 17550.33)	3176.73 (2875.06, 3510.07)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	226	5.00 (5.00, 5.00)	1953.02 (1770.10, 2154.84)	390.60 (354.02, 430.97)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	73	0.02 (0.02, 0.02)	8399.02 (5561.59, 12684.06)	347374.10 (230261.89, 524050.12)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	0.27 (0.27, 0.27)	215353.16 (165458.59, 280293.59)	791739.54 (608303.64, 1030491.12)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	0.09 (0.09, 0.10)	118368.75 (102113.55, 137211.58)	1284612.55 (1107699.66, 1489780.55)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	73	5.00 (5.00, 5.00)	45302.51 (38314.50, 53565.04)	9060.50 (7662.90, 10713.01)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	73	5.00 (5.00, 5.00)	5416.78 (4538.51, 6465.02)	1083.36 (907.70, 1293.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	37	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	37	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	37	5.00 (5.00, 5.00)	5.18 (4.83, 5.56)	1.04 (0.97, 1.11)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	73	0.02 (0.02, 0.02)	1136.96 (664.28, 1945.99)	47373.35 (27678.33, 81082.73)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	73	0.27 (0.27, 0.27)	43229.76 (28989.15, 64465.93)	158932.96 (106577.76, 237007.09)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	73	0.09 (0.09, 0.09)	34335.80 (26089.81, 45188.05)	381508.92 (289886.73, 502089.40)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	73	5.00 (5.00, 5.00)	5445.13 (4550.33, 6515.89)	1089.03 (910.07, 1303.18)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	73	5.00 (5.00, 5.00)	948.92 (808.13, 1114.24)	189.78 (161.63, 222.85)



Table 6e. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Sex								
Male	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	391	0.02 (0.02, 0.02)	63.73 (48.94, 83.00)	2655.47 (2038.97, 3458.39)
Male	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	391	0.27 (0.27, 0.28)	686.74 (538.39, 875.98)	2511.86 (1971.20, 3200.80)
Male	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	391	0.09 (0.09, 0.09)	424.11 (345.09, 521.23)	4712.37 (3834.34, 5791.45)
Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	391	5.00 (5.00, 5.00)	232.36 (207.20, 260.57)	46.47 (41.44, 52.11)
Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	391	5.00 (5.00, 5.00)	46.32 (41.50, 51.70)	9.26 (8.30, 10.34)
Male	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	113	0.02 (0.02, 0.03)	128.96 (81.98, 202.86)	5278.07 (3367.80, 8271.89)
Male	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	113	0.27 (0.27, 0.27)	1679.06 (1146.41, 2459.20)	6173.03 (4214.75, 9041.19)
Male	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	113	0.09 (0.09, 0.09)	890.79 (627.61, 1264.34)	9830.31 (6933.93, 13936.53)
Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	113	5.00 (5.00, 5.00)	392.07 (325.19, 472.71)	78.41 (65.04, 94.54)
Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	113	5.00 (5.00, 5.00)	73.92 (63.98, 85.41)	14.78 (12.80, 17.08)
Male	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	60	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Male	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	60	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Male	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	60	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	60	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	60	5.21 (4.81, 5.64)	5.00 (5.00, 5.00)	0.96 (0.89, 1.04)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Male	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	122	0.02 (0.02, 0.02)	29.73 (18.99, 46.54)	1238.71 (791.26, 1939.21)
Male	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	122	0.27 (0.27, 0.27)	375.73 (244.88, 576.49)	1381.34 (900.29, 2119.45)
Male	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	122	0.09 (0.09, 0.09)	186.79 (132.30, 263.73)	2069.58 (1466.53, 2920.61)
Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	122	5.00 (5.00, 5.00)	108.95 (87.10, 136.29)	21.79 (17.42, 27.26)
Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	122	5.00 (5.00, 5.00)	24.29 (20.06, 29.42)	4.86 (4.01, 5.88)
Male	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	391	0.02 (0.02, 0.02)	860.98 (647.12, 1145.53)	35874.18 (26963.15, 47730.22)
Male	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	391	0.27 (0.27, 0.28)	32724.44 (25648.10, 41753.15)	119693.95 (93893.20, 152584.43)
Male	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	391	0.09 (0.09, 0.09)	22736.75 (18515.45, 27920.45)	252630.53 (205727.24, 310227.18)
Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	391	5.00 (5.00, 5.00)	10067.09 (8894.08, 11394.80)	2013.42 (1778.82, 2278.96)
Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	391	5.00 (5.00, 5.00)	1448.63 (1278.89, 1640.90)	289.73 (255.78, 328.18)
Male	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	113	0.02 (0.02, 0.03)	2852.89 (1608.45, 5060.14)	116765.47 (65939.33, 206768.50)
Male	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	113	0.27 (0.27, 0.27)	79526.50 (57294.11, 110385.94)	292376.83 (210640.10, 405830.65)
Male	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	113	0.09 (0.09, 0.09)	51096.13 (36091.24, 72339.28)	563868.63 (398409.93, 798041.94)
Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	113	5.00 (5.00, 5.00)	29355.83 (24695.73, 34895.28)	5871.17 (4939.15, 6979.06)
Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	113	5.00 (5.00, 5.00)	4573.39 (3833.83, 5455.62)	914.68 (766.77, 1091.12)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Male	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	60	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Male	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	60	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Male	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	60	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	60	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	60	5.21 (4.81, 5.64)	5.06 (4.95, 5.17)	0.97 (0.89, 1.05)
Male	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	122	0.02 (0.02, 0.02)	486.99 (283.09, 837.75)	20291.13 (11795.25, 34906.43)
Male	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	122	0.27 (0.27, 0.27)	12582.62 (8551.77, 18513.39)	46259.62 (31440.33, 68063.95)
Male	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	122	0.09 (0.09, 0.09)	7272.61 (5061.17, 10450.32)	80577.63 (56094.67, 115746.39)
Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	122	5.00 (5.00, 5.00)	3292.67 (2674.97, 4053.01)	658.53 (534.99, 810.60)
Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	122	5.00 (5.00, 5.00)	778.67 (645.62, 939.14)	155.73 (129.12, 187.83)
Female	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	524	0.02 (0.02, 0.02)	62.33 (51.30, 75.73)	2578.96 (2121.84, 3134.56)
Female	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	524	0.27 (0.27, 0.27)	708.96 (597.35, 841.42)	2606.47 (2196.16, 3093.45)
Female	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	524	0.09 (0.09, 0.09)	404.40 (347.20, 471.03)	4493.38 (3857.83, 5233.62)
Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	524	5.00 (5.00, 5.00)	220.56 (201.24, 241.73)	44.11 (40.25, 48.35)
Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	524	5.00 (5.00, 5.00)	47.10 (43.13, 51.43)	9.42 (8.63, 10.29)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Female	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	156	0.02 (0.02, 0.02)	89.72 (65.17, 123.51)	3732.99 (2711.72, 5138.89)
Female	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	156	0.28 (0.27, 0.29)	1060.09 (795.02, 1413.53)	3835.71 (2905.30, 5064.07)
Female	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	156	0.09 (0.09, 0.09)	695.25 (542.26, 891.39)	7616.29 (5963.59, 9726.99)
Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	156	5.00 (5.00, 5.00)	332.78 (288.74, 383.54)	66.56 (57.75, 76.71)
Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	156	5.00 (5.00, 5.00)	77.42 (66.65, 89.93)	15.48 (13.33, 17.99)
Female	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	95	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.98, 1.01)
Female	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	95	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Female	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	95	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	95	5.09 (4.95, 5.23)	5.02 (4.98, 5.06)	0.99 (0.97, 1.01)
Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	95	5.04 (4.96, 5.12)	5.06 (4.98, 5.14)	1.00 (0.98, 1.03)
Female	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	154	0.02 (0.02, 0.02)	28.69 (20.03, 41.10)	1195.60 (834.63, 1712.68)
Female	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	154	0.27 (0.27, 0.27)	364.55 (272.15, 488.32)	1340.26 (1000.57, 1795.28)
Female	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	154	0.09 (0.09, 0.09)	186.23 (140.19, 247.39)	2069.25 (1557.70, 2748.79)
Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	154	5.00 (5.00, 5.00)	110.18 (94.06, 129.07)	22.04 (18.81, 25.81)
Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	154	5.00 (5.00, 5.00)	25.86 (22.29, 30.00)	5.17 (4.46, 6.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Female	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	524	0.02 (0.02, 0.02)	857.25 (658.34, 1116.26)	35469.85 (27218.24, 46223.05)
Female	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	524	0.27 (0.27, 0.27)	30356.48 (24829.23, 37114.15)	111604.71 (91283.94, 136449.09)
Female	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	524	0.09 (0.09, 0.09)	20373.35 (17108.20, 24261.67)	226370.59 (190091.08, 269574.16)
Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	524	5.00 (5.00, 5.00)	10151.98 (9238.25, 11156.09)	2030.40 (1847.65, 2231.22)
Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	524	5.00 (5.00, 5.00)	1474.56 (1353.14, 1606.88)	294.91 (270.63, 321.38)
Female	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	156	0.02 (0.02, 0.02)	1883.05 (1269.61, 2792.88)	78351.46 (52831.15, 116199.46)
Female	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	156	0.28 (0.27, 0.29)	69930.48 (50459.38, 96915.01)	253028.78 (183497.23, 348907.53)
Female	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	156	0.09 (0.09, 0.09)	51479.11 (40279.83, 65792.22)	563943.69 (442409.61, 718864.33)
Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	156	5.00 (5.00, 5.00)	26431.53 (22340.26, 31272.05)	5286.31 (4468.05, 6254.41)
Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	156	5.00 (5.00, 5.00)	4305.52 (3631.22, 5105.02)	861.10 (726.24, 1021.00)
Female	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	95	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.98, 1.01)
Female	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	95	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Female	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	95	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	95	5.09 (4.95, 5.23)	5.00 (5.00, 5.00)	0.98 (0.96, 1.01)
Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	95	5.04 (4.96, 5.12)	5.00 (5.00, 5.00)	0.99 (0.98, 1.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Female	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	154	0.02 (0.02, 0.02)	309.85 (204.43, 469.64)	12910.40 (8517.85, 19568.13)
Female	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	154	0.27 (0.27, 0.27)	13609.31 (9748.76, 18998.66)	50034.23 (35841.02, 69848.01)
Female	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	154	0.09 (0.09, 0.09)	6833.23 (5149.68, 9067.18)	75924.83 (57218.68, 100746.46)
Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	154	5.00 (5.00, 5.00)	3708.74 (3194.21, 4306.14)	741.75 (638.84, 861.23)
Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	154	5.00 (5.00, 5.00)	759.20 (647.30, 890.45)	151.84 (129.46, 178.09)




Table 6f. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age, sex								
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	266	0.02 (0.02, 0.02)	52.32 (41.41, 66.10)	2161.18 (1709.84, 2731.67)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	266	0.27 (0.27, 0.27)	586.22 (477.60, 719.53)	2155.20 (1755.89, 2645.33)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	266	0.09 (0.09, 0.09)	332.67 (277.17, 399.28)	3696.34 (3079.71, 4436.43)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	266	5.00 (5.00, 5.00)	208.25 (186.54, 232.50)	41.65 (37.31, 46.50)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	266	5.00 (5.00, 5.00)	45.18 (40.63, 50.25)	9.04 (8.13, 10.05)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	90	0.02 (0.02, 0.02)	71.96 (49.60, 104.40)	2998.15 (2066.49, 4349.84)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	90	0.28 (0.27, 0.29)	865.76 (620.13, 1208.68)	3122.73 (2264.76, 4305.73)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	90	0.09 (0.09, 0.09)	589.41 (441.63, 786.64)	6438.86 (4848.40, 8551.04)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	90	5.00 (5.00, 5.00)	295.10 (250.45, 347.71)	59.02 (50.09, 69.54)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	90	5.00 (5.00, 5.00)	72.72 (61.02, 86.67)	14.54 (12.20, 17.33)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	50	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.98, 1.01)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	50	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	50	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	50	5.08 (4.92, 5.25)	5.02 (4.98, 5.07)	0.99 (0.97, 1.01)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	50	5.05 (4.95, 5.15)	5.00 (5.00, 5.00)	0.99 (0.97, 1.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	85	0.02 (0.02, 0.02)	21.95 (14.41, 33.42)	914.40 (600.42, 1392.59)
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	85	0.27 (0.27, 0.27)	291.67 (206.65, 411.68)	1072.33 (759.73, 1513.54)
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	85	0.09 (0.09, 0.09)	142.39 (102.03, 198.73)	1582.13 (1133.64, 2208.06)
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	85	5.00 (5.00, 5.00)	100.42 (83.32, 121.02)	20.08 (16.66, 24.20)
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	85	5.00 (5.00, 5.00)	24.03 (20.17, 28.62)	4.81 (4.03, 5.72)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	266	0.02 (0.02, 0.02)	700.73 (509.35, 964.01)	28946.21 (21020.50, 39860.28)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	266	0.27 (0.27, 0.27)	24346.16 (19116.30, 31006.82)	89507.95 (70280.52, 113995.65)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	266	0.09 (0.09, 0.09)	16770.41 (13590.72, 20694.03)	186337.90 (151007.96, 229933.66)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	266	5.00 (5.00, 5.00)	9837.17 (8794.76, 11003.14)	1967.43 (1758.95, 2200.63)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	266	5.00 (5.00, 5.00)	1440.80 (1299.69, 1597.23)	288.16 (259.94, 319.45)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	90	0.02 (0.02, 0.02)	1432.97 (904.78, 2269.49)	59707.07 (37699.33, 94562.25)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	90	0.28 (0.27, 0.29)	57041.36 (38864.72, 83719.01)	205743.46 (141064.17, 300078.84)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	90	0.09 (0.09, 0.09)	43840.57 (32785.50, 58623.35)	478923.97 (359327.49, 638326.24)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	90	5.00 (5.00, 5.00)	23628.65 (19415.79, 28755.60)	4725.73 (3883.16, 5751.12)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	90	5.00 (5.00, 5.00)	4108.12 (3361.98, 5019.85)	821.62 (672.40, 1003.97)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	50	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.98, 1.01)
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	50	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	50	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	50	5.08 (4.92, 5.25)	5.00 (5.00, 5.00)	0.98 (0.95, 1.02)
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	50	5.05 (4.95, 5.15)	5.00 (5.00, 5.00)	0.99 (0.97, 1.01)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	85	0.02 (0.02, 0.02)	239.00 (146.75, 389.25)	9958.49 (6114.68, 16218.59)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	85	0.27 (0.27, 0.27)	10551.82 (7136.45, 15601.72)	38793.46 (26236.96, 57359.26)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	85	0.09 (0.09, 0.09)	4982.39 (3591.66, 6911.63)	55359.87 (39907.31, 76795.84)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	85	5.00 (5.00, 5.00)	3439.26 (2884.31, 4100.97)	687.85 (576.86, 820.19)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	85	5.00 (5.00, 5.00)	734.98 (606.97, 889.99)	147.00 (121.39, 178.00)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	173	0.02 (0.02, 0.02)	47.18 (33.63, 66.19)	1965.86 (1401.32, 2757.85)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	173	0.27 (0.27, 0.28)	496.48 (363.24, 678.59)	1815.67 (1330.18, 2478.35)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	173	0.09 (0.09, 0.09)	302.84 (233.08, 393.48)	3364.89 (2589.79, 4371.97)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	173	5.00 (5.00, 5.00)	207.18 (178.99, 239.82)	41.44 (35.80, 47.96)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	173	5.00 (5.00, 5.00)	42.64 (37.03, 49.09)	8.53 (7.41, 9.82)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	56	0.02 (0.02, 0.03)	95.50 (54.57, 167.13)	3887.46 (2233.42, 6766.46)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	56	0.27 (0.27, 0.27)	1272.62 (793.15, 2041.95)	4678.76 (2915.99, 7507.18)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	56	0.09 (0.09, 0.09)	646.54 (420.84, 993.29)	7183.77 (4675.95, 11036.58)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	56	5.00 (5.00, 5.00)	335.85 (267.77, 421.23)	67.17 (53.55, 84.25)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	56	5.00 (5.00, 5.00)	69.04 (57.83, 82.42)	13.81 (11.57, 16.48)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	27	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	27	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	27	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	27	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	27	5.29 (4.74, 5.91)	5.00 (5.00, 5.00)	0.94 (0.85, 1.05)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	63	0.02 (0.02, 0.02)	22.05 (12.74, 38.17)	918.92 (530.92, 1590.44)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	63	0.27 (0.27, 0.27)	280.99 (166.00, 475.62)	1033.04 (610.30, 1748.61)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	63	0.09 (0.09, 0.09)	134.91 (88.77, 205.03)	1499.02 (986.37, 2278.11)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	63	5.00 (5.00, 5.00)	98.69 (74.76, 130.28)	19.74 (14.95, 26.06)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	63	5.00 (5.00, 5.00)	22.30 (17.59, 28.26)	4.46 (3.52, 5.65)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	173	0.02 (0.02, 0.02)	621.62 (432.26, 893.94)	25900.91 (18010.87, 37247.36)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	173	0.27 (0.27, 0.28)	23614.57 (17287.13, 32257.97)	86360.01 (63294.48, 117831.00)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	173	0.09 (0.09, 0.09)	16888.00 (12988.38, 21958.42)	187644.40 (144315.37, 243982.47)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	173	5.00 (5.00, 5.00)	8935.47 (7635.96, 10456.14)	1787.09 (1527.19, 2091.23)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	173	5.00 (5.00, 5.00)	1327.27 (1130.08, 1558.87)	265.45 (226.02, 311.77)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	56	0.02 (0.02, 0.03)	2140.61 (1037.06, 4418.46)	87133.63 (42312.36, 179433.84)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	56	0.27 (0.27, 0.27)	57152.08 (38247.10, 85401.53)	210117.95 (140614.32, 313976.22)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	56	0.09 (0.09, 0.09)	41330.85 (26530.18, 64388.51)	459231.65 (294779.81, 715427.93)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	56	5.00 (5.00, 5.00)	27150.79 (21897.54, 33664.30)	5430.16 (4379.51, 6732.86)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	56	5.00 (5.00, 5.00)	4439.05 (3557.09, 5539.70)	887.81 (711.42, 1107.94)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	27	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	27	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	27	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	27	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	27	5.29 (4.74, 5.91)	5.00 (5.00, 5.00)	0.94 (0.85, 1.05)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	63	0.02 (0.02, 0.02)	383.79 (196.58, 749.28)	15991.11 (8190.77, 31219.97)
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	63	0.27 (0.27, 0.27)	8575.22 (5437.68, 13523.13)	31526.54 (19991.46, 49717.38)
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	63	0.09 (0.09, 0.09)	5130.27 (3306.26, 7960.57)	57003.03 (36736.20, 88450.78)
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	63	5.00 (5.00, 5.00)	2923.96 (2269.14, 3767.74)	584.79 (453.83, 753.55)
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	63	5.00 (5.00, 5.00)	717.95 (569.55, 905.01)	143.59 (113.91, 181.00)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	218	0.02 (0.02, 0.02)	157.72 (125.55, 198.14)	6571.82 (5231.40, 8255.70)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	0.27 (0.27, 0.28)	1825.52 (1508.02, 2209.86)	6680.18 (5521.30, 8082.30)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	0.09 (0.09, 0.09)	1170.24 (995.80, 1375.24)	13002.66 (11064.40, 15280.46)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	218	5.00 (5.00, 5.00)	328.29 (293.31, 367.45)	65.66 (58.66, 73.49)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	218	5.00 (5.00, 5.00)	59.47 (53.35, 66.30)	11.89 (10.67, 13.26)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	57	0.02 (0.02, 0.02)	343.21 (220.13, 535.10)	14300.48 (9172.24, 22295.93)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	57	0.27 (0.27, 0.27)	4143.69 (2844.30, 6036.70)	15234.17 (10456.99, 22193.76)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	57	0.09 (0.09, 0.10)	2531.76 (1814.49, 3532.55)	27323.72 (19850.03, 37611.32)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	57	5.00 (5.00, 5.00)	649.36 (527.11, 799.97)	129.87 (105.42, 159.99)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	57	5.00 (5.00, 5.00)	92.36 (76.33, 111.76)	18.47 (15.27, 22.35)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	33	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	33	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	33	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	59	0.02 (0.02, 0.02)	87.68 (56.86, 135.21)	3653.23 (2369.02, 5633.57)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	59	0.27 (0.27, 0.27)	1076.11 (749.69, 1544.66)	3956.29 (2756.21, 5678.90)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	59	0.09 (0.09, 0.09)	606.91 (457.49, 805.13)	6655.50 (5055.11, 8762.56)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	59	5.00 (5.00, 5.00)	155.88 (129.03, 188.33)	31.18 (25.81, 37.67)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	59	5.00 (5.00, 5.00)	33.11 (27.56, 39.77)	6.62 (5.51, 7.95)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	218	0.02 (0.02, 0.02)	2297.83 (1738.54, 3037.05)	95742.93 (72439.06, 126543.72)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	0.27 (0.27, 0.28)	87473.39 (71286.39, 107335.96)	320094.78 (260923.58, 392684.59)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	0.09 (0.09, 0.09)	55710.29 (47159.64, 65811.28)	619003.26 (523996.04, 731236.50)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	218	5.00 (5.00, 5.00)	14420.06 (12597.51, 16506.29)	2884.01 (2519.50, 3301.26)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	218	5.00 (5.00, 5.00)	1885.68 (1685.17, 2110.03)	377.14 (337.03, 422.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	57	0.02 (0.02, 0.02)	7275.85 (4530.79, 11684.05)	303160.38 (188782.93, 486835.40)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	57	0.27 (0.27, 0.27)	233434.03 (173634.71, 313828.06)	858213.34 (638362.92, 1153779.63)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	57	0.09 (0.09, 0.10)	102004.55 (83418.77, 124731.25)	1100873.09 (901106.57, 1344925.90)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	57	5.00 (5.00, 5.00)	37863.91 (30980.10, 46277.32)	7572.78 (6196.02, 9255.46)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	57	5.00 (5.00, 5.00)	5040.13 (4110.77, 6179.59)	1008.03 (822.15, 1235.92)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	33	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	33	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	33	5.00 (5.00, 5.00)	5.20 (4.82, 5.62)	1.04 (0.96, 1.12)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	59	0.02 (0.02, 0.02)	1153.70 (652.07, 2041.21)	48070.73 (27169.65, 85050.62)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	59	0.27 (0.27, 0.27)	50450.18 (33144.60, 76791.42)	185478.60 (121855.13, 282321.39)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	59	0.09 (0.09, 0.09)	25736.28 (19104.18, 34670.75)	282229.92 (210348.71, 378674.68)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	59	5.00 (5.00, 5.00)	5062.20 (4098.06, 6253.16)	1012.44 (819.61, 1250.63)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	59	5.00 (5.00, 5.00)	1044.85 (868.63, 1256.81)	208.97 (173.73, 251.36)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	258	0.02 (0.02, 0.02)	131.59 (106.10, 163.20)	5482.91 (4420.84, 6800.12)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	258	0.27 (0.27, 0.27)	1595.85 (1306.73, 1948.93)	5867.09 (4804.17, 7165.18)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	258	0.09 (0.09, 0.09)	930.53 (791.39, 1094.14)	10339.25 (8793.21, 12157.13)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	258	5.00 (5.00, 5.00)	281.77 (253.52, 313.16)	56.35 (50.70, 62.63)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	258	5.00 (5.00, 5.00)	56.23 (51.08, 61.89)	11.25 (10.22, 12.38)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	66	0.02 (0.02, 0.02)	274.36 (190.49, 395.16)	11335.60 (7869.43, 16328.48)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	66	0.27 (0.27, 0.27)	2957.62 (2062.39, 4241.44)	10873.60 (7582.33, 15593.54)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	66	0.09 (0.09, 0.09)	1605.23 (1182.33, 2179.40)	17835.88 (13136.95, 24215.55)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	66	5.00 (5.00, 5.00)	611.76 (516.06, 725.22)	122.35 (103.21, 145.04)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	66	5.00 (5.00, 5.00)	106.31 (89.02, 126.96)	21.26 (17.80, 25.39)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	45	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	45	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	45	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	45	5.10 (4.91, 5.29)	5.00 (5.00, 5.00)	0.98 (0.94, 1.02)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	45	5.00 (5.00, 5.00)	5.28 (4.91, 5.68)	1.06 (0.98, 1.14)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	69	0.02 (0.02, 0.02)	97.21 (61.27, 154.22)	4050.27 (2552.90, 6425.91)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	69	0.27 (0.27, 0.27)	1005.84 (715.64, 1413.71)	3697.93 (2631.02, 5197.48)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	69	0.09 (0.09, 0.09)	631.68 (475.18, 839.73)	7018.72 (5279.82, 9330.33)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	69	5.00 (5.00, 5.00)	168.09 (137.04, 206.18)	33.62 (27.41, 41.24)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	69	5.00 (5.00, 5.00)	36.11 (29.64, 44.00)	7.22 (5.93, 8.80)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	258	0.02 (0.02, 0.02)	2026.66 (1555.75, 2640.11)	84444.17 (64822.83, 110004.72)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	258	0.27 (0.27, 0.27)	77839.10 (63430.65, 95520.46)	286173.16 (233200.93, 351178.18)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	258	0.09 (0.09, 0.09)	46749.14 (39284.12, 55632.72)	519434.94 (436490.21, 618141.38)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	258	5.00 (5.00, 5.00)	11612.78 (10143.10, 13295.41)	2322.56 (2028.62, 2659.08)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	258	5.00 (5.00, 5.00)	1627.78 (1463.40, 1810.62)	325.56 (292.68, 362.12)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	66	0.02 (0.02, 0.02)	7514.89 (4955.01, 11397.28)	310490.34 (205021.51, 470215.30)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	66	0.27 (0.27, 0.27)	196321.44 (149772.65, 257337.41)	721769.98 (550634.75, 946093.41)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	66	0.09 (0.09, 0.09)	116163.88 (100005.55, 134932.97)	1290709.72 (1111172.79, 1499255.21)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	66	5.00 (5.00, 5.00)	46644.01 (39166.26, 55549.44)	9328.80 (7833.25, 11109.89)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	66	5.00 (5.00, 5.00)	5461.33 (4548.48, 6557.38)	1092.27 (909.70, 1311.48)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	45	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	45	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	45	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	45	5.10 (4.91, 5.29)	5.00 (5.00, 5.00)	0.98 (0.94, 1.02)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	45	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	69	0.02 (0.02, 0.02)	1009.72 (606.19, 1681.86)	42071.51 (25257.90, 70077.54)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	69	0.27 (0.27, 0.27)	43321.33 (28822.13, 65114.47)	159269.60 (105963.70, 239391.45)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	69	0.09 (0.09, 0.09)	28767.28 (21312.22, 38830.14)	319636.46 (236802.45, 431445.98)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	69	5.00 (5.00, 5.00)	5227.64 (4334.16, 6305.30)	1045.53 (866.83, 1261.06)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	69	5.00 (5.00, 5.00)	879.92 (755.03, 1025.47)	175.98 (151.01, 205.09)

Table 6g. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Hispanic or Latino ethnicity

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Hispanic or Latino ethnicity								
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	130	0.02 (0.02, 0.02)	60.33 (36.37, 100.10)	2513.91 (1515.26, 4170.75)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	130	0.28 (0.27, 0.28)	649.64 (426.15, 990.35)	2353.06 (1555.36, 3559.89)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	130	0.09 (0.09, 0.09)	429.89 (300.02, 615.99)	4776.61 (3333.57, 6844.32)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	130	5.00 (5.00, 5.00)	218.54 (178.87, 267.01)	43.71 (35.77, 53.40)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	130	5.00 (5.00, 5.00)	47.19 (40.03, 55.63)	9.44 (8.01, 11.13)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	34	0.02 (0.02, 0.02)	156.84 (97.66, 251.86)	6534.88 (4069.35, 10494.21)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	34	0.27 (0.27, 0.27)	1802.92 (997.30, 3259.31)	6628.38 (3666.55, 11982.76)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	34	0.09 (0.09, 0.09)	860.11 (483.13, 1531.23)	9447.32 (5325.16, 16760.42)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	34	5.00 (5.00, 5.00)	422.79 (343.71, 520.07)	84.56 (68.74, 104.01)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	34	5.00 (5.00, 5.00)	99.26 (72.44, 136.00)	19.85 (14.49, 27.20)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	22	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	22	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	22	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	22	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	22	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	25	0.02 (0.02, 0.02)	27.27 (11.85, 62.73)	1136.06 (493.79, 2613.74)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	25	0.27 (0.27, 0.27)	287.56 (144.28, 573.16)	1057.22 (530.43, 2107.20)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	25	0.09 (0.09, 0.09)	153.40 (83.92, 280.40)	1704.48 (932.49, 3115.59)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	25	5.00 (5.00, 5.00)	95.90 (70.22, 130.96)	19.18 (14.04, 26.19)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	25	5.00 (5.00, 5.00)	19.66 (12.45, 31.04)	3.93 (2.49, 6.21)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	130	0.02 (0.02, 0.02)	879.44 (524.28, 1475.18)	36643.16 (21844.99, 61465.85)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	130	0.28 (0.27, 0.28)	33410.70 (21948.17, 50859.60)	121016.53 (80024.07, 183007.43)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	130	0.09 (0.09, 0.09)	22661.15 (16064.43, 31966.75)	251790.57 (178493.70, 355186.15)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	130	5.00 (5.00, 5.00)	9829.86 (8024.03, 12042.10)	1965.97 (1604.81, 2408.42)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	130	5.00 (5.00, 5.00)	1555.12 (1293.23, 1870.04)	311.02 (258.65, 374.01)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	34	0.02 (0.02, 0.02)	4237.38 (2216.18, 8101.97)	176557.69 (92340.90, 337581.92)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	34	0.27 (0.27, 0.27)	74710.38 (43552.70, 128158.30)	274670.51 (160120.23, 471170.23)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	34	0.09 (0.09, 0.09)	63564.70 (40153.56, 100625.47)	698185.90 (441276.17, 1104667.75)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	34	5.00 (5.00, 5.00)	31045.07 (22915.33, 42059.02)	6209.01 (4583.07, 8411.80)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	34	5.00 (5.00, 5.00)	5552.76 (4103.33, 7514.16)	1110.55 (820.67, 1502.83)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	22	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	22	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	22	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	22	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	22	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	25	0.02 (0.02, 0.02)	385.13 (160.23, 925.71)	16047.12 (6676.18, 38571.44)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	25	0.27 (0.27, 0.27)	9826.60 (4321.51, 22344.55)	36127.21 (15887.89, 82149.08)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	25	0.09 (0.09, 0.09)	5657.91 (2980.05, 10742.12)	62865.72 (33111.61, 119356.88)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	25	5.00 (5.00, 5.00)	4437.92 (2841.54, 6931.14)	887.58 (568.31, 1386.23)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	25	5.00 (5.00, 5.00)	679.28 (482.63, 956.05)	135.86 (96.53, 191.21)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	690	0.02 (0.02, 0.02)	65.21 (54.65, 77.82)	2702.45 (2264.41, 3225.23)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	690	0.27 (0.27, 0.27)	718.94 (613.76, 842.15)	2641.62 (2255.20, 3094.27)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	690	0.09 (0.09, 0.09)	406.18 (355.64, 463.90)	4513.10 (3951.55, 5154.46)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	690	5.00 (5.00, 5.00)	226.42 (208.69, 245.65)	45.28 (41.74, 49.13)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	690	5.00 (5.00, 5.00)	46.77 (43.20, 50.64)	9.35 (8.64, 10.13)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	197	0.02 (0.02, 0.02)	100.08 (73.54, 136.20)	4165.43 (3060.99, 5668.37)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	197	0.28 (0.27, 0.28)	1196.84 (936.10, 1530.21)	4343.98 (3423.20, 5512.44)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	197	0.09 (0.09, 0.09)	734.74 (583.20, 925.66)	8053.91 (6412.75, 10115.08)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	197	5.00 (5.00, 5.00)	351.93 (308.42, 401.59)	70.39 (61.68, 80.32)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	197	5.00 (5.00, 5.00)	73.00 (64.52, 82.59)	14.60 (12.90, 16.52)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	118	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	118	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	118	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	118	5.02 (4.98, 5.05)	5.00 (5.00, 5.00)	1.00 (0.99, 1.00)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	118	5.12 (4.93, 5.32)	5.02 (4.98, 5.07)	0.98 (0.94, 1.02)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	222	0.02 (0.02, 0.02)	26.83 (19.52, 36.90)	1118.12 (813.21, 1537.34)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	222	0.27 (0.27, 0.27)	347.35 (264.93, 455.41)	1277.03 (974.02, 1674.30)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	222	0.09 (0.09, 0.09)	180.77 (141.23, 231.39)	2005.76 (1567.18, 2567.08)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	222	5.00 (5.00, 5.00)	107.35 (92.28, 124.88)	21.47 (18.46, 24.98)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	222	5.00 (5.00, 5.00)	25.54 (22.37, 29.16)	5.11 (4.47, 5.83)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	690	0.02 (0.02, 0.02)	848.00 (678.26, 1060.22)	35140.45 (28092.31, 43956.91)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	690	0.27 (0.27, 0.27)	30702.10 (25812.13, 36518.45)	112809.26 (94842.79, 134179.18)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	690	0.09 (0.09, 0.09)	21967.61 (18906.24, 25524.68)	244084.52 (210069.31, 283607.59)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	690	5.00 (5.00, 5.00)	10230.06 (9395.39, 11138.88)	2046.01 (1879.08, 2227.78)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	690	5.00 (5.00, 5.00)	1434.87 (1323.77, 1555.30)	286.97 (264.75, 311.06)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	197	0.02 (0.02, 0.02)	2136.00 (1467.76, 3108.47)	88900.46 (61091.43, 129368.26)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	197	0.28 (0.27, 0.28)	71208.98 (53904.99, 94067.70)	258455.12 (196441.22, 340045.99)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	197	0.09 (0.09, 0.09)	49850.34 (39401.72, 63069.74)	546435.12 (432765.83, 689960.52)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	197	5.00 (5.00, 5.00)	26571.74 (22955.30, 30757.94)	5314.35 (4591.06, 6151.59)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	197	5.00 (5.00, 5.00)	4334.34 (3733.53, 5031.84)	866.87 (746.71, 1006.37)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	118	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	118	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	118	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	118	5.02 (4.98, 5.05)	5.00 (5.00, 5.00)	1.00 (0.99, 1.00)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	118	5.12 (4.93, 5.32)	5.03 (4.98, 5.07)	0.98 (0.94, 1.02)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	222	0.02 (0.02, 0.02)	351.33 (239.85, 514.62)	14638.77 (9993.78, 21442.68)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	222	0.27 (0.27, 0.27)	13001.44 (9786.27, 17272.92)	47799.42 (35978.94, 63503.37)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	222	0.09 (0.09, 0.09)	6907.85 (5381.50, 8867.11)	76645.78 (59715.78, 98375.59)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	222	5.00 (5.00, 5.00)	3445.73 (3009.83, 3944.76)	689.15 (601.97, 788.95)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	222	5.00 (5.00, 5.00)	765.56 (665.91, 880.11)	153.11 (133.18, 176.02)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	95	0.02 (0.02, 0.02)	51.26 (32.44, 81.01)	2136.02 (1351.75, 3375.30)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	95	0.27 (0.27, 0.27)	628.56 (402.57, 981.43)	2310.89 (1480.03, 3608.20)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	95	0.09 (0.09, 0.09)	435.85 (279.03, 680.78)	4842.74 (3100.38, 7564.28)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	95	5.00 (5.00, 5.00)	222.39 (179.35, 275.75)	44.48 (35.87, 55.15)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	95	5.00 (5.00, 5.00)	46.61 (37.76, 57.53)	9.32 (7.55, 11.51)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	38	0.03 (0.02, 0.03)	94.68 (46.77, 191.66)	3768.48 (1897.61, 7483.85)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	38	0.27 (0.27, 0.27)	1374.69 (613.01, 3082.77)	5054.00 (2253.71, 11333.71)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	38	0.09 (0.09, 0.09)	878.75 (493.89, 1563.51)	9763.89 (5487.67, 17372.32)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	38	5.00 (5.00, 5.00)	332.76 (243.29, 455.12)	66.55 (48.66, 91.02)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	38	5.00 (5.00, 5.00)	79.08 (60.14, 103.98)	15.82 (12.03, 20.80)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	15	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.97 (0.92, 1.03)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	15	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	15	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	15	5.38 (4.65, 6.22)	5.11 (4.89, 5.34)	0.95 (0.86, 1.05)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	15	5.00 (5.00, 5.00)	5.15 (4.85, 5.47)	1.03 (0.97, 1.09)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	29	0.02 (0.02, 0.02)	62.14 (37.66, 102.51)	2589.00 (1569.33, 4271.18)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	29	0.27 (0.27, 0.27)	752.52 (384.29, 1473.56)	2766.61 (1412.85, 5417.51)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	29	0.09 (0.09, 0.09)	281.80 (166.29, 477.54)	3131.08 (1847.64, 5306.05)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	29	5.00 (5.00, 5.00)	145.79 (114.57, 185.52)	29.16 (22.91, 37.10)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	29	5.00 (5.00, 5.00)	26.92 (21.26, 34.10)	5.38 (4.25, 6.82)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	95	0.02 (0.02, 0.02)	913.21 (498.21, 1673.91)	38050.56 (20758.75, 69746.26)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	95	0.27 (0.27, 0.27)	33206.04 (19716.89, 55923.67)	122081.01 (72488.56, 205601.72)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	95	0.09 (0.09, 0.09)	16248.13 (10509.97, 25119.17)	180534.76 (116777.43, 279101.88)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	95	5.00 (5.00, 5.00)	9659.01 (7544.15, 12366.74)	1931.80 (1508.83, 2473.35)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	95	5.00 (5.00, 5.00)	1587.54 (1255.01, 2008.17)	317.51 (251.00, 401.63)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	38	0.03 (0.02, 0.03)	1798.25 (673.61, 4800.54)	71576.64 (27102.99, 189027.67)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	38	0.27 (0.27, 0.27)	85427.72 (47001.77, 155268.53)	314072.51 (172800.62, 570840.19)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	38	0.09 (0.09, 0.09)	52088.94 (29682.61, 91409.01)	578766.03 (329806.76, 1015655.70)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	38	5.00 (5.00, 5.00)	30571.57 (22852.32, 40898.28)	6114.31 (4570.46, 8179.66)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	38	5.00 (5.00, 5.00)	4170.50 (3140.86, 5537.69)	834.10 (628.17, 1107.54)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	15	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.97 (0.92, 1.03)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	15	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	15	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	15	5.38 (4.65, 6.22)	5.00 (5.00, 5.00)	0.93 (0.80, 1.08)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	15	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	29	0.02 (0.02, 0.02)	622.61 (294.33, 1317.02)	25942.02 (12263.84, 54875.86)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	29	0.27 (0.27, 0.27)	18343.57 (9662.64, 34823.47)	67439.61 (35524.42, 128027.47)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	29	0.09 (0.09, 0.09)	9346.96 (4825.37, 18105.49)	103855.10 (53615.18, 201172.14)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	29	5.00 (5.00, 5.00)	3686.49 (2496.63, 5443.43)	737.30 (499.33, 1088.69)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	29	5.00 (5.00, 5.00)	854.83 (659.14, 1108.61)	170.97 (131.83, 221.72)

Table 6h. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Race

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Race								
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	359	0.02 (0.02, 0.02)	70.77 (56.05, 89.37)	2923.24 (2313.80, 3693.21)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	0.27 (0.27, 0.27)	773.49 (621.49, 962.67)	2841.05 (2282.80, 3535.81)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	0.09 (0.09, 0.09)	422.61 (352.48, 506.70)	4695.71 (3916.46, 5630.01)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	359	5.00 (5.00, 5.00)	235.11 (211.32, 261.58)	47.02 (42.26, 52.32)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	359	5.00 (5.00, 5.00)	50.07 (45.40, 55.23)	10.01 (9.08, 11.05)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	107	0.02 (0.02, 0.02)	85.84 (58.74, 125.44)	3576.69 (2447.66, 5226.50)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	107	0.28 (0.27, 0.29)	1255.38 (899.56, 1751.96)	4515.86 (3287.26, 6203.64)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	107	0.09 (0.09, 0.10)	832.71 (610.95, 1134.96)	9041.96 (6673.66, 12250.70)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	107	5.00 (5.00, 5.00)	348.92 (294.71, 413.10)	69.78 (58.94, 82.62)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	107	5.00 (5.00, 5.00)	75.10 (62.84, 89.77)	15.02 (12.57, 17.95)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	62	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	62	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	62	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	62	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	62	5.05 (4.95, 5.16)	5.04 (4.96, 5.13)	1.00 (0.97, 1.03)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	127	0.02 (0.02, 0.02)	23.47 (15.78, 34.91)	977.93 (657.54, 1454.41)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	127	0.27 (0.27, 0.27)	316.63 (227.60, 440.49)	1164.07 (836.75, 1619.43)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	127	0.09 (0.09, 0.09)	171.59 (123.82, 237.80)	1906.59 (1375.77, 2642.23)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	127	5.00 (5.00, 5.00)	101.14 (83.06, 123.15)	20.23 (16.61, 24.63)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	127	5.00 (5.00, 5.00)	24.15 (20.58, 28.34)	4.83 (4.12, 5.67)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	359	0.02 (0.02, 0.02)	925.49 (690.41, 1240.61)	38226.45 (28486.24, 51297.09)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	0.27 (0.27, 0.27)	34327.41 (27434.02, 42952.92)	126085.61 (100767.96, 157764.23)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	0.09 (0.09, 0.09)	23871.82 (19501.19, 29222.00)	265242.43 (216679.87, 324688.89)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	359	5.00 (5.00, 5.00)	10804.86 (9666.02, 12077.88)	2160.97 (1933.20, 2415.58)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	359	5.00 (5.00, 5.00)	1468.18 (1326.37, 1625.16)	293.64 (265.27, 325.03)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	107	0.02 (0.02, 0.02)	2249.02 (1326.44, 3813.30)	93709.29 (55268.22, 158887.54)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	107	0.28 (0.27, 0.29)	72774.32 (48721.26, 108702.06)	261783.35 (176679.37, 387880.72)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	107	0.09 (0.09, 0.10)	44161.88 (31425.62, 62059.94)	479532.76 (342860.23, 670686.33)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	107	5.00 (5.00, 5.00)	27316.51 (23011.03, 32427.56)	5463.30 (4602.21, 6485.51)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	107	5.00 (5.00, 5.00)	4354.20 (3537.98, 5358.73)	870.84 (707.60, 1071.75)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	62	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	62	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	62	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	62	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	62	5.05 (4.95, 5.16)	5.05 (4.96, 5.14)	1.00 (0.97, 1.03)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	127	0.02 (0.02, 0.02)	250.49 (157.30, 398.86)	10436.90 (6554.37, 16619.26)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	127	0.27 (0.27, 0.27)	11525.87 (8138.57, 16322.99)	42374.53 (29921.20, 60010.98)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	127	0.09 (0.09, 0.09)	6096.79 (4463.25, 8328.19)	67742.06 (49591.70, 92535.40)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	127	5.00 (5.00, 5.00)	3155.01 (2644.10, 3764.64)	631.00 (528.82, 752.93)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	127	5.00 (5.00, 5.00)	732.01 (614.16, 872.46)	146.40 (122.83, 174.49)
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	202	0.02 (0.02, 0.02)	52.42 (39.17, 70.17)	2184.34 (1631.93, 2923.73)
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	202	0.27 (0.27, 0.27)	620.22 (474.43, 810.80)	2280.20 (1744.23, 2980.87)
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	202	0.09 (0.09, 0.09)	387.21 (305.84, 490.23)	4302.35 (3398.23, 5447.01)
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	202	5.00 (5.00, 5.00)	212.14 (186.86, 240.85)	42.43 (37.37, 48.17)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	202	5.00 (5.00, 5.00)	41.78 (36.97, 47.21)	8.36 (7.39, 9.44)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	50	0.03 (0.02, 0.03)	196.59 (104.35, 370.40)	7700.73 (4164.49, 14239.75)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	0.27 (0.27, 0.27)	1479.60 (829.63, 2638.80)	5439.72 (3050.11, 9701.47)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	0.09 (0.09, 0.09)	818.12 (557.51, 1200.57)	9014.42 (6162.62, 13185.92)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	50	5.00 (5.00, 5.00)	435.79 (335.60, 565.89)	87.16 (67.12, 113.18)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	50	5.00 (5.00, 5.00)	78.24 (63.94, 95.74)	15.65 (12.79, 19.15)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	23	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	23	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	23	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	23	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	23	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Black or African American	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	58	0.02 (0.02, 0.02)	28.70 (17.47, 47.16)	1195.90 (727.82, 1965.02)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Black or African American	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	58	0.27 (0.27, 0.27)	338.23 (204.94, 558.22)	1243.49 (753.44, 2052.27)
Black or African American	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	58	0.09 (0.09, 0.09)	179.69 (125.87, 256.51)	1983.62 (1392.52, 2825.64)
Black or African American	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	58	5.00 (5.00, 5.00)	113.50 (91.67, 140.53)	22.70 (18.33, 28.11)
Black or African American	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	58	5.00 (5.00, 5.00)	27.30 (21.59, 34.52)	5.46 (4.32, 6.90)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	202	0.02 (0.02, 0.02)	738.67 (516.16, 1057.10)	30777.92 (21506.70, 44045.84)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	202	0.27 (0.27, 0.27)	27279.78 (19431.21, 38298.52)	100293.31 (71438.26, 140803.37)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	202	0.09 (0.09, 0.09)	20087.93 (15736.42, 25642.75)	223199.24 (174849.06, 284919.45)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	202	5.00 (5.00, 5.00)	10042.98 (8775.43, 11493.62)	2008.60 (1755.09, 2298.72)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	202	5.00 (5.00, 5.00)	1420.41 (1260.42, 1600.72)	284.08 (252.08, 320.14)
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	50	0.03 (0.02, 0.03)	4111.66 (2413.36, 7005.07)	161056.25 (95237.94, 272361.15)
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	0.27 (0.27, 0.27)	84576.93 (48644.19, 147052.68)	310944.61 (178838.92, 540634.86)
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	0.09 (0.09, 0.09)	64957.80 (45985.03, 91758.46)	715730.73 (506892.91, 1010608.89)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	50	5.00 (5.00, 5.00)	27598.17 (21558.09, 35330.55)	5519.63 (4311.62, 7066.11)
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	50	5.00 (5.00, 5.00)	4845.70 (4021.54, 5838.75)	969.14 (804.31, 1167.75)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	23	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	23	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	23	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	23	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	23	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	58	0.02 (0.02, 0.02)	623.51 (345.55, 1125.06)	25979.52 (14397.84, 46877.56)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	58	0.27 (0.27, 0.27)	14588.83 (9060.46, 23490.40)	53635.39 (33310.53, 86361.75)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	58	0.09 (0.09, 0.09)	6206.43 (4239.35, 9086.23)	68514.92 (46867.93, 100160.06)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	58	5.00 (5.00, 5.00)	3855.38 (3059.99, 4857.51)	771.08 (612.00, 971.50)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	58	5.00 (5.00, 5.00)	879.96 (673.10, 1150.39)	175.99 (134.62, 230.08)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Asian	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	58	0.02 (0.02, 0.02)	69.59 (41.46, 116.83)	2899.72 (1727.35, 4867.81)
Asian	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	58	0.27 (0.27, 0.27)	764.80 (467.68, 1250.68)	2811.76 (1719.41, 4598.10)
Asian	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	58	0.09 (0.09, 0.09)	442.90 (321.43, 610.28)	4921.13 (3571.45, 6780.86)
Asian	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	58	5.00 (5.00, 5.00)	219.76 (175.38, 275.39)	43.95 (35.08, 55.08)
Asian	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	58	5.00 (5.00, 5.00)	50.55 (40.41, 63.22)	10.11 (8.08, 12.64)
Asian	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	19	0.02 (0.02, 0.02)	133.55 (66.57, 267.93)	5564.48 (2773.57, 11163.75)
Asian	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	19	0.27 (0.27, 0.27)	1081.45 (380.81, 3071.21)	3975.93 (1400.03, 11291.20)
Asian	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	19	0.09 (0.09, 0.09)	685.37 (350.63, 1339.68)	7615.20 (3895.86, 14885.35)
Asian	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	19	5.00 (5.00, 5.00)	424.25 (310.80, 579.12)	84.85 (62.16, 115.82)
Asian	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	19	5.00 (5.00, 5.00)	58.38 (48.10, 70.84)	11.68 (9.62, 14.17)
Asian	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	13	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Asian	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	13	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Asian	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	13	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Asian	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	13	5.13 (4.87, 5.40)	5.00 (5.00, 5.00)	0.97 (0.93, 1.03)
Asian	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	13	5.81 (4.39, 7.67)	5.00 (5.00, 5.00)	0.86 (0.65, 1.14)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Asian	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	18	0.02 (0.02, 0.02)	41.69 (14.44, 120.37)	1737.10 (601.63, 5015.59)
Asian	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	18	0.27 (0.27, 0.27)	626.25 (273.15, 1435.79)	2302.40 (1004.24, 5278.65)
Asian	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	18	0.09 (0.09, 0.09)	287.83 (112.62, 735.63)	3198.15 (1251.36, 8173.64)
Asian	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	18	5.00 (5.00, 5.00)	116.33 (67.78, 199.64)	23.27 (13.56, 39.93)
Asian	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	18	5.00 (5.00, 5.00)	29.61 (14.92, 58.74)	5.92 (2.98, 11.75)
Asian	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	58	0.02 (0.02, 0.02)	822.44 (370.89, 1823.72)	34268.23 (15453.84, 75988.29)
Asian	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	58	0.27 (0.27, 0.27)	25888.47 (15267.00, 43899.45)	95178.19 (56128.67, 161395.03)
Asian	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	58	0.09 (0.09, 0.09)	23238.49 (15781.39, 34219.25)	258205.42 (175348.78, 380213.88)
Asian	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	58	5.00 (5.00, 5.00)	9016.02 (7117.66, 11420.70)	1803.20 (1423.53, 2284.14)
Asian	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	58	5.00 (5.00, 5.00)	1458.82 (1150.77, 1849.34)	291.76 (230.15, 369.87)
Asian	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	19	0.02 (0.02, 0.02)	2895.47 (1440.80, 5818.80)	120644.40 (60033.25, 242450.13)
Asian	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	19	0.27 (0.27, 0.27)	60327.08 (28464.78, 127854.76)	221790.75 (104649.91, 470054.26)
Asian	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	19	0.09 (0.09, 0.09)	31276.83 (16469.52, 59396.98)	347520.29 (182994.69, 659966.44)
Asian	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	19	5.00 (5.00, 5.00)	32100.41 (23835.64, 43230.91)	6420.08 (4767.13, 8646.18)
Asian	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	19	5.00 (5.00, 5.00)	3203.90 (1752.84, 5856.21)	640.78 (350.57, 1171.24)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Asian	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	13	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Asian	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	13	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Asian	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	13	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Asian	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	13	5.13 (4.87, 5.40)	5.00 (5.00, 5.00)	0.97 (0.93, 1.03)
Asian	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	13	5.81 (4.39, 7.67)	5.00 (5.00, 5.00)	0.86 (0.65, 1.14)
Asian	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	18	0.02 (0.02, 0.02)	1689.81 (521.28, 5477.86)	70408.94 (21719.81, 228244.11)
Asian	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	18	0.27 (0.27, 0.27)	21925.41 (8565.77, 56121.45)	80608.13 (31491.81, 206328.88)
Asian	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	18	0.09 (0.09, 0.09)	15372.32 (5814.76, 40639.33)	170803.51 (64608.48, 451548.11)
Asian	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	18	5.00 (5.00, 5.00)	5168.98 (3146.00, 8492.79)	1033.80 (629.20, 1698.56)
Asian	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	18	5.00 (5.00, 5.00)	836.93 (474.22, 1477.08)	167.39 (94.84, 295.42)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	22	0.02 (0.02, 0.02)	41.62 (11.12, 155.70)	1734.09 (463.52, 6487.44)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	22	0.27 (0.27, 0.27)	426.30 (143.40, 1267.31)	1567.28 (527.21, 4659.22)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	22	0.09 (0.09, 0.09)	309.74 (144.02, 666.14)	3441.56 (1600.26, 7401.53)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	22	5.00 (5.00, 5.00)	193.23 (102.70, 363.58)	38.65 (20.54, 72.72)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	22	5.00 (5.00, 5.00)	38.71 (26.82, 55.86)	7.74 (5.36, 11.17)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	7	0.02 (0.02, 0.02)	299.44 (235.70, 380.42)	12476.69 (9820.91, 15850.63)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	7	0.27 (0.27, 0.27)	1006.23 (553.15, 1830.42)	3699.39 (2033.65, 6729.49)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	7	0.09 (0.09, 0.09)	546.85 (199.35, 1500.08)	6076.10 (2215.02, 16667.54)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	7	5.00 (5.00, 5.00)	470.94 (411.86, 538.48)	94.19 (82.37, 107.70)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	7	5.00 (5.00, 5.00)	95.50 (57.44, 158.76)	19.10 (11.49, 31.75)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	4	0.03 (0.02, 0.04)	0.02 (0.02, 0.02)	0.85 (0.61, 1.19)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	4	7.39 (3.28, 16.69)	5.62 (4.41, 7.16)	0.76 (0.43, 1.35)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	4	0.02 (0.02, 0.02)	7.28 (5.54, 9.56)	303.30 (230.89, 398.43)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	4	0.27 (0.27, 0.27)	82.52 (34.36, 198.19)	303.39 (126.32, 728.65)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	4	0.09 (0.09, 0.09)	39.39 (17.54, 88.47)	437.65 (194.85, 982.99)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)	70.42 (57.81, 85.79)	14.08 (11.56, 17.16)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)	12.16 (6.86, 21.57)	2.43 (1.37, 4.31)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	22	0.02 (0.02, 0.02)	623.84 (153.56, 2534.29)	25993.30 (6398.49, 105595.56)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	22	0.27 (0.27, 0.27)	18798.13 (7373.08, 47926.98)	69110.77 (27106.92, 176202.14)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	22	0.09 (0.09, 0.09)	10898.97 (4756.30, 24974.76)	121099.62 (52847.78, 277497.34)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	22	5.00 (5.00, 5.00)	7991.67 (6041.09, 10572.07)	1598.33 (1208.22, 2114.41)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	22	5.00 (5.00, 5.00)	1394.65 (810.96, 2398.47)	278.93 (162.19, 479.69)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	7	0.02 (0.02, 0.02)	2449.33 (344.90, 17393.92)	102055.50 (14370.99, 724746.66)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	7	0.27 (0.27, 0.27)	111270.11 (31885.09, 388301.85)	409081.29 (117224.58, 1427580.32)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	7	0.09 (0.09, 0.09)	93808.44 (46821.32, 187949.08)	1042316.02 (520236.86, 2088323.14)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	7	5.00 (5.00, 5.00)	46209.69 (25394.88, 84085.28)	9241.94 (5078.98, 16817.06)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	7	5.00 (5.00, 5.00)	7891.42 (6621.02, 9405.57)	1578.28 (1324.20, 1881.11)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	4	0.03 (0.02, 0.04)	0.02 (0.02, 0.02)	0.85 (0.61, 1.19)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	4	7.39 (3.28, 16.69)	5.00 (5.00, 5.00)	0.68 (0.30, 1.53)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	4	0.02 (0.02, 0.02)	30.79 (1.14, 830.37)	1283.00 (47.58, 34598.93)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	4	0.27 (0.27, 0.27)	1689.25 (684.84, 4166.79)	6210.48 (2517.78, 15319.07)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	4	0.09 (0.09, 0.09)	3036.98 (1287.44, 7164.04)	33744.27 (14304.88, 79600.47)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)	1815.62 (967.91, 3405.75)	363.12 (193.58, 681.15)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)	383.53 (327.73, 448.83)	76.71 (65.55, 89.77)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	11	0.02 (0.02, 0.02)	51.33 (14.95, 176.18)	2138.64 (623.05, 7340.98)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	11	0.27 (0.27, 0.27)	1035.86 (188.21, 5701.08)	3808.30 (691.95, 20959.85)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	11	0.09 (0.09, 0.09)	308.62 (75.49, 1261.75)	3429.09 (838.74, 14019.46)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	11	5.00 (5.00, 5.00)	183.85 (103.40, 326.89)	36.77 (20.68, 65.38)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	11	5.00 (5.00, 5.00)	46.76 (24.37, 89.71)	9.35 (4.87, 17.94)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	6	0.02 (0.02, 0.02)	58.71 (9.44, 365.30)	2446.31 (393.18, 15220.72)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	0.27 (0.27, 0.27)	898.14 (139.86, 5767.71)	3301.97 (514.18, 21204.83)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	0.09 (0.09, 0.09)	598.08 (134.42, 2661.10)	6645.34 (1493.54, 29567.77)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	6	5.00 (5.00, 5.00)	224.65 (101.43, 497.57)	44.93 (20.29, 99.51)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	6	5.00 (5.00, 5.00)	62.52 (30.81, 126.85)	12.50 (6.16, 25.37)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	5	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	5	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	5	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	5	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	5	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	4	0.02 (0.02, 0.02)	51.71 (16.43, 162.76)	2154.39 (684.41, 6781.59)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	4	0.27 (0.27, 0.27)	855.53 (326.10, 2244.47)	3145.31 (1198.90, 8251.72)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	4	0.09 (0.09, 0.09)	297.09 (102.82, 858.42)	3301.04 (1142.46, 9538.05)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)	130.33 (72.06, 235.72)	26.07 (14.41, 47.14)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)	41.50 (30.63, 56.21)	8.30 (6.13, 11.24)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	11	0.02 (0.02, 0.02)	1583.05 (143.29, 17489.39)	65960.45 (5970.40, 728724.74)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	11	0.27 (0.27, 0.27)	22166.22 (4016.60, 122327.82)	81493.46 (14766.89, 449734.63)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	11	0.09 (0.09, 0.09)	21332.32 (5492.11, 82858.49)	237025.80 (61023.45, 920649.93)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	11	5.00 (5.00, 5.00)	13135.28 (7969.15, 21650.41)	2627.06 (1593.83, 4330.08)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	11	5.00 (5.00, 5.00)	1911.89 (1127.47, 3242.05)	382.38 (225.49, 648.41)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	6	0.02 (0.02, 0.02)	1699.48 (289.41, 9979.75)	70811.75 (12058.75, 415822.91)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	6	0.27 (0.27, 0.27)	73472.20 (13302.98, 405786.15)	270118.37 (48908.00, 1491860.85)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	6	0.09 (0.09, 0.09)	35073.79 (8119.82, 151502.23)	389708.80 (90220.22, 1683358.11)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	6	5.00 (5.00, 5.00)	34285.62 (10528.62, 111648.42)	6857.12 (2105.72, 22329.68)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	6	5.00 (5.00, 5.00)	3522.47 (1406.94, 8818.97)	704.49 (281.39, 1763.79)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	5	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	5	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	5	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	5	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	5	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	4	0.02 (0.02, 0.02)	840.40 (258.53, 2731.86)	35016.87 (10772.29, 113827.39)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	4	0.27 (0.27, 0.27)	38923.51 (28410.91, 53325.98)	143101.15 (104451.89, 196051.41)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	4	0.09 (0.09, 0.09)	27169.76 (15245.45, 48420.73)	301886.25 (169393.93, 538008.11)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)	2408.35 (1380.09, 4202.74)	481.67 (276.02, 840.55)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)	1338.63 (850.69, 2106.44)	267.73 (170.14, 421.29)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	60	0.02 (0.02, 0.02)	55.11 (27.73, 109.50)	2296.04 (1155.41, 4562.70)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	60	0.27 (0.27, 0.27)	575.00 (339.93, 972.61)	2113.96 (1249.76, 3575.76)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	60	0.09 (0.09, 0.09)	357.72 (246.30, 519.55)	3974.68 (2736.63, 5772.81)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	60	5.00 (5.00, 5.00)	226.10 (174.72, 292.59)	45.22 (34.94, 58.52)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	60	5.00 (5.00, 5.00)	53.45 (41.88, 68.20)	10.69 (8.38, 13.64)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	11	0.02 (0.02, 0.02)	110.28 (33.79, 359.87)	4594.93 (1408.05, 14994.78)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	11	0.27 (0.27, 0.27)	842.92 (269.03, 2641.00)	3098.96 (989.08, 9709.57)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	11	0.09 (0.09, 0.09)	657.77 (146.44, 2954.53)	7308.58 (1627.12, 32828.13)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	11	5.00 (5.00, 5.00)	338.14 (192.74, 593.24)	67.63 (38.55, 118.65)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	11	5.00 (5.00, 5.00)	99.51 (52.04, 190.28)	19.90 (10.41, 38.06)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Multiracial	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	10	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	10	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	10	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	10	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	10	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	14	0.02 (0.02, 0.02)	28.40 (12.34, 65.36)	1183.17 (514.05, 2723.25)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	14	0.27 (0.27, 0.27)	207.00 (99.98, 428.59)	761.03 (367.56, 1575.70)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	14	0.09 (0.09, 0.09)	102.78 (58.21, 181.49)	1142.00 (646.74, 2016.54)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	14	5.00 (5.00, 5.00)	92.32 (65.91, 129.32)	18.46 (13.18, 25.86)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	14	5.00 (5.00, 5.00)	16.00 (9.25, 27.69)	3.20 (1.85, 5.54)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	60	0.02 (0.02, 0.02)	1056.78 (465.41, 2399.56)	44032.66 (19392.28, 99981.80)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	60	0.27 (0.27, 0.27)	30098.69 (18275.30, 49571.36)	110656.96 (67188.59, 182247.65)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	60	0.09 (0.09, 0.09)	23197.01 (15392.49, 34958.69)	257744.57 (171027.67, 388429.92)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	60	5.00 (5.00, 5.00)	9070.94 (6824.45, 12056.94)	1814.19 (1364.89, 2411.39)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	60	5.00 (5.00, 5.00)	1351.04 (1109.85, 1644.63)	270.21 (221.97, 328.93)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	11	0.02 (0.02, 0.02)	1970.31 (483.58, 8027.89)	82096.04 (20149.03, 334495.56)
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	11	0.27 (0.27, 0.27)	32820.90 (8779.20, 122700.48)	120665.09 (32276.46, 451104.71)
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	11	0.09 (0.09, 0.09)	43616.02 (15105.29, 125939.78)	484622.42 (167836.56, 1399330.94)
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	11	5.00 (5.00, 5.00)	23660.37 (12308.57, 45481.58)	4732.07 (2461.71, 9096.32)
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	11	5.00 (5.00, 5.00)	4331.41 (2462.23, 7619.54)	866.28 (492.45, 1523.91)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	10	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	10	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	10	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	10	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	10	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	14	0.02 (0.02, 0.02)	410.91 (155.76, 1084.06)	17121.44 (6489.89, 45169.28)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	14	0.27 (0.27, 0.27)	7705.74 (3441.63, 17253.01)	28329.92 (12653.04, 63430.18)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	14	0.09 (0.09, 0.09)	3367.56 (1816.17, 6244.14)	37417.32 (20179.72, 69379.33)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	14	5.00 (5.00, 5.00)	3188.11 (2095.39, 4850.68)	637.62 (419.08, 970.14)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	14	5.00 (5.00, 5.00)	594.43 (437.77, 807.14)	118.89 (87.55, 161.43)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Other	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	21	0.02 (0.02, 0.02)	27.23 (13.78, 53.82)	1134.68 (574.17, 2242.37)
Other	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	21	0.27 (0.27, 0.27)	418.49 (221.82, 789.53)	1538.55 (815.50, 2902.69)
Other	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	21	0.09 (0.09, 0.09)	234.97 (115.77, 476.92)	2610.80 (1286.31, 5299.09)
Other	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	21	5.00 (5.00, 5.00)	163.35 (128.16, 208.20)	32.67 (25.63, 41.64)
Other	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	21	5.00 (5.00, 5.00)	35.94 (20.73, 62.31)	7.19 (4.15, 12.46)
Other	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	8	0.02 (0.02, 0.02)	192.12 (77.42, 476.73)	8004.88 (3225.88, 19863.78)
Other	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	8	0.27 (0.27, 0.27)	2930.46 (1290.00, 6657.09)	10773.77 (4742.63, 24474.60)
Other	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	8	0.09 (0.09, 0.09)	845.09 (362.50, 1970.15)	9389.84 (4027.72, 21890.56)
Other	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	8	5.00 (5.00, 5.00)	437.76 (290.31, 660.11)	87.55 (58.06, 132.02)
Other	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	8	5.00 (5.00, 5.00)	77.88 (50.06, 121.14)	15.58 (10.01, 24.23)
Other	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	4	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Other	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Other	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Other	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Other	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Other	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	7	0.02 (0.02, 0.02)	19.07 (4.60, 79.10)	794.57 (191.56, 3295.79)
Other	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	7	0.27 (0.27, 0.27)	390.93 (123.89, 1233.60)	1437.26 (455.47, 4535.29)
Other	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	7	0.09 (0.09, 0.09)	201.95 (66.38, 614.36)	2243.88 (737.60, 6826.23)
Other	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	7	5.00 (5.00, 5.00)	101.94 (54.01, 192.42)	20.39 (10.80, 38.48)
Other	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	7	5.00 (5.00, 5.00)	22.80 (11.37, 45.72)	4.56 (2.27, 9.14)
Other	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	21	0.02 (0.02, 0.02)	895.74 (160.73, 4991.76)	37322.47 (6697.27, 207990.17)
Other	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	21	0.27 (0.27, 0.27)	18055.97 (4458.23, 73127.28)	66382.25 (16390.55, 268850.28)
Other	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	21	0.09 (0.09, 0.09)	15473.74 (7185.26, 33323.31)	171930.49 (79836.25, 370259.04)
Other	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	21	5.00 (5.00, 5.00)	5915.17 (3335.14, 10491.08)	1183.03 (667.03, 2098.22)
Other	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	21	5.00 (5.00, 5.00)	1374.55 (847.70, 2228.84)	274.91 (169.54, 445.77)
Other	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	8	0.02 (0.02, 0.02)	5603.16 (2097.03, 14971.36)	233464.83 (87376.13, 623806.82)
Other	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	8	0.27 (0.27, 0.27)	60786.89 (33758.87, 109454.06)	223481.20 (124113.49, 402404.65)
Other	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	8	0.09 (0.09, 0.09)	63547.88 (25199.21, 160256.37)	706087.56 (279991.17, 1780626.29)
Other	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	8	5.00 (5.00, 5.00)	28339.45 (18536.74, 43326.09)	5667.89 (3707.35, 8665.22)
Other	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	8	5.00 (5.00, 5.00)	5463.27 (2666.19, 11194.77)	1092.65 (533.24, 2238.95)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Other	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	4	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	7	0.02 (0.02, 0.02)	373.78 (63.76, 2191.26)	15574.09 (2656.58, 91302.31)
Other	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	7	0.27 (0.27, 0.27)	9100.48 (2896.08, 28596.84)	33457.63 (10647.34, 105135.45)
Other	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	7	0.09 (0.09, 0.09)	8645.11 (2704.19, 27637.86)	96056.80 (30046.53, 307087.36)
Other	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	7	5.00 (5.00, 5.00)	3363.07 (2119.12, 5337.24)	672.61 (423.82, 1067.45)
Other	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	7	5.00 (5.00, 5.00)	552.38 (332.19, 918.54)	110.48 (66.44, 183.71)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	86	0.02 (0.02, 0.02)	55.01 (33.04, 91.59)	2292.07 (1376.57, 3816.44)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	86	0.28 (0.27, 0.28)	595.75 (406.96, 872.13)	2163.05 (1486.70, 3147.10)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	86	0.09 (0.09, 0.09)	362.48 (255.95, 513.35)	4027.60 (2843.93, 5703.93)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	86	5.00 (5.00, 5.00)	210.20 (165.11, 267.60)	42.04 (33.02, 53.52)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	86	5.00 (5.00, 5.00)	36.20 (28.27, 46.35)	7.24 (5.65, 9.27)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	25	0.02 (0.02, 0.02)	75.01 (28.93, 194.46)	3125.43 (1205.57, 8102.64)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	25	0.27 (0.27, 0.27)	1072.44 (640.30, 1796.24)	3942.80 (2354.05, 6603.81)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	25	0.09 (0.09, 0.09)	609.57 (316.48, 1174.10)	6773.02 (3516.43, 13045.55)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	25	5.00 (5.00, 5.00)	304.00 (205.97, 448.70)	60.80 (41.19, 89.74)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	25	5.00 (5.00, 5.00)	72.96 (53.68, 99.18)	14.59 (10.74, 19.84)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	19	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	19	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	19	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	19	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	19	5.00 (5.00, 5.00)	5.12 (4.88, 5.38)	1.02 (0.98, 1.08)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	24	0.02 (0.02, 0.02)	111.72 (36.48, 342.08)	4654.93 (1520.21, 14253.54)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	24	0.27 (0.27, 0.27)	918.16 (340.70, 2474.41)	3375.60 (1252.56, 9097.10)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	24	0.09 (0.09, 0.09)	361.93 (163.87, 799.38)	4021.45 (1820.77, 8881.98)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	24	5.00 (5.00, 5.00)	191.84 (121.39, 303.15)	38.37 (24.28, 60.63)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	24	5.00 (5.00, 5.00)	36.92 (23.53, 57.94)	7.38 (4.71, 11.59)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	86	0.02 (0.02, 0.02)	662.31 (365.26, 1200.94)	27596.31 (15219.26, 50038.97)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	86	0.28 (0.27, 0.28)	24290.22 (14883.34, 39642.62)	88192.83 (54303.18, 143232.38)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	86	0.09 (0.09, 0.09)	16435.89 (10879.55, 24829.93)	182621.00 (120883.92, 275888.07)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	86	5.00 (5.00, 5.00)	9186.30 (7186.05, 11743.33)	1837.26 (1437.21, 2348.67)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	86	5.00 (5.00, 5.00)	1301.38 (1005.32, 1684.62)	260.28 (201.06, 336.92)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	25	0.02 (0.02, 0.02)	1029.28 (418.57, 2531.03)	42886.47 (17440.29, 105459.79)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	25	0.27 (0.27, 0.27)	72598.19 (43488.88, 121191.84)	266905.12 (159885.59, 445558.23)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	25	0.09 (0.09, 0.09)	65369.01 (42302.55, 101012.97)	726322.28 (470028.39, 1122366.38)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	25	5.00 (5.00, 5.00)	21255.49 (13116.68, 34444.39)	4251.10 (2623.34, 6888.88)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	25	5.00 (5.00, 5.00)	4235.58 (2991.27, 5997.50)	847.12 (598.25, 1199.50)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	19	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	19	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	19	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	19	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	19	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	24	0.02 (0.02, 0.02)	944.69 (294.27, 3032.73)	39362.14 (12261.24, 126363.84)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	24	0.27 (0.27, 0.27)	34049.21 (9185.79, 126211.18)	125180.93 (33771.27, 464011.68)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	24	0.09 (0.09, 0.09)	15466.09 (4535.90, 52734.84)	171845.41 (50398.86, 585942.66)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	24	5.00 (5.00, 5.00)	4758.56 (2708.14, 8361.41)	951.71 (541.63, 1672.28)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	24	5.00 (5.00, 5.00)	1102.39 (759.70, 1599.66)	220.48 (151.94, 319.93)

Table 6i. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Underrepresented minority status								
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	420	0.02 (0.02, 0.02)	57.98 (45.97, 73.14)	2415.85 (1915.24, 3047.30)
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	420	0.27 (0.27, 0.28)	664.37 (542.05, 814.30)	2430.98 (1986.59, 2974.77)
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	420	0.09 (0.09, 0.09)	405.04 (342.49, 479.00)	4500.42 (3805.47, 5322.27)
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	420	5.00 (5.00, 5.00)	218.67 (198.49, 240.90)	43.73 (39.70, 48.18)
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	420	5.00 (5.00, 5.00)	46.34 (42.33, 50.73)	9.27 (8.47, 10.15)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	110	0.02 (0.02, 0.03)	168.27 (116.47, 243.10)	6830.11 (4757.99, 9804.64)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	110	0.27 (0.27, 0.27)	1358.84 (945.07, 1953.77)	4995.75 (3474.54, 7182.97)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	110	0.09 (0.09, 0.09)	765.48 (567.32, 1032.87)	8475.21 (6285.16, 11428.36)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	110	5.00 (5.00, 5.00)	408.66 (349.47, 477.89)	81.73 (69.89, 95.58)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	110	5.00 (5.00, 5.00)	80.17 (68.61, 93.68)	16.03 (13.72, 18.74)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	66	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.97, 1.01)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	66	5.17 (4.90, 5.45)	5.04 (4.96, 5.12)	0.97 (0.94, 1.01)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	66	5.24 (4.78, 5.73)	5.00 (5.00, 5.00)	0.96 (0.87, 1.05)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	112	0.02 (0.02, 0.02)	28.33 (19.89, 40.35)	1180.47 (828.93, 1681.09)
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	112	0.27 (0.27, 0.27)	326.35 (231.97, 459.13)	1199.82 (852.84, 1687.97)
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	112	0.09 (0.09, 0.09)	167.58 (126.64, 221.76)	1855.60 (1403.19, 2453.86)
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	112	5.00 (5.00, 5.00)	107.63 (92.18, 125.68)	21.53 (18.44, 25.14)
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	112	5.00 (5.00, 5.00)	24.98 (20.54, 30.39)	5.00 (4.11, 6.08)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	420	0.02 (0.02, 0.02)	853.62 (637.81, 1142.44)	35567.38 (26575.58, 47601.54)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	420	0.27 (0.27, 0.28)	28930.91 (22912.52, 36530.15)	105859.64 (83949.30, 133488.47)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	420	0.09 (0.09, 0.09)	21293.85 (17960.45, 25245.92)	236598.33 (199560.57, 280510.17)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	420	5.00 (5.00, 5.00)	9791.89 (8862.62, 10818.59)	1958.38 (1772.52, 2163.72)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	420	5.00 (5.00, 5.00)	1481.62 (1347.39, 1629.23)	296.32 (269.48, 325.85)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	110	0.02 (0.02, 0.03)	3358.53 (2264.87, 4980.30)	136324.00 (92165.92, 201638.89)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	110	0.27 (0.27, 0.27)	73040.18 (51647.13, 103294.58)	268530.08 (189879.14, 379759.50)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	110	0.09 (0.09, 0.09)	57796.58 (43867.82, 76147.94)	639908.49 (485728.89, 843027.62)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	110	5.00 (5.00, 5.00)	30116.79 (25155.99, 36055.86)	6023.36 (5031.20, 7211.17)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	110	5.00 (5.00, 5.00)	4843.03 (4028.40, 5822.39)	968.61 (805.68, 1164.48)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	66	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.97, 1.01)
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	66	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	66	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	66	5.17 (4.90, 5.45)	5.00 (5.00, 5.00)	0.97 (0.92, 1.02)
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	66	5.24 (4.78, 5.73)	5.00 (5.00, 5.00)	0.96 (0.87, 1.05)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	112	0.02 (0.02, 0.02)	547.77 (327.05, 917.44)	22823.59 (13627.02, 38226.71)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	112	0.27 (0.27, 0.27)	12723.66 (8864.28, 18263.34)	46778.15 (32589.28, 67144.63)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	112	0.09 (0.09, 0.09)	6914.16 (5158.96, 9266.54)	76559.20 (57147.15, 102565.22)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	112	5.00 (5.00, 5.00)	3911.62 (3256.22, 4698.94)	782.32 (651.24, 939.79)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	112	5.00 (5.00, 5.00)	783.30 (648.80, 945.68)	156.66 (129.76, 189.14)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	359	0.02 (0.02, 0.02)	70.77 (56.05, 89.37)	2923.24 (2313.80, 3693.21)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	0.27 (0.27, 0.27)	773.49 (621.49, 962.67)	2841.05 (2282.80, 3535.81)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	0.09 (0.09, 0.09)	422.61 (352.48, 506.70)	4695.71 (3916.46, 5630.01)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	359	5.00 (5.00, 5.00)	235.11 (211.32, 261.58)	47.02 (42.26, 52.32)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	359	5.00 (5.00, 5.00)	50.07 (45.40, 55.23)	10.01 (9.08, 11.05)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	107	0.02 (0.02, 0.02)	85.84 (58.74, 125.44)	3576.69 (2447.66, 5226.50)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	107	0.28 (0.27, 0.29)	1255.38 (899.56, 1751.96)	4515.86 (3287.26, 6203.64)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	107	0.09 (0.09, 0.10)	832.71 (610.95, 1134.96)	9041.96 (6673.66, 12250.70)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	107	5.00 (5.00, 5.00)	348.92 (294.71, 413.10)	69.78 (58.94, 82.62)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	107	5.00 (5.00, 5.00)	75.10 (62.84, 89.77)	15.02 (12.57, 17.95)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	62	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	62	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	62	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	62	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	62	5.05 (4.95, 5.16)	5.04 (4.96, 5.13)	1.00 (0.97, 1.03)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	127	0.02 (0.02, 0.02)	23.47 (15.78, 34.91)	977.93 (657.54, 1454.41)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	127	0.27 (0.27, 0.27)	316.63 (227.60, 440.49)	1164.07 (836.75, 1619.43)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	127	0.09 (0.09, 0.09)	171.59 (123.82, 237.80)	1906.59 (1375.77, 2642.23)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	127	5.00 (5.00, 5.00)	101.14 (83.06, 123.15)	20.23 (16.61, 24.63)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	127	5.00 (5.00, 5.00)	24.15 (20.58, 28.34)	4.83 (4.12, 5.67)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	359	0.02 (0.02, 0.02)	925.49 (690.41, 1240.61)	38226.45 (28486.24, 51297.09)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	359	0.27 (0.27, 0.27)	34327.41 (27434.02, 42952.92)	126085.61 (100767.96, 157764.23)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	359	0.09 (0.09, 0.09)	23871.82 (19501.19, 29222.00)	265242.43 (216679.87, 324688.89)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	359	5.00 (5.00, 5.00)	10804.86 (9666.02, 12077.88)	2160.97 (1933.20, 2415.58)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	359	5.00 (5.00, 5.00)	1468.18 (1326.37, 1625.16)	293.64 (265.27, 325.03)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	107	0.02 (0.02, 0.02)	2249.02 (1326.44, 3813.30)	93709.29 (55268.22, 158887.54)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	107	0.28 (0.27, 0.29)	72774.32 (48721.26, 108702.06)	261783.35 (176679.37, 387880.72)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	107	0.09 (0.09, 0.10)	44161.88 (31425.62, 62059.94)	479532.76 (342860.23, 670686.33)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	107	5.00 (5.00, 5.00)	27316.51 (23011.03, 32427.56)	5463.30 (4602.21, 6485.51)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	107	5.00 (5.00, 5.00)	4354.20 (3537.98, 5358.73)	870.84 (707.60, 1071.75)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	62	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	62	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	62	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	62	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	62	5.05 (4.95, 5.16)	5.05 (4.96, 5.14)	1.00 (0.97, 1.03)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	127	0.02 (0.02, 0.02)	250.49 (157.30, 398.86)	10436.90 (6554.37, 16619.26)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	127	0.27 (0.27, 0.27)	11525.87 (8138.57, 16322.99)	42374.53 (29921.20, 60010.98)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	127	0.09 (0.09, 0.09)	6096.79 (4463.25, 8328.19)	67742.06 (49591.70, 92535.40)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	127	5.00 (5.00, 5.00)	3155.01 (2644.10, 3764.64)	631.00 (528.82, 752.93)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	127	5.00 (5.00, 5.00)	732.01 (614.16, 872.46)	146.40 (122.83, 174.49)




Table 6j. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age, Underrepresented minority status								
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	202	0.02 (0.02, 0.02)	49.67 (37.19, 66.33)	2069.57 (1549.76, 2763.73)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	202	0.27 (0.27, 0.28)	527.70 (409.41, 680.17)	1928.30 (1499.25, 2480.15)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	202	0.09 (0.09, 0.09)	323.55 (262.58, 398.67)	3595.00 (2917.61, 4429.66)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	202	5.00 (5.00, 5.00)	205.17 (182.08, 231.19)	41.03 (36.42, 46.24)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	202	5.00 (5.00, 5.00)	44.63 (39.89, 49.93)	8.93 (7.98, 9.99)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	60	0.02 (0.02, 0.03)	148.07 (95.13, 230.48)	5991.64 (3881.83, 9248.15)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	60	0.27 (0.27, 0.27)	1085.62 (699.91, 1683.89)	3991.27 (2573.21, 6190.79)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	60	0.09 (0.09, 0.09)	608.97 (424.50, 873.59)	6766.29 (4716.68, 9706.56)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	60	5.00 (5.00, 5.00)	367.95 (305.38, 443.34)	73.59 (61.08, 88.67)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	60	5.00 (5.00, 5.00)	76.60 (63.42, 92.51)	15.32 (12.68, 18.50)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	30	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.96, 1.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	30	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	30	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	30	5.17 (4.84, 5.53)	5.05 (4.95, 5.15)	0.98 (0.93, 1.02)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	30	5.31 (4.72, 5.98)	5.00 (5.00, 5.00)	0.94 (0.84, 1.06)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	65	0.02 (0.02, 0.02)	19.80 (13.13, 29.87)	825.17 (547.15, 1244.44)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	65	0.27 (0.27, 0.27)	231.94 (154.95, 347.18)	852.73 (569.68, 1276.41)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	65	0.09 (0.09, 0.09)	122.42 (88.21, 169.90)	1360.21 (980.09, 1887.77)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	65	5.00 (5.00, 5.00)	97.27 (81.18, 116.56)	19.45 (16.24, 23.31)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	65	5.00 (5.00, 5.00)	22.27 (17.59, 28.20)	4.45 (3.52, 5.64)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	202	0.02 (0.02, 0.02)	703.91 (488.76, 1013.76)	29329.56 (20365.17, 42239.94)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	202	0.27 (0.27, 0.28)	22699.33 (16955.83, 30388.35)	82946.49 (62067.49, 110849.01)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	202	0.09 (0.09, 0.09)	17344.59 (14041.15, 21425.23)	192717.68 (156012.78, 238058.10)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	202	5.00 (5.00, 5.00)	9504.36 (8419.55, 10728.95)	1900.87 (1683.91, 2145.79)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	202	5.00 (5.00, 5.00)	1445.62 (1285.26, 1625.99)	289.12 (257.05, 325.20)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	60	0.02 (0.02, 0.03)	2983.13 (1857.90, 4789.86)	120709.98 (75411.99, 193217.26)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	60	0.27 (0.27, 0.27)	56076.90 (36777.54, 85503.79)	206165.07 (135211.53, 314352.16)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	60	0.09 (0.09, 0.09)	48389.96 (34492.47, 67886.94)	537666.25 (383249.70, 754299.33)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	60	5.00 (5.00, 5.00)	27755.32 (22312.67, 34525.58)	5551.06 (4462.53, 6905.12)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	60	5.00 (5.00, 5.00)	4756.11 (3797.88, 5956.12)	951.22 (759.58, 1191.22)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	30	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.96, 1.01)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	30	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	30	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	30	5.17 (4.84, 5.53)	5.00 (5.00, 5.00)	0.97 (0.90, 1.03)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	30	5.31 (4.72, 5.98)	5.00 (5.00, 5.00)	0.94 (0.84, 1.06)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	65	0.02 (0.02, 0.02)	462.53 (248.62, 860.48)	19272.12 (10359.27, 35853.36)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	65	0.27 (0.27, 0.27)	9500.81 (6175.91, 14615.71)	34929.43 (22705.55, 53734.22)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	65	0.09 (0.09, 0.09)	4840.29 (3438.86, 6812.85)	53781.00 (38209.51, 75698.33)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	65	5.00 (5.00, 5.00)	3601.45 (2895.47, 4479.57)	720.29 (579.09, 895.91)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	65	5.00 (5.00, 5.00)	731.08 (582.87, 916.97)	146.22 (116.57, 183.39)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	171	0.02 (0.02, 0.02)	55.95 (41.96, 74.61)	2305.76 (1728.21, 3076.31)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	171	0.27 (0.27, 0.27)	612.78 (467.83, 802.62)	2252.85 (1719.98, 2950.81)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	171	0.09 (0.09, 0.09)	332.43 (266.04, 415.38)	3693.62 (2955.98, 4615.33)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	171	5.00 (5.00, 5.00)	217.19 (190.45, 247.69)	43.44 (38.09, 49.54)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	171	5.00 (5.00, 5.00)	48.05 (42.59, 54.21)	9.61 (8.52, 10.84)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	56	0.02 (0.02, 0.02)	60.13 (38.16, 94.77)	2505.57 (1589.80, 3948.85)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	56	0.28 (0.27, 0.29)	984.16 (658.56, 1470.74)	3520.18 (2406.16, 5149.97)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	56	0.09 (0.09, 0.10)	663.42 (456.28, 964.61)	7193.64 (4984.45, 10381.98)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	56	5.00 (5.00, 5.00)	296.17 (242.20, 362.17)	59.23 (48.44, 72.43)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	56	5.00 (5.00, 5.00)	68.60 (55.21, 85.24)	13.72 (11.04, 17.05)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	32	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	32	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	32	5.07 (4.93, 5.22)	5.00 (5.00, 5.00)	0.99 (0.96, 1.01)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.02)	18.41 (11.49, 29.49)	767.09 (478.92, 1228.67)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)	258.27 (174.34, 382.62)	949.53 (640.95, 1406.68)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)	133.01 (89.97, 196.63)	1477.87 (999.71, 2184.73)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	64	5.00 (5.00, 5.00)	91.90 (72.58, 116.37)	18.38 (14.52, 23.27)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	64	5.00 (5.00, 5.00)	22.78 (18.83, 27.54)	4.56 (3.77, 5.51)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	171	0.02 (0.02, 0.02)	717.12 (499.17, 1030.25)	29550.99 (20541.68, 42511.68)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	171	0.27 (0.27, 0.27)	26979.94 (20466.97, 35565.46)	99190.96 (75246.22, 130755.36)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	171	0.09 (0.09, 0.09)	19303.30 (15027.58, 24795.56)	214481.08 (166973.12, 275506.22)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	171	5.00 (5.00, 5.00)	10081.72 (8805.33, 11543.13)	2016.34 (1761.07, 2308.63)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	171	5.00 (5.00, 5.00)	1390.12 (1227.25, 1574.61)	278.02 (245.45, 314.92)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	56	0.02 (0.02, 0.02)	1640.17 (857.37, 3137.69)	68340.45 (35723.74, 130737.05)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	56	0.28 (0.27, 0.29)	53872.53 (32928.51, 88137.91)	192692.50 (119070.08, 311836.54)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	56	0.09 (0.09, 0.10)	35348.28 (23164.17, 53941.10)	383289.46 (252741.15, 581269.85)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	56	5.00 (5.00, 5.00)	24417.31 (19839.35, 30051.64)	4883.46 (3967.87, 6010.33)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	56	5.00 (5.00, 5.00)	4132.14 (3200.69, 5334.67)	826.43 (640.14, 1066.93)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	32	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	32	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	32	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	32	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	32	5.07 (4.93, 5.22)	5.00 (5.00, 5.00)	0.99 (0.96, 1.01)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.02)	188.68 (108.49, 328.13)	7861.61 (4520.57, 13671.93)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)	8590.33 (5712.34, 12918.32)	31582.10 (21001.23, 47493.83)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)	4474.39 (3095.25, 6468.02)	49715.41 (34391.66, 71866.91)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	64	5.00 (5.00, 5.00)	2904.62 (2352.77, 3585.92)	580.92 (470.55, 717.18)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	64	5.00 (5.00, 5.00)	699.22 (565.84, 864.05)	139.84 (113.17, 172.81)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	218	0.02 (0.02, 0.02)	100.21 (78.15, 128.49)	4175.23 (3256.20, 5353.64)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	0.27 (0.27, 0.27)	1500.16 (1219.10, 1846.03)	5515.30 (4481.97, 6786.87)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	0.09 (0.09, 0.09)	896.38 (752.55, 1067.69)	9959.75 (8361.69, 11863.24)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age \geq 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	218	5.00 (5.00, 5.00)	273.96 (243.07, 308.77)	54.79 (48.61, 61.75)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	218	5.00 (5.00, 5.00)	52.92 (47.74, 58.66)	10.58 (9.55, 11.73)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	50	0.02 (0.02, 0.03)	278.52 (169.10, 458.75)	11444.88 (6946.50, 18856.28)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	0.27 (0.27, 0.27)	3291.51 (2147.99, 5043.80)	12101.13 (7897.02, 18543.39)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	0.09 (0.09, 0.09)	1885.63 (1328.32, 2676.76)	20587.14 (14669.26, 28892.41)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	50	5.00 (5.00, 5.00)	618.00 (495.72, 770.44)	123.60 (99.14, 154.09)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	50	5.00 (5.00, 5.00)	95.96 (79.19, 116.28)	19.19 (15.84, 23.26)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	36	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	36	5.17 (4.84, 5.52)	5.00 (5.00, 5.00)	0.97 (0.91, 1.03)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	36	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	47	0.02 (0.02, 0.02)	125.96 (74.24, 213.72)	5248.33 (3093.16, 8905.12)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	47	0.27 (0.27, 0.27)	1353.98 (895.38, 2047.47)	4977.86 (3291.82, 7527.47)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	47	0.09 (0.09, 0.09)	620.10 (430.84, 892.50)	6768.15 (4753.97, 9635.71)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	47	5.00 (5.00, 5.00)	164.09 (127.59, 211.03)	32.82 (25.52, 42.21)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	47	5.00 (5.00, 5.00)	40.29 (32.64, 49.73)	8.06 (6.53, 9.95)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	218	0.02 (0.02, 0.02)	1688.22 (1269.07, 2245.80)	70342.37 (52877.98, 93574.86)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	218	0.27 (0.27, 0.27)	68222.07 (54395.34, 85563.41)	250816.43 (199982.85, 314571.37)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	218	0.09 (0.09, 0.09)	43986.32 (36438.31, 53097.87)	488736.89 (404870.08, 589976.29)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	218	5.00 (5.00, 5.00)	10880.29 (9417.18, 12570.71)	2176.06 (1883.44, 2514.14)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	218	5.00 (5.00, 5.00)	1616.29 (1444.18, 1808.92)	323.26 (288.84, 361.78)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	50	0.02 (0.02, 0.03)	5358.34 (3114.03, 9220.17)	220181.77 (128421.05, 377508.30)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	50	0.27 (0.27, 0.27)	206976.79 (149201.94, 287123.54)	760944.07 (548536.55, 1055601.25)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	50	0.09 (0.09, 0.09)	116399.58 (93420.70, 145030.61)	1270840.05 (1019719.55, 1583802.56)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	50	5.00 (5.00, 5.00)	41550.09 (33605.32, 51373.13)	8310.02 (6721.06, 10274.63)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	50	5.00 (5.00, 5.00)	5201.33 (4241.88, 6377.77)	1040.27 (848.38, 1275.55)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	36	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	36	5.17 (4.84, 5.52)	5.00 (5.00, 5.00)	0.97 (0.91, 1.03)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	36	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	47	0.02 (0.02, 0.02)	1108.29 (597.42, 2056.02)	46178.92 (24892.64, 85667.58)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	47	0.27 (0.27, 0.27)	42969.45 (28034.74, 65860.20)	157975.91 (103068.89, 242133.09)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	47	0.09 (0.09, 0.09)	30550.91 (21148.88, 44132.75)	333451.57 (232062.96, 479137.02)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	47	5.00 (5.00, 5.00)	5518.88 (4280.94, 7114.80)	1103.78 (856.19, 1422.96)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	47	5.00 (5.00, 5.00)	1044.20 (831.98, 1310.54)	208.84 (166.40, 262.11)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	188	0.02 (0.02, 0.02)	170.43 (135.85, 213.81)	7101.16 (5660.42, 8908.61)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	188	0.27 (0.27, 0.28)	1848.52 (1494.71, 2286.07)	6765.92 (5473.32, 8363.78)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	188	0.09 (0.09, 0.09)	1037.28 (871.16, 1235.07)	11525.30 (9679.53, 13723.02)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	188	5.00 (5.00, 5.00)	316.28 (282.70, 353.84)	63.26 (56.54, 70.77)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	188	5.00 (5.00, 5.00)	58.43 (52.42, 65.12)	11.69 (10.48, 13.02)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	51	0.02 (0.02, 0.02)	336.52 (222.95, 507.95)	14021.62 (9289.45, 21164.40)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	51	0.27 (0.27, 0.27)	3195.40 (2152.61, 4743.36)	11747.81 (7914.01, 17438.83)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	51	0.09 (0.09, 0.09)	1992.25 (1397.99, 2839.13)	21750.27 (15403.21, 30712.71)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	51	5.00 (5.00, 5.00)	654.56 (534.20, 802.05)	130.91 (106.84, 160.41)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	51	5.00 (5.00, 5.00)	106.35 (87.08, 129.88)	21.27 (17.42, 25.98)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	30	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	30	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	30	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	30	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	30	5.00 (5.00, 5.00)	5.18 (4.84, 5.53)	1.04 (0.97, 1.11)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	63	0.02 (0.02, 0.02)	69.22 (43.28, 110.72)	2884.23 (1803.27, 4613.18)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	63	0.27 (0.27, 0.27)	784.51 (544.71, 1129.89)	2884.23 (2002.60, 4154.01)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	63	0.09 (0.09, 0.09)	533.61 (412.78, 689.81)	5928.99 (4586.46, 7664.51)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	63	5.00 (5.00, 5.00)	154.97 (127.43, 188.47)	30.99 (25.49, 37.69)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	63	5.00 (5.00, 5.00)	31.37 (25.59, 38.45)	6.27 (5.12, 7.69)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	188	0.02 (0.02, 0.02)	2402.91 (1815.63, 3180.15)	100121.27 (75651.24, 132506.33)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	188	0.27 (0.27, 0.28)	84508.84 (67880.09, 105211.17)	309318.27 (248509.18, 385007.09)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	188	0.09 (0.09, 0.09)	52840.35 (44230.13, 63126.71)	587115.04 (491445.93, 701407.92)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	188	5.00 (5.00, 5.00)	14000.79 (12068.14, 16242.96)	2800.16 (2413.63, 3248.59)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	188	5.00 (5.00, 5.00)	1801.06 (1600.12, 2027.24)	360.21 (320.02, 405.45)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	51	0.02 (0.02, 0.02)	7555.31 (4785.85, 11927.38)	314804.62 (199410.62, 496974.28)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	51	0.27 (0.27, 0.27)	230839.41 (173912.58, 306400.11)	848674.30 (639384.48, 1126470.98)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	51	0.09 (0.09, 0.09)	103785.84 (86236.46, 124906.57)	1133074.13 (941934.56, 1363000.18)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	51	5.00 (5.00, 5.00)	42020.27 (34485.98, 51200.60)	8404.05 (6897.20, 10240.12)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	51	5.00 (5.00, 5.00)	5323.15 (4305.26, 6581.69)	1064.63 (861.05, 1316.34)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	30	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	30	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	30	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	30	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	30	5.00 (5.00, 5.00)	5.18 (4.83, 5.56)	1.04 (0.97, 1.11)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age \geq 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	63	0.02 (0.02, 0.02)	884.92 (523.48, 1495.94)	36871.82 (21811.57, 62330.72)
Age \geq 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	63	0.27 (0.27, 0.27)	42687.87 (27119.91, 67192.49)	156940.70 (99705.54, 247031.23)
Age \geq 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	63	0.09 (0.09, 0.09)	24187.43 (17726.62, 33003.01)	268749.18 (196962.39, 366700.06)
Age \geq 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	63	5.00 (5.00, 5.00)	4559.82 (3733.36, 5569.23)	911.96 (746.67, 1113.85)
Age \geq 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	63	5.00 (5.00, 5.00)	897.72 (765.46, 1052.85)	179.54 (153.09, 210.57)

Table 7a. The ratios of GMTs/GMCs between groups by Age

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age							
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.98, 1.01)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (0.99, 1.01)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (0.98, 1.01)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.28 (0.27, 0.28)	0.99 (0.97, 1.01)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (0.97, 1.03)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (0.99, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.06 (4.95, 5.17)	5.06 (4.95, 5.17)	1.00 (0.97, 1.03)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.13 (4.93, 5.34)	0.97 (0.94, 1.01)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 vs Age < 65	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.01 (0.99, 1.02)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	142.97 (122.29, 167.15)	50.34 (41.46, 61.11)	2.84 (2.21, 3.64)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	1697.17 (1476.47, 1950.87)	550.94 (463.04, 655.53)	3.08 (2.47, 3.85)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	1033.49 (921.14, 1159.53)	321.20 (276.30, 373.39)	3.22 (2.66, 3.89)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	302.19 (279.71, 326.47)	207.85 (190.33, 226.99)	1.45 (1.29, 1.63)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	57.69 (53.68, 61.99)	44.22 (40.61, 48.14)	1.30 (1.17, 1.46)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	305.43 (229.49, 406.50)	79.94 (58.66, 108.95)	3.82 (2.51, 5.82)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	3476.30 (2675.49, 4516.80)	999.08 (758.84, 1315.39)	3.48 (2.38, 5.09)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	1996.92 (1588.01, 2511.12)	610.04 (478.76, 777.31)	3.27 (2.35, 4.57)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	629.50 (550.72, 719.56)	309.64 (271.19, 353.54)	2.03 (1.68, 2.45)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	99.38 (87.21, 113.25)	71.33 (62.71, 81.14)	1.39 (1.16, 1.67)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 vs Age < 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.02 (4.98, 5.05)	1.00 (0.99, 1.00)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.16 (4.94, 5.38)	5.00 (5.00, 5.00)	1.03 (0.99, 1.08)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	92.71 (67.40, 127.53)	21.99 (15.74, 30.72)	4.22 (2.66, 6.69)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	1037.48 (810.01, 1328.81)	287.32 (213.80, 386.13)	3.61 (2.46, 5.31)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	620.20 (506.97, 758.71)	139.33 (107.34, 180.85)	4.45 (3.20, 6.19)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	162.38 (141.07, 186.91)	99.72 (85.10, 116.85)	1.63 (1.32, 2.01)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	34.70 (30.29, 39.75)	23.32 (20.23, 26.87)	1.49 (1.22, 1.81)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	2146.59 (1771.78, 2600.69)	670.07 (526.00, 853.60)	3.20 (2.35, 4.36)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	82110.63 (71014.15, 94941.01)	24070.27 (19874.19, 29152.28)	3.41 (2.68, 4.34)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	50657.32 (44864.13, 57198.57)	16814.24 (14267.46, 19815.61)	3.01 (2.46, 3.70)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	12822.88 (11646.56, 14118.02)	9490.17 (8656.06, 10404.66)	1.35 (1.18, 1.54)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	1741.16 (1611.24, 1881.54)	1397.30 (1279.13, 1526.39)	1.25 (1.11, 1.40)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	7399.38 (5407.50, 10124.98)	1663.57 (1123.53, 2463.21)	4.45 (2.69, 7.35)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	213304.93 (174553.45, 260659.38)	57082.50 (42972.14, 75826.14)	3.74 (2.64, 5.29)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	109149.12 (96376.34, 123614.67)	42890.13 (33529.63, 54863.81)	2.54 (1.93, 3.35)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	42208.09 (36925.09, 48246.95)	24881.39 (21477.94, 28824.16)	1.70 (1.39, 2.07)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	5255.28 (4583.13, 6026.00)	4228.18 (3638.81, 4913.01)	1.24 (1.01, 1.52)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.09 (4.92, 5.26)	5.00 (5.00, 5.00)	1.02 (0.98, 1.05)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	1073.37 (733.41, 1570.91)	289.22 (193.94, 431.30)	3.71 (2.14, 6.45)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	46456.10 (34649.89, 62285.03)	9706.29 (7200.73, 13083.69)	4.79 (3.15, 7.27)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	27335.34 (22100.74, 33809.76)	5041.42 (3870.53, 6566.51)	5.42 (3.86, 7.61)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	5151.11 (4476.77, 5927.03)	3221.65 (2778.88, 3734.97)	1.60 (1.30, 1.96)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	952.05 (844.89, 1072.80)	728.07 (628.05, 844.02)	1.31 (1.08, 1.58)

Table 7b. The ratios of GMTs/GMCs between groups by Risk for Severe Covid-19

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Risk for Severe Covid-19							
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.98, 1.01)
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (0.99, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.97, 1.01)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.28 (0.27, 0.28)	0.99 (0.96, 1.01)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	0.98 (0.96, 1.01)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.01 (0.99, 1.03)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.18 (4.90, 5.49)	5.00 (5.00, 5.00)	1.04 (0.98, 1.10)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.08 (4.92, 5.25)	5.11 (4.90, 5.33)	0.99 (0.94, 1.05)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
At-risk vs Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.01)
At-risk vs Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	77.19 (63.87, 93.30)	58.20 (47.48, 71.34)	1.33 (1.00, 1.75)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	789.30 (668.92, 931.35)	669.28 (557.20, 803.92)	1.18 (0.92, 1.51)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	491.89 (424.55, 569.92)	385.41 (329.00, 451.48)	1.28 (1.03, 1.59)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	235.72 (214.95, 258.50)	221.23 (201.80, 242.53)	1.07 (0.94, 1.21)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	45.83 (42.33, 49.62)	47.16 (43.11, 51.59)	0.97 (0.86, 1.10)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	102.78 (69.98, 150.97)	103.67 (75.22, 142.90)	0.99 (0.60, 1.64)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	1259.80 (895.65, 1771.99)	1273.21 (956.64, 1694.55)	0.99 (0.63, 1.55)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	765.93 (596.13, 984.11)	766.38 (591.79, 992.49)	1.00 (0.70, 1.44)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	361.93 (307.30, 426.28)	352.51 (306.78, 405.06)	1.03 (0.83, 1.27)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	73.56 (62.44, 86.67)	76.90 (67.33, 87.82)	0.96 (0.77, 1.18)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
At-risk vs Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.04 (4.96, 5.12)	5.00 (5.00, 5.00)	1.01 (0.99, 1.02)
At-risk vs Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.12 (4.96, 5.29)	5.00 (5.00, 5.00)	1.02 (0.99, 1.06)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	37.13 (27.28, 50.54)	26.82 (18.76, 38.36)	1.38 (0.86, 2.22)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	424.65 (331.07, 544.67)	352.08 (256.56, 483.16)	1.21 (0.81, 1.81)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	244.01 (195.94, 303.87)	170.28 (128.67, 225.34)	1.43 (1.00, 2.05)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	111.25 (96.73, 127.96)	109.14 (92.18, 129.23)	1.02 (0.82, 1.27)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	27.62 (24.40, 31.27)	24.43 (20.99, 28.43)	1.13 (0.93, 1.38)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	945.85 (763.79, 1171.29)	828.01 (640.59, 1070.26)	1.14 (0.82, 1.60)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	34720.06 (28933.29, 41664.21)	30051.32 (24568.10, 36758.30)	1.16 (0.88, 1.52)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	21888.00 (18578.88, 25786.52)	21038.85 (17721.65, 24976.97)	1.04 (0.82, 1.32)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	9196.69 (8308.44, 10179.89)	10489.39 (9525.84, 11550.39)	0.88 (0.76, 1.01)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	1390.11 (1276.66, 1513.64)	1493.34 (1360.60, 1639.02)	0.93 (0.82, 1.06)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	2297.78 (1510.26, 3495.95)	2189.27 (1449.90, 3305.67)	1.05 (0.58, 1.89)
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	85028.77 (62305.26, 116039.82)	69976.84 (52002.56, 94163.80)	1.22 (0.79, 1.87)
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	40668.98 (31140.77, 53112.55)	55600.01 (43091.39, 71739.64)	0.73 (0.50, 1.06)
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	28755.58 (24251.77, 34095.79)	27138.15 (23277.88, 31638.58)	1.06 (0.84, 1.33)
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	4090.48 (3547.49, 4716.60)	4523.62 (3856.72, 5305.85)	0.90 (0.73, 1.12)
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.03 (4.97, 5.09)	0.99 (0.98, 1.01)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	486.41 (324.43, 729.28)	341.72 (224.08, 521.11)	1.42 (0.79, 2.56)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	19654.96 (14854.37, 26007.01)	11510.67 (8354.80, 15858.60)	1.71 (1.11, 2.62)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	8847.05 (6916.88, 11315.83)	6482.33 (4883.38, 8604.81)	1.36 (0.94, 1.99)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	4062.41 (3499.24, 4716.23)	3367.31 (2880.87, 3935.88)	1.21 (0.97, 1.50)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	820.34 (722.23, 931.77)	750.04 (641.36, 877.15)	1.09 (0.89, 1.34)

Table 7c. The ratios of GMTs/GMCs between groups by Age < 65, Risk for Severe Covid-19

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65, Risk for Severe Covid-19							
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.98, 1.01)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (0.99, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.97, 1.01)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.28 (0.27, 0.28)	0.98 (0.96, 1.01)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	0.99 (0.96, 1.01)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	1.02 (0.98, 1.06)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.24 (4.78, 5.74)	5.00 (5.00, 5.00)	1.05 (0.96, 1.15)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.14 (4.87, 5.42)	5.13 (4.88, 5.39)	1.00 (0.93, 1.08)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	54.07 (40.95, 71.40)	49.40 (39.10, 62.40)	1.09 (0.76, 1.57)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	503.60 (397.09, 638.67)	564.12 (457.06, 696.27)	0.89 (0.65, 1.23)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	332.00 (268.07, 411.17)	318.42 (265.52, 381.85)	1.04 (0.79, 1.38)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	212.49 (186.23, 242.45)	206.65 (185.92, 229.69)	1.03 (0.87, 1.22)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	41.10 (36.64, 46.11)	45.07 (40.66, 49.97)	0.91 (0.78, 1.06)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	67.42 (40.49, 112.26)	83.86 (57.94, 121.39)	0.80 (0.43, 1.51)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	817.14 (525.77, 1269.97)	1057.18 (760.21, 1470.16)	0.77 (0.45, 1.34)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	535.85 (390.80, 734.74)	632.69 (469.91, 851.86)	0.85 (0.55, 1.31)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	287.26 (233.02, 354.12)	316.24 (269.66, 370.86)	0.91 (0.70, 1.18)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	65.43 (52.75, 81.15)	73.09 (62.68, 85.22)	0.90 (0.69, 1.17)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.07 (4.93, 5.21)	5.00 (5.00, 5.00)	1.01 (0.99, 1.04)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	26.22 (17.94, 38.32)	20.99 (13.93, 31.65)	1.25 (0.71, 2.18)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	315.62 (233.23, 427.13)	280.30 (194.63, 403.69)	1.13 (0.70, 1.81)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	159.73 (122.51, 208.25)	134.41 (97.41, 185.46)	1.19 (0.78, 1.80)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	96.69 (80.78, 115.72)	100.53 (82.75, 122.13)	0.96 (0.74, 1.25)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	25.25 (21.55, 29.59)	22.83 (19.18, 27.18)	1.11 (0.87, 1.40)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	628.93 (463.68, 853.08)	681.33 (507.23, 915.18)	0.92 (0.60, 1.41)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	22762.87 (17544.34, 29533.64)	24426.63 (19367.89, 30806.69)	0.93 (0.66, 1.32)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	15450.04 (12172.41, 19610.21)	17192.84 (14108.05, 20952.13)	0.90 (0.66, 1.22)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	8428.13 (7385.70, 9617.68)	9791.25 (8763.61, 10939.39)	0.86 (0.72, 1.02)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	1285.60 (1142.45, 1446.69)	1428.27 (1283.08, 1589.89)	0.90 (0.77, 1.06)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	1486.58 (855.25, 2583.97)	1717.03 (1064.38, 2769.88)	0.87 (0.42, 1.80)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	56974.72 (37716.89, 86065.40)	57112.84 (40456.58, 80626.59)	1.00 (0.58, 1.71)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	27693.95 (19363.41, 39608.45)	48503.57 (35987.59, 65372.42)	0.57 (0.36, 0.91)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	25397.99 (20296.59, 31781.59)	24738.04 (20712.74, 29545.62)	1.03 (0.77, 1.37)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	3733.57 (3118.28, 4470.27)	4378.70 (3637.43, 5271.02)	0.85 (0.66, 1.10)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	338.79 (197.52, 581.09)	277.43 (170.92, 450.31)	1.22 (0.59, 2.52)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	12141.73 (8663.79, 17015.83)	9150.84 (6343.15, 13201.30)	1.33 (0.81, 2.18)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	5816.74 (4249.24, 7962.47)	4855.12 (3513.49, 6709.03)	1.20 (0.76, 1.88)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	3737.70 (3080.39, 4535.26)	3098.09 (2588.80, 3707.57)	1.21 (0.93, 1.57)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	759.28 (641.98, 898.01)	720.07 (600.63, 863.27)	1.05 (0.82, 1.35)

MOCK

Table 7d. The ratios of GMTs/GMCs between groups by Age ≥ 65 , Risk for Severe Covid-19

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65, Risk for Severe Covid-19							
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.28)	0.27 (0.27, 0.27)	1.00 (1.00, 1.01)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.98, 1.01)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.10)	0.98 (0.95, 1.01)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.11 (4.90, 5.32)	5.00 (5.00, 5.00)	1.02 (0.98, 1.06)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.01 (0.99, 1.04)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	131.44 (105.77, 163.33)	156.30 (124.69, 195.94)	0.84 (0.61, 1.15)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	1545.48 (1268.71, 1882.61)	1874.30 (1540.73, 2280.09)	0.82 (0.62, 1.09)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	885.47 (747.60, 1048.77)	1217.52 (1045.45, 1417.92)	0.73 (0.58, 0.91)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	275.29 (244.82, 309.56)	333.58 (302.43, 367.93)	0.83 (0.71, 0.96)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	53.93 (48.92, 59.45)	61.96 (55.76, 68.86)	0.87 (0.75, 1.00)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	266.81 (177.47, 401.13)	335.19 (226.79, 495.41)	0.80 (0.45, 1.40)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	3354.69 (2235.79, 5033.53)	3562.49 (2532.00, 5012.37)	0.94 (0.55, 1.60)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	1718.71 (1241.63, 2379.11)	2213.98 (1618.00, 3029.47)	0.78 (0.49, 1.22)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	610.47 (501.61, 742.97)	642.93 (536.91, 769.89)	0.95 (0.73, 1.24)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	95.89 (77.90, 118.03)	101.86 (86.13, 120.46)	0.94 (0.72, 1.23)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.30 (4.90, 5.74)	5.00 (5.00, 5.00)	1.06 (0.98, 1.15)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	73.96 (45.08, 121.37)	110.24 (72.93, 166.64)	0.67 (0.35, 1.28)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	764.29 (508.32, 1149.16)	1311.30 (975.26, 1763.13)	0.58 (0.35, 0.97)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	564.82 (411.46, 775.35)	666.29 (514.14, 863.47)	0.85 (0.56, 1.28)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	146.90 (119.82, 180.10)	175.33 (144.79, 212.33)	0.84 (0.63, 1.11)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	33.00 (27.31, 39.89)	36.06 (29.78, 43.67)	0.92 (0.70, 1.20)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	1741.05 (1331.24, 2277.00)	2680.19 (2040.81, 3519.89)	0.65 (0.44, 0.95)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	65274.79 (52121.10, 81748.04)	104726.56 (87880.85, 124801.38)	0.62 (0.47, 0.83)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	36847.42 (30394.53, 44670.29)	70991.30 (62313.78, 80877.21)	0.52 (0.41, 0.65)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	10478.59 (8946.35, 12273.26)	15883.67 (14375.29, 17550.33)	0.66 (0.55, 0.80)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	1562.43 (1389.38, 1757.04)	1953.02 (1770.10, 2154.84)	0.80 (0.69, 0.93)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	6154.26 (3806.20, 9950.87)	8399.02 (5561.59, 12684.06)	0.73 (0.39, 1.38)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	210361.50 (154533.61, 286358.15)	215353.16 (165458.59, 280293.59)	0.98 (0.65, 1.47)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	97009.56 (78402.66, 120032.33)	118368.75 (102113.55, 137211.58)	0.82 (0.63, 1.06)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	38081.92 (30737.43, 47181.34)	45302.51 (38314.50, 53565.04)	0.84 (0.64, 1.10)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	5028.99 (4054.58, 6237.58)	5416.78 (4538.51, 6465.02)	0.93 (0.70, 1.23)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.18 (4.83, 5.56)	0.96 (0.90, 1.03)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	995.72 (587.77, 1686.79)	1136.96 (664.28, 1945.99)	0.88 (0.41, 1.86)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	51030.23 (33245.99, 78327.78)	43229.76 (28989.15, 64465.93)	1.18 (0.66, 2.12)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	20301.57 (14770.16, 27904.48)	34335.80 (26089.81, 45188.05)	0.59 (0.39, 0.90)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	4791.24 (3838.80, 5979.99)	5445.13 (4550.33, 6515.89)	0.88 (0.66, 1.17)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	956.14 (799.60, 1143.33)	948.92 (808.13, 1114.24)	1.01 (0.79, 1.28)

MOCK

Table 7e. The ratios of GMTs/GMCs between groups by Sex

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Sex							
Male vs Female	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.98, 1.01)
Male vs Female	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.28)	0.27 (0.27, 0.27)	1.01 (1.00, 1.01)
Male vs Female	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	1.02 (0.98, 1.05)
Male vs Female	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.28 (0.27, 0.29)	0.98 (0.95, 1.02)
Male vs Female	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	0.99 (0.96, 1.02)
Male vs Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.98, 1.01)
Male vs Female	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.09 (4.95, 5.23)	0.98 (0.96, 1.01)
Male vs Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.21 (4.81, 5.64)	5.04 (4.96, 5.12)	1.03 (0.95, 1.12)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Male vs Female	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.01)
Male vs Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Male vs Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	63.73 (48.94, 83.00)	62.33 (51.30, 75.73)	1.02 (0.74, 1.42)
Male vs Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	686.74 (538.39, 875.98)	708.96 (597.35, 841.42)	0.97 (0.72, 1.31)
Male vs Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	424.11 (345.09, 521.23)	404.40 (347.20, 471.03)	1.05 (0.81, 1.36)
Male vs Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	232.36 (207.20, 260.57)	220.56 (201.24, 241.73)	1.05 (0.91, 1.22)
Male vs Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	46.32 (41.50, 51.70)	47.10 (43.13, 51.43)	0.98 (0.85, 1.13)
Male vs Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	128.96 (81.98, 202.86)	89.72 (65.17, 123.51)	1.44 (0.82, 2.52)
Male vs Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	1679.06 (1146.41, 2459.20)	1060.09 (795.02, 1413.53)	1.58 (0.98, 2.56)
Male vs Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	890.79 (627.61, 1264.34)	695.25 (542.26, 891.39)	1.28 (0.83, 1.97)
Male vs Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	392.07 (325.19, 472.71)	332.78 (288.74, 383.54)	1.18 (0.93, 1.49)
Male vs Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	73.92 (63.98, 85.41)	77.42 (66.65, 89.93)	0.95 (0.78, 1.18)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Male vs Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Male vs Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Male vs Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Male vs Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.02 (4.98, 5.06)	1.00 (0.99, 1.00)
Male vs Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.06 (4.98, 5.14)	0.99 (0.97, 1.00)
Male vs Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	29.73 (18.99, 46.54)	28.69 (20.03, 41.10)	1.04 (0.58, 1.85)
Male vs Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	375.73 (244.88, 576.49)	364.55 (272.15, 488.32)	1.03 (0.61, 1.74)
Male vs Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	186.79 (132.30, 263.73)	186.23 (140.19, 247.39)	1.00 (0.64, 1.58)
Male vs Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	108.95 (87.10, 136.29)	110.18 (94.06, 129.07)	0.99 (0.75, 1.30)
Male vs Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	24.29 (20.06, 29.42)	25.86 (22.29, 30.00)	0.94 (0.74, 1.20)
Male vs Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	860.98 (647.12, 1145.53)	857.25 (658.34, 1116.26)	1.00 (0.68, 1.48)
Male vs Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	32724.44 (25648.10, 41753.15)	30356.48 (24829.23, 37114.15)	1.08 (0.78, 1.48)
Male vs Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	22736.75 (18515.45, 27920.45)	20373.35 (17108.20, 24261.67)	1.12 (0.85, 1.46)
Male vs Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	10067.09 (8894.08, 11394.80)	10151.98 (9238.25, 11156.09)	0.99 (0.85, 1.16)
Male vs Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	1448.63 (1278.89, 1640.90)	1474.56 (1353.14, 1606.88)	0.98 (0.84, 1.14)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Male vs Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	2852.89 (1608.45, 5060.14)	1883.05 (1269.61, 2792.88)	1.52 (0.75, 3.06)
Male vs Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	79526.50 (57294.11, 110385.94)	69930.48 (50459.38, 96915.01)	1.14 (0.71, 1.81)
Male vs Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	51096.13 (36091.24, 72339.28)	51479.11 (40279.83, 65792.22)	0.99 (0.65, 1.52)
Male vs Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	29355.83 (24695.73, 34895.28)	26431.53 (22340.26, 31272.05)	1.11 (0.87, 1.42)
Male vs Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	4573.39 (3833.83, 5455.62)	4305.52 (3631.22, 5105.02)	1.06 (0.83, 1.36)
Male vs Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Male vs Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Male vs Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Male vs Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Male vs Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.06 (4.95, 5.17)	5.00 (5.00, 5.00)	1.01 (0.99, 1.03)
Male vs Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	486.99 (283.09, 837.75)	309.85 (204.43, 469.64)	1.57 (0.79, 3.13)
Male vs Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	12582.62 (8551.77, 18513.39)	13609.31 (9748.76, 18998.66)	0.92 (0.55, 1.55)
Male vs Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	7272.61 (5061.17, 10450.32)	6833.23 (5149.68, 9067.18)	1.06 (0.67, 1.70)
Male vs Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	3292.67 (2674.97, 4053.01)	3708.74 (3194.21, 4306.14)	0.89 (0.69, 1.15)
Male vs Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	778.67 (645.62, 939.14)	759.20 (647.30, 890.45)	1.03 (0.80, 1.31)

Table 7f. The ratios of GMTs/GMCs between groups by Hispanic or Latino ethnicity

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino ethnicity							
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.98, 1.01)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.28 (0.27, 0.28)	0.27 (0.27, 0.27)	1.01 (0.99, 1.04)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.28 (0.27, 0.28)	0.99 (0.96, 1.01)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (0.97, 1.03)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.02 (4.98, 5.05)	1.00 (0.99, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.12 (4.93, 5.32)	0.98 (0.94, 1.01)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	60.33 (36.37, 100.10)	65.21 (54.65, 77.82)	0.93 (0.54, 1.58)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	649.64 (426.15, 990.35)	718.94 (613.76, 842.15)	0.90 (0.58, 1.42)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	429.89 (300.02, 615.99)	406.18 (355.64, 463.90)	1.06 (0.72, 1.55)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	218.54 (178.87, 267.01)	226.42 (208.69, 245.65)	0.97 (0.78, 1.20)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	47.19 (40.03, 55.63)	46.77 (43.20, 50.64)	1.01 (0.84, 1.21)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	156.84 (97.66, 251.86)	100.08 (73.54, 136.20)	1.57 (0.89, 2.75)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	1802.92 (997.30, 3259.31)	1196.84 (936.10, 1530.21)	1.51 (0.79, 2.86)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	860.11 (483.13, 1531.23)	734.74 (583.20, 925.66)	1.17 (0.63, 2.18)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	422.79 (343.71, 520.07)	351.93 (308.42, 401.59)	1.20 (0.94, 1.54)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	99.26 (72.44, 136.00)	73.00 (64.52, 82.59)	1.36 (0.97, 1.91)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.02 (4.98, 5.07)	1.00 (0.99, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	27.27 (11.85, 62.73)	26.83 (19.52, 36.90)	1.02 (0.42, 2.49)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	287.56 (144.28, 573.16)	347.35 (264.93, 455.41)	0.83 (0.39, 1.75)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	153.40 (83.92, 280.40)	180.77 (141.23, 231.39)	0.85 (0.44, 1.63)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	95.90 (70.22, 130.96)	107.35 (92.28, 124.88)	0.89 (0.63, 1.26)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	19.66 (12.45, 31.04)	25.54 (22.37, 29.16)	0.77 (0.48, 1.24)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	879.44 (524.28, 1475.18)	848.00 (678.26, 1060.22)	1.04 (0.59, 1.82)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	33410.70 (21948.17, 50859.60)	30702.10 (25812.13, 36518.45)	1.09 (0.69, 1.72)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	22661.15 (16064.43, 31966.75)	21967.61 (18906.24, 25524.68)	1.03 (0.71, 1.50)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	9829.86 (8024.03, 12042.10)	10230.06 (9395.39, 11138.88)	0.96 (0.77, 1.20)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	1555.12 (1293.23, 1870.04)	1434.87 (1323.77, 1555.30)	1.08 (0.89, 1.33)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	4237.38 (2216.18, 8101.97)	2136.00 (1467.76, 3108.47)	1.98 (0.94, 4.20)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	74710.38 (43552.70, 128158.30)	71208.98 (53904.99, 94067.70)	1.05 (0.57, 1.93)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	63564.70 (40153.56, 100625.47)	49850.34 (39401.72, 63069.74)	1.28 (0.76, 2.14)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	31045.07 (22915.33, 42059.02)	26571.74 (22955.30, 30757.94)	1.17 (0.83, 1.64)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	5552.76 (4103.33, 7514.16)	4334.34 (3733.53, 5031.84)	1.28 (0.91, 1.80)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.03 (4.98, 5.07)	1.00 (0.99, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	385.13 (160.23, 925.71)	351.33 (239.85, 514.62)	1.10 (0.42, 2.85)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	9826.60 (4321.51, 22344.55)	13001.44 (9786.27, 17272.92)	0.76 (0.32, 1.81)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	5657.91 (2980.05, 10742.12)	6907.85 (5381.50, 8867.11)	0.82 (0.41, 1.64)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	4437.92 (2841.54, 6931.14)	3445.73 (3009.83, 3944.76)	1.29 (0.81, 2.05)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	679.28 (482.63, 956.05)	765.56 (665.91, 880.11)	0.89 (0.61, 1.28)

MOCK

Table 7g. The ratios of GMTs/GMCs between groups by Underrepresented minority status

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Underrepresented minority status							
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.99 (0.97, 1.01)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.28)	0.27 (0.27, 0.27)	1.00 (0.99, 1.01)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	1.03 (0.98, 1.07)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.28 (0.27, 0.29)	0.98 (0.94, 1.02)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.10)	0.98 (0.94, 1.02)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.01 (0.99, 1.03)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.17 (4.90, 5.45)	5.00 (5.00, 5.00)	1.03 (0.98, 1.09)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.24 (4.78, 5.73)	5.05 (4.95, 5.16)	1.04 (0.94, 1.14)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.01)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	57.98 (45.97, 73.14)	70.77 (56.05, 89.37)	0.82 (0.59, 1.14)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	664.37 (542.05, 814.30)	773.49 (621.49, 962.67)	0.86 (0.64, 1.16)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	405.04 (342.49, 479.00)	422.61 (352.48, 506.70)	0.96 (0.75, 1.23)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	218.67 (198.49, 240.90)	235.11 (211.32, 261.58)	0.93 (0.81, 1.07)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	46.34 (42.33, 50.73)	50.07 (45.40, 55.23)	0.93 (0.81, 1.06)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	168.27 (116.47, 243.10)	85.84 (58.74, 125.44)	1.96 (1.16, 3.33)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	1358.84 (945.07, 1953.77)	1255.38 (899.56, 1751.96)	1.08 (0.66, 1.77)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	765.48 (567.32, 1032.87)	832.71 (610.95, 1134.96)	0.92 (0.60, 1.41)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	408.66 (349.47, 477.89)	348.92 (294.71, 413.10)	1.17 (0.93, 1.47)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	80.17 (68.61, 93.68)	75.10 (62.84, 89.77)	1.07 (0.84, 1.35)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.04 (4.96, 5.12)	5.00 (5.00, 5.00)	1.01 (0.99, 1.02)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.04 (4.96, 5.13)	0.99 (0.97, 1.01)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	28.33 (19.89, 40.35)	23.47 (15.78, 34.91)	1.21 (0.71, 2.05)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	326.35 (231.97, 459.13)	316.63 (227.60, 440.49)	1.03 (0.64, 1.66)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	167.58 (126.64, 221.76)	171.59 (123.82, 237.80)	0.98 (0.64, 1.50)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	107.63 (92.18, 125.68)	101.14 (83.06, 123.15)	1.06 (0.83, 1.37)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	24.98 (20.54, 30.39)	24.15 (20.58, 28.34)	1.03 (0.80, 1.33)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	853.62 (637.81, 1142.44)	925.49 (690.41, 1240.61)	0.92 (0.61, 1.39)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	28930.91 (22912.52, 36530.15)	34327.41 (27434.02, 42952.92)	0.84 (0.61, 1.16)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	21293.85 (17960.45, 25245.92)	23871.82 (19501.19, 29222.00)	0.89 (0.68, 1.16)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	9791.89 (8862.62, 10818.59)	10804.86 (9666.02, 12077.88)	0.91 (0.78, 1.05)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	1481.62 (1347.39, 1629.23)	1468.18 (1326.37, 1625.16)	1.01 (0.88, 1.16)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	3358.53 (2264.87, 4980.30)	2249.02 (1326.44, 3813.30)	1.49 (0.77, 2.89)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	73040.18 (51647.13, 103294.58)	72774.32 (48721.26, 108702.06)	1.00 (0.59, 1.71)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	57796.58 (43867.82, 76147.94)	44161.88 (31425.62, 62059.94)	1.31 (0.84, 2.03)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	30116.79 (25155.99, 36055.86)	27316.51 (23011.03, 32427.56)	1.10 (0.86, 1.41)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	4843.03 (4028.40, 5822.39)	4354.20 (3537.98, 5358.73)	1.11 (0.84, 1.47)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.05 (4.96, 5.14)	0.99 (0.97, 1.01)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	547.77 (327.05, 917.44)	250.49 (157.30, 398.86)	2.19 (1.09, 4.38)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	12723.66 (8864.28, 18263.34)	11525.87 (8138.57, 16322.99)	1.10 (0.67, 1.82)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	6914.16 (5158.96, 9266.54)	6096.79 (4463.25, 8328.19)	1.13 (0.74, 1.74)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	3911.62 (3256.22, 4698.94)	3155.01 (2644.10, 3764.64)	1.24 (0.96, 1.60)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	783.30 (648.80, 945.68)	732.01 (614.16, 872.46)	1.07 (0.83, 1.38)

MOCK

Table 8a. Differences in the responder rates, 2FRs, 4FRs between the groups by Arm

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Arm							
Vaccine vs Placebo	Negative	-	Day 29	Anti N IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Vaccine vs Placebo	Negative	-	Day 29	Anti RBD IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Vaccine vs Placebo	Negative	-	Day 29	Anti Spike IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Vaccine vs Placebo	Negative	-	Day 29	Pseudovirus-nAb ID50	99.7% (99.1%, 99.9%)	100% (100%, 100%)	100% (100%, 100%)
Vaccine vs Placebo	Negative	-	Day 29	Pseudovirus-nAb ID80	87.1% (83.8%, 89.8%)	97.4% (94.5%, 98.5%)	97.4% (94.5%, 98.5%)
Vaccine vs Placebo	Positive	-	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 29	Pseudovirus-nAb ID50	1.4% (0.3%, 7.1%)	0.2% (0%, 1.7%)	0.2% (0%, 1.7%)
Vaccine vs Placebo	Positive	-	Day 29	Pseudovirus-nAb ID80	35.8% (27.3%, 44.2%)	7.7% (4.4%, 13.3%)	7.7% (4.4%, 13.3%)
Vaccine vs Placebo	Negative	-	Day 57	Anti N IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Vaccine vs Placebo	Negative	-	Day 57	Anti RBD IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Vaccine vs Placebo	Negative	-	Day 57	Anti Spike IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Vaccine vs Placebo	Negative	-	Day 57	Pseudovirus-nAb ID50	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Vaccine vs Placebo	Negative	-	Day 57	Pseudovirus-nAb ID80	100% (100%, 100%)	99.6% (97.3%, 99.9%)	99.6% (97.3%, 99.9%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Vaccine vs Placebo	Positive	-	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8b. Differences in the responder rates, 2FRs, 4FRs between the groups by Baseline SARS-CoV-2

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Baseline SARS-CoV-2							
Positive vs Negative	-	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 29	Anti N IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Positive vs Negative	-	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 29	Anti RBD IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Positive vs Negative	-	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 29	Anti Spike IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Positive vs Negative	-	Vaccine	Day 29	Pseudovirus-nAb ID50	0.3% (0.1%, 0.9%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 29	Pseudovirus-nAb ID50	98.6% (92.9%, 99.7%)	99.8% (98.3%, 100%)	99.8% (98.3%, 100%)
Positive vs Negative	-	Vaccine	Day 29	Pseudovirus-nAb ID80	10.2% (5.8%, 13.8%)	1.9% (0.9%, 3.7%)	1.9% (0.9%, 3.7%)
Positive vs Negative	-	Placebo	Day 29	Pseudovirus-nAb ID80	61.6% (53.2%, 69.3%)	91.5% (85.5%, 94.9%)	91.5% (85.5%, 94.9%)
Positive vs Negative	-	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 57	Anti N IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Positive vs Negative	-	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 57	Anti RBD IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Positive vs Negative	-	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Positive vs Negative	-	Placebo	Day 57	Anti Spike IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Positive vs Negative	-	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 57	Pseudovirus-nAb ID50	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Positive vs Negative	-	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 57	Pseudovirus-nAb ID80	100% (100%, 100%)	99.6% (97.3%, 99.9%)	99.6% (97.3%, 99.9%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8c. Differences in the responder rates, 2FRs, 4FRs between the groups by Age

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age							
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	0.1% (-1.5%, 0.9%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	3.9% (-0.6%, 8.7%)	1% (-0.9%, 3.5%)	1% (-0.9%, 3.5%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	3.2% (0.8%, 12.2%)	3.2% (0.8%, 12.2%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	1.7% (0.3%, 8.8%)	0.3% (0%, 2.1%)	0.3% (0%, 2.1%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	0.6% (-4.4%, 5.4%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	20.3% (7.8%, 32.3%)	4.5% (-2.2%, 11.9%)	4.5% (-2.2%, 11.9%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	1.6% (0.2%, 10.9%)	1.6% (0.2%, 10.9%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8d. Differences in the responder rates, 2FRs, 4FRs between the groups by Risk for Severe Covid-19

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Risk for Severe Covid-19							
At-risk vs Not at-risk	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	-1.2% (-3.3%, -0.5%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	-4.5% (-9.7%, 1%)	-0.8% (-3.3%, 2.3%)	-0.8% (-3.3%, 2.3%)
At-risk vs Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	2.5% (0.6%, 9.4%)	2.5% (0.6%, 9.4%)
At-risk vs Not at-risk	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
At-risk vs Not at-risk	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	0.6% (-5.2%, 9.6%)	-1% (-6.6%, -0.1%)	-1% (-6.6%, -0.1%)
At-risk vs Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	-5.4% (-12.2%, 2.9%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	8.8% (-4.5%, 22.1%)	3.9% (-3.2%, 11.9%)	3.9% (-3.2%, 11.9%)
At-risk vs Not at-risk	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	-0.5% (-3.8%, -0.1%)	-0.5% (-3.8%, -0.1%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
At-risk vs Not at-risk	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8e. Differences in the responder rates, 2FRs, 4FRs between the groups by Age < 65, Risk for Severe Covid-19

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age < 65, Risk for Severe Covid-19							
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	-1.7% (-5.3%, -0.6%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	-7.4% (-14.6%, -0.2%)	-1.8% (-5.9%, 2.1%)	-1.8% (-5.9%, 2.1%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	0.4% (-8.2%, 11%)	-1.4% (-9.9%, -0.2%)	-1.4% (-9.9%, -0.2%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	-5.7% (-15.4%, 4.2%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	8.1% (-8.5%, 24.2%)	2.9% (-6.7%, 12.7%)	2.9% (-6.7%, 12.7%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8f. Differences in the responder rates, 2FRs, 4FRs between the groups by Age ≥ 65 , Risk for Severe Covid-19

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age ≥ 65, Risk for Severe Covid-19							
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	-0.5% (-3.5%, -0.1%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	-2.6% (-8.2%, 3%)	0.6% (-2.1%, 3.6%)	0.6% (-2.1%, 3.6%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	6.1% (1.5%, 22.1%)	6.1% (1.5%, 22.1%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	-5.4% (-16.2%, -1.7%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	-2.6% (-18.2%, 12.1%)	3.9% (-7.6%, 12.8%)	3.9% (-7.6%, 12.8%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	-3.4% (-21.7%, -0.4%)	-3.4% (-21.7%, -0.4%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8g. Differences in the responder rates, 2FRs, 4FRs between the groups by Sex

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Sex							
Male vs Female	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	-0.5% (-1.8%, 0.6%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	-1.9% (-8.8%, 4.1%)	-0.2% (-3.6%, 2.9%)	-0.2% (-3.6%, 2.9%)
Male vs Female	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	-1.2% (-4.6%, -0.3%)	-1.2% (-4.6%, -0.3%)
Male vs Female	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Male vs Female	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0%	0%
Male vs Female	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	-2.4% (-17.3%, 1.1%)	0.4% (0.1%, 2.9%)	0.4% (0.1%, 2.9%)
Male vs Female	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	1.9% (-2.3%, 7.9%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	0.8% (-15.6%, 16.8%)	-4.5% (-15.6%, 4.8%)	-4.5% (-15.6%, 4.8%)
Male vs Female	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	1% (0.1%, 7.4%)	1% (0.1%, 7.4%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Male vs Female	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8h. Differences in the responder rates, 2FRs, 4FRs between the groups by Hispanic or Latino ethnicity

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Hispanic or Latino ethnicity							
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	0.2% (0%, 0.8%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	-0.1% (-9.5%, 6.5%)	1.5% (-0.7%, 4%)	1.5% (-0.7%, 4%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	-0.5% (-3.3%, -0.1%)	-0.5% (-3.3%, -0.1%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	1.7% (0.3%, 8.5%)	0.3% (0%, 2.1%)	0.3% (0%, 2.1%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	-1.1% (-12.1%, 4.7%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	-17.2% (-40.5%, 8.5%)	-12.3% (-43%, 3.2%)	-12.3% (-43%, 3.2%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	-0.5% (-3.3%, -0.1%)	-0.5% (-3.3%, -0.1%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8i. Differences in the responder rates, 2FRs, 4FRs between the groups by Underrepresented minority status

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Underrepresented minority status							
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	0.2% (0%, 1.4%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	-4.6% (-10.6%, 1.3%)	0.1% (-0.9%, 1.2%)	0.1% (-0.9%, 1.2%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	-0.8% (-6%, -0.1%)	-0.8% (-6%, -0.1%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	2.6% (0.5%, 12.7%)	0.4% (0.1%, 3.1%)	0.4% (0.1%, 3.1%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	0.7% (-3.6%, 10.8%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	-0.5% (-16.9%, 16%)	-6.1% (-17.4%, 5.2%)	-6.1% (-17.4%, 5.2%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	-0.8% (-6%, -0.1%)	-0.8% (-6%, -0.1%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 9. Antibody levels in the baseline SARS-CoV-2 negative per-protocol cohort (vaccine vs. placebo)

Visit	Marker	Baseline SARS-CoV-2 Negative							
		Vaccine				Placebo			
N	Resp rate	GMT/GMC	N	Resp rate	GMT/GMC	Resp Rate Difference	GMTR/GMCR		
Day 29	Anti N IgG (IU/ml)	915 13297/13297 = 100.0% (100.0%, 100.0%)	62.87 (53.77, 73.52)	155	0/13381 = 0.0% (0.0%, 0.0%)	0.02 (0.02, 0.02)	100% (100%, 100%)	2619.77 (2240.57, 3063.14)	
Day 29	Anti RBD IgG (IU/ml)	915 13297/13297 = 100.0% (100.0%, 100.0%)	700.18 (608.59, 805.55)	155	0/13381 = 0.0% (0.0%, 0.0%)	0.27 (0.27, 0.27)	100% (100%, 100%)	2574.19 (2237.47, 2961.57)	
Day 29	Anti Spike IgG (IU/ml)	915 13297/13297 = 100.0% (100.0%, 100.0%)	412.01 (364.96, 465.13)	155	0/13381 = 0.0% (0.0%, 0.0%)	0.09 (0.09, 0.09)	100% (100%, 100%)	4577.87 (4055.08, 5168.07)	
Day 29	Pseudovirus-nAb ID50	915 13297/13297 = 100.0% (100.0%, 100.0%)	225.10 (209.62, 241.74)	155	0/13381 = 0.0% (0.0%, 0.0%)	5.01 (4.99, 5.04)	100% (100%, 100%)	44.91 (41.81, 48.23)	
Day 29	Pseudovirus-nAb ID80	915 13049.1/13297 = 98.1% (96.3%, 99.1%)	46.79 (43.69, 50.12)	155	100.2/13381 = 0.7% (0.2%, 2.9%)	5.04 (4.99, 5.09)	97.4% (94.5%, 98.5%)	9.29 (8.67, 9.96)	
Day 57	Anti N IgG (IU/ml)	915 13297/13297 = 100.0% (100.0%, 100.0%)	858.71 (706.57, 1043.61)	155	0/13381 = 0.0% (0.0%, 0.0%)	0.02 (0.02, 0.02)	100% (100%, 100%)	35779.46 (29440.26, 43483.65)	
Day 57	Anti RBD IgG (IU/ml)	915 13297/13297 = 100.0% (100.0%, 100.0%)	31262.39 (26797.12, 36471.73)	155	0/13381 = 0.0% (0.0%, 0.0%)	0.27 (0.27, 0.27)	100% (100%, 100%)	114935.27 (98518.81, 134087.25)	
Day 57	Anti Spike IgG (IU/ml)	915 13297/13297 = 100.0% (100.0%, 100.0%)	21267.84 (18637.15, 24269.85)	155	0/13381 = 0.0% (0.0%, 0.0%)	0.09 (0.09, 0.09)	100% (100%, 100%)	236309.31 (207079.50, 269664.99)	
Day 57	Pseudovirus-nAb ID50	915 13297/13297 = 100.0% (100.0%, 100.0%)	10118.66 (9384.97, 10909.71)	155	0/13381 = 0.0% (0.0%, 0.0%)	5.00 (5.00, 5.00)	100% (100%, 100%)	2023.73 (1876.99, 2181.94)	
Day 57	Pseudovirus-nAb ID80	915 13297/13297 = 100.0% (100.0%, 100.0%)	1464.36 (1363.33, 1572.87)	155	50.1/13381 = 0.4% (0.1%, 2.7%)	5.02 (4.98, 5.06)	99.6% (97.3%, 99.9%)	291.69 (271.44, 313.44)	

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 10. Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (vaccine vs. placebo)

Visit	Marker	Baseline SARS-CoV-2 Positive							
		Vaccine				Placebo			
N	Resp rate	GMT/GMC	N	Resp rate	GMT/GMC	Resp Rate Difference	GMTR/GMCR		
Day 29	Anti N IgG (IU/ml)	269 1399/1399 = 100.0% (100.0%, 100.0%)	103.45 (79.96, 133.83)	276 1276/1276 = 100.0% (100.0%, 100.0%)	29.12 (22.05, 38.45)	0% (0%, 0%)	3.55 (2.43, 5.19)		
Day 29	Anti RBD IgG (IU/ml)	269 1399/1399 = 100.0% (100.0%, 100.0%)	1269.77 (1009.63, 1596.93)	276 1276/1276 = 100.0% (100.0%, 100.0%)	369.13 (289.11, 471.31)	0% (0%, 0%)	3.44 (2.46, 4.81)		
Day 29	Anti Spike IgG (IU/ml)	269 1399/1399 = 100.0% (100.0%, 100.0%)	766.27 (626.05, 937.90)	276 1276/1276 = 100.0% (100.0%, 100.0%)	186.46 (150.24, 231.43)	0% (0%, 0%)	4.11 (3.06, 5.52)		
Day 29	Pseudovirus-nAb ID50	269 1399/1399 = 100.0% (100.0%, 100.0%)	354.90 (317.58, 396.60)	276 1272.9/1276 = 99.8% (98.3%, 100.0%)	109.67 (96.21, 125.02)	0.2% (0%, 1.7%)	3.24 (2.73, 3.84)		
Day 29	Pseudovirus-nAb ID80	269 1399/1399 = 100.0% (100.0%, 100.0%)	76.03 (68.29, 84.64)	276 1177.1/1276 = 92.3% (86.7%, 95.6%)	25.20 (22.40, 28.34)	7.7% (4.4%, 13.3%)	3.02 (2.57, 3.54)		
Day 57	Anti N IgG (IU/ml)	269 1399/1399 = 100.0% (100.0%, 100.0%)	2216.51 (1602.80, 3065.20)	276 1276/1276 = 100.0% (100.0%, 100.0%)	373.57 (268.20, 520.32)	0% (0%, 0%)	5.93 (3.73, 9.43)		
Day 57	Anti RBD IgG (IU/ml)	269 1399/1399 = 100.0% (100.0%, 100.0%)	73550.05 (58195.76, 92955.40)	276 1276/1276 = 100.0% (100.0%, 100.0%)	13174.89 (10267.01, 16906.37)	0% (0%, 0%)	5.58 (3.97, 7.86)		
Day 57	Anti Spike IgG (IU/ml)	269 1399/1399 = 100.0% (100.0%, 100.0%)	51328.47 (41972.47, 62770.00)	276 1276/1276 = 100.0% (100.0%, 100.0%)	7011.64 (5627.97, 8735.50)	0% (0%, 0%)	7.32 (5.43, 9.86)		
Day 57	Pseudovirus-nAb ID50	269 1399/1399 = 100.0% (100.0%, 100.0%)	27542.73 (24378.19, 31118.07)	276 1276/1276 = 100.0% (100.0%, 100.0%)	3530.63 (3123.48, 3990.86)	0% (0%, 0%)	7.80 (6.56, 9.27)		
Day 57	Pseudovirus-nAb ID80	269 1399/1399 = 100.0% (100.0%, 100.0%)	4408.72 (3893.97, 4991.51)	276 1276/1276 = 100.0% (100.0%, 100.0%)	767.20 (679.53, 866.17)	0% (0%, 0%)	5.75 (4.83, 6.84)		

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 11. Antibody levels in the per-protocol cohort (vaccine recipients)

Visit	Marker	Vaccine Recipients							
		Baseline SARS-CoV-2 Positive				Baseline SARS-CoV-2 Negative			Comparison
N	Resp rate	GMT/GMC	N	Resp rate	GMT/GMC	Resp Rate Difference	GMTR/GMCR		
Day 29	Anti N IgG (IU/ml)	269	1399/1399 = 100.0% (100.0%, 100.0%)	103.45 (79.96, 133.83)	915	13297/13297 = 100.0% (100.0%, 100.0%)	62.87 (53.77, 73.52)	0% (0%, 0%)	1.65 (1.22, 2.22)
Day 29	Anti RBD IgG (IU/ml)	269	1399/1399 = 100.0% (100.0%, 100.0%)	1269.77 (1009.63, 1596.93)	915	13297/13297 = 100.0% (100.0%, 100.0%)	700.18 (608.59, 805.55)	0% (0%, 0%)	1.81 (1.39, 2.37)
Day 29	Anti Spike IgG (IU/ml)	269	1399/1399 = 100.0% (100.0%, 100.0%)	766.27 (626.05, 937.90)	915	13297/13297 = 100.0% (100.0%, 100.0%)	412.01 (364.96, 465.13)	0% (0%, 0%)	1.86 (1.47, 2.35)
Day 29	Pseudovirus-nAb ID50	269	1399/1399 = 100.0% (100.0%, 100.0%)	354.90 (317.58, 396.60)	915	13297/13297 = 100.0% (100.0%, 100.0%)	225.10 (209.62, 241.74)	0% (0%, 0%)	1.58 (1.38, 1.80)
Day 29	Pseudovirus-nAb ID80	269	1399/1399 = 100.0% (100.0%, 100.0%)	76.03 (68.29, 84.64)	915	13049.1/13297 = 98.1% (96.3%, 99.1%)	46.79 (43.69, 50.12)	1.9% (0.9%, 3.7%)	1.62 (1.43, 1.85)
Day 57	Anti N IgG (IU/ml)	269	1399/1399 = 100.0% (100.0%, 100.0%)	2216.51 (1602.80, 3065.20)	915	13297/13297 = 100.0% (100.0%, 100.0%)	858.71 (706.57, 1043.61)	0% (0%, 0%)	2.58 (1.77, 3.77)
Day 57	Anti RBD IgG (IU/ml)	269	1399/1399 = 100.0% (100.0%, 100.0%)	73550.05 (58195.76, 92955.40)	915	13297/13297 = 100.0% (100.0%, 100.0%)	31262.39 (26797.12, 36471.73)	0% (0%, 0%)	2.35 (1.78, 3.11)
Day 57	Anti Spike IgG (IU/ml)	269	1399/1399 = 100.0% (100.0%, 100.0%)	51328.47 (41972.47, 62770.00)	915	13297/13297 = 100.0% (100.0%, 100.0%)	21267.84 (18637.15, 24269.85)	0% (0%, 0%)	2.41 (1.90, 3.07)
Day 57	Pseudovirus-nAb ID50	269	1399/1399 = 100.0% (100.0%, 100.0%)	27542.73 (24378.19, 31118.07)	915	13297/13297 = 100.0% (100.0%, 100.0%)	10118.66 (9384.97, 10909.71)	0% (0%, 0%)	2.72 (2.36, 3.14)
Day 57	Pseudovirus-nAb ID80	269	1399/1399 = 100.0% (100.0%, 100.0%)	4408.72 (3893.97, 4991.51)	915	13297/13297 = 100.0% (100.0%, 100.0%)	1464.36 (1363.33, 1572.87)	0% (0%, 0%)	3.01 (2.61, 3.47)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 12. Antibody levels in the per-protocol cohort (placebo recipients)

Visit	Marker	Placebo Recipients							
		Baseline SARS-CoV-2 Positive				Baseline SARS-CoV-2 Negative		Comparison	
N	Resp rate	GMT/GMC	N	Resp rate	GMT/GMC	Resp Rate Difference	GMTR/GMCR		
Day 29	Anti N IgG (IU/ml)	276 1276/1276 = 100.0% (100.0%, 100.0%)	29.12 (22.05, 38.45)	155 0/13381 = 0.0% (0.0%, 0.0%)	0.02 (0.02, 0.02)	100% (100%, 100%)	1213.25 (918.71, 1602.22)		
Day 29	Anti RBD IgG (IU/ml)	276 1276/1276 = 100.0% (100.0%, 100.0%)	369.13 (289.11, 471.31)	155 0/13381 = 0.0% (0.0%, 0.0%)	0.27 (0.27, 0.27)	100% (100%, 100%)	1357.10 (1062.90, 1732.74)		
Day 29	Anti Spike IgG (IU/ml)	276 1276/1276 = 100.0% (100.0%, 100.0%)	186.46 (150.24, 231.43)	155 0/13381 = 0.0% (0.0%, 0.0%)	0.09 (0.09, 0.09)	100% (100%, 100%)	2071.82 (1669.29, 2571.41)		
Day 29	Pseudovirus-nAb ID50	276 1272.9/1276 = 99.8% (98.3%, 100.0%)	109.67 (96.21, 125.02)	155 0/13381 = 0.0% (0.0%, 0.0%)	5.01 (4.99, 5.04)	99.8% (98.3%, 100%)	21.88 (19.19, 24.94)		
Day 29	Pseudovirus-nAb ID80	276 1177.1/1276 = 92.3% (86.7%, 95.6%)	25.20 (22.40, 28.34)	155 100.2/13381 = 0.7% (0.2%, 2.9%)	5.04 (4.99, 5.09)	91.5% (85.5%, 94.9%)	5.00 (4.45, 5.63)		
Day 57	Anti N IgG (IU/ml)	276 1276/1276 = 100.0% (100.0%, 100.0%)	373.57 (268.20, 520.32)	155 0/13381 = 0.0% (0.0%, 0.0%)	0.02 (0.02, 0.02)	100% (100%, 100%)	15565.21 (11175.19, 21679.81)		
Day 57	Anti RBD IgG (IU/ml)	276 1276/1276 = 100.0% (100.0%, 100.0%)	13174.89 (10267.01, 16906.37)	155 0/13381 = 0.0% (0.0%, 0.0%)	0.27 (0.27, 0.27)	100% (100%, 100%)	48437.11 (37746.36, 62155.76)		
Day 57	Anti Spike IgG (IU/ml)	276 1276/1276 = 100.0% (100.0%, 100.0%)	7011.64 (5627.97, 8735.50)	155 0/13381 = 0.0% (0.0%, 0.0%)	0.09 (0.09, 0.09)	100% (100%, 100%)	77907.14 (62533.03, 97061.08)		
Day 57	Pseudovirus-nAb ID50	276 1276/1276 = 100.0% (100.0%, 100.0%)	3530.63 (3123.48, 3990.86)	155 0/13381 = 0.0% (0.0%, 0.0%)	5.00 (5.00, 5.00)	100% (100%, 100%)	706.13 (624.70, 798.17)		
Day 57	Pseudovirus-nAb ID80	276 1276/1276 = 100.0% (100.0%, 100.0%)	767.20 (679.53, 866.17)	155 50.1/13381 = 0.4% (0.1%, 2.7%)	5.02 (4.98, 5.06)	99.6% (97.3%, 99.9%)	152.82 (135.32, 172.58)		

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Chapter 2

Graphical Description of Immunogenicity Data

2.1 Pairs plots of antibody markers for overall per-protocol cohort

2.1.1 Baseline SARS-CoV-2 Negative




Figure 2.1: Pair plots of D29 Ab markers: baseline negative vaccine arm




Figure 2.2: Pair plots of D57 Ab markers: baseline negative vaccine arm




Figure 2.3: Pair plots of D29 fold-rise over D1 Ab markers: baseline negative vaccine arm




Figure 2.4: Pair plots of D57 fold-rise over D1 Ab markers: baseline negative vaccine arm




Figure 2.5: Pair plots of D1, D29 and D57 Binding Antibody to N: baseline negative vaccine arm




Figure 2.6: Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline negative vaccine arm

Binding Antibody to RBD: baseline negative vaccine arm




Figure 2.7: Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline negative vaccine arm




Figure 2.8: Pair plots of D1, D29 and D57 nAb Neutralization 50% Titer: baseline negative vaccine arm




Figure 2.9: Pair plots of D1, D29 and D57 nAb Neutralization 80% Titer: Baseline negative vaccine arm

2.1.2 Baseline SARS-CoV-2 Positive




Figure 2.10: Pair plots of D29 Ab markers: baseline positive vaccine arm




Figure 2.11: Pair plots of D57 Ab markers: baseline positive vaccine arm




Figure 2.12: Pair plots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm




Figure 2.13: Pair plots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm




Figure 2.14: Pair plots of D1, D29 and D57 Binding Antibody to N: baseline positive vaccine arm




Figure 2.15: Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline positive vaccine arm




Figure 2.16: Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline positive vaccine arm

PsV Neutralization 50% Titer: baseline positive vaccine arm




Figure 2.17: Pair plots of D1, D29 and D57 nAb Neutralization 50% Titer: baseline positive vaccine arm




Figure 2.18: Pair plots of D1, D29 and D57 nAb Neutralization 80% Titer: Baseline positive vaccine arm

MOCK

2.2 RCDF plots of antibody markers for overall per-protocol cohort




Figure 2.19: RCDF plots for D29 Ab markers: by baseline status x randomization arm




Figure 2.20: RCDF plots for D57 Ab markers: by baseline status x randomization arm




Figure 2.21: RCDF plots for D29 fold-rise over D1 Ab markers: by baseline status x randomization arm




Figure 2.22: RCDF plots for D57 fold-rise over D1 Ab markers: by baseline status x randomization arm




Figure 2.23: RCDF plots for D29 bAb markers: by baseline status for the vaccine arm




Figure 2.24: RCDF plots for D29 nAb markers: by baseline status for the vaccine arm




Figure 2.25: RCDF plots for D57 bAb markers: by baseline status for the vaccine arm




Figure 2.26: RCDF plots for D57 nAb markers: by baseline status for the vaccine arm




Figure 2.27: RCDF plots for D29 over D1 fold-rise bAb markers: by baseline status for the vaccine arm




Figure 2.28: RCDF plots for D29 over D1 fold-rise nAb markers: by baseline status for the vaccine arm




Figure 2.29: RCDF plots for D57 fold-rise over D1 bAb markers: by baseline status for the vaccine arm




Figure 2.30: RCDF plots for D57 fold-rise over D1 nAb markers: by baseline status for the vaccine arm




Figure 2.31: RCDF plots for D29 bAb markers: baseline negative vaccine arm




Figure 2.32: RCDF plots for D29 nAb markers: baseline negative vaccine arm




Figure 2.33: RCDF plots for D57 bAb markers: baseline negative vaccine arm




Figure 2.34: RCDF plots for D57 nonAb markers: baseline negative vaccine arm




Figure 2.35: RCDF plots for D29 fold-rise over D1 bAb markers: baseline negative vaccine arm




Figure 2.36: RCDF plots for D29 fold-rise over D1 nAb markers: baseline negative vaccine arm




Figure 2.37: RCDF plots for D57 fold-rise over D1 bAb markers: baseline negative vaccine arm




Figure 2.38: RCDF plots for D57 fold-rise over D1 nAb markers: baseline negative vaccine arm




Figure 2.39: RCDF plots for D29 bAb markers: baseline positive vaccine arm




Figure 2.40: RCDF plots for D29 nAb markers: baseline positive vaccine arm




Figure 2.41: RCDF plots for D57 bAb markers: baseline positive vaccine arm




Figure 2.42: RCDF plots for D57 nonAb markers: baseline positive vaccine arm




Figure 2.43: RCDF plots for D29 fold-rise over D1 bAb markers: baseline/positive vaccine arm




Figure 2.44: RCDF plots for D29 fold-rise over D1 nAb markers: baseline/positive vaccine arm




Figure 2.45: RCDF plots for D57 fold-rise over D1 bAb markers: baseline/positive vaccine arm




Figure 2.46: RCDF plots for D57 fold-rise over D1 nAb markers: baseline/positive vaccine arm

2.3 Scatter plots of antibody markers versus age for overall per-protocol cohort

MOCK

2.3.1 Baseline SARS-CoV-2 negative




Figure 2.47: Scatter plots for D29 Ab markers vs. age: baseline negative vaccine arm




Figure 2.48: Scatter plots for D57 Ab markers vs. age: baseline negative vaccine arm

2.3. SCATTER PLOTS OF ANTIBODY MARKERS VERSUS AGE FOR OVERALL PER-PROTOCOL COHORT461

2.3.2 Baseline SARS-CoV-2 positive




Figure 2.49: Scatter plots for D29 Ab markers vs. age: baseline positive vaccine arm




Figure 2.50: Scatter plots for D57 Ab markers vs. age: baseline positive vaccine arm

2.4 Box plots of antibody markers for overall per-protocol cohort

MOCK

2.4.1 Baseline SARS-CoV-2 negative




Figure 2.51: Boxplots of D29 Ab markers: baseline negative vaccine + placebo arms




Figure 2.52: Boxplots of D57 Ab markers: baseline negative vaccine + placebo arms




Figure 2.53: Boxplots of D29 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms




Figure 2.54: Boxplots of D57 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms

2.4.2 Baseline SARS-CoV-2 positive




Figure 2.55: Boxplots of D29 Ab markers: baseline positive vaccine + placebo arms




Figure 2.56: Boxplots of D57 Ab markers: baseline positive vaccine + placebo arms




Figure 2.57: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms




Figure 2.58: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms

2.4.3 Baseline negative vs. positive vaccine recipients




Figure 2.59: Boxplots of D29 Ab markers: baseline positive + negative vaccine arm




Figure 2.60: Boxplots of D57 Ab markers: baseline positive + negative vaccine arm




Figure 2.61: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm




Figure 2.62: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm

2.4.4 Baseline negative vs. positive placebo recipients




Figure 2.63: Boxplots of D29 Ab markers: baseline positive + negative placebo arm




Figure 2.64: Boxplots of D57 Ab markers: baseline positive + negative placebo arm




Figure 2.65: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative placebo arm




Figure 2.66: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative placebo arm

2.5 Spaghetti plots of antibody markers over time for the overall per-protocol cohort

MOCK

2.5. SPAGHETTI PLOTS OF ANTIBODY MARKERS OVER TIME FOR THE OVERALL PER-PROTOCOL COHORT48

2.5.1 Baseline SARS-CoV-2 negative




Figure 2.67: Spaghetti plots of Ab markers over time: baseline negative vaccine + placebo arm

2.5.2 Baseline SARS-CoV-2 positive




Figure 2.68: Spaghetti plots of Ab markers over time: baseline positive vaccine + placebo arm

2.6 RCDF plots of antibody markers by demographics for per-protocol cohort

MOCK

2.6.1 Baseline SARS-CoV-2 negative




Figure 2.69: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT485




Figure 2.70: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age groups.




Figure 2.71: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT487




Figure 2.72: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups.




Figure 2.73: RCDF plots for D29 Ab markers: baseline negative vaccine arm by high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT489




Figure 2.74: RCDF plots for D57 Ab markers: baseline negative vaccine arm by high-risk condition.




Figure 2.75: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT491




Figure 2.76: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition.




Figure 2.77: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT493




Figure 2.78: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and high-risk condition.




Figure 2.79: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT495




Figure 2.80: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition.




Figure 2.81: RCDF plots for D29 Ab markers: baseline negative vaccine arm by sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT497




Figure 2.82: RCDF plots for D57 Ab markers: baseline negative vaccine arm by sex assigned at birth.




Figure 2.83: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT499




Figure 2.84: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth.




Figure 2.85: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT501




Figure 2.86: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.




Figure 2.87: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT503




Figure 2.88: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex at birth.




Figure 2.89: RCDF plots for D29 Ab markers: baseline negative vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT505




Figure 2.90: RCDF plots for D57 Ab markers: baseline negative vaccine arm by ethnicity.




Figure 2.91: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT507




Figure 2.92: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity.




Figure 2.93: RCDF plots for D29 Ab markers: baseline negative vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT509




Figure 2.94: RCDF plots for D57 Ab markers: baseline negative vaccine arm by race.




Figure 2.95: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT511




Figure 2.96: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by race.




Figure 2.97: RCDF plots for D29 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.98: RCDF plots for D57 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.99: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT515




Figure 2.100: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.101: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT517




Figure 2.102: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.




Figure 2.103: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT519




Figure 2.104: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.6.2 Baseline SARS-CoV-2 positive




Figure 2.105: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT521




Figure 2.106: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age groups.




Figure 2.107: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT523




Figure 2.108: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups.




Figure 2.109: RCDF plots for D29 Ab markers: baseline positive vaccine arm by high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT525




Figure 2.110: RCDF plots for D57 Ab markers: baseline positive vaccine arm by high-risk condition.




Figure 2.111: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT527




Figure 2.112: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.




Figure 2.113: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT529




Figure 2.114: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and high-risk condition.




Figure 2.115: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT531




Figure 2.116: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.




Figure 2.117: RCDF plots for D29 Ab markers: baseline positive vaccine arm by sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT533




Figure 2.118: RCDF plots for D57 Ab markers: baseline positive vaccine arm by sex assigned at birth.




Figure 2.119: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT535




Figure 2.120: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.




Figure 2.121: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT537




Figure 2.122: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.




Figure 2.123: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT539




Figure 2.124: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.




Figure 2.125: RCDF plots for D29 Ab markers: baseline positive vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT541




Figure 2.126: RCDF plots for D57 Ab markers: baseline positive vaccine arm by ethnicity.




Figure 2.127: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT543




Figure 2.128: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.




Figure 2.129: RCDF plots for D29 Ab markers: baseline positive vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT545




Figure 2.130: RCDF plots for D57 Ab markers: baseline positive vaccine arm by race.




Figure 2.131: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT547




Figure 2.132: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.




Figure 2.133: RCDF plots for D29 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT549




Figure 2.134: RCDF plots for D57 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.135: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT551




Figure 2.136: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.137: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT553




Figure 2.138: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.




Figure 2.139: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT555




Figure 2.140: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.

2.7 Boxplots of antibody markers by demographics for per-protocol cohort

MOCK

2.7.1 Baseline SARS-CoV-2 negative




Figure 2.141: Boxplots of D29 Ab markers: Baseline negative vaccine arm by age group.




Figure 2.142: Boxplots of D57 Ab markers: Baseline negative vaccine arm by age group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT559




Figure 2.143: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth.




Figure 2.144: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT561




Figure 2.145: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity.




Figure 2.146: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT563




Figure 2.147: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race.




Figure 2.148: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT565




Figure 2.149: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.150: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT567




Figure 2.151: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.




Figure 2.152: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT569

2.7.2 Baseline SARS-CoV-2 positive

MOCK




Figure 2.153: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT571




Figure 2.154: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group.




Figure 2.155: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT573




Figure 2.156: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.




Figure 2.157: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT575




Figure 2.158: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.




Figure 2.159: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT577




Figure 2.160: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.




Figure 2.161: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT579




Figure 2.162: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.




Figure 2.163: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT581




Figure 2.164: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.




Figure 2.165: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT583




Figure 2.166: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.




Figure 2.167: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT585




Figure 2.168: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.169: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT587




Figure 2.170: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.